<p>There are over 30 reported variations of CYP-450 enzymes. Enzymes are classified according to families and subfamilies. For example, CYP2A6 is cytochrome P-450, subfamily IIA, polypeptide 6. CYP1A2 and the enzymes in the CYP2 and CYP3 families are considered to be most important in drug metabolism. Some of the enzymes reported to inhibit or induce drug metabolism include CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5-7. The genes coding for these enzymes are located throughout the genome.</p>
<p>Genetic polymorphisms of cytochrome P-450 genes are unequally distributed geographically and in different ethnic populations. Testing for these polymorphisms is used to predict the response to drugs sensitive to metabolism by this enzyme system. In the laboratory, testing for CYP-450 polymorphisms is performed by allele-specific PCR for particular polymorphisms. Multiple P-450 genetic variants may be screened by microarray or bead array technology.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="single-gene-disorders-with-nonclassical-patterns-of-inheritance">Single-Gene Disorders With Nonclassical Patterns of Inheritance<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#single-gene-disorders-with-nonclassical-patterns-of-inheritance" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Mitochondrial mutations, genomic imprinting, and gonadal mosaicism do not follow mendelian rules of inheritance. Mitochondrial mutations are inherited maternally (Fig. 13-11). Genomic imprinting is responsible for specific expression of genes in different cells and tissues. Imprinting is reset at meiosis and fertilization and is different in egg and sperm production.</p>
<p>Gonadal mosaicism is the generation of new mutations in germ line cells. The mutated cells give rise to eggs or sperm carrying the mutation, which then becomes a heritable phenotype. Unusual pedigrees result (Fig. 13-12). Gonadal mosaicism is expected when phenotypically normal parents have more than one affected child, e.g. in osteogenesis imperfecta, an autosomal-dominant phenotype in a child from unaffected parents.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="mutations-in-mitochondrial-genes">Mutations in Mitochondrial Genes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mutations-in-mitochondrial-genes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Mitochondria are cellular organelles responsible for energy production. Mitochondria contain their own ge</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<p><img src="assets/images/image-20251222-6cf06924.jpeg" alt="img-319.jpeg">
Figure 13-11 Mitochondrial mutations are maternally inherited.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="advanced-concepts">Advanced Concepts<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#advanced-concepts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>An example of the nature of imprinting is illustrated by comparison of mules and hinnies. A mule is the product of a male horse and a female donkey. A hinny is the product of a female horse and a male donkey. These animals are quite different in phenotype, even though they contain essentially the same genotype. Another illustration of the effects of imprinting is seen in animals cloned by nuclear transfer. Because this process bypasses the generation of eggs and sperm and fertilization, imprinting is not reset, and cloned animals display unexpected phenotypes, such as larger size or early onset of age-related diseases.</p>
<p>nome, a circular DNA molecule 16,569 base pairs in length (Fig. 13-13). The mitochondrial genome contains 37 genes, including a 12S and 16S rRNA, 22 tRNAs, and 13 genes required for oxidative phosphorylation. In addition, the mtDNA contains a 1000-nt control region that encompasses transcription and replication regula</p>
<p><img src="assets/images/image-20251222-f43cf16c.jpeg" alt="img-320.jpeg">
Figure 13-12 Gonadal mosaicism arises as a result of a new mutation. In this example, a dominant disease phenotype has been inherited from two unaffected parents. The mutation is present only in the germ cells of the first-generation parents but is inherited in all cells of the offspring.</p>
<p>tory elements (see Chapter 11). A database of mitochondrial genes and mutations is available at <a href="http://www.MITOMAP.org" target="_blank" rel="noopener noreferrer">www.MITOMAP.org</a></p>
<p>Mutations in mitochondrial genes affect energy production and are therefore manifested as diseases in the most energy-demanding organs, muscle and the nervous system.[9,10] Mutations in several genes in the mitochondrial genome have been defined. These mutations result in a number of disease syndromes involving muscular and neurological disorders (Table 13.6).</p>
<p>Mitochondrial mutations are easily detected by a variety of molecular methods. Southern blot is used for detecting large deletions (Fig. 13-14). Point mutations are frequently analyzed by PCR-RFLP (Fig. 13-15). Interpretation of mutation analysis is complicated, however, by the extent of heteroplasmy (mutated mitochondria and normal mitochondria in the same cell) and the nature of the mutation.[11] A range of phenotypes may be present, even in the same family.</p>
<p><img src="assets/images/image-20251222-0595789e.jpeg" alt="img-321.jpeg">
Figure 13-13 Mutations and deletions throughout the mitochondrial genome are associated with muscular and neurological disorders.</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Molecular Detection of Inherited Diseases Chapter 13</p>
<p>Table 13.6 Diseases Resulting From Mutations in Mitochondrial Genes</p>
<table><thead><tr><th>Disorder</th><th>Gene Affected</th><th>Molecular Methodology</th></tr></thead><tbody><tr><td>Kearnes-Sayre syndrome</td><td>2–7 kb deletions28</td><td>Southern blot, PCR, PCR-RFLP</td></tr><tr><td>Pearson's syndrome</td><td>Deletions</td><td>Southern blot analysis of leukocytes, PCR-RFLP29</td></tr><tr><td>Pigmentary retinopathy, chronic progressive external ophthalmoplegia</td><td>tRNA (tyr) deletion,30 deletions</td><td>PCR-RFLP, Southern blot analysis of muscle biopsy31</td></tr><tr><td>Leber's hereditary optic neuropathy</td><td>Cyt6 and URF* point mutations</td><td>PCR-RFLP</td></tr><tr><td>Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes</td><td>tRNA (leu) point mutations</td><td>PCR-RFLP, sequencing</td></tr><tr><td>Myoclonic epilepsy with ragged red fibers</td><td>tRNA (lys) point mutations</td><td>PCR-RFLP</td></tr><tr><td>Deafness</td><td></td><td></td></tr><tr><td>Neuropathy, ataxia, retinitis pigmentosa (NARP)</td><td>ATPase VI point mutation</td><td>PCR-RFLP</td></tr><tr><td>Subacute necrotizing encephalomyelopathy with neurogenic muscle weakness, ataxia, retinitis pigmentosa (Leigh's with NARP)</td><td>ATPase VI, NADH:ubiquinone oxidoreductase subunit mutations</td><td>PCR-RFLP</td></tr><tr><td>Mitochondrial DNA depletion syndrome</td><td>Thymidine kinase gene mutations</td><td>PCR, sequencing</td></tr></tbody></table>
<p>*Unknown reading frame</p>
<p><img src="assets/images/image-20251222-dd8c1cec.jpeg" alt="img-322.jpeg">
Figure 13-14 A mitochondrial deletion as revealed by Southern blot. DNA was cut with Pvull, a restriction enzyme that cuts once in the mitochondrial genome. The membrane was probed for mitochondrial sequences. Normal mitochondria (N) yield one band at  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>16.6</mn><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">b</mi></mrow></mrow><annotation encoding="application/x-tex">16.6\mathrm{kb}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">16.6</span><span class="mord"><span class="mord mathrm">kb</span></span></span></span></span></span>  when cut with Pvull (C). Supercoiled, nicked, and a few linearized mitochondrial DNA circles can be seen in the uncut DNA (U). DNA from a patient with Kearnes-Sayres syndrome (P) yields two mitochondrial populations, one of which has about  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">b</mi></mrow></mrow><annotation encoding="application/x-tex">5\mathrm{kb}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm">kb</span></span></span></span></span></span>  of the mitochondrial genome-deleted sequences. Because both normal and mutant mitochondria are present, this is a state of heteroplasmy. (Photo courtesy of Dr. Elizabeth Berry-Kravis, Rush University Medical Center.)</p>
<p>Genes that control mitochondrial functions are also found on the nuclear genome (Table 13.7). Unlike mitochondrial mutations that display maternal inheritance, these disorders have autosomal patterns of inheritance. Although the causative gene mutation is located on a nuclear gene, analysis of mitochondria may still show deletions or other mutations caused by the loss of the nuclear gene function.</p>
<p><img src="assets/images/image-20251222-3d230c56.jpeg" alt="img-323.jpeg">
Figure 13-15 Detection of the NARP mitochondrial point mutation (ATPase VI 8993T&gt;C or T&gt;G) by PCR-RFLP. The PCR product was digested with the enzyme Mspl (C) or undigested (U). If the mutation is present, the enzyme will cut the PCR product into two pieces, as seen is specimen 3. (Photo courtesy of Dr. Elizabeth Berry-Kravis, Rush University Medical Center.)</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<p>Table 13.7 Some Disorders Caused by Nuclear Gene Mutations</p>
<table><thead><tr><th>Disorder</th><th>Gene Affected (Location)</th><th>Molecular Methodology</th></tr></thead><tbody><tr><td>Mitochondrial DNA depletion syndrome</td><td>Succinate-CoA ligase, ADP-forming, beta subunit, SUCLA 2 (13q12.2-q13)</td><td>Southern blot</td></tr><tr><td>Mitochondrial neurogastrointestinal encephalomyopathy</td><td>Platelet-derived endothelial cell growth factor, ECGF (22q13-qter)</td><td>Sequencing</td></tr><tr><td>Progressive external ophthalmoplegia</td><td>Chromosome 10 open reading frame 2, C10ORF2 (10q24); polymerase, DNA, gamma, POLG (15q25); solute carrier family 25 (mitochondrial carrier), member 4, SLC25A4/ANT1, (4q25)</td><td>Southern blot, SSCP, sequencing32</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="trinucleotide-repeat-expansion-disorders">Trinucleotide Repeat Expansion Disorders<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#trinucleotide-repeat-expansion-disorders" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Triplet repeats are short tandem repeats (STRs) with 3-bp repeating units (see Chapter 11 for more detailed explanation of STRs). During DNA replication and meiosis, these STRs can expand (or contract) in length. Triplet-repeat mutations may occur in coding and noncoding sequences of genes. The most well-known examples of triplet repeat expansion diseases are fragile X syndrome and Huntington's disease.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="fragile-x-syndrome">Fragile X Syndrome<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#fragile-x-syndrome" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Fragile X syndrome is associated with a triplet repeat (CGG) expansion in the noncoding region  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>5</mn><mo mathvariant="normal" lspace="0em" rspace="0em">′</mo></msup></mrow><annotation encoding="application/x-tex">5^{\prime}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7519em;"></span><span class="mord"><span class="mord">5</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7519em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">′</span></span></span></span></span></span></span></span></span></span></span></span></span>  to the fragile X mental retardation gene, FMR-1 (Fig. 13-16). The expansion becomes so large in full fragile X syn</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="advanced-concepts">Advanced Concepts<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#advanced-concepts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>In addition to family history, clinical tests including electroencephalography, neuroimaging, cardiac electrocardiography, echocardiography, magnetic resonance spectroscopy, and exercise testing are important for accurate diagnosis of mitochondrial disorders. High blood or cerebrospinal fluid lactate concentrations as well as high blood glucose levels are observed in patients with some mitochondrial diseases. More direct tests, such as histological examination of muscle biopsies and respiratory chain complex studies on skeletal muscle and skin fibroblasts, are more specific for mitochondrial dysfunction.</p>
<p>drome (more than 2000 CGG repeats) that the region is microscopically visible (Fig. 13-17). The CGG repeat expansion  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>5</mn><mo mathvariant="normal" lspace="0em" rspace="0em">′</mo></msup></mrow><annotation encoding="application/x-tex">5^{\prime}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7519em;"></span><span class="mord"><span class="mord">5</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7519em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">′</span></span></span></span></span></span></span></span></span></span></span></span></span>  to the FMR-1 gene also results in methylation of the region and transcriptional shut-down of FMR-1.</p>
<p>Symptoms of fragile X syndrome include learning disorders and mental retardation (IQ  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>∼</mo><mn>20</mn></mrow><annotation encoding="application/x-tex">\sim 20</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">∼</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">20</span></span></span></span></span> ), long face, large ears, and macro-orchidism (large genitalia). Symptoms are more apparent at puberty. Symptoms increase in severity with each generation in a fragile X family (Fig. 13-18).</p>
<p>In addition to the fragile X chromosome observed by karyotyping, the state of the repeat expansion is also analyzed using PCR and by Southern blot. Although premutations in fragile X carriers are easily detected by PCR, Southern blot is required to detect the full fragile X expansion that could cover thousands of base pairs.</p>
<p><img src="assets/images/image-20251222-b28d7cd6.jpeg" alt="img-324.jpeg">
Figure 13-16 Triplet (CGG) repeat expansions in sequences  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>5</mn><mo mathvariant="normal" lspace="0em" rspace="0em">′</mo></msup></mrow><annotation encoding="application/x-tex">5^{\prime}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7519em;"></span><span class="mord"><span class="mord">5</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7519em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">′</span></span></span></span></span></span></span></span></span></span></span></span></span>  to the FMR-1 gene are observed in fragile X carriers (up to 200 repeats) and fully affected individuals (more than 200 repeats). Normally there are fewer than 60 repeats. Expansion results from amplification of the triplet sequences during meiotic recombination events. The very large repeats (more than 200 repeats) are methylated on the C residues. This methylation turns off FMR-1 transcription.</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Molecular Detection of Inherited Diseases Chapter 13</p>
<p><img src="assets/images/image-20251222-18937bcf.jpeg" alt="img-325.jpeg">
Fragile X chromosome (in metaphase)</p>
<p><img src="assets/images/image-20251222-d4ba7324.jpeg" alt="img-326.jpeg">
Figure 13-17 The fragile X chromosome is characterized by a threadlike process just at the telomere of the long arm (arrow). This is the site of disorganization of chromatin structure by the GC-rich repeat expansions.
Unaffected carrier
Learning disabled
FXS</p>
<p>Southern blot also reveals cases of mosaicism where both premutations and full fragile X chromosomes are present in separate cell populations from the same patient (Fig. 13-19).</p>
<p><img src="assets/images/image-20251222-dc553dca.jpeg" alt="img-327.jpeg">
Premutations</p>
<p><img src="assets/images/image-20251222-bfde2a72.jpeg" alt="img-328.jpeg">
Figure 13-18 The symptoms of fragile X syndrome (FXS) become more severe with each generation. The fragile X chromosome cannot be transmitted from fathers to sons but can be transmitted from grandfathers to grandsons through their daughters.
Full Mutations
Figure 13-19 Detection of premutations by PCR (left) and full fragile X mutations by Southern blot (right). Primers (one of which is labeled with  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>32</mn></msup><mi mathvariant="normal">P</mi></mrow><annotation encoding="application/x-tex">^{32}\mathrm{P}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">32</span></span></span></span></span></span></span></span></span><span class="mord mathrm">P</span></span></span></span></span> ) flanking the repeat region are used to generate labeled PCR products. Premutations appear as large amplicons in the 50-90 repeat range on the autoradiogram at left. Normal samples fall in the 20-40 repeat range. Full fragile X repeats are too large and GC rich to detect by standard PCR. Southern blots reveal full mutations in three of the samples shown. The inactive (methylated) X chromosome in four female patients is detected by cutting the DNA with a methylation-specific restriction enzyme. (Photos courtesy of Dr. Elizabeth Berry-Kravis, Rush University Medical Center.)</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="advanced-concepts">Advanced Concepts<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#advanced-concepts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The function of the FMR-1 gene product is not fully understood. The FMR protein has domains similar to those of RNA binding proteins. Based on these observations, FMR may control expression of other genes by binding to certain RNA structures and preventing translation. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mrow><mn>35</mn><mo separator="true">,</mo><mn>36</mn></mrow></msup></mrow><annotation encoding="application/x-tex">^{35,36}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">35</span><span class="mpunct mtight">,</span><span class="mord mtight">36</span></span></span></span></span></span></span></span></span></span></span></span></span></p>
<p>sion, the sequence CAG expands from 9–37 repeats to 38–86 in the Huntington gene. The clinical symptoms of Huntington’s disease include impaired judgment, slurred speech, difficulty in swallowing, abnormal body movements (chorea), personality changes, depression, mood swings, unsteady gait, and an intoxicated appearance. With an onset in the thirties or forties, these symptoms do not become obvious until the fourth or fifth decade of life, usually after family planning. The child of a person with Huntington’s disease has a 50% chance of inheriting the disorder. Genetic counseling, therefore, is important for younger persons with family histories of this disease, especially with regard to having children.</p>
<p>In contrast to fragile X, where the repeat expansion takes place 5′ to the coding sequences, the Huntington expansion occurs within the coding region of the gene. The triplet expansion inserts multiple glutamine residues in the 5′ end of the Huntingtin protein. This causes the</p>
<p>protein to aggregate in plaques, especially in nervous tissue, causing the neurological symptoms seen in this disease. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>12</mn></msup></mrow><annotation encoding="application/x-tex">^{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span></span></span></span></span></span></span></span></span> The expansion does not reach the size of the fragile X expansion and is detectable by standard PCR methods (Fig. 13-20).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="idiopathic-congenital-central-hypoventilation-syndrome">Idiopathic Congenital Central Hypoventilation Syndrome<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#idiopathic-congenital-central-hypoventilation-syndrome" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Idiopathic congenital central hypoventilation syndrome (CCHS) is a rare pediatric disorder characterized by inadequate breathing while asleep. More-affected children may also experience hypoventilation while awake. CCHS occurs in association with an intestinal disorder called Hirschsprung’s disease and symptoms of diffuse autonomic nervous system dysregulation/dysfunction. A number of gene mutations have been observed in CCHS, including a polyalanine expansion of the paired-like homeobox (PHOX2b) gene (4p12)13. The Phox2b protein is a transcription factor containing a domain (homeobox) similar to other proteins that bind DNA.</p>
<p>In CCHS a triplet repeat expansion occurs inside of the PHOX2b gene, resulting in the insertion of multiple alanine residues into the protein. The severity of the disease increases with increasing numbers of repeats. The expansion is detected by PCR (Fig. 13-21). <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>14</mn></msup></mrow><annotation encoding="application/x-tex">^{14}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">14</span></span></span></span></span></span></span></span></span></span></span></span></span></p>
<p>CCHS is usually apparent at birth. In some children, a late onset of the disease occurs at 2–4 years of age. An estimated 62%–98% of patients with CCHS have the PHOX2b gene mutation. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>15</mn></msup></mrow><annotation encoding="application/x-tex">^{15}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">15</span></span></span></span></span></span></span></span></span></span></span></span></span></p>
<p><img src="assets/images/image-20251222-cd7312b8.jpeg" alt="img-329.jpeg">
Figure 13-20 The Huntingtin repeat expansion occurs within the coding region of the Huntingtin gene. The expansion is detected directly by PCR using primers flanking the expanded region (top). A <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>32</mn></msup><mi mathvariant="normal">P</mi></mrow><annotation encoding="application/x-tex">^{32}\mathrm{P}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">32</span></span></span></span></span></span></span></span></span><span class="mord mathrm">P</span></span></span></span></span>-labeled primer is used, and the bands are detected by autoradiography of the polyacrylamide gel (bottom). In this example, PCR products from the patient (P) fall within the normal range with the negative control (-). The positive control (+) displays the band sizes expected in Huntington’s disease. (Photos courtesy of Dr. Elizabeth Berry-Kravis, Rush University Medical Center.)</p>
<p>Copyright ©2007 by F. A. Davis.
Molecular Detection of Inherited Diseases Chapter 13 325</p>
<p><img src="assets/images/image-20251222-fe55c835.jpeg" alt="img-330.jpeg">
Figure 13-21 The triplet repeat expansion of PHOX2b includes triplets that code for alanine (top). The expansion is detected by PCR with a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>32</mn></msup><mi mathvariant="normal">P</mi></mrow><annotation encoding="application/x-tex">^{32}\mathrm{P}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">32</span></span></span></span></span></span></span></span></span><span class="mord mathrm">P</span></span></span></span></span>-labeled primer and polyacrylamide gel electrophoresis (center) or by standard PCR and agarose gel electrophoresis (bottom). Normal specimens yield a single PCR product. CCHS specimens yield another larger product in addition to the normal product. The standard PCR test can rapidly show the presence of the expansion, and the PAGE test allows determination of the exact number of alanine codons that are present in the expansion. (Photos courtesy of Dr. Elizabeth Berry-Kravis, Rush University Medical Center.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="other-triplet-expansion-disorders">Other Triplet Expansion Disorders<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#other-triplet-expansion-disorders" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Fragile X, Huntington's disease, and CCHS are three of a group of diseases caused by trinucleotide repeat disorders. This category of diseases is subclassified into polyglutamine expansion disorders, which includes Huntington's disease, and nonpolyglutamine expansion disorders, examples of which are listed in Table 13.8.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="genomic-imprinting">Genomic Imprinting<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#genomic-imprinting" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Genomic imprinting is transcriptional silencing through histone or DNA modification. Imprinting occurs during egg and sperm production and is different in DNA brought in by the egg or the sperm upon fertilization. The difference is exhibited in genetic disorders in which one or the other allele of a gene is lost.</p>
<p>Uniparental disomy/deletion demonstrates the nature of imprinting on chromosome 15. A deletion in the paternal chromosome 15, del(15)(q11q13), causes Prader-Willi syndrome. Symptoms of this disorder include mental retardation, short stature, obesity, and hypogonadism. Loss of the same region from the maternal chromosome 15 results in Angelman's syndrome, a disorder with very different symptoms, including ataxia, seizures, and inap-</p>
<table><thead><tr><th>Disorder</th><th>Gene</th><th>Repeat</th><th>Expansion, (Normal) – (Symptomatic)*</th></tr></thead><tbody><tr><td>Fragile XE</td><td>Fragile X mental retardation 2 (Xq28)</td><td>GCC</td><td>(6–35) – (over 200)</td></tr><tr><td>Friedreich’s ataxia</td><td>Frataxin, FRDA or X25 (9q13)</td><td>GAA</td><td>(7–34) – (over 100)</td></tr><tr><td>Myotonic dystrophy</td><td>Dystrophia myotonica protein kinase (9q13.2–13.3)</td><td>CTG</td><td>(5–37) – (over 50)</td></tr><tr><td>Spinocerebellar ataxia type 8</td><td>Spinocerebellar ataxia type 8 (13q21)</td><td>CTG</td><td>(16–37) – (110–250)</td></tr><tr><td>Spinocerebellar ataxia type 12†</td><td>Spinocerebellar ataxia type 12 (5q31–33)</td><td>CAG</td><td>(7–28) – (66–78)</td></tr></tbody></table>
<p>*The phenotypic effects of intermediate numbers of repeats is not known.
†Although CAG codes for glutamine, this expansion occurs outside of the coding region of this gene and is not translated.</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<p>propriate laughter. Both syndromes can occur in four ways: a deletion on the paternal or maternal chromosome 15, a mutation on the paternal or maternal chromosome 15, a translocation with loss of the critical region from one chromosome, and maternal or paternal uniparental disomy in which both chromosomes 15 are inherited from the mother and none from the father or vice versa.</p>
<p>Cytogenetic methods are still used to test for these genetic lesions. Translocations and some deletions are detectable by standard karyotyping. High resolution karyotyping can detect smaller deletions; however, other cases are not detectable microscopically. Newer methods such as FISH with labeled probes to the deleted region[16] can detect over  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>99</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">99\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">99%</span></span></span></span></span>  of cases. PCR of RFLP or STR analysis has been used to demonstrate uniparental disomy.[17] As imprinting (DNA methylation) is different on maternal and paternal chromosomes, methylation-specific  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">R</mi></mrow><mn>18</mn></msup></mrow><annotation encoding="application/x-tex">\mathrm{PCR}^{18}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8873em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PCR</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8873em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">18</span></span></span></span></span></span></span></span></span></span></span></span></span>  and Southern blot using methylation-specific restriction enzymes[19] have also been proposed as methods to aid in the diagnosis of these disorders.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="multifactorial-inheritance">Multifactorial Inheritance<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#multifactorial-inheritance" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Most disorders (and normal conditions) are controlled by multiple genetic and environmental factors. Multifactorial inheritance is displayed as a continuous variation in populations, with normal distribution, rather than as a specific inheritance pattern. Nutritional or chemical exposures alter this distribution. The range may be discontinuous, with a threshold of manifestation. The phenotypic expression is conditioned by the number of controlling genes inherited. The chance of a first-degree relative having a similar phenotype is  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi><mo>−</mo><mn>7</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2\% - 7\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.0833em;"></span><span class="mord">2%</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">7%</span></span></span></span></span> .</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="limitations-to-molecular-testing">Limitations to Molecular Testing<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#limitations-to-molecular-testing" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Although molecular testing for inherited diseases is extremely useful for early diagnosis and genetic counseling, there are circumstances in which genetic testing may not be the optimal methodology. To date, most therapeutic targets are phenotypic so that treatment is better directed to the phenotype. In genes with variable expressivity, finding a gene mutation may not predict the severity of the phenotype. For instance, clotting time and transferrin saturation are better guides for anticoagulant treatment than the demonstration of the causative gene mutations.</p>
<p>Molecular testing may discover genetic lesions in the absence of symptoms. This raises a possible problem as to whether treatment is indicated. Finally, most diseases are caused by dysfunction of multicomponent systems so that several genetic lesions may be present or polymorphic states of other normal genes may influence the disease state. As array technology and haplotype mapping designed to scan at the genomic level are further developed, these methods may contribute to better diagnosis of complex diseases.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="7e5f0ce8">Case Study 13·1<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#7e5f0ce8" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A young mother was worried about her son. Having observed others, she was very aware of how her baby was expected to grow and acquire basic skills. As the child grew, however, he showed signs of slow development. His protruding ears and long face were becoming more noticeable as well. The pediatrician recommended chromosomal analysis for the mother and child. A constriction at the end of the X chromosome was found in the son's karyotype. The mother's karyotype was normal 46,XX. A Southern blot analysis for Fragile X was performed on a blood specimen from the mother, but showed not obvious abnormality. PCR analysis produced the following results:</p>
<p><img src="assets/images/image-20251222-b186966c.jpeg" alt="img-331.jpeg">
PCR analysis of the FMR promoter region showing two normal patterns (lanes 1 and 2) and the mother's pattern.</p>
<p>Copyright ©2007 by F. A. Davis.
Molecular Detection of Inherited Diseases Chapter 13 327</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="b7768d0e">Case Study 13 • 2<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b7768d0e" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A 14-year-old girl with muscle weakness and vision difficulties (retinopathy) was referred for clinical tests. A muscle biopsy was performed, and aberrant mitochondria were observed in thin sections. Histochemical analysis of the muscle tissue revealed cytochrome oxidase deficiency in the muscle cells. A skeletal muscle biopsy specimen was sent to the molecular genetics laboratory for analysis of mitochondrial DNA. Southern blot analysis of PvuII cut mitochondrial DNA exhibited a band at 16,000 bp in addition to the normal mitochondrial band at 16,500 bp as shown below:</p>
<p><img src="assets/images/image-20251222-a85e9261.jpeg" alt="img-332.jpeg"></p>
<p>Southern blot of mitochondrial DNA uncut (U) and cut with PvuII (C). Lanes 1 and 2, normal control; lanes 3 and 4, patient. Arrow points to a 16,000 kb band.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cab50d80">Case Study 13 • 3<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cab50d80" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A 40-year-old man was experiencing increasing joint pain, fatigue, and loss of appetite. He became alarmed when he suffered heart problems and consulted his physician. Routine blood testes revealed high serum iron (900 µg/dL) and 80% transferrin saturation. Total iron binding capacity was low (100 µg/dL). The man denied any extensive alcohol intake. A blood specimen was sent to the molecular genetics laboratory for analysis. The results are shown below:</p>
<p><img src="assets/images/image-20251222-ab2816ca.jpeg" alt="img-333.jpeg"></p>
<p>PCR-RFLP analysis of exon 4 of the HFE gene. The PCR product contains 1 recognition site for the restriction enzyme, RsaI. An additional RsaI site is created by the C282Y (G→A) mutation, the most common inherited mutation in hemochromatosis. This extra site results in a fragments of 240 bp, 110 bp (arrow) and ← 30 bp (not shown) instead of the 240 bp and 140 bp normal fragments. Lane 1, molecular weight markers; lane 2, normal control; lane 3, homozygous C282Y; lane 4, heterozygous C282Y; lane 5, patient specimen; lane 6, reagent blank.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="bddf2e27">Case Study 13 • 4<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#bddf2e27" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A 30-year-old woman was brought to the emergency room with a painfully swollen left leg. She informed the nurses that she was taking contraceptives. Deep vein thrombosis was suspected, and compression ultrasound was ordered to look for pulmonary embolism. A clotting test for APC resistance resulted in a 1.5 ratio of clotting time with and without APC. An ELISA test for D-dimer was positive. The patient was immediately treated with heparin, and blood samples were taken. A blood sample was sent to the molecular genetics laboratory to test for the factor V Leiden 1691 G→A mutation and prothrombin 20210 G→A mutations. The results are shown below:</p>
<p>(continued on following page)</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="continued">(continued)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#continued" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><img src="assets/images/image-20251222-f153ab3d.jpeg" alt="img-334.jpeg"></p>
<p>Agarose gel electrophoresis showing the band pattern for prothombin 20210/factor V Leiden mutation detection by multiplex SSP-PCR-RFLP. Specimens were cut with HindIII. Lane 1, molecular weight marker; lane 2, normal control (prothrombin, 407 bp + 99 bp, factor V, 241 bp); lane 3, heterozygous control, prothrombin (407, 384, 99, 23 bp)/factor V Leiden (241, 209, 323 bp); lane 4, homozygous factor V Leiden, normal prothrombin; lane 5, homozygous prothrombin 20210 mutation/normal factor V; lane 6, patient specimen; lanes 7 and 8, normal specimens.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="study-questions">STUDY QUESTIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#study-questions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Which of the following is not a triplet repeat expansion disorder?</li>
</ol>
<p>a. Fragile X syndrome
b. Huntington's disease
c. Factor V Leiden
d. Congenital central hypoventilation syndrome</p>
<ol start="2">
<li>
<p>A gene was mapped to region 3, band 1, subband 1, of the long arm of chromosome 2. How would you express this location from an idiogram?</p>
</li>
<li>
<p>Which of the following can be detected by PCR?</p>
</li>
</ol>
<p>a. Large mitochondrial deletions
b. Full fragile X disorder
c. Mitochondrial point mutations</p>
<ol start="4">
<li>A patient was tested for Huntington's disease. PCR followed by PAGE revealed 25 CAG units.</li>
</ol>
<p>a. This patient has Huntington's disease
b. This patient has a 1/25 chance of contracting Huntington's disease
c. This patient is normal at the Huntington locus
d. The test is inconclusive</p>
<ol start="5">
<li>The factor V Leiden mutation can be detected by:</li>
</ol>
<p>a. PCR-RFLP
b. SSP-PCR
c. Invader technology
d. All of the above methods</p>
<ol start="6">
<li>
<p>The most frequently occurring mutation in the HFE gene results in the replacement of cysteine (C) with tyrosine (Y) at position 282. How is this expressed according to the recommended nomenclature?</p>
</li>
<li>
<p>MELAS is a disease condition that results from an A to G mutation at position 3243 of the mitochondrial genome. This change creates a single ApaI restriction site in a PCR product, including the mutation site. What would you expect from a PCR-RFLP analysis for this mutation on a patient with MELAS?</p>
</li>
</ol>
<p>a. A single PCR product resistant to digestion with ApaI
b. A single PCR product that cuts into two fragments upon digestion with ApaI
c. A single PCR product only if the mutation is present
d. Two PCR products</p>
<ol start="8">
<li>A father affected with a single gene disorder and an unaffected mother have four children (three boys and</li>
</ol>
<p>Copyright ©2007 by F. A. Davis.
Molecular Detection of Inherited Diseases Chapter 13 329</p>
<p>a girl), two of whom (one boy and the girl) are affected. Draw the pedigree diagram for this family.</p>
<p>D16S539, an STR, was analyzed in the family. The result showed that the father had the 6,8 alleles, the mother had the 5,7 alleles. The affected children had the 5,6 and 6,7 alleles, and the unaffected children had the 5,8 and 7,8 alleles.</p>
<p>a. If D16S539 is located on chromosome 16, where is the gene for this disorder likely to be located?
b. To which allele of D16S539 is the gene linked? How might one perform a DNA analysis for the presence of the disorder?</p>
<p>a. Analyze D16S539 for the 6 allele by PCR
b. Sequence the entire region of the chromosome where D16S539 was located
c. Test as many STRs as possible by PCR
d. Use Invader technology to detect the unknown gene mutation.</p>
<ol start="9">
<li>Exon 4 of the HFE gene from a patient suspected of having hereditary hemachromatosis was amplified by PCR. The G to A mutation, frequently found in hemachromatosis, creates an Rsa1 site in exon 4. When the PCR products are digested with Rsa1, which of the following results would you expect to see if the patient has the mutation?</li>
</ol>
<p>a. None of the PCR products will be cut by Rsa1
b. There will be no PCR product amplified from the patient DNA
c. The patient's PCR product will yield extra bands upon Rsa1 digestion
d. The normal control PCR products will yield extra Rsa1 bands compared with the patient sample Rsa1 will not distinguish normal from mutant.</p>
<ol start="10">
<li>Most people with the C282Y or H63D HFE gene mutations develop hemachromatosis symptoms. This is a result of:</li>
</ol>
<p>a. Iron loss
b. Excessive drinking
c. High penetrance
d. Healthy lifestyle
e. Glycogen accumulation</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="references">References<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#references" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>
<p>Cotran RS, Kumer V, Collins T. Robbins Pathological Basis of Disease, 6th ed. Philadelphia: W. B. Saunders, 1999.</p>
</li>
<li>
<p>Huber S, McMaster KJ, Voelkerding KV. Analytical evaluation of primer engineered multiplex polymerase chain reaction–restriction fragment length polymorphism for detection of factor V Leiden and prothrombin G20210A. Journal of Molecular Diagnostics 2000;2:153–57.</p>
</li>
<li>
<p>Kerem B, Buchanan JA, Durie P, et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. American Journal of Human Genetics 1989;44:827–34.</p>
</li>
<li>
<p>Orlando R, Piccoli P, De Martin S, et al. Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function. British Journal of Clinical Pharmacology 2003;55:86–93.</p>
</li>
<li>
<p>Orlando R, Piccoli P, De Martin S, et al. Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: Effects of liver function. Clinical Pharmacology and Therapeutics 2004;75:80–88.</p>
</li>
<li>
<p>Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. Journal of the National Cancer Institute 2005; 97:30–39.</p>
</li>
<li>
<p>Granfors M, Backman JT, Laitila J, et al. Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. Clinical Pharmacology and Therapeutics 2005;78:400–11.</p>
</li>
<li>
<p>Brandon M, Lott MT, Nguyen KC, et al. MITOMAP: A human mitochondrial genome database—2004 update. <em>Nucleic Acids Research</em> 2005;33: D611–D13.</p>
</li>
<li>
<p>Leonard J, Schapira AH. Mitochondrial respiratory chain disorders I: Mitochondrial DNA defects. Lancet 2000;355:299–304.</p>
</li>
<li>
<p>Leonard J, Schapira AH. Mitochondrial respiratory chain disorders II: Neurodegenerative disorders and nuclear gene defects. Lancet 2000;355: 389–94.</p>
</li>
<li>
<p>Moraes C, Atencio DP, Oca-Cossio J, et al. Techniques and pitfalls in the detection of pathogenic mitochondrial DNA mutations. Journal of Molecular Diagnostics 2003;5:197–208.</p>
</li>
</ol>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<ol start="12">
<li>
<p>Marx J. Huntington's research points to possible new therapies. Science 2005;310:43-45.</p>
</li>
<li>
<p>Amiel J, Laudier B, Attié-Bitach T, et al. Polyalanine expansion and frameshift mutations of the paired-like homeobox gene PHOX2b in congenital central hypoventilation syndrome. Nature Genetics 2003;33:459-61.</p>
</li>
<li>
<p>Weese-Mayer D, Berry-Kravis EM, Zhou L, et al. Idiopathic congenital central hypoventilation syndrome: Analysis of genes pertinent to early autonomic nervous system embryologic development and identification of mutations in PHOX2b. American Journal of Medical Genetics 2003; 123A:267-78.</p>
</li>
<li>
<p>D'Alessandro V, Mason II TBA, Pallone MN, et al. Late-onset hypoventilation without PHOX2b mutation or hypothalamic abnormalities. Journal of Clinical Sleep Medicine 2005;1:169-72.</p>
</li>
<li>
<p>Nieuwint A, Van Hagen JM, Heins YM, et al. Rapid detection of microdeletions using fluorescence in situ hybridisation (FISH) on buccal smears. Journal of Medical Genetics 2000;37:e4.</p>
</li>
<li>
<p>Mutirangura A, Greenberg F, Butler MG, et al. Multiplex PCR of three dinucleotide repeats in the Prader-Willi/Angelman critical region (15q11-q13): Molecular diagnosis and mechanism of uniparental disomy. Human Molecular Genetics 1993;2:143-51.</p>
</li>
<li>
<p>Chotai K, Payne SJ. A rapid, PCR-based test for differential molecular diagnosis of Prader-Willi and Angelman syndromes. Journal of Medical Genetics 1998;35:472-75.</p>
</li>
<li>
<p>Glenn C, Saitoh S, Jong MT, et al. Gene structure, DNA methylation, and imprinted expression of the human SNRPN gene. American Journal of Human Genetics 1996;58:335-46.</p>
</li>
<li>
<p>Toudjarska I, Kilpatrick MW, Lembessis P, et al. Novel approach to the molecular diagnosis of Marfan syndrome: Application to sporadic cases and in prenatal diagnosis. American Journal of Medical Genetics 2001;99:294-302.</p>
</li>
<li>
<p>Upadhyaya M, Maynard J, Rogers MT, et al. Improved molecular diagnosis of facioscapulohumeral muscular dystrophy (FSHD): Validation of the differential double digestion for FSHD. Journal of Medical Genetics 1997;34:476-79.</p>
</li>
<li>
<p>Wang J, Ban MR, Hegele RA. Multiplex ligation-dependent probe amplification of LDLR enhances molecular diagnosis of familial hypercholesterolemia. Journal of Lipid Research 2005;46:366-72.</p>
</li>
<li>
<p>Ramos S, Hernandez M, Roces A, et al. Molecular diagnosis of alkaptonuria mutation by analysis of homogentisate 1,2 dioxygenase mRNA from urine and blood. American Journal of Medical Genetics 1998;78:192-94.</p>
</li>
<li>
<p>Felbor U, Mutsch Y, Grehn F, et al. Ocular ochronosis in alkaptonuria patients carrying mutations in the homogentisate 1,2-dioxygenase gene. British Journal of Ophthalmology 1999; 83:680-83.</p>
</li>
<li>
<p>Landegren U, Kaiser R, Sanders J, et al. A ligase-mediated gene detection technique. Science 1988; 24:1077-80.</p>
</li>
<li>
<p>Tuchman M. Molecular diagnosis of medium-chain acyl-coA dehydrogenase deficiency by oligonucleotide ligation assay. Clinical Chemistry 1998;44: 10-11.</p>
</li>
<li>
<p>Carlucci F, Tabucchi A, Aiuti A, et al. Capillary electrophoresis in diagnosis and monitoring of adenosine deaminase deficiency. Clinical Chemistry 2003;49:1830-38.</p>
</li>
<li>
<p>Zeviani M, Moraes CT, DiMauro S, et al. Deletions of mitochondrial DNA in Kearnes-Sayre syndrome. Neurology 1988;38:1339-46.</p>
</li>
<li>
<p>De Coo I, Gussinklo T, Arts PJ, et al. A PCR test for progressive external ophthalmoplegia and Kearns-Sayre syndrome on DNA from blood samples. Journal of Neurological Science 1997; 149:37-40.</p>
</li>
<li>
<p>Raffelsberger T, Rossmanith W, Thaller-Antlanger H, et al. CPEO associated with a single nucleotide deletion in the mitochondrial tRNATyr gene. <em>Neurology</em> 2001;57:2298-301.</p>
</li>
<li>
<p>Moraes C, DiMauro S, Zeviani M, et al. Mitochondrial DNA deletions in progressive external ophthalmoplegia and Kearns-Sayre syndrome. New England Journal of Medicine 1989;320:1293-99.</p>
</li>
<li>
<p>Kiechl S, Horváth R, Luoma P, et al. Two families with autosomal-dominant progressive external ophthalmoplegia. Journal of Neurology Neurosurgery and Psychiatry 2004;75:1125-28.</p>
</li>
</ol>
<p>Copyright ©2007 by F. A. Davis.
Molecular Detection of Inherited Diseases Chapter 13 331</p>
<ol start="33">
<li>Anderson J. The Lyon hypothesis. British Medical Journal 1963;5367:1215–16.</li>
<li>Davidson R. The Lyon hypothesis. Journal of Pediatrics 1964;65:765–75.</li>
<li>Sohn E. Fragile X’s missing partners identified. Science 2001;294:1809.</li>
<li>Moine H, Mandel J-L. Do G quartets orchestrate fragile X pathology? Science 2001;294:2487–88.</li>
</ol>
<p>Copyright ©2007 by F. A. Davis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="14">14<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#14" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-14">Chapter 14<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-14" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Lela Buckingham</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="molecular-oncology">Molecular Oncology<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#molecular-oncology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="outline">OUTLINE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#outline" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>CLASSIFICATION OF NEOPLASMS</li>
<li>MOLECULAR BASIS OF CANCER</li>
<li>ANALYTICAL TARGETS OF MOLECULAR TESTING</li>
<li>Gene and Chromosomal Mutations in Solid Tumors</li>
<li>Microsatellite Instability</li>
<li>Loss of Heterozygosity</li>
<li>GENE REARRANGEMENTS IN LEUKEMIA AND LYMPHOMA</li>
<li>V(D)J Recombination</li>
<li>Detection of Clonality</li>
<li>Translocations in Hematological Malignancies</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="objectives">OBJECTIVES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#objectives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Identify checkpoints in the cell division cycle that are critical for regulated cell proliferation.</li>
<li>List molecular targets that are useful for diagnosing and monitoring solid tumors.</li>
<li>Explain how microsatellite instability is detected.</li>
<li>Describe loss of heterozygosity and its detection.</li>
<li>Contrast cell-specific and tumor-specific molecular targets.</li>
<li>Show how clonality is detected using antibody and T-cell receptor gene rearrangements.</li>
<li>Describe translocations associated with hematological malignancies that can be used for molecular testing.</li>
<li>Interpret data obtained from the molecular analysis of patients' cells, and determine if a tumor population is present.</li>
</ul>
<p>Oncology is the study of tumors. A tumor, or neoplasm, is a growth of tissue that exceeds and is not coordinated with normal tissue. Tumors are either benign (not recurrent) or malignant (invasive and tending to recur at multiple sites). Cancer is a term that includes all malignant tumors. Molecular oncology is the study of cancer at the molecular level, using techniques that allow direct detection of genetic alterations, down to single base pair changes.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="classification-of-neoplasms">Classification of Neoplasms<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification-of-neoplasms" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Cancer is generally divided into two broad groups, solid tumors and hematological malignancies. Solid tumors are designated according to the tissue of origin as carcinomas (epithelial) or sarcomas (bone, cartilage, muscle, blood vessels, fat). Teratocarcinomas consist of multiple cell types. Benign tumors are named by adding the suffix “-oma” directly to the tissue of origin. For example, an adenoma is a benign glandular growth. An adenocarcinoma is malignant.</p>
<p>Metastasis is the movement of dislodged tumor cells from the original (primary) site to other locations. Only malignant tumors are metastatic. No one characteristic of the primary tumor predicts the likelihood of metastasis. Both tumor and normal cell factors are involved. The presence of metastasis increases the difficulty of treatment. Clinical analysis may be performed to detect the presence of relocated or circulating metastasized cells to aid in treatment strategy.</p>
<p>With regard to hematological malignancies, tumors arising from white blood cells are referred to as leukemias and lymphomas. Leukemia is a neoplastic disease of blood-forming tissue in which large numbers of white blood cells populate the bone marrow and peripheral blood. Lymphoma is a neoplasm of lymphocytes that forms discrete tissue masses. The difference between these diseases is not clear, as lymphocytic leukemias and lymphomas can display bone marrow and blood symptoms similar to those of leukemias. Furthermore, chronic lymphomas can progress to leukemia. Conversely, leukemias can display lymphomatous masses without overpopulation of cells in the bone marrow.</p>
<p>Within lymphomas, Hodgkin's disease is a histologically and clinically different disease than all other types of lymphoma, termed non-Hodgkin's lymphoma (NHL). Plasma cell neoplasms, which arise from terminally differentiated B cells, are also classified in a separate category. Some of the physiological symptoms of plasma cell tumors are related to the secretion of immunoglobulin fragments by these tumors.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="advanced-concepts">Advanced Concepts<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#advanced-concepts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>As imaging technology advanced, several efforts were made for classification of NHL. The earliest was the Rappaport classification in 1966, developed at the Armed Forces Institute of Pathology. The Keil classification, used in Europe, and the Lukes and Collins classification, used in the United States, were proposed in 1974. In 1982 an international group of hematopathologists proposed the Working Formulation for Clinical Usage for classification of NHL.139 The Working Formulation was revised in 1994 by the International Lymphoma Study Group, which proposed the World Health Organization/ Revised European-American Classification of Lymphoid Neoplasms (REAL). The REAL classification included genetic characteristics in addition to morphological tissue architecture. With increasing ability to detect molecular characteristics of cells, including patterns of gene expression, classification will continue to evolve.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="molecular-basis-of-cancer">Molecular Basis of Cancer<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#molecular-basis-of-cancer" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Cancer is caused by nonlethal mutations in DNA. The mutations affect two types of genes: oncogenes and tumor suppressor genes. These genes control the cell division cycle (Fig. 14-1).</p>
<p>Oncogenes promote cell division. Oncogenes include cell membrane receptors that are bound by growth factors, hormones, and other extracellular signals. These receptors transduce signals through the cell membrane into the cytoplasm through a series of protein modifications that ultimately reach the nucleus and activate factors that initiate DNA synthesis (move the cell from G1 to S phase of the cell cycle) or mitosis (move from G2 to M). Oncogenes also support cell survival by inhibiting apoptosis, or self-directed cell death. More than 100 oncogenes have been identified in the human genome.</p>
<p>Tumor suppressors slow down or stop cell division. Tumor suppressors include factors that control transcri</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<p><img src="assets/images/image-20251222-6c7acdf3.jpeg" alt="img-335.jpeg">
Figure 14-1 The cell division cycle. After mitosis (M), there are two haploid (one diploid) complements of chromosomes (46 chromosomes) in the G1 phase of the cell division cycle. DNA is replicated during the S phase, resulting in four haploid (two diploid) complements in the G2 phase. The chromosomes are distributed to two daughter cells at mitosis each receiving 46 chromosomes. Cancer results when the cell division cycle proceeds from G1 to S or G2 to M phase inappropriately.</p>
<p>tion, or translation of genes required for cell division. Tumor suppressors also participate in repairing DNA damage and in promoting apoptosis. Tumor suppressors counteract the movement of the cell from G1 to S or G2 to M phase. These two points are therefore referred to as the G1 checkpoint and G2 checkpoint in the cell division cycle. More than 30 tumor suppressor genes have been identified.</p>
<p>In cancer cells, mutations in oncogenes are usually gain of function mutations, resulting from amplification or translocation of DNA regions containing the genes or activating mutations that cause aberrant activity of the proteins. Mutations in tumor suppressor genes are usually loss of function mutations, resulting in inactivation of the tumor suppressor gene products. These mutations may occur through deletion, translocation, or mutation of the genes. Molecular laboratory testing aids in the diagnosis and treatment strategies for tumors by detecting abnormalities in specific tumor suppressors or oncogenes.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="analytical-targets-of-molecular-testing">Analytical Targets of Molecular Testing<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#analytical-targets-of-molecular-testing" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Although not yet completely standardized, several tests are performed in almost every molecular pathology labo</p>
<p>ratory. These include tests that target tissue-specific or tumor-specific genes. Tissue-specific targets are molecular characteristics of the type of tissue from which a tumor arose. The presence of DNA or RNA from these targets in abnormal amounts or locations is used to detect and monitor the presence of the tumor. For example, molecular tests are designed to detect DNA or RNA from cytokeritin genes in gastric cancer, carcinoembryonic antigen in breast cancer, and rearranged immunoglobulin or T-cell receptor genes in lymphoma. Although tissue-specific markers are useful, they are also expressed by normal cells, and their presence does not always prove the presence of cancer.</p>
<p>In contrast, tumor-specific genes are not expressed in normal cells and are, therefore, more definitive with respect to the presence of tumor. Tumor-specific genetic structures result from genome, chromosomal, or gene abnormalities in oncogenes and tumor suppressor genes that are associated with the development of the tumor. Gene mutations and chromosomal translocations are found in solid tumors, leukemias, and lymphomas. Genome mutations, or aneuploidy, result in part from the loss of coordinated DNA synthesis and cell division that occurs when tumor suppressors or oncogenes are dysfunctional. Research is ongoing to find more of these</p>
<p>Copyright ©2007 by F. A. Davis.
Molecular Oncology Chapter 14 335</p>
<p>tumor-specific markers to improve molecular oncology testing.</p>
<p>The following sections describe procedures most commonly performed in molecular pathology laboratories; however, due to the rapid advances in this area, the descriptions cannot be all-inclusive. The discussion is divided into solid tumor testing and testing for hematological malignancies. As will be apparent, however, some tests are applicable to both types of malignancies.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="gene-and-chromosomal-mutations-in-solid-tumors">Gene and Chromosomal Mutations in Solid Tumors<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#gene-and-chromosomal-mutations-in-solid-tumors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A number of tests are routinely performed to aid in the diagnosis, characterization, and monitoring of solid tumors. Some of these tests have been part of molecular pathology for many years. Others are relatively new to the clinical laboratory. The methods applied to detect molecular characteristics of tumors are described in Chapters 6–10 of this text.</p>
<ul>
<li>Human Epidermal Growth Factor Receptor 2, HER2/neu/erb-b2 1 (17q21.1)</li>
</ul>
<p>HER2/neu was discovered in rat neuro/glioblastoma cell lines in 1985.¹ Later it was found to be the same gene</p>
<p>as the avian erythroblastic leukemia viral oncogene homolog 2, or ERBB2, which codes for a 185-kd cell membrane protein that adds phosphate groups to tyrosines on itself and other proteins (tyrosine kinase activity). This receptor is one of several transmembrane proteins with tyrosine kinase activity (Fig. 14-2). It is very similar to a family of epidermal growth factor receptors that are overexpressed in some cancers² (Fig. 14-3).</p>
<p>In normal cells, this protein is required for cells to grow and divide. HER2/neu is overexpressed in 25%–30% of human breast cancers, in which overexpression of HER2/neu is a predictor of a more aggressive growth and metastasis of the tumor cells. It is also an indication for use of anti-HER2/neu antibody drug, Herceptin (trastuzumab) therapy, which works best on tumors overexpressing HER2/neu. Herceptin therapy is indicated presently for women with HER2/neu-positive (HER2/neu overexpressed) breast cancer that has spread to lymph nodes or other organs.</p>
<p>Of all testing for the overexpression of the HER2/neu oncogene, 80%–95% is performed by immunohistochemistry (IHC) using monoclonal and polyclonal antibodies to detect the HER2/neu protein. The HercepTest was developed by Dako and Genentech as a method to define conditions for performance and interpretation of</p>
<p><img src="assets/images/image-20251222-083060a3.jpeg" alt="img-336.jpeg"></p>
<p>Figure 14-2 Receptor tyrosine kinases include epidermal growth factor receptor (EGFR), insulin growth factor receptor (IGFR), nerve growth factor receptor (NGFR), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR), and ephrin receptor (EPHR). These molecules share similarities in that they include a kinase domain, transmembrane domain, cysteine-rich domain, and immunoglobulin-like domain. The EPH receptor has two fibronectin type III domains.</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<p><img src="assets/images/image-20251222-ca2c7546.jpeg" alt="img-337.jpeg">
Cytoplasm
Figure 14-3 The ErbB family of growth factor receptors includes the HER2 receptor and EGFR. The factors that bind to these receptors on the cell surface begin a cascade of events including autophosphorylation and phosphorylation of other proteins by the receptors. These factors include the epidermal growth factor (EGF), human transforming growth factor alpha (TGF- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> ), heregulins, and neuregulins (NRG). EGF, NRG heregulins are small peptides that are active in the development of various cell types such as gastric mucosa, the heart, and the nervous system.</p>
<p>the IHC test. The IHC test, which is cheaper and more readily available in most institutions, works best on fresh or frozen tissue. Fluorescent in situ hybridization (FISH), which measures DNA and RNA of  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>H</mi><mi>E</mi><mi>R</mi><mn>2</mn><mi mathvariant="normal">/</mi><mi>n</mi><mi>e</mi><mi>u</mi></mrow><annotation encoding="application/x-tex">HER2/neu</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span><span class="mord mathnormal" style="margin-right: 0.00773em;">ER</span><span class="mord">2/</span><span class="mord mathnormal">n</span><span class="mord mathnormal">e</span><span class="mord mathnormal">u</span></span></span></span></span> , is more reliable than IHC, especially in older, fixed tissue, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mrow><mn>3</mn><mo separator="true">,</mo><mn>4</mn></mrow></msup></mrow><annotation encoding="application/x-tex">^{3,4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span><span class="mpunct mtight">,</span><span class="mord mtight">4</span></span></span></span></span></span></span></span></span></span></span></span></span>  but is less readily available.</p>
<p>Southern, Northern, and Western studies have shown that HER2/neu gene amplification is highly correlated with the presence of increased HER2/neu RNA and protein. In contrast to IHC, which measures increased amounts of HER2/Neu protein, FISH directly detects increased copy numbers of the HER2/neu gene in DNA. HER2/neu gene amplification occurs as a result of tandem duplication of the gene or other genetic events as the tumor cells continue to divide. FISH testing for HER2/neu gene amplification requires a labeled probe for the HER2/neu gene and a differently labeled control probe for the centromere of chromosome 17. For instance, the PathVysion reagent set (Vysis) includes the HER-2 probe that spans the entire HER2/neu gene labeled in Spectrum</p>
<p>Orange and a CEP 17 probe that binds to the centromere of chromosome 17 labeled in SpectrumGreen. The copy number of  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>H</mi><mi>E</mi><mi>R</mi><mn>2</mn><mi mathvariant="normal">/</mi><mi>n</mi><mi>e</mi><mi>u</mi></mrow><annotation encoding="application/x-tex">HER2/neu</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span><span class="mord mathnormal" style="margin-right: 0.00773em;">ER</span><span class="mord">2/</span><span class="mord mathnormal">n</span><span class="mord mathnormal">e</span><span class="mord mathnormal">u</span></span></span></span></span>  relative to the copy number of CEP 17 indicates whether  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>H</mi><mi>E</mi><mi>R</mi><mn>2</mn><mi mathvariant="normal">/</mi><mi>n</mi><mi>e</mi><mi>u</mi></mrow><annotation encoding="application/x-tex">HER2/neu</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span><span class="mord mathnormal" style="margin-right: 0.00773em;">ER</span><span class="mord">2/</span><span class="mord mathnormal">n</span><span class="mord mathnormal">e</span><span class="mord mathnormal">u</span></span></span></span></span>  is amplified (present in multiple copies on the same chromosome). Data are reported as a ratio of the number of HER2 signals to chromosome 17 centromere signals. A ratio of more than 2 is considered positive or amplified. The number of signals are enumerated in 50-100 cells.</p>
<p>Chromogenic in situ hybridization (CISH) is another method that has been used to detect  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>H</mi><mi>E</mi><mi>R</mi><mn>2</mn><mi mathvariant="normal">/</mi><mi>n</mi><mi>e</mi><mi>u</mi></mrow><annotation encoding="application/x-tex">HER2/neu</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span><span class="mord mathnormal" style="margin-right: 0.00773em;">ER</span><span class="mord">2/</span><span class="mord mathnormal">n</span><span class="mord mathnormal">e</span><span class="mord mathnormal">u</span></span></span></span></span>  gene amplification <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mrow><mn>6</mn><mo separator="true">,</mo><mn>7</mn></mrow></msup></mrow><annotation encoding="application/x-tex">^{6,7}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">6</span><span class="mpunct mtight">,</span><span class="mord mtight">7</span></span></span></span></span></span></span></span></span></span></span></span></span>  CISH is a less expensive method that may be more accessible to community laboratories. Using a standard bright field microscope, CISH technology also detects deletions, translocations, or change in the number of chromosomes. An attractive feature of CISH is that the slide images are permanent, facilitating documentation and consultations. Initially, in situ hybridization with chromogenic detection by gene-specific probes was limited by high background and low signal intensity. Newer highly specific probes with repetitive sequences removed, such as Zymed's Subtraction Probe Technology, were designed to address these limitations. CISH has shown  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>86</mn><mi mathvariant="normal">%</mi><mo>−</mo><mn>96</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">86\% - 96\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.0833em;"></span><span class="mord">86%</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">96%</span></span></span></span></span>  concordance with FISH in comparison studies of  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>H</mi><mi>e</mi><mi>r</mi><mo>−</mo><mn>2</mn><mi mathvariant="normal">/</mi><mi>n</mi><mi>e</mi><mi>u</mi></mrow><annotation encoding="application/x-tex">Her-2/neu</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord mathnormal" style="margin-right: 0.02778em;">Her</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2/</span><span class="mord mathnormal">n</span><span class="mord mathnormal">e</span><span class="mord mathnormal">u</span></span></span></span></span>  amplification. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>8</mn></msup></mrow><annotation encoding="application/x-tex">^{8}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">8</span></span></span></span></span></span></span></span></span></span></span></span></span></p>
<p>Although FISH and CISH are more accurate and less subjective methods than IHC, IHC is faster, less expensive, and allows the pathologist to assess target gene expression along with other visible landmarks on the slide. Furthermore, protein overexpression (detectable by IHC) can occur without gene amplification (detectable by ISH). Some laboratories use IHC as an initial screening method and then confirm results with FISH or CISH.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="epidermal-growth-factor-receptor-egfr-7p12">- Epidermal Growth Factor Receptor, EGFR (7p12)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#epidermal-growth-factor-receptor-egfr-7p12" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The epidermal growth factor receptor gene (EGFR, ERBB1) is another member of the ERBB family of growth factor receptors that also includes ERB3/HER3 and ERB4/HER4 (see Fig. 14-3). All of these proteins are located in the cell membrane and form dimers with one another upon binding of growth factor from outside the cell (Fig. 14-4). Binding of growth factors evokes the tyrosine kinase activity of the receptors and initiates proliferation signals through the cell cytoplasm.</p>
<p>EGFR is frequently overexpressed in solid tumors. Overexpression has been correlated with poor clinical outcome in research studies. For this reason the EGF</p>
<p>Copyright ©2007 by F. A. Davis.
Molecular Oncology Chapter 14 337</p>
<p><img src="assets/images/image-20251222-93e69d3c.jpeg" alt="img-338.jpeg">
Figure 14-4 Upon binding by epidermal growth factor (EGF), the EGFR receptor in the cell membrane forms a dimer with itself or with other members of the ERBB family of receptors. The dimerization initiates a cascade of events, starting with phosphorylation of the receptor itself catalyzed by the kinase domain.</p>
<p>receptor has been an attractive target for design of therapeutic drugs. Monoclonal antibodies such as cetuximab (Erbitux) have been developed to block ligand (growth factor) binding to the receptor. Agents have also been designed to inhibit the kinase activity of the receptor. Of these tyrosine kinase inhibitors, erlotinib (Tarceva), gefitinib (Iressa), and sunitinib malate (Sutent) have had the most study in clinical trials.</p>
<p>IHC analysis of EGFR expression, similar to the testing for HER2/neu overexpression, has been used to predict response to monoclonal antibody drugs.9 The Dako Cytomation EGFR PharmDx test kit has been approved by the United States Food and Drug Administration for this application. Interpretation of the results of EGFR expression testing and the predictive value of the test are not always straightforward, however.10 Quantitative real-time polymerase chain reaction (PCR) and FISH analysis have also been proposed as methods to assess EGFR gene copy number.11</p>
<p>One possible predictor of response to tyrosine kinase inhibiting agents is specific mutations found in the kinase domain of the protein.12-15 These mutations can be detected by a number of methods, including sequence-specific PCR, single-strand conformational polymorphism (SSCP), and direct sequencing.12,16,17 To date, detection of mutations in the EGFR kinase region is not yet approved as a clinical test. Testing for predictors</p>
<p>of response or prognosis is complex because several clinical and genetic factors contribute to response to targeted therapies as well as the natural course of the tumor. These include intronic polymorphisms in the EGFR gene,18 expression of other components of the signal transduction pathway,19,20 or other tumor suppressors such as p53.21</p>
<ul>
<li>Kirsten rat sarcoma viral oncogene homolog, K-ras (12p12), Neuroblastoma ras, N-ras (1p13), Harvey rat sarcoma viral oncogene homolog, H-ras (11p15)</li>
</ul>
<p>Signals from extracellular stimuli, such as growth factors or hormones, are transmitted through the cell cytoplasm to the nucleus, resulting in cell proliferation or differentiation (Fig. 14-5). The mitogen-activated protein kinase (MAPK) pathway is a cascade of phosphorylation events that is the major pathway of signal transduction from the cell membrane to the nucleus. Critical compo</p>
<p><img src="assets/images/image-20251222-92264af7.jpeg" alt="img-339.jpeg">
Figure 14-5 Normally, cells grow in the presence of nutrients and factors that stimulate cell division (mitogens). Lack of mitogen stimulation results in cell arrest, or apoptosis. If oncogene or tumor suppressor gene mutations stimulate aberrant growth signals, cells grow in the absence of controlled stimulation.</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<p>nents of this pathway are small proteins that bind to GTP in order to become active. These small GTP binding proteins include the ras genes that receive signals from the cell surface proteins and activate the initial steps of the MAPK cascade (Fig. 14-6). Mutations in ras proto-oncogenes occur in many types of cancers.</p>
<p><img src="assets/images/image-20251222-f6cde67d.jpeg" alt="img-340.jpeg">
Figure 14-6 Activation of membrane-bound K-ras is initiated by activated receptors bound to mitogens (growth factors or hormones). Active K-ras bound to GTP then initiates a cascade of phosphorylation events that end in the nucleus, where transcription factors modulate gene expression. GDP/GTP exchange on K-ras is modulated by GTPase activating proteins (GAPs), guanosine nucleotide exchange factors (GEFs), and guanosine nucleotide dissociation inhibitors (GDIs).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="advanced-concepts">Advanced Concepts<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#advanced-concepts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Regulation of ras GTPase activity is controlled by rasGAP. Several other GAP proteins besides rasGAP are important in signal transduction. Two clinically important proteins of the GAP family of proteins are the gene product of the neurofibromatosis type-1 (NF1) locus and the gene product of the breakpoint cluster region (BCR) gene. The NF1 gene is a tumor suppressor gene, and the protein encoded is called neurofibromin. The BCR locus is rearranged in the Philadelphia+ chromosome  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><msup><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">h</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(\mathrm{Ph}^{+})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.1057em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord"><span class="mord"><span class="mord mathrm">Ph</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8557em;"><span style="top: -3.1473em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mclose">)</span></span></span></span></span>  observed in chronic myelogenous leukemias and acute lymphocytic leukemias.</p>
<p>Mammals have three different ras genes that produce four similar proteins, K-ras4A, K-ras4B, N-ras, and H-ras. The Ras proteins differ only in their carboxy termini, the end of the proteins that anchor them to the inner surface of the cell membrane (Table 14.1, Fig. 14-7). Because they bind and hydrolyze GTP for energy, the ras genes are members of a family of G-proteins. The GTP hydrolysis is regulated by GTPase activating proteins (GAPs).</p>
<p>Mutations in  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>K</mi></mrow><annotation encoding="application/x-tex">K</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">K</span></span></span></span></span> -ras are the most common oncogene mutations in human cancers. The most frequently occurring mutations are located in codons 12, 13, 22, and 61 of the ras gene. These mutations affect sequences coding for the GTP-binding domain of the protein and throw the Ras</p>
<p>Table 14.1 Four ras Proteins Synthesized From Three Genes,  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>K</mi></mrow><annotation encoding="application/x-tex">K</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">K</span></span></span></span></span>  -ras,  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>N</mi></mrow><annotation encoding="application/x-tex">N</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.10903em;">N</span></span></span></span></span>  -ras,and  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>H</mi></mrow><annotation encoding="application/x-tex">H</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span></span></span></span></span>  -ras*</p>
<table><thead><tr><th>Protein</th><th>Modification</th><th>Location</th></tr></thead><tbody><tr><td>K-ras4A</td><td>Farnesylation + palmitoylation</td><td>?</td></tr><tr><td>K-ras4B</td><td>Farnesylation + polybasic aminoacids</td><td>Plasma membrane</td></tr><tr><td>N-ras</td><td>Farnesylation + palmitoylation</td><td>Golgi</td></tr><tr><td>H-ras</td><td>Farnesylation + palmitoylation</td><td>Golgi</td></tr></tbody></table>
<p>*K-ras4A and K-ras4B arise from alternate splicing of transcripts of the same gene.</p>
<p>Copyright ©2007 by F. A. Davis.
Molecular Oncology Chapter 14 339</p>
<p><img src="assets/images/image-20251222-f4633757.jpeg" alt="img-341.jpeg">
Figure 14-7 Ras proteins are anchored to the cell membrane through farnesyl groups (chemical structure at bottom) and palmitoyl groups on the ras proteins. K-ras has only farnesyl groups, whereas N-ras and H-ras have both farnesyl and palmitoyl groups.</p>
<p>protein into a permanently active state that does not require stimulation from GTP hydrolysis. As a result, the Ras proteins harboring these single nucleotide substitutions remain constitutively active in the GTP-bound form.</p>
<p>K-ras mutations are highly correlated with tumor histology and may predict the progress of tumorigenesis in early-stage tumors. Furthermore, the presence of K-ras mutations may affect treatment strategy, especially with targeted therapies such as kinase inhibitors and farnesyl transferase inhibitors (K-ras protein is localized to the cell membrane through a farnesyl group). ras mutations are detected and identified by SSCP screening and direct sequencing. Site-specific methods such as pyrosequencing have also been developed. The PyroMark KRAS kit can be used to specifically genotype codons 12 and 13. In addition, mutations in codon 61 can be analyzed using a second primer set provided in the test. A biochip test for detection of multiple specific mutations by hybridization is also available.²²,²³</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="advanced-concepts">Advanced Concepts<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#advanced-concepts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>K-ras must be associated with cellular membranes in order to act. The membrane association is driven by the hydrophobic farnesyl group covalently attached to the ras protein by the enzyme farnesyl transferase. In the absence of farnesyl modification, even mutated ras proteins are not active. Therefore, therapies have been designed to inhibit the farnesylation of ras. These are farnesyl transferase inhibitors.</p>
<ul>
<li>Ewing Sarcoma, EWS (22q12)</li>
</ul>
<p>A group of tumors arising from primitive neuroectodermal tissue (PNET)/Ewing's sarcomas comprise a family of childhood neoplasms referred to as the Ewing family. Although immunohistochemical staining for the cell surface enzyme HBA71 (p30/p32MIC2), a neuron-specific enzyme, is helpful in diagnosis of these tumors, no unique characteristics distinguish the different types of tumors that make up this group.</p>
<p>Detection of specific translocations by cytogenetic or molecular methods is useful for diagnostic and prognostic accuracy (Table 14.2). Translocations involving the EWS gene at 22q12 (also called EWSR1 for EWS breakpoint region 1) with the FLI-1 gene at 11q24, t(11;22)(q24;q12) are present in 85% of Ewing's sarcomas. Another translocation between EWS and the ERG gene at 21q22 is present in 5%–10% of Ewing's sarcomas. Other partners for the EWS gene, such as ETV1 at 7p22, E1AF at 17q12, and FEV at 2q33, are present in fewer than 1% of cases.²⁴,²⁵</p>
<p>Table 14.2 EWS Translocation Partners</p>
<table><thead><tr><th>Translocation</th><th>Tumor</th></tr></thead><tbody><tr><td>EWS-FLI-1</td><td>Ewing’s sarcoma, peripheral PNET (72%)</td></tr><tr><td>EWS-ERG</td><td>Ewing’s sarcoma, peripheral PNET (11%)</td></tr><tr><td>EWS-WT1*</td><td>Desmoplastic small round cell tumor</td></tr><tr><td>EWS-ATF1</td><td>Clear cell sarcoma</td></tr></tbody></table>
<p>*The WT1 gene is also associated with Wilms’ tumor (WT), one of the common solid tumors of childhood, accounting for 8% of childhood cancers. Several genes or chromosomal areas affect the development of WT: WT1 at 11p13, WT2 at 11p15.5, WT3 at 16q, WT5 at 7p15-p11.2, and WT4 at 17q12-q21.</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<p>The occurrence of these rearrangements was first revealed by cytogenetics <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mrow><mn>26</mn><mo separator="true">,</mo><mn>27</mn></mrow></msup></mrow><annotation encoding="application/x-tex">^{26,27}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">26</span><span class="mpunct mtight">,</span><span class="mord mtight">27</span></span></span></span></span></span></span></span></span></span></span></span></span> and then by PCR methods. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>28</mn></msup></mrow><annotation encoding="application/x-tex">^{28}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">28</span></span></span></span></span></span></span></span></span></span></span></span></span></p>
<p>Current laboratory testing at the molecular level involves detection of the tumor-specific translocations by reverse transcriptase polymerase chain reaction (RT-PCR) (Fig. 14-8). Positive results are revealed by the presence of a 120-190-bp PCR product. Negative specimens will not yield a product. As with all assays of this type, an amplification control, such as GAPDH or 18S RNA (see Chapter 7), must accompany all samples to avoid false-negative results. These tests can be performed on fresh, frozen, or paraffin-embedded tissue.[25,29,30] Primers to additional EWS translocation partners are used to detect related PNET tumors.</p>
<ul>
<li>Synovial sarcoma translocation, chromosome 18—synovial sarcoma breakpoint 1 and 2, SYT-SSX1, SYT-SSX2 t(X;18)(p11.2;q11.2)</li>
</ul>
<p>A recurrent reciprocal translocation between chromosome 18 and the X chromosome is found in synovial sarcoma, a rare type of cancer of the muscle, fat, fibrous tissue, blood vessels, or other supporting tissue of the body. Synovial sarcoma accounts for 8%–10% of all sarcomas and occurs mostly in young adults. About 80% of cases have the t(X;18) translocation.</p>
<p>The t(X;18) translocation fuses the synovial sarcoma translocation, chromosome 18 gene (SS18 or SYT) with</p>
<p>either of two related genes on the X chromosome, synovial sarcoma translocated to X (SSX1 and SSX2). The latter genes are two of five variants, SSX1, SSX2, SSX3, SSX4, and SSX5. With rare exceptions, only SSX1 and SSX2 are fused to SYT in the t(X;18) translocation.[31] The fusion gene acts as an aberrant transcription factor, with both activation and repression functions from the SYT and SSX portions, respectively.</p>
<p>The t(X;18) translocation is detected by FISH or RT-PCR. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mrow><mn>32</mn><mo separator="true">,</mo><mn>31</mn></mrow></msup></mrow><annotation encoding="application/x-tex">^{32,31}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">32</span><span class="mpunct mtight">,</span><span class="mord mtight">31</span></span></span></span></span></span></span></span></span></span></span></span></span> In the latter method, total RNA reverse-transcribed to cDNA is amplified with primers specific for SSX and SYT genes. In a seminested version of this procedure, the SSX primer used in the first round is a consensus primer for both SYT-SSX1 and SYT-SSX2. After the first amplification, SSX1- and SSX2-specific primers discriminate between the two translocation types. The PCR products are detected by agarose gel electrophoresis and ethidium bromide staining. This method can be performed on fresh, frozen, or fixed tissue, depending on the condition of the specimen RNA.</p>
<ul>
<li>Paired box-Forkhead in rhabdomyosarcoma, PAX3-FKHR, PAX7-FKHR, t(1;13), t(2;13)</li>
</ul>
<p>Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma of childhood, accounting for 10% of all solid tumors in children. In addition to alveolar rhabdomyosarcoma (ARMS), there are two additional histo</p>
<p><img src="assets/images/image-20251222-bb8fdbc0.jpeg" alt="img-342.jpeg">
Figure 14-8 RT-PCR is used to detect the t(11:22) mutation in Ewing's sarcoma. One primer is designed to hybridize to the EWS gene on chromosome 22 and one primer to the FLI1 gene on chromosome 11. If the translocation has occurred, the resulting fusion transcript isolated from the tumor cells will yield cDNA that is amplifiable with the EWS and FLI1 primers.</p>
<p>Copyright ©2007 by F. A. Davis.
Molecular Oncology Chapter 14 341</p>
<p>logical forms of RMS: embryonal (RMS-E) and primitive (RMS-P). Although histological classification of RMS is sometimes difficult, accurate diagnosis is important for management and treatment of this malignancy because ARMS has a worse prognosis than other subtypes.</p>
<p>Translocations involving the Forkhead in the Rhabdomyosarcoma Gene (FKHR, also called FOXO1A) and the paired box genes (PAX3 and PAX7) are frequently found in ARMS.33 The chimeric genes resulting from the translocations encode transcriptional activators with DNA-binding motifs homologous to the forkhead transcription factor first discovered in the fruit fly, Drosophila. PAX-FKHR translocations have been observed in all subtypes of RMS but are more characteristic of ARMS. Furthermore, PAX7-FKHR, t(2;13), is associated with better outcome than PAX3-FKHR, t(1;13). Mutations in the PAX3 gene are also found in Waardenburg's syndrome, a congenital auditory pigmentary syndrome.34</p>
<p>The majority of ARMS displays the t(2;13) translocation, with the t(1;13) variant present with 1/3 frequency as t(2;13).35 Both translocations are detected by FISH, RT-PCR, and real-time PCR.36-38</p>
<ul>
<li>Tumor protein 53, TP53 (17p13)</li>
</ul>
<p>Mutations in TP53 are found in all types of cancer, and about 50% of all cancers have TP53 mutations. The gene product of TP53, p53, is a 53,000-dalton DNA-binding protein that controls expression of other genes. Normally, p53 participates in the arrest of cell division in the event of DNA damage. The arrest in the G1 phase of the cell cycle allows repair enzymes to correct the DNA damage before DNA synthesis begins. Once the damage is repaired, p53 protein is removed by binding to another protein, MDM2, and degradation. When p53 is not functional, replication proceeds on damaged templates, resulting in the potential for further genetic abnormalities. Also, the mutant protein does not degrade properly and accumulates in the cell nucleus and cytoplasm.</p>
<p>Several studies have shown that mutated TP53 in tumor tissue is an indicator of poor prognosis in breast, lung, colon, and other types of cancers. The significance of TP53 status as a predictor of decreased survival time or tumor relapse is, however, controversial.39 Part of the controversy arises from the different methods used to detect TP53 mutations. The most common method is detection of the stabilized mutant protein by IHC. Several monoclonal antibodies directed at different epitopes in</p>
<p>the p53 protein have been used for this purpose. Because normal p53 protein is transient, significant staining (+2 or above on a scale of 0 to +4) of p53 is considered positive for the mutation.</p>
<p>SSCP (see Chapter 9) and direct sequencing (see Chapter 10) of microdissected tumor tissue are other methods often used to detect TP53 mutations. Sequencing and SSCP methods cover only exons 5-8 or 4-9 of the TP53 gene, because these exons encode the regions involved in DNA binding and protein-protein interactive functions of the p53 protein. Screening is routinely performed on frozen or fixed paraffin-embedded tumor tissue.</p>
<p>Both IHC analysis of protein and DNA analysis are used to screen for somatic p53 mutations. A number of studies, however have shown that mutations detected by IHC do not correlate with mutations found by direct DNA analysis.40-42 There are several explanations for these discrepancies (Table 14.3). Use of microarray technology to screen expression of multiple genes along with TP53 has been proposed as a more accurate method for predicting survival than either IHC or mutation analysis of TP53 alone.43 Methods that include sequencing of the entire TP53 coding region on cDNA, in combination with IHC, is another accurate approach.41,44</p>
<p>In addition to screening for somatic alterations, mutation analysis of TP53 is also performed to aid in the diagnosis of Li-Fraumeni syndrome, a cancer-prone condition caused by inherited mutations in the p53 gene. In this</p>
<p>Table 14.3 Sources of Potential Inaccuracies of p53 Mutation Analysis</p>
<table><thead><tr><th>Method</th><th>False Positive</th><th>False Negative</th></tr></thead><tbody><tr><td>IHC</td><td>Staining of normal p53 protein</td><td>Deletions or mutations in p53 that remove Ab binding epitopes; promoter mutations</td></tr><tr><td>SSCP</td><td>Alternate conformers; silent DNA polymorphisms</td><td>Less than 5% mutant cells in specimen; mutations outside of the exons screened</td></tr><tr><td>Sequencing</td><td>PCR mutagenesis; high background</td><td>Less than 10% mutant cells in specimen; mutations outside of sequenced area</td></tr></tbody></table>
<p>case, normal tissue will be heterozygous for the mutation, removing the challenge of isolating pure samples of tumor tissue. Once an inherited mutation is detected, further analysis of relatives requires targeting only that mutation.Ataxia telangiectasia mutated gene, ATM (11q22)</p>
<p>Predisposition to cancer is one symptom of the neurological disease ataxia telangiectasia (AT). AT occurs in at least 1/40,000 live births. This disease is caused by mutations in the ATM (A-T mutated) gene on chromosome 11. ATM mutations are also present in some types of leukemias and lymphomas. Carriers of the autosomal-recessive mutations in ATM are at increased risk for developing leukemia, lymphoma, or other types of cancers.</p>
<p>The ATM gene product is a member of the phosphatidylinositol-3 kinase family of proteins that respond to DNA damage by phosphorylating other proteins involved in DNA repair and/or control of the cell cycle. The ATM protein participates in pausing the cell cycle at the G1 or G2 phase to allow completion of DNA repair.</p>
<p>Direct DNA sequencing is the method of choice for detection of ATM mutations, especially in family members of carriers of previously identified mutations. Another method used is SSCP.45,46 A functional test for repair of double-strand breaks induced by irradiation is also performed for ATM. For this assay, exponentially growing cells are irradiated (1.5 Gy/min), and after 2 hours Colcemid (0.06 μg/mL) is added to inhibit spindle formation. The cells are harvested 2 hours later for Giemsa staining, and the karyotypes are examined. The ratio of aberrations/cell is calculated from the number of chromatid and chromosome breaks (counted as one breakage event) in addition to dicentric chromosomes, translocations, ring chromosomes, and chromatid exchange figures (counted as two breakage events).47</p>
<p>If a mutation is identified in a patient with ataxia telangiectasia, other family members may be tested for the presence of the same mutation. Presence of a mutation in family members identifies those with increased risk of AT. Heterozygous carriers of an ATM mutation may also be at increased risk for mantle cell lymphoma, B-cell lymphocytic leukemia, or T-cell prolymphocytic leukemia.Breast Cancer 1 gene, BRCA1 (17q21), and Breast Cancer 2 gene, BRCA2 (13q12)</p>
<p>Approximately 5% of breast cancers result from inherited gene mutations, mostly in the breast cancer genes BRCA148,49 and BRCA2.50,51 Women who carry a mutation in BRCA1 have a 60%--80% lifetime risk of breast or ovarian cancer. Men carrying a mutation, especially in BRCA2, have a 100-fold increased risk of breast cancer compared with men without a mutation, as well as increased risk of colon and prostate cancer. Both men and women can transmit the mutation to subsequent generations.</p>
<p>The BRCA1 gene product has a role in embryonic development, and both BRCA1 and BRCA2 gene products may also be involved in DNA repair. BRCA1 and BRCA2 interact with the RAD51 protein, possibly as a complex to repair damaged DNA.52</p>
<p>SSCP, PTT, ddF (see Chapter 9), and other procedures have been used to screen for mutations in these genes. The screening method used for clinical applications, however, is direct sequencing. Three mutations, 187delAG (also called 185delAG) and 5382insC in BRCA1 and 6174delT in BRCA2, occur frequently in particular ethnic populations.53,54 These known mutations can be easily detected by a number of targeted assays, including sequence-specific PCR and allele-specific oligomer hybridization.</p>
<p>Just as with any genetic analysis, testing for BRCA1 and BRCA2 mutations requires thorough patient counseling and education.55,56 The significance of a BRCA mutation will depend on several factors, including penetrance of the gene mutations.57 If a mutation is not detected in the coding sequences of the genes, the possibility of mutations in the noncoding regions cannot be ruled out.Von Hippel-Lindau gene,VHL (3p26)</p>
<p>Benign blood vessel tumors in the retina were first reported by Eugen von Hippel, a German ophthalmologist, in 1895. In 1926, Arvid Lindau, a Swedish pathologist, further noted that these retinal tumors were linked to tumors in the blood vessels in other parts of the central nervous system, sometimes accompanied by cysts in the kidneys and other internal organs, and that the condition was heritable. The Von Hippel-Lindau syndrome (VHL) is now recognized as a genetic condition involving the abnormal growth of blood vessels in organs, especially those that are particularly rich in blood vessels. It is caused by mutations in the VHL gene, which is located on the short arm of chromosome 3. Normally, VHL functions as a tumor suppressor gene, promoting cell differ</p>
<p>Copyright ©2007 by F. A. Davis.
Molecular Oncology Chapter 14 343</p>
<p>entiation. VHL may also play a role in sensing hypoxia (low oxygen levels in tissues).58 VHL syndrome is a predisposition for renal cell carcinoma and other cancers.59</p>
<p>Deletions, point mutations, and splice site mutations have been described in patients with VHL. In addition, cases of renal cell carcinoma and tumors of the adrenal gland are accompanied by varied somatic mutations in the VHL gene.60,61 Mutations in the VHL gene are detectable by SSCP, and linkage studies have been reported as a method to detect inherited mutations in family members.62 Direct sequencing, however, is the preferred method of testing for VHL gene mutations.</p>
<ul>
<li>V-myc avian myelocytomatosis viral-related oncogene, neuroblastoma-derived, MYCN or n-myc (2p24)</li>
</ul>
<p>The n-myc gene on the short arm of chromosome 2 (2p24) is amplified in cases of neuroblastoma and retinoblastoma. n-myc is an oncogene that is counteracted by the tumor suppressor gene, neurofibromatosis type 1 (NF1). The n-myc gene product is a member of the MYC family of proteins (see c-myc).</p>
<p>n-myc gene amplification is detectable by FISH or dot blot analysis.63-65 Transcription of n-myc may also be measured using real-time PCR.66</p>
<ul>
<li>Rearranged During Transfection (RET) proto-oncogene, (10q11)</li>
</ul>
<p>The RET proto-oncogene is located on the long arm of chromosome 10 (10q11). The RET gene product is a membrane tyrosine kinase that participates in sending cell growth and proliferation signals to the nucleus.67 The RET gene is 55 kb in length. The first intron in the gene covers about 24 kb, with exons 2 to 20 contained in the remaining 31 kb. This general structure of a large first intron with small exons is characteristic of tyrosine kinase receptors, such as the KIT, EGFR, and platelet derived growth factor (PDGF) receptors.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="advanced-concepts">Advanced Concepts<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#advanced-concepts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The n-myc gene encodes a nuclear protein with a basic helix-loop-helix (bHLH) domain that dimerizes with another bHLH protein in order to bind DNA.</p>
<p>The RET gene is an example of how different mutations in the same gene result in different diseases. Translocations that result in overexpression of RET are found in thyroid papillary carcinomas. Point mutations that activate RET (also called MEN2A) are found in inherited multiple endocrine neoplasia (MEN) syndromes, a group of diseases resulting in abnormal growth and function of the pituitary, thyroid, parathyroid, and adrenal glands. In contrast, loss of function mutations in the RET gene are found in Hirschsprung's disease, a rare congenital lack of development of nerve cells in the colon that results in colonic obstruction. Mutations have been reported in about 50% of congenital cases and 20% of sporadic cases of this disorder. Because about 16% of children with congenital central hypoventilation syndrome (CCHS) have Hirschsprung's disease, RET mutations were also sought in CCHS. Most of the mutations detected were determined as polymorphic variants, however.68</p>
<p>Detection of RET gene mutations can aid in diagnosis of MEN diseases.69,70 Clinical testing targets mainly exons 10, 11, and 16, where most reported mutations have been found. Screening for RET gene mutations has been performed by PCR-RFLP, direct sequencing, SSCP, and denaturing gradient gel electrophoresis (DGGE).70-72</p>
<ul>
<li>Other molecular abnormalities</li>
</ul>
<p>Increasing numbers of molecular abnormalities are being used to aid in the diagnosis and monitoring of solid tumors. Some examples of potential diagnostic targets are shown in Table 14.4. As molecular aberrations in oncogenes and tumor suppressor genes are identified, molecular analysis becomes more important in their rapid and accurate detection.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="microsatellite-instability">Microsatellite Instability<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#microsatellite-instability" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Lynch syndrome, or hereditary nonpolyposis colorectal cancer (HNPCC), is an inherited form of colon carcinoma, accounting for about 5% of all colon cancers.73-76 Predisposition to cancer in this syndrome is caused by mutations in the MSH2 and MLH1 genes. Mutations in the MSH6 and hPMS2 genes have also been found. These genes are responsible for correcting replicative errors and mismatched bases in DNA, a process called mismatch repair (MMR). The MMR system was originally discovered in bacteria (Escherichia coli) and further studied in</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<p>Table 14.4 Molecular Abnormalities in Some Solid Tumors</p>
<table><thead><tr><th>Gene</th><th>Location</th><th>Mutation</th><th>Detection Method</th><th>Associated Disease</th></tr></thead><tbody><tr><td>Adenomatous polyposis of the colon</td><td>5q21</td><td>5q deletion, t(5;10)</td><td>Southern blot, FISH, sequencing, SSCP</td><td>Familial adenomatous polyposis of the colon</td></tr><tr><td>Retinoblastoma (Rb, RB1)</td><td>13q14.1</td><td>13q deletion, t(X;13)</td><td>Southern blot, FISH, sequencing</td><td>Retinal neoplasm, osteosarcoma</td></tr><tr><td>MET proto-oncogene, hepatocyte growth factor receptor</td><td>7q31</td><td>Missense mutations</td><td>Sequencing</td><td>Renal carcinoma</td></tr><tr><td>KIT proto-oncogene, stem cell factor receptor (SCFR)</td><td>4q12</td><td>Missense mutations</td><td>Sequencing</td><td>Gastrointestinal stromal tumors</td></tr><tr><td>Folliculin (FLCL, BHD)</td><td>17p11.2</td><td>Insertions, deletions in a C8 tract in exon 11</td><td>Sequencing</td><td>Birt-Hogg-Dube syndrome (hair follicle hamartomas, kidney tumors)</td></tr><tr><td>Fumarate hydratase</td><td>1q42.1</td><td>Frameshift mutations</td><td>Sequencing</td><td>Hereditary leiomyomatosis, renal cell cancer</td></tr></tbody></table>
<p>yeast (Saccharomyces cerevisiae). Similar (homologous) genes were subsequently identified in humans and named after the bacterial and yeast genes (Table 14.5). Their gene products form a protein complex that binds to mismatched bases in the DNA double helix or loops formed by replicative errors. At the end of S phase (DNA replication), the system recognizes errors in the newly synthesized daughter strand and uses the template strand, which is methylated, as a guide for repair (Fig. 14-9).</p>
<p>Included in the types of DNA lesions that are repaired by this system are replication errors (RERs) caused by</p>
<p>Table 14.5 Genes of the MMR System</p>
<table><thead><tr><th>Human Gene</th><th>Bacterial Gene</th><th>Function</th></tr></thead><tbody><tr><td>MSH2</td><td>MutS</td><td>Single mismatch, loop repair</td></tr><tr><td>MSH3</td><td>MutS</td><td>Loop repair</td></tr><tr><td>MSH4</td><td>MutS</td><td>Meiosis</td></tr><tr><td>MSH5</td><td>MutS</td><td>Meiosis</td></tr><tr><td>MSH6/GTBP</td><td>MutS</td><td>Single mismatch repair</td></tr><tr><td>MLH1</td><td>MutL</td><td>Mismatch repair</td></tr><tr><td>hPMS2</td><td>MutL</td><td>Mismatch repair (postmeiotic segregation in yeast)</td></tr><tr><td>hPMS1</td><td>MutL</td><td>Mismatch repair (postmeiotic segregation in yeast)</td></tr></tbody></table>
<p><img src="assets/images/image-20251222-32b9e4bf.jpeg" alt="img-343.jpeg">
Figure 14-9 The mismatch repair system recognizes a mismatch (top) in the newly synthesized unmethylated strand of DNA. The complex of proteins recruits exonucleases, single-strand DNA binding proteins (SSB), and helicases to remove the erroneous base (center). Polymerases and DNA ligase then replace the missing bases.</p>
<p>Copyright ©2007 by F. A. Davis.
Molecular Oncology Chapter 14 345</p>
<p><img src="assets/images/image-20251222-a8f47c32.jpeg" alt="img-344.jpeg">
Figure 14-10 Replication errors result from slippage during DNA replication. If the error is not repaired, the next round of replication will create a new allele (top, right) of the original locus. Additional uncorrected errors will produce more alleles.</p>
<p>slippage between the replication apparatus and the DNA template (Fig. 14-10). RERs occur especially in microsatellites where 1–3 nucleotides are repeated in the DNA sequence (see Chapter 11). If the errors remain in the DNA until the next round of replication, new alleles will arise, generating increasing numbers of alleles for the locus, or microsatellite instability (MSI). In contrast, a stable locus will retain the same alleles through many rounds of replication. Microsatellite slippage occurs about every 1000 to 10,000 normal cell divisions, most of which are repaired in normal cells. Dysfunction of one or more components of the MMR system will result in MSI, an increase in the number of alleles due to loss of repair. The majority of MMR mutations in HNPCC are found in the MSH2 and MLH1 genes. Mutations in hPMS2 account for fewer than 1%, and mutations in hPMS1 and MSH3 are rare. Although direct sequencing of the affected genes is definitive and identifies the specific mutation in a family, the test is expensive and may miss mutations outside of the structural gene sequences or in other genes.77,78</p>
<p>About 90% of HNPCC cases display MSI. Because loss of MMR gene function causes MSI, MSI can be used to screen indirectly for mutations in the MMR genes. If a person has inherited a mutation in one copy of an MMR gene, somatic mutation of the remaining copy will result in the MSI phenotype in the tumor cells. MSI, therefore, will be apparent in the tumor where both functional copies of the gene have been lost but not in normal tissue that retains one normal copy of the gene. To perform this test, therefore, normal and tumor tissue from the patient must be compared. MSI is apparent from the increased number of alleles in the tumor tissue compared with that in the normal tissue. MSI is detected by PCR amplification of microsatellite loci and gel electrophoresis (Fig. 14-11) or capillary gel electrophoresis (Fig. 14-12). The detection of instability (more bands or</p>
<p>peaks in the tumor tissue compared with the normal tissue) is strong evidence for HNPCC.</p>
<p>The National Cancer Institute has recommended that screening two mononucleotide repeat loci, BAT25 and BAT26, and three dinucleotide repeat loci, D5S346, D2S123, and D17S250, is sufficient for determination of MSI.79 Alternate markers have been proposed, and some laboratories test additional loci to ensure amplification of at least five loci.80,81 Further, mononucleotide repeat structures may be more sensitive markers for MSI than dinucleotide repeats, so that some laboratories prefer mononucleotide repeat loci.</p>
<p>If at least two of the five or the majority of loci show instability, the specimen is classified as high instability (MSI-H). Tumors showing MSI in one or a minority of loci tested are classified as low instability (MSI-L). If no MSI is detected in the loci tested, the tumor is stable (MSS). With the present state of clinical correlation, MSI-L and MSS tumors are interpreted as microsatellite-stable, and MSI-H tumors are considered microsatellite-unstable. MSI-H is reported as MSI-unstable with an</p>
<p><img src="assets/images/image-20251222-d71d069d.jpeg" alt="img-345.jpeg">
Figure 14-11 Microsatellite instability (MSI) is detected by increased alleles compared with stability at the same locus.</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<p><img src="assets/images/image-20251222-a7bf0861.jpeg" alt="img-346.jpeg">
Figure 14-12 MSI detected by capillary gel electrophoresis. DNA from tumor (T) is compared with DNA from normal cells from the same patient (N). Increased alleles in the tumor scans reveal instability at those loci (top four scans). Stable loci look the same in normal and tumor tissue (bottom two scans).</p>
<p>increased likelihood that the patient has HNPCC.79 If MSI is discovered, the inherited mutation can be confirmed by immunohistochemistry and/or direct sequencing of the MLH1, MSH2, and/or MSH6 genes.82</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="loss-of-heterozygosity">Loss of Heterozygosity<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#loss-of-heterozygosity" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Once a gene mutation is identified in a family, targeted resequencing is used to test for the mutation in other family members. In an inherited condition such as HNPCC or inherited breast and ovarian cancer, blood samples are sufficient for mutation analysis in unaffected individuals. In tumor cells, further testing for loss of heterozygosity (LOH) may be performed. LOH reveals the loss of the "good allele" at a locus, uncovering the homologous locus with a recessive mutation. LOH can be detected by PCR amplification of heterozygous STR or variable num</p>
<p>ber tandem repeats (VNTR) loci closely linked to the disease gene. Amplification of loci in tumor cells with LOH will reveal a loss of the allele linked to the normal allele of the gene when compared with the mutant allele (Fig. 14-13). Comparing peak heights in normal (N) and tumor (T) tissues, the formula for LOH is:</p>
<p>(peak height of normal allele in N/peak height of normal allele in T)</p>
<p>(peak height of mutant allele in T/peak height of mutant allele in N)</p>
<p>A ratio of less than 0.5 or more than 2 indicates LOH. Alternately, LOH is assumed if the peak height of the normal allele in the tumor is less than  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span>  of the height of the normal allele in the normal DNA.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="gene-rearrangements-in-leukemia-and-lymphoma">Gene Rearrangements in Leukemia and Lymphoma<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#gene-rearrangements-in-leukemia-and-lymphoma" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Gene rearrangements analyzed for hematological malignancies include V(D)J recombination, the normal intrachromosomal rearrangements in B and T lymphocytes as well as the abnormal interchromosomal translocations that can occur in any cell type.</p>
<p><img src="assets/images/image-20251222-9bc7d6e3.jpeg" alt="img-347.jpeg"></p>
<p><img src="assets/images/image-20251222-aeac75d1.jpeg" alt="img-348.jpeg">
Figure 14-13 Loss of heterozygosity (LOH) is detected by PCR and capillary electrophoresis of heterozygous STR loci linked to disease genes. A deletion or loss of the normal allele uncovering a recessive mutant allele is identified by the loss of the STR linked to the normal gene (right).</p>
<p>Copyright ©2007 by F. A. Davis.
Molecular Oncology Chapter 14 347</p>
<p><img src="assets/images/image-20251222-f97e832a.jpeg" alt="img-349.jpeg">
Figure 14-14 Gene rearrangements (GR) are normal processes that occur in B and T lymphocytes as they mature from lymphoid stem cells. The genes coding for immunoglobulin heavy and light chains (IgH and IgL, respectively) begin the rearrangement process in early B cells and pre-B cells. The T-cell receptor (TCR) genes rearrange in the order δ, γ, β, and α chains.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="v-d-j-recombination">V(D)J Recombination<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#v-d-j-recombination" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>To develop antibody diversity, lymphocytes undergo normal genetic rearrangement of immunoglobulin (Ig) heavy and light chain genes and T-cell receptor genes (Fig. 14-14). The gene rearrangement process is a series of intrachromosomal recombination events mediated by recombinase enzymes that recognize specific sequences flanking the gene segments. This process occurs independently in each lymphocyte, so that a repertoire of antibodies is available to match any random invading antigen.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="immunoglobulin-heavy-chain-gene-rearrangement-in-b-cells">Immunoglobulin Heavy Chain Gene Rearrangement in B Cells<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#immunoglobulin-heavy-chain-gene-rearrangement-in-b-cells" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Each antibody consists of two heavy chains and two light chains. The locus coding for the immunoglobulin heavy chain is located on chromosome 14. The unrearranged, or germline, configuration of the immunoglobulin heavy chain locus consists of a series of gene segments or repeated exons coding for the functional parts of the antibody protein (Fig. 14-15). These include 123–129 variable (V_H) regions (38–46 functional gene segments) and 9 joining (J_H) regions (6 functional), one of which will connect one variable region with a constant (C_H) region of the antibody or receptor. There are 11 constant regions (9 functional). The immunoglobulin heavy chain gene also contains 27 diversity (D_H) regions (23 functional), one of which will connect the variable and joining regions. The V segments are each preceded by a leader region (L). The leader region codes for a short sequence of amino acids found on the amino terminus of the protein that mark the antibody for secretion or membrane insertion.</p>
<p>As B lymphocytes mature, selected gene segments are joined together so that the rearranged gene contains only one of each V_H, D_H, and J_H segment (see Fig. 14-15). Initially, one D_H and one J_H segment are joined together. The DNA between the two segments is looped out and lost. The D_H–J_H rearrangement occurs in both alleles of the heavy chain gene locus on both chromosomes. Then in only one allele, a V_H segment is chosen and joined to</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<p><img src="assets/images/image-20251222-65082944.jpeg" alt="img-350.jpeg">
Figure 14-15 Immunoglobulin heavy chain gene on chromosome 14 consists of a series of variable (V), diversity (D), and joining (J) gene segments (germline configuration). The V segments are accompanied by a short leader region (L). One of each type of segment, V, D, and J, is selected and combined by an intrachromosomal recombination event, first D and J, and then V and D. The C (constant) segments are joined through splicing or a secondary recombination event, class switching.</p>
<p>the  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">D</mi><mi mathvariant="normal">H</mi></msub></mrow><annotation encoding="application/x-tex">\mathrm{D_H}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">D</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mathrm mtight">H</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>  segment. The completion of the gene rearrangement process on only one of the two immunoglobulin heavy chain gene alleles is referred to as allelic exclusion. The rearrangement on the other chromosome will proceed if the first rearrangement fails or is not productive.</p>
<p>When the DNA is cut in the process of the gene rearrangement, terminal deoxynucleotidyl transferase may add nucleotides at the V-D-J junctions, further diversifying the coding sequences of individual antibody genes. After the V(D)J rearrangement occurs, the gene is transcribed, and one of the constant regions is joined to the final messenger RNA by splicing or, alternatively,</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="advanced-concepts">Advanced Concepts<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#advanced-concepts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The recombination events of the gene rearrangement are mediated by recombination activating genes RAG1 and RAG2. These genes code for enzymes that recognize short recombination signal sequences in the DNA where they form a complex that initiates the cutting and religating of the DNA.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="advanced-concepts">Advanced Concepts<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#advanced-concepts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The constant region determines the isotype of the antibody IgM, IgD, IgG, IgE, or IgA. Each cell can make only one heavy chain protein, although the isotype of the heavy chain may change. A mature B cell will initially produce IgD and some membrane IgM that will migrate to the cell surface to act as the antigen receptor. Upon antigen stimulation, the B cell will differentiate into a plasma cell expressing large amounts of secreted IgM. Some cells will undergo a class-switch recombination, placing the VDJ gene next to the genes encoding the IgG, IgE, or IgA constant regions. The B cells will express a different isotype during the secondary response. Most commonly, IgM (primary response) gives way to IgG (secondary response). Production of IgE or IgA instead of IgG can also occur, although the regulation of these switching events is not well understood. Class switching is mediated by different recombinase enzymes than those responsible for VDJ recombination.</p>
<p>by a secondary recombination event (class switching). The maintenance of the constant regions in the DNA allows for antibody-type switching during the immune response.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="immunoglobulin-light-chain-gene-rearrangement-in-b-cells">Immunoglobulin Light Chain Gene Rearrangement in B Cells<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#immunoglobulin-light-chain-gene-rearrangement-in-b-cells" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Like the Ig heavy chain gene on chromosome 14, the Ig light chain genes consist of a series of gene segments in the germline configuration (Fig. 14-16). Two separate genes code for the Ig light chains, the kappa locus on chromosome 2 and the lambda locus on chromosome 22. At the kappa locus, there is a single constant gene segment, 5 joining  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><msub><mi mathvariant="normal">J</mi><mi>κ</mi></msub><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(\mathrm{J}_{\kappa})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord"><span class="mord mathrm">J</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.1514em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">κ</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose">)</span></span></span></span></span>  gene segments and at least 76 variable  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><msub><mi mathvariant="normal">V</mi><mi>κ</mi></msub><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(\mathrm{V}_{\kappa})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">V</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.1514em;"><span style="top: -2.55em; margin-left: -0.0139em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">κ</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose">)</span></span></span></span></span>  gene segments (30-35 functional) belonging to 7 sequence-related families.[83,84] In addition there is a kappa deleting element (KDE) located  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>24</mn><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">b</mi><mi mathvariant="normal">p</mi></mrow><msup><mn>3</mn><mo mathvariant="normal" lspace="0em" rspace="0em">′</mo></msup></mrow><annotation encoding="application/x-tex">24\mathrm{kbp}3^{\prime}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9463em; vertical-align: -0.1944em;"></span><span class="mord">24</span><span class="mord"><span class="mord mathrm">kbp</span></span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7519em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">′</span></span></span></span></span></span></span></span></span></span></span></span></span>  to the constant region. This element determines deletion of the Ig <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>κ</mi></mrow><annotation encoding="application/x-tex">\kappa</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal">κ</span></span></span></span></span>  constant region in cells producing Ig lambda light chains. The Ig lambda gene locus consists of 52 variable</p>
<p>Copyright ©2007 by F. A. Davis.
Molecular Oncology Chapter 14 349</p>
<p><img src="assets/images/image-20251222-017c66e9.jpeg" alt="img-351.jpeg"></p>
<p><img src="assets/images/image-20251222-b7ddb431.jpeg" alt="img-352.jpeg">
Figure 14-16 Immunoglobulin kappa (A) and lambda (B) light chain loci consist of gene segments for variable (V), joining (J), and constant (C) regions. The variable regions are classified into sequence-related families (V1-Vn). Each member of the family is given a number; for example, V7-4 is the fourth member of the V7 sequence family. Some of the gene segments are nonfunctional (open boxes). Recombination sites (triangles) are juxtaposed to each gene segment. Arrows denote primer binding sites for PCR clonality testing.</p>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><msub><mi mathvariant="normal">V</mi><mi>λ</mi></msub><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(\mathrm{V}_{\lambda})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">V</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3361em;"><span style="top: -2.55em; margin-left: -0.0139em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">λ</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose">)</span></span></span></span></span> gene segments (29–33 functional) from <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><msub><mi mathvariant="normal">V</mi><mi>λ</mi></msub></mrow><annotation encoding="application/x-tex">10\mathrm{V}_{\lambda}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">V</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3361em;"><span style="top: -2.55em; margin-left: -0.0139em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">λ</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> families and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>7</mn><msub><mi mathvariant="normal">J</mi><mi>λ</mi></msub></mrow><annotation encoding="application/x-tex">7\mathrm{J}_{\lambda}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord">7</span><span class="mord"><span class="mord mathrm">J</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3361em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">λ</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> (4–5 functional) and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>7</mn><mtext>–</mtext><mn>11</mn><msub><mi mathvariant="normal">C</mi><mi>λ</mi></msub></mrow><annotation encoding="application/x-tex">7–11\mathrm{C}_{\lambda}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord">7–11</span><span class="mord"><span class="mord mathrm">C</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3361em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">λ</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> gene segments (4–5 functional) occupying 1140-kb of DNA.85</p>
<p>Immunoglobulin light chain gene rearrangement is similar to that described for the immunoglobulin heavy chain gene. Selected gene segments are joined together with loss of the intervening DNA and possible insertion of nucleotides at the junction. The kappa locus rearranges first and then the lambda locus, if necessary. If the lambda locus rearranges, the kappa locus undergoes a secondary recombination through the KDE so that the cell does not produce both types of light chains.</p>
<p>During differentiation of the B cells from precursor stem cells, rearrangement, recombination, and mutation of the immunoglobulin V, D, and J regions ultimately results in functional VJ (light chain) and VDJ (heavy chain) genes.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="t-cell-receptor-gene-rearrangement">T-Cell Receptor Gene Rearrangement<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#t-cell-receptor-gene-rearrangement" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The T-cell receptor is composed of two of four chains, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span>, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>γ</mi></mrow><annotation encoding="application/x-tex">\gamma</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.625em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05556em;">γ</span></span></span></span></span>, and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>δ</mi></mrow><annotation encoding="application/x-tex">\delta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord mathnormal" style="margin-right: 0.03785em;">δ</span></span></span></span></span>, with characteristic structures resembling immunoglobulin V, J and C regions (Fig. 14-17). The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>δ</mi></mrow><annotation encoding="application/x-tex">\delta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord mathnormal" style="margin-right: 0.03785em;">δ</span></span></span></span></span> chains are encoded on chromosome 14 (the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>δ</mi></mrow><annotation encoding="application/x-tex">\delta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord mathnormal" style="margin-right: 0.03785em;">δ</span></span></span></span></span> gene is located inside of the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> gene), and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>γ</mi></mrow><annotation encoding="application/x-tex">\gamma</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.625em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05556em;">γ</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> are located</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="advanced-concepts">Advanced Concepts<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#advanced-concepts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Antibody diversity is ensured by three separate events during and after the gene rearrangement process. The first is the selection of gene segments. The second is the imprecise joining of the segments together with addition of nucleotide bases at the junction.[140] Third, after the gene rearrangement process has finished and the B cell has encountered antigen, somatic hypermutation occurs in the variable regions of the rearranged heavy and light chain genes. This mutation process requires the action of an enzyme called activation-induced cytidine deaminase, altering C residues to base pair with A instead of G residues, resulting in different amino acid substitutions in the antibody protein. Changing of the variable region sequences underlies the process of affinity maturation. As the B cells replicate, those producing antibodies with greater affinity to the antigen are favored, generating subclones of cells that may replace the original reactive clone. Over the course of an infection, therefore, antibodies with increased affinity are produced.</p>
<p>on chromosome 7. The four chains form pairs, making two types of receptors,  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi><mi>β</mi></mrow><annotation encoding="application/x-tex">\alpha \beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>  and  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>γ</mi><mi>δ</mi></mrow><annotation encoding="application/x-tex">\gamma \delta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05556em;">γ</span><span class="mord mathnormal" style="margin-right: 0.03785em;">δ</span></span></span></span></span> . T-cell receptor genes have fewer variable gene segments than the immunoglobulin genes, and the genes for the  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>γ</mi></mrow><annotation encoding="application/x-tex">\gamma</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.625em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05556em;">γ</span></span></span></span></span>  and  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span>  chains have no diversity regions (Table 14.6). The V regions of the receptor chains undergo gene rearrangement by intrachromosomal recombination as described for the immunoglobulin genes (Fig. 14-18).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="advanced-concepts">Advanced Concepts<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#advanced-concepts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The T-cell receptor  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>δ</mi></mrow><annotation encoding="application/x-tex">\delta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord mathnormal" style="margin-right: 0.03785em;">δ</span></span></span></span></span>  gene is flanked by TCR  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>δ</mi></mrow><annotation encoding="application/x-tex">\delta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord mathnormal" style="margin-right: 0.03785em;">δ</span></span></span></span></span> -deleting elements. Recombination between these elements or between  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">V</mi><mi>α</mi></mrow><annotation encoding="application/x-tex">\mathrm{V}\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathrm" style="margin-right: 0.01389em;">V</span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span>  and  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">J</mi><mi>α</mi></mrow><annotation encoding="application/x-tex">\mathrm{J}\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathrm">J</span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span>  result in deletion of the TCR <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>δ</mi></mrow><annotation encoding="application/x-tex">\delta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord mathnormal" style="margin-right: 0.03785em;">δ</span></span></span></span></span>  gene.</p>
<p>Rearrangement of the T-cell receptor chains proceeds in a similar manner as in the immunoglobulin genes. The V, (D), and J segments are joined together with addition or deletion (trimming) of nucleotides at the junctions between the gene segments.</p>
<p>The extracellular domains of the T-cell receptor dimers are held in conformation by interchain disulfide bridges between cysteine residues in the T-cell receptor peptides. The T-cell receptor chains also have a hydrophobic transmembrane region and a short cytoplasmic region. Although most cells express the  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi><mi>β</mi></mrow><annotation encoding="application/x-tex">\alpha \beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>  receptor,  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>λ</mi><mi>δ</mi></mrow><annotation encoding="application/x-tex">\lambda \delta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord mathnormal">λ</span><span class="mord mathnormal" style="margin-right: 0.03785em;">δ</span></span></span></span></span>  receptors can represent a predominant population in certain tissues, such as the intestinal tract.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="detection-of-clonality">Detection of Clonality<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#detection-of-clonality" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Gene rearrangements occur independently in each lymphocyte so that a normal population of lymphocytes is polyclonal with respect to their rearranged immunoglobulin or T-cell receptor genes. Over-representation of a single rearrangement in a specimen cell population can be an indication of and characteristic for a lymphoma or leukemia. When over  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span>  of cells make the same gene rearrangement, the cell population is referred to as monoclonal with respect to the rearranged genes.</p>
<p><img src="assets/images/image-20251222-1b42b9d4.jpeg" alt="img-353.jpeg">
Figure 14-17 General structure of the T-cell receptor genes. The gene for the delta T-cell receptor chain is contained in the alpha locus (top). The beta and gamma chains are located at separate loci.</p>
<p>Copyright ©2007 by F. A. Davis.
Molecular Oncology Chapter 14 351</p>
<p><img src="assets/images/image-20251222-b47cce8d.jpeg" alt="img-354.jpeg">
Figure 14-18 T-cell receptor gamma gene rearrangement occurs through selection of variable (V) and joining (J) segments.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="advanced-concepts">Advanced Concepts<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#advanced-concepts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>It is important to distinguish a large monoclonal population of tumor cells from a reactive clone or oligoclone or reactive clone of cells responding to an antigen. Oligoclones are not only smaller but transient in nature so that they should not be consistently present in serial analyses.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="immunoglobulin-heavy-chain-gene-rearrangements">Immunoglobulin Heavy Chain Gene Rearrangements<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#immunoglobulin-heavy-chain-gene-rearrangements" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Clonality can be detected by Southern blot.86-88 With regard to the immunoglobulin heavy chain gene, restriction sites are mapped in the germline configuration. BamH1, EcoR1, and HindIII are enzymes commonly used for this procedure (Fig. 14-19). When the germline sequence is rearranged, the restriction sites are moved, created, or deleted, resulting in a unique restriction pattern for every gene rearrangement. DNA cut with the restriction enzymes is transferred to a nitrocellulose membrane and probed to the joining region of the gene. Normal results should reveal the expected fragments generated from the germline DNA, in the example, an 18kbp EcoR1 fragment, an 18 kbp BamH1 fragment, and an 11 kbp Hind III fragment. The normal fragments</p>
<p>Table 14.6 T-Cell Receptor Gene Segments</p>
<table><thead><tr><th>T-Cell Receptor Chain</th><th>Variable Gene Segments*</th><th>Diversity Gene Segments</th><th>Joining Gene Segments*</th><th>Constant Gene Segments</th></tr></thead><tbody><tr><td>α</td><td>54/45</td><td>0</td><td>60/50</td><td>1</td></tr><tr><td>β</td><td>67/47</td><td>2</td><td>14/13</td><td>2</td></tr><tr><td>δ</td><td>3</td><td>3</td><td>4</td><td>2</td></tr><tr><td>γ</td><td>14/6</td><td>0</td><td>5</td><td>2</td></tr></tbody></table>
<p>*Total gene segments/functional gene segments</p>
<p>are visible for two reasons. First, a normal patient specimen contains cells other than lymphocytes that do not undergo gene rearrangement. The second reason for the presence of the germline bands is that only one chromosome in a lymphocyte undergoes gene rearrangement, leaving the homologous chromosome in the germline state. If the first rearrangement fails or is unproductive, then the second chromosome will rearrange. This occurs in fewer than 10% of lymphocytes for the heavy chain gene.</p>
<p>In a normal specimen, there will be millions of immunoglobulin gene rearrangements so that no one rearrangement is present in high enough amounts to be visible as non-germline bands on the membrane or autoradiogram; thus, only the germline bands will be visible. If, however, 2%-5% of the cells in the specimen consist of a clone of cells all with the same gene rearrangement, that clone will be detected by the presence of additional bands different from the germline bands (Fig. 14-20). Interpretation of the results is positive if extra bands are present and negative if only the germline bands are present.</p>
<p><img src="assets/images/image-20251222-1b6b1229.jpeg" alt="img-355.jpeg">
Figure 14-19 Restriction map of the germline immunoglobulin heavy chain gene. The fragments indicated by the arrows will be detectable with the probe shown at the bottom. Gene rearrangement will affect the placement of the restriction sites such that fragments of different sizes will be generated from a rearranged gene.</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="advanced-concepts">Advanced Concepts<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#advanced-concepts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Three enzymes are used for this assay to avoid false-positive results due to cross-hybridization artefacts (see Chapter 6). The chance of true rearranged bands being identical to cross-hybridization patterns for all three enzymes is negligible. In addition, cross-hybridization patterns are constant with the same hybridization conditions, in contrast to true monoclonal gene rearrangement bands that differ for each monoclonal population.</p>
<p>Analysis of clonality by Southern blot affords the advantage of detecting all gene rearrangements, including incomplete rearrangements involving only the D and J regions of the gene. The Southern blot method is limited by the requirement for at least  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mo>−</mo><mn>30</mn><mi>μ</mi><mi mathvariant="normal">g</mi></mrow><annotation encoding="application/x-tex">20 - 30\mu \mathrm{g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">30</span><span class="mord mathnormal">μ</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span>  of high-quality</p>
<p><img src="assets/images/image-20251222-a50b3928.jpeg" alt="img-356.jpeg">
Figure 14-20 Colorimetric results from an immunoglobulin heavy chain gene rearrangement test by Southern blot with colorimetric detection. Lane 1, molecular weight markers. Lanes 2, 6, and 8 show the normal 18-kbp, 18-kbp, and 11-kbp bands expected from the germline gene in a normal specimen cut with EcoR1, BamH1, and HindIII, respectively. Lanes 3, 6, and 9 show patient DNA with a monoclonal cell population. Lanes 4, 7, and 10 show a patient with no detectable monoclonality.</p>
<p>DNA from the specimen. This is not always available, either because the specimen is limiting with respect to cell number or it is in poor condition as in paraffin-embedded specimens. Moreover, artifacts such as cross-hybridizations may complicate interpretation of Southern blot results.</p>
<p>Gene rearrangement monoclonality at the immunoglobulin heavy chain gene locus is also analyzed by PCR. For this method, forward primers complementary to the variable region and reverse primers to the joining or constant regions of the B cell-rearranged genes are used.[89] The resulting amplicons are resolved by agarose, polyacrylamide or capillary electrophoresis. A normal cell population will yield amplicons consisting of fragments of different lengths, yielding a cloud or smear of bands. A monoclonal cell population will yield a predominant or single band. The presence of the band is interpreted as a positive result.</p>
<p>For immunoglobulin heavy chain gene rearrangement, different approaches to the variable region primer binding sites have been taken (Fig. 14-21). The immunoglobulin heavy chain gene variable region is divided into two types of domains. The complementarity determining regions (CDRs) code for the amino acids that will contact the antigen. The CDRs, therefore, are the most variable, or unstable, in sequence. The framework regions (FRs) code for the amino acids that have more of a structural role in the antibody protein and are more stable in</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="advanced-concepts">Advanced Concepts<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#advanced-concepts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The main limitation to detection of clonality by PCR is the loss of the FR3 primer binding site due to the gene rearrangement process that may destroy or remove the sequences bound by the FR3 primer. To address this issue, some laboratories use additional forward primers that bind to framework 2 (FR2) and framework 1 (FR1). Other methods utilize primers to the leader region in addition to the FR primers.[92,141,142] These primers increase the number of gene rearrangements that can be amplified and therefore detected by this assay. If the gene rearrangement cannot be amplified, clonality at the immunoglobulin heavy chain gene locus cannot be used for diagnosis or monitoring.</p>
<p>Copyright ©2007 by F. A. Davis.
Molecular Oncology Chapter 14 353</p>
<p><img src="assets/images/image-20251222-17e7bb30.jpeg" alt="img-357.jpeg"></p>
<p><img src="assets/images/image-20251222-ac9182f7.jpeg" alt="img-358.jpeg">
Figure 14-21 Immunglobulin heavy chain gene rearrangement by PCR with amplification from the variable region. Forward primers complementary to the variable region and reverse primers complementary to the joining region are used to amplify the diversity region (top). In a polyclonal specimen, amplification products in a range of sizes will result. These products produce a dispersed pattern on an ethidium bromide-stained agarose gel (lanes 4, 8, 11). If at least 1% of the sample is representative of a monoclonal gene rearrangement, that product will be amplified preferentially and revealed as a sharp band by gel electrophoresis (lanes 3, 6, 9, and 10).</p>
<p>sequence. Standard methods for clonality utilize a forward consensus primer to the innermost framework region (FR3) and the reverse primer complementary to the joining region. The consensus primer has sequences that match the most frequently occurring sequences in the FR3 region and may not be identical to any one sequence. Enough nucleotides will hydrogen-bond, however, to match most rearranged variable regions.</p>
<p>Primers directed at the diversity region are useful for amplification of the germline configuration of the immunoglobulin heavy chain genes as well as D_H-J_H rearranged genes.90 Primers complementary to the 7 family-specific sequences of the diversity region and a primer to the</p>
<p><img src="assets/images/image-20251222-44a7fb82.jpeg" alt="img-359.jpeg">
Figure 14-22 Immunglobulin heavy chain gene rearrangement by PCR with amplification from the diversity region. Forward primers complementary to the diversity region and reverse primers complementary to the joining region yield a polyclonal pattern in normal samples. The D_H7 primer will yield a specific 350-bp product from the unrearranged (germline) gene due to the short distance between the D_H7 gene segment and the joining region primer.</p>
<p>5'-most joining region (J_H1) are used to amplify the D_H-J_H junction. The primer complementary to the D_H7-27 segment, the sequences closest to the joining region, will yield a defined product from the Ig heavy chain gene in the germline configuration (Fig. 14-22). Diversity region primers are also useful for targeting incomplete rearrangements where the variable region primer binding sites are lost91,92</p>
<p>Another approach to the detection of B-cell clonality is to make patient-specific primers. For this method, a consensus primer is used to amplify the rearranged gene from a positive specimen. The amplification product is then purified from the gel or from the PCR reaction mix and sequenced. Primers exactly matching the variable region sequence of that specimen are then manufactured for use on subsequent samples. The advantage of this method is that it is more sensitive, as fewer or none of the gene rearrangements from normal cells are amplified. Furthermore, the tumor load can be measured quantitatively by real-time PCR. The disadvantage of this approach is that the method is more time-consuming to perform, and the primers used are patient-specific. Moreover, in a patient with a chronic condition, for whom monitoring is likely to be done, tumors cells may undergo mutation in the variable region and inactivate the specific primer binding, requiring manufacture of new primers.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="immunoglobulin-light-chain-gene-rearrangements">Immunoglobulin Light Chain Gene Rearrangements<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#immunoglobulin-light-chain-gene-rearrangements" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The immunoglobulin light chain genes are also targets for clonality detection.93-95 In addition to Southern blot, PCR</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<p>and RT-PCR have been used to detect light chain gene clonality. Targeting the immunoglobulin light chain genes is especially useful for tumors arising from terminally differentiated B cells (plasma cells) that have undergone extensive somatic hypermutation at the heavy chain gene locus. In these tumors, the rearranged heavy chain genes are frequently unamplifiable, yielding false-negative results because of accumulation of base changes in the variable region primer binding sites. Most of these tumors are amplifiable, however, at the light chain genes.[96]</p>
<p>Gene rearrangements in the kappa light chain locus are amplified using primers complementary to the sequence families of the  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">V</mi><mi>κ</mi></msub></mrow><annotation encoding="application/x-tex">\mathrm{V}_{\kappa}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">V</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.1514em;"><span style="top: -2.55em; margin-left: -0.0139em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">κ</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>  region or to the intron between the  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">J</mi><mi>κ</mi></msub></mrow><annotation encoding="application/x-tex">\mathrm{J}_{\kappa}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">J</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.1514em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">κ</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>  regions and  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">C</mi><mi>κ</mi></msub></mrow><annotation encoding="application/x-tex">\mathrm{C}_{\kappa}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">C</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.1514em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">κ</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> . Opposing primers are complementary to  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">C</mi><mi>κ</mi></msub></mrow><annotation encoding="application/x-tex">\mathrm{C}_{\kappa}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">C</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.1514em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">κ</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>  and to one or more of the five joining regions. Alternately, the KDE can be used for a primer binding site (Fig. 14-23). Using the KDE allows detection of lambda-expressing cells that have deleted  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">J</mi><mi>κ</mi></msub></mrow><annotation encoding="application/x-tex">\mathrm{J}_{\kappa}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">J</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.1514em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">κ</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>  or  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">C</mi><mi>κ</mi></msub></mrow><annotation encoding="application/x-tex">\mathrm{C}_{\kappa}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">C</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.1514em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">κ</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> .</p>
<p>Approximately one-third of B-cell malignancies have  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">g</mi></mrow><mi>λ</mi></msub></mrow><annotation encoding="application/x-tex">\mathrm{Ig}_{\lambda}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9275em; vertical-align: -0.2441em;"></span><span class="mord"><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Ig</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.242em;"><span style="top: -2.4559em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">λ</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.2441em;"><span></span></span></span></span></span></span></span></span></span></span>  gene rearrangements.[98]  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">g</mi></mrow><mi>λ</mi></msub></mrow><annotation encoding="application/x-tex">\mathrm{Ig}_{\lambda}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9275em; vertical-align: -0.2441em;"></span><span class="mord"><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Ig</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.242em;"><span style="top: -2.4559em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">λ</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.2441em;"><span></span></span></span></span></span></span></span></span></span></span>  gene rearrangements are also present in  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi><mo>−</mo><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5\% - 10\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.0833em;"></span><span class="mord">5%</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span>  of kappa-expressing B-cell tumors. Therefore, detection of clonality at the  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">g</mi></mrow><mi>λ</mi></msub></mrow><annotation encoding="application/x-tex">\mathrm{Ig}_{\lambda}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9275em; vertical-align: -0.2441em;"></span><span class="mord"><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Ig</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.242em;"><span style="top: -2.4559em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">λ</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.2441em;"><span></span></span></span></span></span></span></span></span></span></span>  locus on chromosome 22 is also useful for confirming or monitoring diagnosis of B-cell leukemias and lymphomas. Forward primers complementary to  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">V</mi><mi>λ</mi></msub></mrow><annotation encoding="application/x-tex">\mathrm{V}_{\lambda}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">V</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3361em;"><span style="top: -2.55em; margin-left: -0.0139em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">λ</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>  gene segments and reverse primers to the  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">J</mi><mi>λ</mi></msub></mrow><annotation encoding="application/x-tex">\mathrm{J}_{\lambda}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">J</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3361em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">λ</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>  and  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">C</mi><mi>λ</mi></msub></mrow><annotation encoding="application/x-tex">\mathrm{C}_{\lambda}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">C</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3361em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">λ</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>  gene segments are frequently used for these assays (Fig. 14-24).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="t-cell-receptor-gene-rearrangements">T-Cell Receptor Gene Rearrangements<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#t-cell-receptor-gene-rearrangements" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>T-cell receptor gene rearrangements are performed in a manner similar to the immunoglobulin gene rearrange-</p>
<p><img src="assets/images/image-20251222-076533ef.jpeg" alt="img-360.jpeg">
Figure 14-24 The immunoglobulin light chain lambda locus can be amplified by standard PCR procedures from the variable region to the joining region or the constant region. Reverse transcriptase PCR is used with the constant region primers to eliminate the intron between the constant and joining regions.</p>
<p>ments by Southern blot and PCR.[99-101] For Southern blot studies, probes complementary to the variable, joining, and diversity regions of the T-cell receptor genes are used to detect monoclonal populations. Just as with immunoglobulin gene rearrangements, no one gene rearrangement should be visible in a normal specimen. The presence of a large monoclonal population is revealed by the bands detectable in addition to the germline bands seen in the normal control (Fig. 14-25).</p>
<p>The T-cell receptor gene rearrangement assays done by PCR target most often the TCR <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>γ</mi></mrow><annotation encoding="application/x-tex">\gamma</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.625em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05556em;">γ</span></span></span></span></span>  gene. Assays are also performed on the TCR <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>  and TCR <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>δ</mi></mrow><annotation encoding="application/x-tex">\delta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord mathnormal" style="margin-right: 0.03785em;">δ</span></span></span></span></span>  genes. Detection of gene rearrangements in TCR <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span>  is difficult due to the 85-kb length of the J <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span>  gene segments. TCR <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span>  gene rearrangements may be inferred from TCR <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>δ</mi></mrow><annotation encoding="application/x-tex">\delta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord mathnormal" style="margin-right: 0.03785em;">δ</span></span></span></span></span>  gene deletions.[101] Primers are designed complementary to the rearranged gene segments (Fig. 14-26). Multiple primer sets are often used to ensure detection of the maximum potential gene rearrangement.[102] PCR will yield a pro</p>
<p><img src="assets/images/image-20251222-e6bbaf20.jpeg" alt="img-361.jpeg">
Figure 14-23 The immunoglobulin light chain kappa locus can be amplified by standard PCR procedures from the variable region, the intronic region, or the kappa deleting element.</p>
<p>Copyright ©2007 by F. A. Davis.
Molecular Oncology Chapter 14 355</p>
<p><img src="assets/images/image-20251222-074fdc4f.jpeg" alt="img-362.jpeg">
Figure 14-25 T-cell receptor gene rearrangements detected by Southern blot using a probe mixture of sequences complementary to Jβ1 and Jβ2. Lane 1, molecular weight markers. Lanes 2, 5, and 8, normal control cut with EcoR1, BamH1, and HindIII, respectively. Lanes 3, 6, and 9, a negative specimen cut with EcoR1, BamH1, and HindIII, respectively. Lanes 4, 7, and 10, positive specimen cut with EcoR1, BamH1, and HindIII, respectively. Note the additional bands in the positive specimen lanes.</p>
<p>duct consistent with a single gene rearrangement in a positive sample, whereas a normal sample will yield a polyclonal pattern (Fig. 14-27). Due to the limited range of lengths of the population of rearranged T-cell receptor genes, heteroduplex analysis, SSCP, or DGGE may be</p>
<p><img src="assets/images/image-20251222-1992f224.jpeg" alt="img-363.jpeg">
Figure 14-26 T-cell receptor gene rearrangements detected by PCR use primers to the variable, diversity, and joining regions of the rearranged genes.</p>
<p><img src="assets/images/image-20251222-d86103de.jpeg" alt="img-364.jpeg">
Figure 14-27 T-cell receptor gene rearrangement by PCR and heteroduplex analysis. Bands were separated by polyacrylamide gel electrophoresis and stained with ethidium bromide. Lanes 2 and 4 show a polyclonal pattern. A positive result (monoclonal pattern) is shown in lane 3. Lane 1, molecular weight marker; lane 5 reagent blank.</p>
<p>used to improve resolution of the polyclonal and monoclonal patterns.¹⁰³</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="banding-patterns">Banding Patterns<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#banding-patterns" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Interpretation of clonality by PCR depends on gel banding patterns. False-negative results may arise from primers that do not match the gene rearrangement in the tumor. False-positive results arise from artifactual single bands. Patterns of multiple single bands may arise from specimens with low cell numbers, such as cerebrospinal fluids or paraffin sections. In this case, usually more than one or two single bands occur. The bands may not indicate monoclonality, rather that only a few cells are present. These cells may or may not be malignant. False single band patterns may also occur within polyclonal smears detected by nondenaturing polyacrylamide gels (PAGEs). Heteroduplex analysis is recommended if amplicons are resolved by nondenaturing PAGEs.</p>
<p>Similar problems may arise with resolution by capillary electrophoresis where peak heights and widths are compared to distinguish wide polyclonal peaks from narrow monoclonal spikes.¹⁰⁴ Pretreatments such as eosin staining may yield false single bands by capillary electrophoresis.¹⁰⁵</p>
<p>Copyright ©2007 by F. A. Davis.
Section 3 Techniques in the Clinical Lab</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="translocations-in-hematological-malignancies">Translocations in Hematological Malignancies<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#translocations-in-hematological-malignancies" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Gene rearrangements in immunoglobulin and T-cell receptor genes are normal and take place regardless of the presence of malignancy. The unique nature of the gene rearrangement system with cell-specific antibody and antibody receptor formation are exploited in finding abnormal cell populations clonally derived from these cell-specific features. Targeting these gene rearrangements, however, can only be applied to tumors arising from lymphocytes. Other types of malignancies, such as myeloid tumors, cannot be analyzed using these targets.</p>
<p>Often, development of the cancer state results in DNA anomalies, such as translocations or other types of mutations, that can be applied to clinical discovery and monitoring of tumors. These abnormal genetic events aid in diagnosis of specific types of hematological tumors, such as the translocations that are highly associated with chronic myelogenous leukemia, promyelocytic leukemia, or follicular lymphoma. Mutations or disruptions of expression of tumor suppressor genes and oncogenes are usually involved in hematological malignancies, which has helped to determine the molecular events leading to the tumor phenotype.</p>
<p>Translocations are the exchange of DNA between chromosomes (see Chapter 8). If the translocation disrupts activity or expression of oncogenes or tumor suppressor genes, a cancer phenotype can occur. Several translocations are frequently found in certain types of tumors.</p>
<ul>
<li>t(14;18)(q32;q21)</li>
</ul>
<p>The reciprocal translocation between the long arms of chromosomes 14 and 18 moves and disregulates the BCL2 gene located on chromosome 18q21.3. BCL2 (B-cell leukemia and lymphoma 2 or B-cell CLL/lymphoma 2) is an oncogene. The gene product of BCL2 is a member of a group of related proteins that control apoptosis (cell death initiated by internal cellular signals). The Bcl2 protein inhibits apoptosis in B lymphocytes, that is, enhances survival of cells that normally would die. Survival of genetically damaged cells may contribute to the development of tumors. One of the most frequent hematological malignancies, follicular lymphoma, is associated with the t(14;18) translocation.</p>
<p>The translocation partner of chromosome 18 is chromosome 14 in the vicinity of the immunoglobulin heavy chain gene. The translocation may occur through cryptic recognition sites for the gene rearrangement recombinase enzymes on chromosome 18. As a result, an abnormal interchromosomal exchange occurs, instead of the normal intrachromosomal exchange events described in the previous section (Fig. 14-28). There are several breakpoints in the chromosome 18 region 3' to the BCL2 gene, most of which occur in the major breakpoint region (MBR). About 10%-20% of the breakpoints fall into a cluster closer to the BCL2 gene, thousands of bases from the MBR, in the minor cluster region (MCR). An intermediate cluster region (ICR) and other breakpoints outside of MBR and MCR have also been reported.[106,107]</p>
<p>Molecular detection of the t(14;18) translocation is performed by Southern blot or PCR. For Southern blot, a probe to the MBR region of chromosome 18 will reveal the translocation by the presence of bands different from those expected from normal chromosome 18 (Fig. 14-29). The Southern blot procedure has the advantage of detecting all breakpoints. The translocation is more easily and rapidly detected by PCR. Forward primers to chromosome 18 and reverse primers complementary to the Ig heavy chain joining region will yield a product only if the two chromosomes have been joined by the translocation. The amplicons are visualized by gel electrophoresis as shown in Figure 14-30 or by capillary electrophoresis, the latter method requiring fluorescent labeling of one of the PCR primers.</p>
<p>The t(14;18) translocation can also be detected using real-time PCR. Several methods are available for this analysis, and although laboratory methods differ, results are reasonably consistent in comparison testing.[108,109]</p>
<p><img src="assets/images/image-20251222-c9245e0a.jpeg" alt="img-365.jpeg">
Figure 14-28 The t(14;18) translocation moves the BCL2 gene intact to the long arm of chromosome 14 next to the joining region of the immunoglobulin heavy chain gene (IgH). The translocation breakpoints on chromosome 18 are 3' to the BCL2 gene (arrow indicating the direction of transcription).</p>
<p>Copyright ©2007 by F. A. Davis.
Molecular Oncology Chapter 14 357</p>
<p><img src="assets/images/image-20251222-a9ee9074.jpeg" alt="img-366.jpeg">
Figure 14-29 Analysis of the t(14;18) gene translocation by Southern blot with chemiluminescent detection. Lanes 3, 6, and 9 are the normal control cut with EcoR1, BamH1, and HindIII, respectively. Lanes 1, 4, and 7 show results from a normal patient specimen. Lanes 2, 5, and 8 are results from a specimen positive for the t(14;18) translocation. Note the extra bands in the positive specimen.</p>
<p>Most methods include a standard curve for regression analysis of the test sample measurements (Fig. 14-31). Alternatively, internal controls, such as known amounts of plasmid DNA, may be added to the test specimens. In this method, the amount of translocated cells (or translocated chromosomes) is determined relative to the internal control. There are several approaches to reporting final results. Most frequently, results are reported as percent translocated cells in the specimen tested. For instance, the raw number of translocated cells is determined by linear regression analysis (using the formula <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>y</mi><mo>=</mo><mi>m</mi><mi>x</mi><mo>+</mo><mi>b</mi></mrow><annotation encoding="application/x-tex">y = mx + b</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.625em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.03588em;">y</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord mathnormal">m</span><span class="mord mathnormal">x</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord mathnormal">b</span></span></span></span></span>). The raw number of cells is then divided by the number of total cells represented in the PCR reaction.</p>
<p>For example: for a dilution series ranging 50–10,000 translocated cells in 1 million untranslocated cells, the standard curve generates the formula <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>y</mi><mo>=</mo><mn>1.5631</mn><mi>ln</mi><mo>⁡</mo><mo stretchy="false">(</mo><mi>x</mi><mo stretchy="false">)</mo><mo>+</mo><mn>42.396</mn></mrow><annotation encoding="application/x-tex">y = 1.5631 \ln(x) + 42.396</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.625em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.03588em;">y</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1.5631</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mop">ln</span><span class="mopen">(</span><span class="mord mathnormal">x</span><span class="mclose">)</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">42.396</span></span></span></span></span>, where <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>y</mi></mrow><annotation encoding="application/x-tex">y</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.625em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.03588em;">y</span></span></span></span></span> is the threshold cycle number (see Chapter 7) and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>x</mi></mrow><annotation encoding="application/x-tex">x</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal">x</span></span></span></span></span> is the number of translocated cells (50 ng of DNA was used per sample). Using this formula, if a given sample crosses the fluorescent threshold at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>y</mi><mo>=</mo><mn>36</mn></mrow><annotation encoding="application/x-tex">y = 36</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.625em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.03588em;">y</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">36</span></span></span></span></span> cycles (average of duplicate measurements), the number of cells (<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>x</mi></mrow><annotation encoding="application/x-tex">x</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal">x</span></span></span></span></span>) is approximately 60 cells. Assuming that 50 ng of DNA represents 7500 cells (1 ng of DNA = approximately 150 cells), <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mi mathvariant="normal">/</mi><mn>7500</mn><mo>=</mo><mn>0.008</mn></mrow><annotation encoding="application/x-tex">60/7500 = 0.008</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">60/7500</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">0.008</span></span></span></span></span>. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.008</mn><mo>×</mo><mn>100</mn><mo>=</mo><mn>0.8</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.008 \times 100 = 0.8\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.008</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.8%</span></span></span></span></span> translocated cells in the specimen. For the t(14;18) translocation, sensitivities of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.0025</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.0025\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.0025%</span></span></span></span></span> have been</p>
<p><img src="assets/images/image-20251222-5ba9c676.jpeg" alt="img-367.jpeg">
Figure 14-30 Analysis of the t(14;18) gene translocation by PCR with agarose gel electrophoresis. Several primers are used for detection of the translocated chromosome (top). Because the forward primers are on chromosome 18 and the reverse primers are on chromosome 14, a PCR product will be generated only from the t(14;18) translocated chromosome (bottom). M, molecular weight marker; +, positive specimen; -, negative specimen; P, positive control; S, sensitivity control; N, negative control.</p>
<p><img src="assets/images/image-20251222-3b2caae2.jpeg" alt="img-368.jpeg"></p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<p><img src="assets/images/image-20251222-5325a46b.jpeg" alt="img-369.jpeg"></p>
<p><img src="assets/images/image-20251222-dc579f13.jpeg" alt="img-370.jpeg">
Figure 14-31 t(14;18) translocation analysis by real-time PCR. A standard curve is established using cultured cells with the t(13;18) translocation (Dhl-6) counted and diluted into cultured cells without the translocation (HL-60). The results shown are from DNA isolated from each mixture of cells and analyzed by real-time PCR using a TaqMan probe.</p>
<p>reported, with a linear range of  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.01</mn><mi mathvariant="normal">%</mi><mo>−</mo><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.01\% - 10\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.0833em;"></span><span class="mord">0.01%</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> . Data are accumulating to determine the clinical significance of the qualitative and quantitative results.[111-113]</p>
<p>The main limitation of any PCR procedure targeting the t(14;18) translocation is the inability of the primers to detect all of the possible breakpoints on chromosome 18. Several primer pairs and sets of primer pairs have been designed to address this problem.[89] Test reports should</p>
<p>include an estimation of false-negative results expected due to breakpoints that remove the binding sites for the primers used. Unless a translocation has been previously observed by a given PCR method, a negative result may be reported as indeterminate, acknowledging that a translocation may be present but undetectable with the primers used.</p>
<ul>
<li>t(9;22)(q34;q11)</li>
</ul>
<p>The t(9;22) translocation is a reciprocal exchange between the long arms of chromosomes 9 and 22. The translocation generates the Philadelphia chromosome (Ph1), which is present in  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>95</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">95\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">95%</span></span></span></span></span>  of cases of chronic myelogenous leukemia (CML),  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi><mo>−</mo><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25\% -30\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.0833em;"></span><span class="mord">25%</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span>  of adult acute lymphoblastic leukemia (ALL), and  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi><mo>−</mo><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2\% -10\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.0833em;"></span><span class="mord">2%</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span>  of pediatric ALL. The breakpoints of the t(9;22) translocation occur within two genes, the breakpoint cluster region (BCR) gene on chromosome 22 and the cellular counterpart of the Abelson leukemia virus tyrosine kinase (c-abl) on chromosome 9 (Fig. 14-32). The result of the translocation is a chimeric or fusion gene with the head of the BCR gene and the tail of the c-abl gene. Both genes are tyrosine kinases; that is, they phosphorylate other genes at tyrosine residues. The fusion gene is also a kinase but has aberrant kinase activity.</p>
<p>There are two major forms of the BCR/ABL fusion gene, joining either exon 13 or 14 (b2 or b3) of the BCR gene to c-abl exon 2 (a2; Figure 14-33). The b2a2 or b3a2 fusion genes code for a 210 kilodalton protein,</p>
<p><img src="assets/images/image-20251222-444d2a21.jpeg" alt="img-371.jpeg">
Figure 14-32 The t(9;22) translocation begins with breakage of chromosomes 9 and 22 in introns of the BCR and c-abl genes (arrows). The breakpoints are located within introns of both genes.</p>
<p>Copyright ©2007 by F. A. Davis.
Molecular Oncology Chapter 14 359</p>
<p><img src="assets/images/image-20251222-04842243.jpeg" alt="img-372.jpeg"></p>
<p><img src="assets/images/image-20251222-1907afb3.jpeg" alt="img-373.jpeg">
Figure 14-33 p210 and p190 are the two main fusion proteins produced by the t(9;22) translocation. They differ in the amount of the BCR gene that is attached to the c-abl gene.</p>
<p>p210. A third form of the fusion gene joins exon 1 of BCR with exon a2 of c-abl, resulting in expression of an e1a2 transcript, which codes for a p190 protein. Another, less common, fusion junction occurs at exon 19 of the BCR gene (c3). The c3a2 transcript encodes a p230 protein. All of the fusion proteins have been observed in CML; however, p190 occurs mostly in ALL.</p>
<p>Detection of the t(9;22) translocation can be performed by Southern blot in a manner similar to that described above for detection of t(14;18). One probe used for this test is a 1.2-kb fragment complementary to the 3′ end of the BCR gene. Restriction fragment patterns will differ in translocated cells (Fig. 14-34). Other probes to BCR may also be used to ensure detection of all breakpoints.</p>
<p>The common rationale for detection of translocations by PCR is used for t(9;22); that is, forward primers are designed to hybridize to the BCR gene on chromosome 22 and reverse primers to chromosome 9 in the c-abl gene (Fig. 14-35). A product will result only if the two genes are joined by the translocation. Due to the length of the introns that separate the primer binding sites, nested RT</p>
<p><img src="assets/images/image-20251222-47eea21e.jpeg" alt="img-374.jpeg">
Figure 14-34 Southern blot of a t(9;22) translocation with a probe to the 3′ end of the BCR gene. Lane 1, molecular weight marker; lanes 2, 4, and 6, normal control cut with BglII, BamH1, and HindIII, respectively; lanes 3, 5, and 7, a specimen positive for the translocation cut with BglII, BamH1, and HindIII, respectively. Note the shift in the sizes of the bands in lanes 3 and 5 compared with lanes 2 and 4. (A doublet is not quite resolved from the larger band in lane 7.)</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<p><img src="assets/images/image-20251222-b5fd684b.jpeg" alt="img-375.jpeg">
Figure 14-35 Location of primers (horizontal arrows) for PCR analysis of the minor breakpoint region (top) and the major breakpoint region (middle). The c-abl gene itself may be used as an amplification control (bottom). The intron and exon lengths are not drawn to scale. Vertical arrows denote locations of breakpoints.</p>
<p>PCR has been commonly utilized. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mrow><mn>114</mn><mo separator="true">,</mo><mn>115</mn></mrow></msup></mrow><annotation encoding="application/x-tex">^{114,115}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">114</span><span class="mpunct mtight">,</span><span class="mord mtight">115</span></span></span></span></span></span></span></span></span></span></span></span></span>  To minimize the risk of false-positive results, this method may require confirmatory testing, especially for adult ALL. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>116</mn></msup></mrow><annotation encoding="application/x-tex">^{116}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">116</span></span></span></span></span></span></span></span></span></span></span></span></span>  Several recommendations for optimal performance have been proposed, including the use of primers capable of detecting both major and minor breakpoints in the BCR gene and an internal RNA integrity control (or amplification control) to avoid false-negative results from poor RNA quality or inadequate cDNA synthesis. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mrow><mn>117</mn><mo>−</mo><mn>118</mn></mrow></msup></mrow><annotation encoding="application/x-tex">^{117-118}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">117</span><span class="mbin mtight">−</span><span class="mord mtight">118</span></span></span></span></span></span></span></span></span></span></span></span></span>  Transcripts from the abl or BCR genes are used most frequently for</p>
<p>the RNA integrity control for the t(9;22) translocation, but any unique gene with constitutive expression may be used. Target amplicons can be detected by agarose gel electrophoresis and ethidium bromide staining (Fig. 14-36) or by capillary gel electrophoresis. Fluorescent dye-labeled primers are required for the latter detection method.</p>
<p>Real-time PCR provides quantitative estimation of treatment response, especially with novel therapies for CML and ALL. Although cytogenetic methods, espe</p>
<p><img src="assets/images/image-20251222-c83a4e6a.jpeg" alt="img-376.jpeg">
Figure 14-36 Results of a standard RT-PCR test for the t(9;22) translocation. Lane 1, molecular weight marker; lane 2, b3a2 breakpoints; lane 3, b2a2 breakpoints; lanes 4 and 5, e1a2 breakpoints; lane 6, negative specimen; lanes 7-11 are RNA integrity (amplification) controls for specimens in lanes 2-6; lane 12, reagent blank.</p>
<p>Copyright ©2007 by F. A. Davis.
Molecular Oncology Chapter 14 361</p>
<p>cially FISH and standard RT-PCR, are most practical for diagnosis and in the early stages of treatment, quantitative PCR provides a valuable estimation of tumor load over the course of treatment.¹¹⁹,¹²⁰</p>
<p>Because transcript levels are being measured using RT-PCR, it is important to stabilize the specimen RNA on receipt, for example by resuspending the white blood cells in protective buffers (see Chapter 4). Another recommendation is to collect at least 10 mL of peripheral blood for analysis to avoid false-negative results.¹²¹ Primers used for this method are similar to those used for standard PCR. A TaqMan probe provides the fluorescent signal. A standard curve or a high and low positive control and negative control should accompany each run. Frequently used TaqMan methods report measurements as a ratio of the BCR-abl transcript level to the RNA integrity control, usually the abl transcript, the BCR transcript, or the transcript of a housekeeping gene, such as G6PDH¹¹⁹,¹²²⁻¹²⁴ For example, a standard curve for transcript number (Fig. 14-37) generates the formula, y = -1.7318Ln(x) + 48.627, where y is the threshold cycle number and x is the number of transcripts. If quantitative PCR analysis of the patient specimen RNA yielded a threshold cycle number of 39 (average of duplicate samples) for BCR-abl transcripts and a threshold cycle number of 30 for the abl transcripts, then solving for x yields 300 BCR-abl transcripts and 50,000 abl transcripts in the sample. Thus, (300/50,000) × 100 = 0.6%.</p>
<p>Data are still being collected with regard to the clinical significance of the quantitative results. A three-log drop in transcript levels or a BCR-abl/abl × 100 level below 0.05% have been proposed as indicators of good prognosis.¹²⁵ ¹²⁶</p>
<ul>
<li>t(15;17)(q22;q11.2-q12)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="advanced-concepts">Advanced Concepts<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#advanced-concepts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A slightly different formula, [BCR-abl/(abl - BCR-abl)] × 100, for the transcript ratio is used if the abl primers also amplify the BCR-abl translocation.¹⁴³ In the calculation shown in the text, BCR-abl/abl × 100 yields 0.6%; [BCR-abl/(abl - BCR-abl)] × 100 yields 0.85%.</p>
<p><img src="assets/images/image-20251222-018c23aa.jpeg" alt="img-377.jpeg"></p>
<p><img src="assets/images/image-20251222-9e543eb2.jpeg" alt="img-378.jpeg">
Figure 14-37 Real-time PCR analysis of transcript levels requires a standard curve of known transcript numbers. The number of translocated transcripts in the specimen can then be determined from the standard curve.</p>
<p>This reciprocal translocation between the long arms of chromosomes 15 and 17 results in fusion of the retinoic acid receptor alpha (RARA) gene on chromosome 15 with the myelocytic leukemia (MYL, or PML) gene on chromosome 17. Both genes contain zinc finger binding motifs and therefore bind DNA as transcription factors. The PML/RARA fusion is found specifically in promyelocytic leukemia. The presence of this translocation is also a predictor of the response to retinoic acid therapy that is used as treatment for this disease. The translocation forms a fusion gene with the first three (type A or S translocation) or six (type B or L translocation) exons of the PML gene joining to exons 2-6 of the RARA gene (Fig. 14-38).</p>
<p>Test methods similar to those described above for BCR-abl translocation are used to detect t(15;17). Reverse transcriptase PCR and real-time reverse transcriptase PCR are most frequently used. Primers complementary to sequences in exon 3 or 6 of the PML gene and exon 2 of RARA generate products only if the translocation has occurred. The presence of the translocation product, therefore, is interpreted as a positive result. As with any test of this type, an amplification control is required to avoid false-negative results. For quantitative PCR, results normalized to an internal control, using calcula</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<p><img src="assets/images/image-20251222-a65abc09.jpeg" alt="img-379.jpeg">
Figure 14-38 Location of primers for PCR analysis of the long (top) and the short (bottom) translocated genes. The first three or six exons of the PML gene is fused to exon 2 of the RARA gene. The intron and exon lengths are not drawn to scale.</p>
<p>tions as described above, yield the most consistent day-to-day results (lowest coefficient of variance).127</p>
<ul>
<li>t(11;14)(q13;q32)</li>
</ul>
<p>This translocation joins the immunoglobulin heavy chain gene region on chromosome 14 with part of the long arm of chromosome 11. The cyclin D1 (CCND1) gene, also called the parathyroid adenomatosis 1 gene (PRAD 1) or BCL1, on chromosome 11 is attached to the long arm of chromosome 14 in the intron between the immunoglobulin heavy chain gene joining and constant regions. The translocation increases expression of CCND1, resulting in passage of the cell cycle from the G1 to the S phase of the cell cycle. This translocation is found primarily in mantle cell lymphoma (MCL) but may also be present in chronic lymphocytic leukemia, B-prolymphocytic leukemia, plasma cell leukemia, multiple myeloma, and splenic lymphoma. The t(11;14) transloca</p>
<p>tion is thought to be a definite characteristic of MCL; however, only  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi><mo>−</mo><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50\% -70\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.0833em;"></span><span class="mord">50%</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span>  of MCLs have a detectable t(11;14).</p>
<p>Methods for detection of t(11;14) are similar to those used for t(14;18) translocation described above. Southern blot methods have been replaced mostly with PCR and RT-PCR.[128] In situ hybridization to detect an increase in CCDN1 transcription has also been proposed.[129] Of the breakpoints on chromosome 11,  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span>  are in the major translocation cluster  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>5</mn><mo mathvariant="normal" lspace="0em" rspace="0em">′</mo></msup></mrow><annotation encoding="application/x-tex">5^{\prime}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7519em;"></span><span class="mord"><span class="mord">5</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7519em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">′</span></span></span></span></span></span></span></span></span></span></span></span></span>  to the CCND1 gene (Fig. 14-39). The rest are dispersed in other areas  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>5</mn><mo mathvariant="normal" lspace="0em" rspace="0em">′</mo></msup></mrow><annotation encoding="application/x-tex">5^{\prime}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7519em;"></span><span class="mord"><span class="mord">5</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7519em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">′</span></span></span></span></span></span></span></span></span></span></span></span></span>  or  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>3</mn><mo mathvariant="normal" lspace="0em" rspace="0em">′</mo></msup></mrow><annotation encoding="application/x-tex">3^{\prime}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7519em;"></span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7519em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">′</span></span></span></span></span></span></span></span></span></span></span></span></span>  of the gene. PCR analysis detects  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi><mo>−</mo><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40\% -60\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.0833em;"></span><span class="mord">40%</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span>  of the translocation breakpoints.[130] A PCR product will result only if the translocation has occurred (and the primer binding</p>
<p><img src="assets/images/image-20251222-c5dc2ebe.jpeg" alt="img-380.jpeg">
Figure 14-39 The t(11;14) breakpoints in chromosome 11 (top) and chromosome 14 (center) are indicated by the vertical arrows. Primers are complementary to the joining region of the immunoglobulin heavy chain gene and the CCND1 gene (bottom).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="advanced-concepts">Advanced Concepts<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#advanced-concepts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>In this translocation, the reciprocal fusion gene RARA/PML is also expressed in  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mi mathvariant="normal">%</mi><mo>−</mo><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70\% - 80\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.0833em;"></span><span class="mord">70%</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span>  of cases of APL. Nonreciprocal events can produce either fusion alone as well.[144,145] Although the reciprocal fusion may participate in the tumorigenesis process, it does not predict response to all transretinoic acid therapy.[146] The presence of the reverse transcript may be used to confirm the translocation and could be useful in cases where the PML/RARA transcript is poorly expressed.</p>
<p>Copyright ©2007 by F. A. Davis.
Molecular Oncology Chapter 14 363</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="advanced-concepts">Advanced Concepts<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#advanced-concepts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A variety of molecular events can result in the overexpression of c-myc. The DNA virus Epstein Barr virus (EBV) is associated with Burkitt's lymphoma.¹⁴⁷ EBV induces cell proliferation and, thus, provides more opportunity for translocation events. Certain types of another DNA virus, human papillomavirus, inserted into the vicinity of c-myc cause overexpression of the gene.¹⁴⁸ Transposable elements such as LINE-1 elements may also destabilize oncogenes.¹⁴⁹</p>
<p>sites are maintained). The PCR product can be detected by gel or capillary electrophoresis.</p>
<ul>
<li>t(8;14)(q24;q11)</li>
</ul>
<p>The avian myelocytomatosis viral oncogene homolog (c-myc) gene on chromosome 8 is one member of a gene family including n-myc and l-myc. The c-myc gene codes for a helix-loop-helix/leucine zipper transcription factor that binds to another protein, Max, and activates transcription of other genes. The t(8;14) is associated with Burkitt's lymphoma; in addition, translocations at (2;8) and t(8;22) are found in about 10% of Burkitt's lymphomas.</p>
<p>In the t(8;14) translocation, the breakpoints on chromosome 8 are spread over a 190-kbp region 5′ to and within the c-myc gene. As a result of the t(8;14) translocation, the c-myc gene is separated from its normal promoter and regulatory region and moved into the switch recombination region of the immunoglobulin heavy chain gene on chromosome 14. In the t(2;8) and the t(8;22) translocations, the chromosome 8 breakpoints are 3′ to the gene, and c-myc is moved into the immunoglobulin kappa or lambda locus, respectively. Translocations of c-myc into the T-cell receptor alpha gene have also been reported.¹³¹</p>
<p>In the laboratory, c-myc translocations are commonly detected by Southern blot analysis with a probe complementary to exon 3 of the c-myc gene; for instance, a ³²P- or digoxigenin-labeled 1.4-kb ClaI-EcoRI restriction fragment. Interphase FISH and CISH (Invitrogen) can</p>
<p><img src="assets/images/image-20251222-1edaec69.jpeg" alt="img-381.jpeg">
Figure 14-40 The t(8:14) breakpoint detected by CISH (Invitrogen). Two probes labeled with biotin or digoxigenin are complementary to sequences flanking the chromosome 14 breakpoint. In the absence of the translocation (left), the probes will appear next to one another in the nucleus. The translocation (right) will move one probe to chromosome 14, leaving the other behind on chromosome 8, resulting in separation of the signals in the nucleus.</p>
<p>also be used to detect the t(8;14) translocation with separate probes to chromosomes 8 and 14 or with chromosome 14 probe pairs (Fig. 14-40).¹³² Overexpression of c-myc is detectable by Northern blot.¹³³ Amplification of the gene can be detected by FISH using a 120-kb c-myc (8q24.12-q24.13) probe labeled with SpectrumOrange (Vysis).¹³⁴</p>
<ul>
<li>FMS-related Tyrosine Kinase 3 (FLT3), 13q12</li>
</ul>
<p>Four classes of growth factor receptor tyrosine kinases have been categorized (see Figure 14-2).¹³⁵ One class, represented by the ERBB family, was described in earlier sections. A second class includes dimeric receptors such as the insulin growth factor receptor as well as several proto-oncogenes. Members of the third class, including FMS, PDGF, FLT1, and KIT, display five immunoglobulin-like domains in the extracellular region, and the catalytic domain is interrupted by a hydrophilic</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<p>"interkinase" sequence of variable length. The fibroblast growth factor receptors represent the fourth class, which differ from the third class by having only three immunoglobulin-like domains in the extracellular region and a short kinase insert in the intracellular domain. FLT3 is a member of the third class of tyrosine kinase receptors.[136]</p>
<p>Particular mutations in  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>F</mi><mi>L</mi><mi>T</mi><mn>3</mn></mrow><annotation encoding="application/x-tex">FLT3</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">F</span><span class="mord mathnormal">L</span><span class="mord mathnormal" style="margin-right: 0.13889em;">T</span><span class="mord">3</span></span></span></span></span>  aberrantly activate the FLT3 kinase and predict poor prognosis in AML. These</p>
<p>mutations include internal tandem duplications (ITD) close to the transmembrane domain or point mutations affecting an aspartic acid residue in the kinase domain (D835 mutations). The ITD can easily be detected by PCR with primers flanking the potentially duplicated region. The size of the amplicon observed by agarose or capillary gel electrophoresis will increase in the event of an ITD.[137] D835 mutations can be detected by PCR-RFLP, where an EcoRV restriction site is destroyed by</p>
<p>Table 14.7 Chromosomal Abnormalities Associated With Leukemias and Lymphomas</p>
<table><thead><tr><th>Disease</th><th>Chromosomal Mutation</th></tr></thead><tbody><tr><td>Pre-B acute lymphoblastic leukemia</td><td>t(1;19)</td></tr><tr><td>Acute lymphocytic leukemia</td><td>t(4;11), t(11;14), t(9;22), del(12)(p11) or (p11p13) or t(12)(p11), i(17q)</td></tr><tr><td>B-cell leukemia</td><td>t(2;8), t(8;14), t(8;22), t(11;14)</td></tr><tr><td>Acute T-lymphocytic leukemia</td><td>t(11;14), del(9)(p21 or 22)</td></tr><tr><td>Acute myeloid leukemia/myelodysplastic syndrome</td><td>t(11q23)-multiple partners</td></tr><tr><td>Acute myeloid leukemia (M2)</td><td>t(8;21), t(6;9)</td></tr><tr><td>Acute promyelocytic leukemia (M3)</td><td>t(15;17), 14q+</td></tr><tr><td>Acute myelomonocytic leukemia (M4)</td><td>t(11;21), inv(16)(p13q22)</td></tr><tr><td>Acute monocytic leukemia (M5)</td><td>t(9;11), del(11)(q23), t(11q23)-multiple partners</td></tr><tr><td>Chronic myelogenous leukemia</td><td>t(9;22), t(11;22), +8, +12, i(17q)</td></tr><tr><td>Acute lymphocytic leukemia</td><td>t(9;22), t(12;21), t(8;14), t(2;8), t(8;22), t(11q)</td></tr><tr><td>Acute nonlymphocytic leukemia</td><td>t(8;21), -Y</td></tr><tr><td>Chronic lymphocytic leukemia</td><td>14q+, +12, t(14;19), del(11)(q22), del(13q), del(17)(p13)</td></tr><tr><td>T-chronic lymphocytic leukemia</td><td>Inv(14)(q11q32) or t(14;14)(q11;q32)</td></tr><tr><td>Burkitt's lymphoma</td><td>t(8;14), t(2;8), t(8;22)</td></tr><tr><td>Diffuse large B-cell lymphoma</td><td>t(3q27), t(14;18); t(8;14)</td></tr><tr><td>T-cell lymphoma</td><td>t(8;14)</td></tr><tr><td>Follicular lymphoma</td><td>t(14;18), t(8;14)</td></tr><tr><td>Mantle cell lymphoma</td><td>t(11;14)</td></tr><tr><td>Multiple myeloma</td><td>t(14q32), 14q+</td></tr><tr><td>Acute nonlymphocytic leukemia</td><td>inv(3q)(q21q26),dup(3q),t(3q;3q), -5 or</td></tr><tr><td>Myeloproliferative/myelodysplastic disease</td><td>del(5)(q12q33), -7 or del(7)(q22), +8, +9</td></tr><tr><td>Myeloproliferative/myeloblastic disease</td><td>del(13)(q12 or q14), +21</td></tr><tr><td>Hairy cell leukemia</td><td>14q+</td></tr><tr><td>Waldenström's macroglobinemia</td><td>14q+</td></tr><tr><td>Mucosa-associated lymphoid tissue lymphoma</td><td>t(11;18), t(14;18), t(1;14)</td></tr><tr><td>Polycythemia vera</td><td>del(20)(q11.2q13.3)</td></tr></tbody></table>
<p>the presence of the mutation or by real-time PCR with FRET probes.138 In performing these assays, it is important to have adequate representation of tumor cells in the specimen to avoid false-negative results from the presence of an excess of normal cells.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="additional-chromosomal-abnormalities">Additional Chromosomal Abnormalities<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#additional-chromosomal-abnormalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Tumor suppressor genes and oncogenes are disrupted by numerous genetic events. A number of specific abnormalities are associated with particular diseases (Table 14.7). These chromosome irregularities are targets for diagnosis of the associated diseases.</p>
<p>To date, many molecular oncology tests are developed by an individual library from published or original procedures rather than purchased as a set of reagents or in kit form from a commercial source. Often the final details of these procedures are determined empirically so that, in detail, a test procedure can differ from one laboratory to another. Even after the test procedure is established, trouble-shooting performed as the procedure is put to use on a routine basis may further modify the procedure. Some reactions that work well for short-term research purposes may prove to be less consistent under the demands of the clinical laboratory setting.</p>
<p>Biotechnology is rapidly developing standard reagent sets for the most popular tests, but these may also differ from one supplier to another. Furthermore, due to market demands, test reagent kits may be modified or discontinued. If replacement reagents are available, they may not be identical to those previously used. Ongoing tests then have to be optimized. This can be a concern where turnaround times are critical.</p>
<p>It then becomes the responsibility of the technologist to perform and monitor tests on a regular basis to maintain consistency and accuracy of results. The technologist who understands the biochemistry and molecular biology of these tests will be better able to respond to these problems. In addition, with the quickened evolution of the sciences, a knowledgeable technologist can better recognize significant discoveries that offer potential for test improvement.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ff8c5bbb">Case Study 14 • 1<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ff8c5bbb" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A 40-year-old woman with a history of non-Hodgkin's lymphoma reported to her physician for follow-up testing. Her CBC was normal, including a WBC count of 11,000/μL. Morphological studies on a bone marrow biopsy and a bone marrow aspirate revealed several small aggregates of mature and immature lymphocytes. Flow cytometry studies were difficult to interpret as there were too few B cells in the bone marrow aspirate specimen. No chromosomal abnormalities were detected by cytogenetics. A bone marrow aspirate tube was also sent for molecular analysis; namely, immunoglobulin heavy chain gene rearrangement and t(14;18) gene translocation analysis by PCR. The immunoglobulin heavy chain gene rearrangement results are shown in lane 4 of the gel image below:</p>
<p>Immunoglobulin heavy chain gene rearrangement results (left): lane 1, molecular weight marker; lanes 2 to 4, patient specimens; lane 5, positive control; lane 6, sensitivity; lane 7, negative control; lane 8, reagent blank. t(14;18) gene translocation test (right): lane 1, molecular weight marker; lanes 2 to 6, patient specimens; lane 7, positive control; lane 8, sensitivity; lane 9, negative control.</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="2e11ee58">Case Study 14·2<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2e11ee58" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A 54-year-old woman with thrombosis, a high platelet count  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>900</mn><mo separator="true">,</mo><mn>000</mn><mi mathvariant="normal">/</mi><mi>μ</mi><mi>L</mi><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(900,000 / \mu L)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">900</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">000/</span><span class="mord mathnormal">μL</span><span class="mclose">)</span></span></span></span></span> , and a decreased erythrocyte sedimentation rate was tested for polycythemia vera. Megakaryocyte clusters and pyknotic nuclear clusters were observed in a bone marrow biopsy. Overall cellularity was decreased.</p>
<p>In the CBC, white blood cell and neutrophil counts were normal. Iron stores were also in normal range. A blood sample was submitted to the molecular pathology laboratory for JAK2 V617F mutation analysis. The results are shown below:</p>
<p><img src="assets/images/image-20251222-dc150e9e.jpeg" alt="img-382.jpeg"></p>
<p>Agarose gel electrophoresis of SSP-PCR amplicons. Extension of a JAK2 V617F-specific primer produces a 270-bp band in addition to the normal 500- and 230-bp bands. Lane 1, molecular weight markers; lane 2, patient specimen; lane 3, V617F mutant control; lane 4, normal control; lane 5, reagent blank.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="dcec4104">Case Study 14·3<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#dcec4104" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Paraffin-embedded sections were submitted to the molecular diagnostics laboratory for p53 mutation analysis. The specimen was a small tumor (intraductal carcinoma in situ) discovered in a 55-year-old woman. Lymph nodes were negative. Slides stained with hematoxylin and eosin were examined</p>
<p>for confirmation of the location of tumor cells on the sections. These cells were dissected from the slide. DNA isolated from the microdissected tumor cells was screened by SSCP for mutations in exons 4-9 of the p53 gene. The results for exon 5 are shown below:</p>
<p><img src="assets/images/image-20251222-dddff275.jpeg" alt="img-383.jpeg"></p>
<p><img src="assets/images/image-20251222-4439fb63.jpeg" alt="img-384.jpeg"></p>
<p>Polyacrylamide gel electrophoresis with silver stain detection of p53 exon 5 (left). Lane 1, normal; lane 2, patient; lane 3, normal. Direct sequencing (right) revealed a  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">C</mi><mo>→</mo><mi mathvariant="normal">T</mi></mrow><annotation encoding="application/x-tex">\mathrm{C}\rightarrow \mathrm{T}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathrm">C</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">→</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathrm">T</span></span></span></span></span> <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mi mathvariant="normal">G</mi><mo>→</mo><mi mathvariant="normal">A</mi><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(\mathrm{G}\rightarrow \mathrm{A})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord mathrm">G</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">→</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord mathrm">A</span><span class="mclose">)</span></span></span></span></span>  base change, resulting in a  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="double-struck">R</mi><mo>→</mo><mi mathvariant="double-struck">H</mi></mrow><annotation encoding="application/x-tex">\mathbb{R}\to \mathbb{H}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6889em;"></span><span class="mord mathbb">R</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">→</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6889em;"></span><span class="mord mathbb">H</span></span></span></span></span>  amino acid change at position 175.</p>
<p>Copyright ©2007 by F. A. Davis.
Molecular Oncology Chapter 14
367</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="46f9d3d">Case Study 14 • 4<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#46f9d3d" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Colon carcinoma and three polyps were resected in a right hemicolectomy of a 33-year-old man. Without a family history, the man's age and the location of the tumor warranted testing for hereditary nonpolyposis colorectal carcinoma. Histological staining was negative for MSH2 protein. Paraffin sections and a blood sample were submitted to the molecular pathology laboratory for microsatellite instability testing. DNA was isolated from tumor cells dissected from four paraffin sections and from the patient's white blood cells. Both were amplified at the five microsatellite loci recommended by the National Cancer Institute. Results are shown below:</p>
<p><img src="assets/images/image-20251222-f66fde7a.jpeg" alt="img-385.jpeg"></p>
<p>MSI analysis of normal cells (N, top row) and tumor cells (T, bottom row) at the five NCI loci.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="bafceba">Case Study 14 • 5<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#bafceba" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A 23-year-old college student was sent to the student health office with a painful bruise that persisted for several weeks. He was referred to the local hospital, where the physician ordered a bone marrow biopsy and a CBC. His white blood cell count was 28,000/μL; red blood cells, 2 million/μL; hemoglobin 8, hematocrit 20, platelets, 85,000/μL. Neutrophils were 7%, lymphocytes were 5%, and blasts were 95%. The pathologist who examined the bone marrow biopsy requested flow cytometry analysis of the aspirate. The cells expressed 84% CD20, 82% CD34, 92% HLA-DR, and 80% CD10/CD19. The results of these tests indicated a diagnosis of acute lymphoblastic leukemia. A blood specimen was sent to the cytogenetics laboratory for chromosomal analysis. Twenty metaphases examined had a normal 46,XY chromosomal complement. Interphase FISH was negative for t(9;22) in 500 nuclei.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="study-questions">STUDY QUESTIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#study-questions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>What are the two important checkpoints in the cell division cycle that are crossed when the regulation of the cell division cycle is affected?</li>
<li>An EWS-FLI-1 mutation was detected in a solid tumor by RT-PCR. Which of the following does this result support?
a. Normal tissue
b. Ewing's sarcoma
c. Inherited breast cancer
d. Microsatellite instability</li>
<li>Mutation detection, even by sequencing, is not definitive with a negative result. Why?</li>
<li>A PCR test for the bcl-2 translocation is performed on a patient with suspected follicular lymphoma. The results show a bright band at about 300 bp for this patient. How would you interpret these results?</li>
</ol>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<ol start="5">
<li>Which of the following misinterpretations would result from PCR contamination?</li>
</ol>
<p>a. False positive for the t(15;17) translocation
b. False negative for the t(15;17) translocation
c. False negative for a gene rearrangement</p>
<ol start="6">
<li>After amplification of the t(12;21) breakpoint by RT-PCR, the PCR products along with the proper molecular weight standard were loaded and resolved on an agarose gel. What might be the explanation for each of the following observations when the gel is exposed to ultraviolet light? (Assume that positive and amplification controls and a reagent blank control are included in the run.)</li>
</ol>
<p>a. The gel is blank (no bands, no molecular weight standard)
b. Only the molecular weight standard is visible
c. The molecular weight standard is visible; there are bands in every lane at 200 bp, even in the reagent blank lane</p>
<ol start="7">
<li>What is observed on a Southern blot for gene rearrangement in the case of a positive result?</li>
</ol>
<p>a. No bands
b. Germline bands plus rearranged bands
c. Smears
d. Germline bands only</p>
<ol start="8">
<li>Cyclin D1 promotes passage of cells through the G1 to S checkpoint. What test detects translocation of this gene to chromosome 14?</li>
</ol>
<p>a. t(14;18) translocation analysis (BCL2, IGH)
b. t(15;17) translocation analysis (PML/RARA)
c. t(11;14) translocation analysis (BCL1/IGH)
d. t(8;14) translocation analysis (MYC/IGH)</p>
<ol start="9">
<li>Why is the Southern blot procedure superior to the PCR procedure for detecting clonality in some cases?</li>
</ol>
<p>a. Southern blot requires less sample DNA than does PCR
b. The PCR procedure cannot detect certain gene rearrangements that are detectable by Southern blot
c. Southern blot results are easier to interpret than PCR results
d. PCR results are not accepted by the College of American Pathologists</p>
<ol start="10">
<li>Interpret the following results from a translocation assay.</li>
</ol>
<p><img src="assets/images/image-20251222-951e576a.jpeg" alt="img-386.jpeg"></p>
<p>Are the samples positive, negative, or indeterminate?</p>
<p>Sample 1:</p>
<p>Sample 2:</p>
<p>Sample 3:</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="references">References<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#references" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Yang-Feng T, Schechter AL, Weinberg RA, et al. Oncogene from rat neuro/glioblastomas (human gene symbol NGL) is located on the proximal long arm of human chromosome 17 and EGFR is confirmed at 7p13-q11.2. Cytogenetics and Cell Genetics 1985;40:784.</li>
<li>Rowinsky E. The ERBB family: Targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annual Review of Medicine 2004; 55:433-57.</li>
<li>Pauletti G, Godolphin W, Press MF, et al. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996;13: 63-72.</li>
<li>Press M, Slamon DJ, Flom KJ, et al. Evaluation of HER-2/neu gene amplification and overexpression: Comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. Journal of Clinical Oncology 2002;20: 3095-3105.</li>
<li>Slamon D, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.</li>
<li>Kounelis S, Kapranos N, Malamos N, et al. Evaluation of HER-2 gene status in breast cancer by</li>
</ol>
<p>Copyright ©2007 by F. A. Davis.
Molecular Oncology Chapter 14 369</p>
<p>chromogenic in situ hybridization: Comparison with immunohistochemistry. Anticancer Research 2005; 25:939–46.</p>
<ol start="7">
<li>
<p>Tanner M, Gancberg D, Di Leo A, et al. Chromogenic in situ hybridization: A practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. American Journal of Pathology 2000; 157:1467–72.</p>
</li>
<li>
<p>Madrid M, Lo RW. Chromogenic in situ hybridization (CISH): A novel alternative in screening archival breast cancer tissue samples for HER-2/neu status. Breast Cancer Research 2004;6:R593–R600.</p>
</li>
<li>
<p>Spaulding D, Spaulding BO. Epidermal growth factor receptor expression and measurement in solid tumors. Seminars in Oncology 2002;29:45–54.</p>
</li>
<li>
<p>Younes M. Is immunohistochemistry for epidermal growth factor receptor expression a poor predictor of response to epidermal growth factor receptor–targeted therapy? Journal of Clinical Oncology 2005;23:923.</p>
</li>
<li>
<p>Murthy S, Magliocco AM, Demetrick DJ. Copy number analysis of c-erb-B2 (HER-2/neu) and topoisomerase IIa genes in breast carcinoma by quantitative real-time polymerase chain reaction using hybridization probes and fluorescence in situ hybridization. Archives of Pathology and Laboratory Medicine 2005;129:39–46.</p>
</li>
<li>
<p>Paez J, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;304:1497–1500.</p>
</li>
<li>
<p>Lynch T, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New England Journal of Medicine 2004;350:2129–39.</p>
</li>
<li>
<p>Tsao M-S, Sakurada A, Cutz J-C, et al. Erlotinib in lung cancer: Molecular and clinical predictors of outcome. New England Journal of Medicine 2005; 353:133–44.</p>
</li>
<li>
<p>Shepherd F, Pereira JR, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. New England Journal of Medicine 2005;353: 123–32.</p>
</li>
<li>
<p>Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small-cell lung cancer: Analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. Journal of Clinical Oncology 2005;23: 857–65.</p>
</li>
<li>
<p>Pan Q, Pao W, Ladanyi M. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. Journal of Molecular Diagnostics 2005;7:396–403.</p>
</li>
<li>
<p>Taron M, Ichinose Y, Rosell R, et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clinical Cancer Research 2005;11:5878–85.</p>
</li>
<li>
<p>Tonon G, Wong K-K, Maulik G, et al. High-resolution genomic profiles of human lung cancer. Proceedings of the National Academy of Sciences 2005;102:9625–30.</p>
</li>
<li>
<p>Han S, Hwang PG, Chun DH, et al. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib in chemotherapy-resistant non-small cell lung cancer. International Journal of Cancer 2005;113:109–15.</p>
</li>
<li>
<p>Jassem J, Jassem E, Jakobkiewicz-Banecka J, et al. P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma. Cancer 2004;100:1951–60.</p>
</li>
<li>
<p>Fabjani G, Kriegshaeuser G, Schuetz A, et al. Biochip for K-ras mutation screening in ovarian cancer. Clinical Chemistry;51:784–87.</p>
</li>
<li>
<p>Maekawa M, Nagaoka T, Taniguchi T, et al. Three-dimensional microarray compared with PCR single-strand conformation polymorphism analysis/DNA sequencing for mutation analysis of K-ras codons 12 and 13. Clinical Chemistry 2004; 50:1322–27.</p>
</li>
<li>
<p>Navarro S, Noguera R, Pellan A, et al. Atypical pleomorphic extraosseous Ewing tumor/peripheral primitive neuroectodermal tumor with unusual phenotypic/genotypic profile. Diagnostic Molecular Pathology 2002;11:9–15.</p>
</li>
<li>
<p>Qian X, Jin, L, Shearer B, et al. Molecular diagnosis of Ewing’s sarcoma/primitive neuroectodermal tumor in formalin-fixed paraffin-embedded tissues by RT-PCR and fluorescence in situ hybridization. Diagnostic Molecular Pathology 2005;14:23–28.</p>
</li>
<li>
<p>Noguera R. Cytogenetics and tissue culture of small round cell tumors of bone and soft tissue. Seminars in Diagnostic Pathology 1996;13:171–83.</p>
</li>
</ol>
<p>Copyright ©2007 by F. A. Davis.
370 Section 3 Techniques in the Clinical Lab</p>
<ol start="27">
<li>
<p>Akerman M, Dreinhofer K, Rydholm A, et al. Cytogenetic studies on fine-needle aspiration samples from osteosarcoma and Ewing's sarcoma. Diagnostic Cytopathology 1996;15:17–22.</p>
</li>
<li>
<p>Takeuchi T, Iwasaki H, Ohjimi Y, et al. Renal primitive neuroectodermal tumor: A morphologic, cytogenetic, and molecular analysis with the establishment of two cultured cell lines. Diagnostic Molecular Pathology 1997;6:309–17.</p>
</li>
<li>
<p>Adams V, Hany MA, Schmid M, et al. Detection of t(11;22)(q24;q12) translocation breakpoint in paraffin-embedded tissue of the Ewing's sarcoma family by nested reverse transcription-polymerase chain reaction. Diagnostic Molecular Pathology 1996;5:107–13.</p>
</li>
<li>
<p>Kelley T, Tubbs RR, Prayson RA. Molecular diagnostic techniques for the clinical evaluation of gliomas. Diagnostic Molecular Pathology 2005; 14:1–8.</p>
</li>
<li>
<p>Panagopoulos I, Mertens F, Isaksson M, et al. Clinical impact of molecular and cytogenetic findings in synovial sarcoma. Genes Chromosomes Cancer 2001;31:362–72.</p>
</li>
<li>
<p>Nilsson G, Skytting B, Xie Y, et al. The SYT-SSX1 variant of synovial sarcoma is associated with a high rate of tumor cell proliferation and poor clinical outcome. Cancer Research 1999;59:3180–84.</p>
</li>
<li>
<p>Barr F, Galili N, Holick J, et al. Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nature Genetics 1993;3:113–17.</p>
</li>
<li>
<p>Tassabehji M, Newton VE, Liu X-Z, et al. The mutational spectrum in Waardenburg syndrome. Human Molecular Genetics 1995;4:2131–37.</p>
</li>
<li>
<p>Whang-Peng J, Knutsen T, Theil K, et al. Cytogenetic studies in subgroups of rhabdomyosarcoma. Genes Chromosomes Cancer 1992;5:299–310.</p>
</li>
<li>
<p>Jin L, Majerus J, Oliveira A, et al. Detection of fusion gene transcripts in fresh-frozen and formalin-fixed paraffin-embedded tissue sections of soft-tissue sarcomas after laser capture microdissection and RT-PCR. Diagnostic Molecular Pathology 2003;12:224–30.</p>
</li>
<li>
<p>Tiffin N, Williams RD, Shipley J, et al. PAX7 expression in embryonal rhabdomyosarcoma suggests an origin in muscle satellite cells. British Journal of Cancer 2003;89:327–32.</p>
</li>
<li>
<p>Edwards R, Chatten J, Xiong Q-B, et al. Detection of gene fusions in rhabdomyosarcoma by reverse transcriptase-polymerase chain reaction assay of archival samples. Diagnostic Molecular Pathology 1997;6:91–97.</p>
</li>
<li>
<p>Kyzas P, Loizou KT, Ioannidis JP. Selective reporting biases in cancer prognostic factor studies. Journal of the National Cancer Institute 2005; 97:1043–55.</p>
</li>
<li>
<p>Lohmann D, Ruhri C, Schmitt M, et al. Accumulation of p53 protein as an indicator for p53 gene mutation in breast cancer: Occurrence of false-positives and false-negatives. Diagnostic Molecular Pathology 1993;2:36–41.</p>
</li>
<li>
<p>Casey G, Lopez ME, Ramos JC, et al. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 1996;13:1971–81.</p>
</li>
<li>
<p>Visscher D, Sarkar FH, Shimoyama RK, et al. Correlation between p53 immunostaining patterns and gene sequence mutations in breast carcinoma. Diagnostic Molecular Pathology 1996;5:187–93.</p>
</li>
<li>
<p>Miller L, Smeds J, George J, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proceedings of the National Academy of Sciences 2005; 102:13550–555.</p>
</li>
<li>
<p>Falette N, Paperin MP, Treilleux I, et al. Prognostic value of p53 gene mutations in a large series of node-negative breast cancer patients. Cancer Research 1998;58:1451–55.</p>
</li>
<li>
<p>Liu Q, Feng J, Buzin C, et al. Detection of virtually all mutations-SSCP (DOVAM-S): A rapid method for mutation scanning with virtually 100% sensitivity. BioTechniques 1999;26:932–42.</p>
</li>
<li>
<p>Buzin C, Wen CY, Nguyen VQ, et al. Scanning by DOVAM-S detects all unique sequence changes in blinded analyses: Evidence that the scanning conditions are generic. BioTechniques 2000;28:746–53.</p>
</li>
<li>
<p>Girard P-M, Foray N, Stumm M, et al. Radiosensitivity in Nijmegen breakage syndrome cells is attributable to a repair defect and not cell cycle checkpoint defects. Cancer Research 2000; 60:4881–88.</p>
</li>
<li>
<p>Castilla L, Couch FJ, Erdos MR, et al. Mutations in the BRCA1 gene in families with early-onset</p>
</li>
</ol>
<p>Copyright ©2007 by F. A. Davis.
Molecular Oncology Chapter 14 371</p>
<p>breast and ovarian cancer. Nature Genetics 1994; 8:387–91.</p>
<ol start="49">
<li>
<p>Smith S, DiCioccio RA, Struewing JP, et al. Localisation of the breast-ovarian cancer susceptibility gene (BRCA1) on 17q12–21 to an interval of &lt; or = 1 cM. Genes Chromosomes Cancer 1994;10: 71–76.</p>
</li>
<li>
<p>Stratton M, Ford D, Neuhasen S, et al. Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. Nature Genetics 1994;7:103–107.</p>
</li>
<li>
<p>Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789–92.</p>
</li>
<li>
<p>Brugarolas J, Jacks T. Double indemnity: p53, BRCA and cancer. Science 1997;3:721–22.</p>
</li>
<li>
<p>Satagopan J, Offit K, Foulkes W, et al. The life-time risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiology Biomarkers and Prevention 2001;10:467–73.</p>
</li>
<li>
<p>Tonin P, Weber B, Offit K, et al. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nature Medicine 1996;2:1179–83.</p>
</li>
<li>
<p>Lerman C, Narod S, Schulman K, et al. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. Journal of the American Medical Association 1996;275:1885–92.</p>
</li>
<li>
<p>Botkin J, Croyle RT, Smith KR, et al. A model protocol for evaluating the behavioral and psychosocial effects of BRCA1 testing. Journal of the National Cancer Institute 1996;88:872–82.</p>
</li>
<li>
<p>Phelan C, Rebbeck TR, Weber BL, et al. Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nature Genetics 1996;12:309–11.</p>
</li>
<li>
<p>Pastore Y, Jedlickova K, Guan Y, et al. Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia. American Journal of Human Genetics 2003;73:412–19.</p>
</li>
<li>
<p>Wait S, Vortmeyer AO, Lonser RR, et al. Somatic mutations in VHL germline deletion kindred correlate with mild phenotype. Annals of Neurology 2004;55:236–40.</p>
</li>
<li>
<p>Foster K, Prowse A, van den Berg A, et al. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in nonfamilial clear cell renal carcinoma. Human Molecular Genetics 1994;3: 2169–73.</p>
</li>
<li>
<p>Bender B, Gutsche M, Glasker S, et al. Differential genetic alterations in von Hippel-Lindau syndrome–associated and sporadic pheochromocytomas. Journal of Clinical Endocrinology and Metabolism 2000;85:4568–74.</p>
</li>
<li>
<p>Glenn G, Linehan WM, Hosoe S, et al. Screening for von Hippel-Lindau disease by DNA polymorphism analysis. Journal of the American Medical Association 1992;267:1226–31.</p>
</li>
<li>
<p>de Cremoux P, Thioux M, Peter M, et al. Polymerase chain reaction compared with dot blotting for the determination of N-myc gene amplification in neuroblastoma. International Journal of Cancer 1997;72:518–21.</p>
</li>
<li>
<p>Shapiro D, Valentine MB, Rowe ST, et al. Detection of N-myc gene amplification by fluorescence in situ hybridization: Diagnostic utility for neuroblastoma. American Journal of Pathology 1993;142:1339–46.</p>
</li>
<li>
<p>Grady-Leopardi E, Schwab M, Ablin AR, et al. Detection of N-myc oncogene expression in human neuroblastoma by in situ hybridization and blot analysis: relationship to clinical outcome. Cancer Research 1986;46:3196–99.</p>
</li>
<li>
<p>Layfield L, Willmore-Payne C, Shimada H, et al. Assessment of N-myc amplification: A comparison of FISH, quantitative PCR monoplexing, and traditional blotting methods used with formalin-fixed, paraffin-embedded neuroblastomas. Analytical and Quantitative Cytology and Histology 2005;27:5–14.</p>
</li>
<li>
<p>Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 1985;42(2):581–88.</p>
</li>
<li>
<p>Bolk G, Salomon R, Pelet A, et al. Segregation at three loci explains familial and population risk in Hirschsprung disease. Nature Genetics 2002;31: 89–93.</p>
</li>
<li>
<p>Stratakis C. Clinical genetics of multiple endocrine neoplasias, Carney complex and related syndromes. Journal of Endocrinology 2001;24:370–83.</p>
</li>
<li>
<p>Sanso G, Domene HM, Garcia R, et al. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: Presence of</p>
</li>
</ol>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<p>C-cell malignant disease in asymptomatic carriers. Cancer 2002;94:323-30.</p>
<ol start="71">
<li>
<p>Attie T, Pelet A, Edery P, et al. Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease. Human Molecular Genetics 1995;4:1381-86.</p>
</li>
<li>
<p>Seri M, Yin L, Barone A, et al. Frequency of RET mutations in long- and short-segment Hirschsprung disease. Human Mutation 1997;9:243-49.</p>
</li>
<li>
<p>Lynch H, Smyrk TC, Watson P, et al. Genetics, natural history, tumor spectrum and pathology of hereditary nonpolyposis colorectal cancer: An updated review. <em>Gastroenterology</em> 1988;104:1535-49.</p>
</li>
<li>
<p>Lynch H, Smyrk TC, Lynch JF. Overview of natural history, pathology, molecular genetics and management of HNPCC (Lynch syndrome). International Journal of Cancer 1996;69:38-43.</p>
</li>
<li>
<p>Xia L, Shen W, Ritacca F, et al. A truncated hMSH2 transcript occurs as a common variant in the population: Implications for genetic diagnosis. Cancer Research 1996;56:2289-92.</p>
</li>
<li>
<p>Srivastava S, Rossi SC. Early detection research program at the NCI. International Journal of Cancer 1996;69:35-37.</p>
</li>
<li>
<p>Shin K-H, Shin J-H, Kim J-H, et al. Mutational analysis of promoters of mismatch repair genes <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>h</mi><mi>M</mi><mi>S</mi><mi>H</mi><mn>2</mn></mrow><annotation encoding="application/x-tex">hMSH2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord mathnormal">h</span><span class="mord mathnormal" style="margin-right: 0.05764em;">MS</span><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span><span class="mord">2</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>h</mi><mi>M</mi><mi>L</mi><mi>H</mi><mn>1</mn></mrow><annotation encoding="application/x-tex">hMLH1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord mathnormal">h</span><span class="mord mathnormal" style="margin-right: 0.10903em;">M</span><span class="mord mathnormal">L</span><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span><span class="mord">1</span></span></span></span></span> in hereditary nonpolyposis colorectal cancer and early onset colorectal cancer patients: Identification of three novel germline mutations in promoter of the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>h</mi><mi>M</mi><mi>S</mi><mi>H</mi><mn>2</mn></mrow><annotation encoding="application/x-tex">hMSH2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord mathnormal">h</span><span class="mord mathnormal" style="margin-right: 0.05764em;">MS</span><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span><span class="mord">2</span></span></span></span></span> gene. Cancer Research 2002;62:38-42.</p>
</li>
<li>
<p>Sun X, Zheng L, Shen B. Functional alterations of human exonuclease 1 mutants identified in atypical hereditary nonpolyposis colorectal cancer syndrome. Cancer Research 2002;62:6026-30.</p>
</li>
<li>
<p>Boland C, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Research 1998;58: 5248-57.</p>
</li>
<li>
<p>Frazier M, Sinicrope FA, Amos CI, et al. Loci for efficient detection of microsatellite instability in hereditary nonpolyposis colorectal cancer. Oncology Reports 1999;6:497-505.</p>
</li>
<li>
<p>Watanabe T, Wu TT, Catalano PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. New England Journal of Medicine 2001;344:1196-206.</p>
</li>
<li>
<p>Halvarsson B, Lindblom A, Rambech E, et al. Microsatellite instability analysis and/or immunostaining for the diagnosis of hereditary nonpolyposis colorectal cancer? Virchows Archiv 2004;444: 135-41.</p>
</li>
<li>
<p>Weichhold G, Ohnheiser R, Zachau HG. The human immunoglobulin kappa locus consists of two copies that are organized in opposite polarity. Genomics 1993;16:503-11.</p>
</li>
<li>
<p>Barbie V, Lefranc M-P. The human immunoglobulin kappa variable (IGKV) genes and joining (IGKJ) segments. Experimental and Clinical Immunogenetics 1998;15:171-83.</p>
</li>
<li>
<p>Frippiat J-P, Williams SC, Tomlinson IM, et al. Organization of the human immunoglobulin lambda light-chain locus on chromosome 22q11.2. Human Molecular Genetics 1995;4:983-91.</p>
</li>
<li>
<p>Yuen E, Brown RD. Southern blotting of IgH rearrangements in B-cell disorders. Methods in Molecular Medicine 2005;113:85-103.</p>
</li>
<li>
<p>Arber D. Molecular diagnostic approach to non-Hodgkin's lymphoma. Journal of Molecular Diagnostics 2000;2(4):178-90.</p>
</li>
<li>
<p>Beishuizen A, Verhoeven MA, Mol EJ, et al. Detection of immunoglobulin kappa light-chain gene rearrangement patterns by Southern blot analysis. Leukemia 1994;8:2228-36.</p>
</li>
<li>
<p>van Dongen J, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003;12:2257-2317.</p>
</li>
<li>
<p>Muschen M, Rajewsky K, Brauninger A, et al. Rare occurrence of classical Hodgkin's disease as a T-cell lymphoma. Journal of Experimental Medicine 2000;191:387-94.</p>
</li>
<li>
<p>Gonzalez D, Garcia-Sanz R. Incomplete DJH rearrangements. Methods in Molecular Medicine 2005;113:165-73.</p>
</li>
<li>
<p>Gonzalez D, Balanzategui A, Garcia-Sanz R, et al. Incomplete DJH gene rearrangements of the IgH gene are frequent in multiple myeloma patients: Immunobiological characteristics and clinical applications. Leukemia 2003;17:1398-1403.</p>
</li>
</ol>
<p>Copyright ©2007 by F. A. Davis.
Molecular Oncology Chapter 14 373</p>
<ol start="93">
<li>Araujo M, Carvalhais A, Campos A, et al. Clonality detection in apheresis products from multiple myeloma and non-Hodgkin lymphoma patients. Transplantation Proceedings 2000;32:2676.</li>
<li>van der Velden V, Willemse MJ, van der Schoot CE, et al. Immunoglobulin kappa-deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time PCR. Leukemia 2002;16:928–36.</li>
<li>Shiokawa S, Nishimura J, Ohshima K, et al. Establishment of a novel B-cell clonality analysis using single-strand conformation polymorphism of immunoglobulin light chain messenger signals. American Journal of Pathology 1998;153: 1393–1400.</li>
<li>Buckingham L, Vardouniotis A, Coon JS. Molecular detection of multiple myeloma at the immunoglobulin light chain locus. Journal of Molecular Diagnostics 2002;4:241.</li>
<li>Rosenquist R, Menestrina F, Lestani M, et al. Indications for peripheral light-chain revision and somatic hypermutation without a functional B-cell receptor in precursors of a composite diffuse large B-cell and Hodgkin’s lymphoma. Laboratory Investigation 2004;84:253–62.</li>
<li>Tumkaya T, van der Burg M, Garcia-Sanz R, et al. Immunoglobulin lambda isotype gene rearrangements in B-cell malignancies. Leukemia 2001;15: 121–27.</li>
<li>Breit T, Wolvers-Tettero IL, Beishuizen AV, et al. Southern blot patterns, frequencies, and junctional diversity of T-cell receptor delta gene rearrangements in acute lymphoblastic leukemia. Blood 1993;82:3063–74.</li>
<li>Miller J, Wilson SS, Jaye DL, et al. An automated semiquantitative B- and T-cell clonality assay. Journal of Molecular Diagnostics 1999; 4:101–17.</li>
<li>Szczepanski T, Beishuizen A, Pongers-Willemse MJ, et al. Cross-lineage T-cell receptor gene rearrangements occur in more than ninety percent of childhood precursor-B acute lymphoblastic leukemias: Alternative PCR targets for detection of minimal residual disease. Leukemia 1999;13: 196–205.</li>
<li>Lawnicki L, Rubocki RJ, Chan WC, et al. The distribution of gene segments in T-cell receptor gene rearrangements demonstrates the need for multiple primer sets. Journal of Molecular Diagnostics 2003;5:82–87.</li>
<li>Theodorou I, Bigorgne C, Delfau MH, et al. VJ rearrangements of the TCR gamma locus in peripheral T-cell lymphomas: Analysis by polymerase chain reaction and denaturing gradient gel electrophoresis. Journal of Pathology 1996; 178:303–10.</li>
<li>Lee S, Berg KD, Racke FK, et al. Pseudo-spikes are common in histologically benign lymphoid tissues. Journal of Molecular Diagnostics 2000; 2:145–52.</li>
<li>Murphy K, Berg KD, Geiger T, et al. Capillary electrophoresis artifact due to eosin: implications for the interpretation of molecular diagnostic assays. Journal of Molecular Diagnostics 2005; 7:143–48.</li>
<li>Batstone P, Goodlad JR. Efficacy of screening the intermediate cluster region of the bcl2 gene in follicular lymphoma by PCR. Journal of Clinical Pathology 2004;58:81–82.</li>
<li>Albinger-Hegyi A, Hochreutener B, Abdou M-T, et al. High frequency of t(14;18)-translocation breakpoints outside of major breakpoint and minor cluster regions in follicular lymphomas: Improved polymerase chain reaction protocols for their detection. American Journal of Pathology 2002;160:823–32.</li>
<li>Gomez M, Wu X, Wang YL. Detection of bcl-2-IGH using single-round PCR assays. Diagnostic Molecular Pathology 2005;14:17–22.</li>
<li>Hsi E, Tubbs RR, Lovell MA, et al. Detection of bcl-2/J(H) translocation by polymerase chain reaction: A summary of the experience of the molecular oncology survey of the College of American Pathologists. Archives of Pathology and Laboratory Medicine 2002;126:902–908.</li>
<li>McGregor D, Keever-Taylor CA, Bredeson C, et al. The implication of follicular lymphoma patients receiving allogeneic stem cell transplantation from donors carrying t(14;18)-positive cells. Bone Marrow Transplant 2005; 35:1049–54.</li>
<li>Montoto S, Lopez-Guillermo A, Colomer D, et al. Incidence and clinical significance of bcl-2/IgH rearrangements in follicular lymphoma. Leukemia and Lymphoma 2003;44:71–76.</li>
</ol>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<ol start="112">
<li>
<p>Ladetto M, Mantoan B, Ricca I, et al. Recurrence of bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone. Experimental Hematology 2003;31(9): 784–88.</p>
</li>
<li>
<p>Colleoni G, Duarte LC, Kerbauy FR, et al. Possible influence of clinical stage and type of treatment in the persistence of residual circulating t(14;18)-positive cells in follicular lymphoma patients. Leukemia and Lymphoma 2004;45: 539–45.</p>
</li>
<li>
<p>Maurer J, Janssen JW, Thiel E, et al. Detection of chimeric bcr-abl genes in acute lymphoblastic leukaemia by the polymerase chain reaction. Lancet 1991;337:1055–58.</p>
</li>
<li>
<p>Gleissner B, Gakbuget N, Bartram CR, et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: A prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 2002; 99:1536–43.</p>
</li>
<li>
<p>Gleissner B, Rieder H, Thiel EF, et al. Prospective bcr-abl analysis by polymerase chain reaction in adult acute B-lineage lymphoblastic leukemia: Reliability of RT-nested PCR and comparison to cytogenetic data. Leukemia 2001;15:1834–40.</p>
</li>
<li>
<p>Burmeister T, Maurer J, Aivado M, et al. Quality assurance in RT-PCR-based BCR/ABL diagnostics: Results of an interlaboratory test and a standardization approach. Leukemia 2000;14:1850–56.</p>
</li>
<li>
<p>van der Velden V, Boeckx N, Gonzalez M, et al. Differential stability of control gene and fusion gene transcripts over time may hamper accurate quantification of minimal residual disease: A study within the Europe Against Cancer Program. Leukemia 2004;18:884–86.</p>
</li>
<li>
<p>Lion T, Gaiger A, Henn T, et al. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon. Leukemia 1995;9: 1353–60.</p>
</li>
<li>
<p>Branford S, Hughes TP, Rudzki Z. Monitoring chronic leukemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. British Journal of Haematology 1999;107:587–99.</p>
</li>
<li>
<p>Muller M, Hardt T, Paschka P, et al. Standardization of preanalytical factors for minimal residual disease analysis in chronic myelogenous leukemia. Acta Haematologica 2004;112:30–33.</p>
</li>
<li>
<p>Moravcova J, Regner J, Mouckova D, et al. Disease status in patients with chronic myeloid leukemia is better characterized by bcr-abl/bcr transcript ratio than by bcr-abl transcript level, which may suggest a role of normal bcr gene in the disease pathogenesis. Neoplasma 2005;52: 119–25.</p>
</li>
<li>
<p>Jones C, Yeung C, Zehnder JL. Comprehensive validation of a real-time quantitative bcr-abl assay for clinical laboratory use. American Journal of Clinical Pathology 2003;120(1):42–48.</p>
</li>
<li>
<p>Neumann F, Herold C, Hildebrandt B, et al. Quantitative real-time reverse-transcription polymerase chain reaction for diagnosis of bcr-abl positive leukemias and molecular monitoring following allogeneic stem cell transplantation. European Journal of Haematology 2003;70:1–10.</p>
</li>
<li>
<p>Hughes T, Kaeda J, Branford S, et al: International Randomised study of interferon versus STI571 study group: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. New England Journal of Medicine 2003;349:1423–32.</p>
</li>
<li>
<p>Cortes J, Talpaz M, O'Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clinical Cancer Research 2005;11(9): 3425–32.</p>
</li>
<li>
<p>Slack J, Bi WL, Livak KJ, et al. Preclinical validation of a novel, highly sensitive assay to detect PML-RARα mRNA using real-time reverse-transcription polymerase chain reaction. Journal of Molecular Diagnostics 2005;3:141–49.</p>
</li>
<li>
<p>Fan H, Gulley ML, Gascoyne RD, et al. Molecular methods for detecting t(11;14) translocations in mantle-cell lymphomas. Diagnostic Molecular Pathology 1998;7:209–14.</p>
</li>
<li>
<p>Williams M, Nichols GE, Swerdlow SH, et al. In situ hybridization detection of cyclin D1 mRNA</p>
</li>
</ol>
<p>Copyright ©2007 by F. A. Davis.
Molecular Oncology Chapter 14 375</p>
<p>in centrocytic/mantle cell lymphoma. Annals of Oncology 1995;6:297–99.</p>
<ol start="130">
<li>
<p>Wijers-Koster P, Droese J, et al. t(11;14) with BCL1-IGH rearrangement. Leukemia 2003;17: 2296–98.</p>
</li>
<li>
<p>Erikson J, Finger L, Sun L, et al. Deregulation of c-myc by translocation of the alpha-locus of the T-cell receptor in T-cell leukemias. Science 1986; 232:884–86.</p>
</li>
<li>
<p>Siebert R, Matthiesen P, Harder S, et al. Application of interphase fluorescence in situ hybridization for the detection of the Burkitt translocation t(8;14)(q24;q32) in B-cell lymphomas. Blood 1998;91:984–90.</p>
</li>
<li>
<p>Choi J-Y, Hong Y-S, Park H-Y. Stimulation of c-myc proto-oncogene expression by transforming growth factor a in human ovarian cancer cells. Experimental and Molecular Medicine 1997;29: 203–208.</p>
</li>
<li>
<p>Blancato J, Singh B, Liu A, et al. Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses. British Journal of Cancer 2004;90: 1612–19.</p>
</li>
<li>
<p>Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990; 61:203–12.</p>
</li>
<li>
<p>Rosnet O, Mattei M-G, Marchetto S, et al. Isolation and chromosomal localization of a novel FMS-like tyrosine kinase gene. Genomics 1991;9: 380–85.</p>
</li>
<li>
<p>Mills K, Gilkes AF, Walsh V, et al. Rapid and sensitive detection of internal tandem duplication and activating loop mutations of FLT3. British Journal of Haematology 2005; 130:203–208.</p>
</li>
<li>
<p>Scholl S, Krause C, Loncarevic IF, et al. Specific detection of Flt3 point mutations by highly sensitive real-time polymerase chain reaction in acute myeloid leukemia. Journal of Laboratory and Clinical Medicine 2005;145:295–304.</p>
</li>
<li>
<p>Institute NC. Sponsored study of classification of non-Hodgkin’s lymphomas: Summary and description of working formulation for clinical usage. Cancer 1982;49:2112–35.</p>
</li>
<li>
<p>Meier J, Lewis SM. P nucleotides in V(D)J recombination: A fine-structure analysis. Molecular and Cellular Biology 1993;13:1078–92.</p>
</li>
<li>
<p>Szczepaski T, Willemse MJ, van Wering ER, et al. Precursor-B-ALL with DH-JH gene rearrangements have an immature immunogenotype with a high frequency of oligoclonality and hyperdiploidy of chromosome 14. Leukemia 2001; 15:1415–23.</p>
</li>
<li>
<p>Campbell M, Zelenetz AD, Levy S, et al. Use of family-specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire. Molecular Immunology 1992;29:193–203.</p>
</li>
<li>
<p>Wang L, Pearson K, Pillitteri L, et al. Serial monitoring of bcr-abl by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia. British Journal of Haematology 2002;118:771–77.</p>
</li>
<li>
<p>Lafage-Pochitaloff M, Alcalay M, Brunel V, et al. Acute promyelocytic leukemia cases with nonreciprocal PML/RARA or RARA/PML fusion genes. Blood 1995;85:1169–74.</p>
</li>
<li>
<p>Vizmanos J, Larráyoz MJ, Odero MD, et al. Two new molecular PML-RARA variants: Implications for the molecular diagnosis of APL. Haematologica 2002;87:ELT37.</p>
</li>
<li>
<p>Mozziconacci M, Liberatore C, Brunel V, et al. In vitro response to all-trans retinoic acid of acute promyelocytic leukemias with nonreciprocal PML/RARA or RARA/PML fusion genes. Genes Chromosomes Cancer 1998;22:241–50.</p>
</li>
<li>
<p>Lacy J, Summers WP, Watson M, et al. Amplification and deregulation of myc following Epstein-Barr virus infection of a human B-cell line. Proceedings of the National Academy of Sciences 1987;84:5838–42.</p>
</li>
<li>
<p>Lazo P, DiPaolo JA, Popescu NC. Amplification of the integrated viral transforming genes of human papillomavirus 18 and its 5′-flanking cellular sequence located near the myc protooncogene in HeLa cells. Cancer Research 1989;49:4305–10.</p>
</li>
<li>
<p>Morse B, Rotherg PG, South VJ, et al. Insertional mutagenesis of the myc locus by a LINE-1 sequence in a human breast carcinoma. Nature 1988;333:87–90.</p>
</li>
</ol>
<p>Copyright ©2007 by F. A. Davis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="chapter-15">Chapter 15<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-15" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Lela Buckingham</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="dna-based-tissue-typing">DNA-Based Tissue Typing<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#dna-based-tissue-typing" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="outline">OUTLINE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#outline" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><strong>THE MHC LOCUS</strong></p>
<p><strong>HLA POLYMORPHISMS</strong>
HLA Nomenclature</p>
<p><strong>MOLECULAR ANALYSIS OF THE MHC</strong>
Serological Analysis
DNA-Based Typing
Combining Typing Results
HLA Test Discrepancies
Coordination of HLA Test Methods</p>
<p><strong>ADDITIONAL RECOGNITION FACTORS</strong>
Minor Histocompatibility Antigens
Nonconventional MHC Antigens
Killer Cell Immunoglobulin-like Receptors</p>
<p><strong>MHC DISEASE ASSOCIATION</strong></p>
<p><strong>SUMMARY OF LABORATORY TESTING</strong></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="objectives">OBJECTIVES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#objectives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Describe the structure and function of the major histocompatibility (MHC) locus.</li>
<li>List the human leukocyte antigens (HLAs) that are encoded by the MHC locus, and explain their role in tissue engraftment and rejection.</li>
<li>Compare and contrast the levels of typing resolution that are achieved by different laboratory methods.</li>
<li>Describe the laboratory methods used to identify HLAs by serology testing.</li>
<li>Describe the DNA-based testing methods used for the identification of HLAs.</li>
<li>Explain how combining different test methods to identify HLAs increases resolution and resolves ambiguities.</li>
<li>Discuss factors, in addition to the HLAs, that affect engraftment.</li>
<li>Relate the use of HLA typing for confirming disease diagnosis and predisposition.</li>
</ul>
<p>Copyright ©2007 by F. A. Davis.
DNA-Based Tissue Typing Chapter 15
377</p>
<p>The major histocompatibility complex (MHC) is a group of genes located on the short arm of chromosome 6. In humans, the MHC gene products are called human leukocyte antigens (HLAs). The HLAs were named for their role in rejection of transplanted organs. Kidney, heart, liver, lungs, skin, pancreas, corneas, blood, bone marrow, and hematopoietic stem cells can be transplanted from one human to another. Transplanted organs, except in the case of identical twins, are allografts, indicating genetic differences between the donor of the organ and the recipient. When a transplant is performed, compatibility (matching) of the HLA of the organ donor and the recipient increases the chance for a successful engraftment that will function for several years. If the donor and recipient are not HLA-matched, then the recipient's immune system (primarily mediated by T lymphocytes as well as B lymphocytes) will recognize the donor organ as non-self (foreign) and will mount an immune response against the organ, resulting in its destruction, loss of function, and rejection by the recipient.</p>
<p>The role of the clinical laboratory is to evaluate the HLAs of potential donors and recipients and to aid in prediction of successful engraftment and the avoidance of graft versus host disease (GVHD). GVHD is the reciprocal of graft rejection whereby immunocompetent cells in the donor organ recognize recipient cells as foreign and attack and destroy the recipient cells, resulting in significant morbidity and potential mortality to the recipient. The process of HLA identification utilizes methods targeting cell-associated antigens as well as serum antibodies. Most tissue typing, as HLA identification is commonly called, is performed by serological methods using antibodies to the different HLA found in the human population. Increasingly, however, DNA typing methods are being implemented for this purpose, increasing the sensitivity and specificity of the typing procedure.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="the-mhc-locus">The MHC Locus<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#the-mhc-locus" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The human MHC locus was discovered in the early 1950s. Investigators independently noted that blood from women who had borne children or from previously transfused persons contained antibodies that agglutinated leukocytes. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mrow><mn>1</mn><mo separator="true">,</mo><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">^{1,2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mpunct mtight">,</span><span class="mord mtight">2</span></span></span></span></span></span></span></span></span></span></span></span></span> This discovery led to serological typing methods that originally identified two polymorphic gene loci, HLA-A and HLA-B, followed soon after by the identification of HLA-C and other genes. A test for typing these loci was designed from the observation that large immature mononuclear cells proliferated if lymphocytes from unrelated individuals were mixed and cultured together. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mrow><mn>3</mn><mo separator="true">,</mo><mn>4</mn></mrow></msup></mrow><annotation encoding="application/x-tex">^{3,4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span><span class="mpunct mtight">,</span><span class="mord mtight">4</span></span></span></span></span></span></span></span></span></span></span></span></span> Results from this mixed lymphocyte culture (MLC) reaction did not always agree with the results of serological typing, however. The discrepancy was partly resolved by the discovery of additional genes comprising the HLA-D locus. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mrow><mn>5</mn><mo>−</mo><mn>7</mn></mrow></msup></mrow><annotation encoding="application/x-tex">^{5-7}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">5</span><span class="mbin mtight">−</span><span class="mord mtight">7</span></span></span></span></span></span></span></span></span></span></span></span></span></p>
<p>HLAs are divided into three classes (I, II, and III), all encoded by a gene complex located on chromosome 6p (Fig. 15-1). The MHC locus includes genes other than those that code for the HLA. Cytokine genes and genes encoding tumor necrosis factor <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> (TNF-<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span>) and tumor necrosis factor <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> (TNF-<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>) are located inside of the main HLA complex. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>8</mn></msup></mrow><annotation encoding="application/x-tex">^{8}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">8</span></span></span></span></span></span></span></span></span></span></span></span></span></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="historical-highlights">Historical Highlights<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#historical-highlights" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The genetic contribution to transplant rejection was first proposed in 1927 when Bover observed that skin transplants between identical twins were not rejected like those from genetically distinct individuals. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>70</mn></msup></mrow><annotation encoding="application/x-tex">^{70}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">70</span></span></span></span></span></span></span></span></span></span></span></span></span> The genes involved were first described in mice by Gorer. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>71</mn></msup></mrow><annotation encoding="application/x-tex">^{71}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">71</span></span></span></span></span></span></span></span></span></span></span></span></span> Snell <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>72</mn></msup></mrow><annotation encoding="application/x-tex">^{72}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">72</span></span></span></span></span></span></span></span></span></span></span></span></span> used mouse cell lines to further define a genetic locus, which he called H for histocompatibility. Gorer referred to the gene products of this locus as antigen II, and the combined term H-2 was subsequently used for the MHC locus in mice.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="advanced-concepts">Advanced Concepts<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#advanced-concepts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Despite the discovery of the MHC gene products as mediators of transplant rejection, recognition of allografts (organs from genetically different donors) is not the main function of these glycoproteins. HLAs appear on the surface of cells of the immune system, allowing cell-cell communication during immune functions. Immune reactions involve and are restricted by interactions between T lymphocytes (cells involved in cell-mediated immunity), B lymphocytes (antibody-producing cells), and the MHC molecules. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mrow><mn>73</mn><mo separator="true">,</mo><mn>74</mn></mrow></msup></mrow><annotation encoding="application/x-tex">^{73,74}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">73</span><span class="mpunct mtight">,</span><span class="mord mtight">74</span></span></span></span></span></span></span></span></span></span></span></span></span></p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<p><img src="assets/images/image-20251222-9672f6f1.jpeg" alt="img-387.jpeg">
Figure 15-1 The MHC locus on chromosome 6 covers about 4 Mb of DNA, depending on the individual. Class I genes are 3-6 kb long, and class II genes are 4-11 kb in length. TNF- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span>  and TNF- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>  are not part of the polymorphic HLA system.</p>
<p>In addition to the main MHC locus, gene regions extending beyond the HLA-DP genes toward the centromere and HLA-F toward the telomere comprise the extended MHC locus (xMHC). The xMHC locus covers 8 Mb and includes the hemochromatosis gene HLA-F (also called  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>H</mi><mi>F</mi><mi>E</mi></mrow><annotation encoding="application/x-tex">HFE</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span><span class="mord mathnormal" style="margin-right: 0.05764em;">FE</span></span></span></span></span> ), the farthest telomeric gene in the complex.[9,10] The most centromeric locus of the extended MHC is the tapasin region. Tapasin is required for antigenic peptide processing.[11,12] Some genes that are associated with disease conditions, such as  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>H</mi><mi>F</mi><mi>E</mi></mrow><annotation encoding="application/x-tex">HFE</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span><span class="mord mathnormal" style="margin-right: 0.05764em;">FE</span></span></span></span></span>  linked to the MHC locus, are the basis for the association of particular disease states with HLA type (see Chapter 11). The role of the immune system in other disease states, such as autoimmune diseases and susceptibility to infections, also links HLA type to disease.</p>
<p>The gene products of the MHC, class I, II, and III proteins, are present in different amounts on different tissues (Table 15.1). Class I and II are the strongest antigens expressed on cells. Class I molecules (designated as A, B, or C) are expressed on all nucleated cells, whereas class II</p>
<p>molecules (designated as D) are only expressed constitutively on "professional antigen-presenting cells," such as B lymphocytes, dendritic cells, and macrophages. As illustrated in Figure 15-2, class I molecules consist of a long (heavy) chain of 346 amino acids (44 kD) associated with a smaller peptide, called  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> -2 microglobulin, which is 99 amino acids (12 kD) in size and is not encoded in the MHC. The two chains are associated with one another on the cell surface by noncovalent bonds. The class I heavy chain displays short branched-chained sugars, making this molecule a glycoprotein. The heavy chain is also a transmembrane polypeptide, anchoring the complex at the surface of the cell. Class II molecules consist of two transmembrane polypeptides, an  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span>  chain with three domains,  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ,  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> , and  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> , and a  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>  chain, with two domains,  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>  and  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> . The two polypeptides associate, forming a groove between the  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>  and  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>  domains that will hold fragments of antigen that have been engulfed and processed by the cell (extracellular antigens). In contrast, antigens bound to class I molecules (where the peptide-binding domain is</p>
<p>Table 15.1 Genes of the Major Histocompatibility Locus</p>
<table><thead><tr><th>MHC Region</th><th>Gene Products</th><th>Tissue Location</th><th>Function</th></tr></thead><tbody><tr><td>Class I</td><td>HLA-A, HLA-B, HLA-C</td><td>All nucleated cells</td><td>Identification and destruction of abnormal or infected cells by cytotoxic T cells</td></tr><tr><td>Class II</td><td>HLA-D</td><td>B lymphocytes, monocytes, macrophages, dendritic cells, activated T cells, activated endothelial cells, skin (Langerhans' cells)</td><td>Identification of foreign antigen by helper T cells</td></tr><tr><td>Class III</td><td>Complement C2, C4, B</td><td>Plasma proteins</td><td>Defense against extracellular pathogens</td></tr><tr><td>Cytokine genes</td><td>TNF-α, TNF-β</td><td>Plasma proteins</td><td>Cell growth and differentiation</td></tr></tbody></table>
<p>Copyright ©2007 by F. A. Davis.
DNA-Based Tissue Typing Chapter 15
379</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="advanced-concepts">Advanced Concepts<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#advanced-concepts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Class I and II molecules present fragments of antigens, usually about nine amino acids long, to T lymphocytes. Class I and II molecules vary from one another (are polymorphic), sometimes by a single amino acid. Due to these polymorphisms, different HLA molecules (HLA types) vary in their efficiency of binding antigen fragments, resulting in a range of immune responses to a given antigen. This distinction can affect symptoms of disease; for example, the likelihood of persons of a particular HLA type infected with HIV to develop full immunodeficiency.⁶⁸,⁷⁵,⁷⁶</p>
<p>formed between the α₁ and α₂ domains) are generated from the processing of macromolecules synthesized within the cell (intracellular antigens).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="hla-polymorphisms">HLA Polymorphisms<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hla-polymorphisms" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Genes of the MHC are the most polymorphic genes of the human genome. Polymorphisms in this locus were first defined phenotypically by acceptance or rejection of tissue or by reaction with defined antibodies (serological typing). Molecular typing methods reveal HLA polymorphisms as base changes in the DNA sequence</p>
<p><img src="assets/images/image-20251222-504afd70.jpeg" alt="img-388.jpeg">
Figure 15-2 Class II (left) and class I (right) polypeptides. Class II antigens consist of two chains, α and β. Class I antigens consist of a heavy chain and a light chain associated together with a molecule of β-2 microglobulin.</p>
<p>(Fig. 15-3). The changes range from a single base pair (single nucleotide polymorphisms) to loss or gain of entire genes. A particular sequence, or version, of an HLA gene is an allele of that gene. The HLA type is the col</p>
<p>(A)</p>
<p>CGG GCC GCG GTG GAC ACC TAC TGC AGA CAC AAC TAC GGG GTT GGT GAG AGC TTC ACA</p>
<p>CGG GCC GCG GTG GAC ACC TAT TGC AGA CAC AAC TAC GGG GCT GTG GAG AGC TTC ACA</p>
<p>CGG GCC GCC GTG GAC ACC TAT TGC AGA CAC AAC TAC GGG GCT GTG GNN NNN NNN NNN</p>
<p>(B)</p>
<p>CGG GCC GCG GTG GAC ACC TAC TGC AGA CAC AAC TAC GGG GTT GGT GAG AGC TTC ACA</p>
<hr>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<p>lection of alleles detected by phenotypic or genotypic typing methods.</p>
<p>Thus, each HLA gene can differ in sequence from one individual to another, except for identical twins. A set of particular alleles on the same chromosome is a haplotype (Fig. 15-4). These alleles are inherited together as a block of chromosomal sequence, unless a rare recombination within the region separates the alleles. An HLA haplotype is, therefore, the combination of polymorphic sequences or alleles in the HLA gene regions.</p>
<p>Polymorphisms are concentrated in exons 2 and 3 of the class I genes and in exon 2 of the class II genes. These exons code for the amino acids that interact with antigenic peptides, affecting the recognition of nonself peptides. Molecular methods target these exons in HLA-A, HLA-B, and HLA-C class I genes and mostly HLA-DRB class II genes. Other areas including introns have been investigated for potentially useful alleles.[13]</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="hla-nomenclature">HLA Nomenclature<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hla-nomenclature" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Polymorphisms are alterations in DNA and/or protein sequences shared by at least 2% of a defined population. Formally, alterations present at lower frequencies are called mutations or variants. Structurally, mutations and polymorphisms are the same thing, changes from a consensus amino acid or nucleotide sequence. When these changes occur in a gene, the different versions of the gene are referred to as alleles. The polymorphic nature of the MHC, therefore, means that there are multiple alleles of each HLA gene present in the human population. These alleles differ by nucleotide sequence at the DNA level (polymorphisms) and by amino acid sequence and antigenicity at the protein level. Polymorphisms arise mostly as a result of gene conversion events and rare chromosomal recombinations. Each person will have a particular group of HLA alleles inherited from his or her parents</p>
<p><img src="assets/images/image-20251222-88f8a45b.jpeg" alt="img-389.jpeg">
Figure 15-4 A haplotype is the combination of alleles that are inherited together. In this example, parental genotypes (top) can produce four possible genotypes in the offspring (bottom).</p>
<p>Copyright ©2007 by F. A. Davis.
DNA-Based Tissue Typing Chapter 15 381</p>
<p>(see Chapter 11 on Human Identification.) The maternal and paternal HLA antigens are expressed codominantly on cells.</p>
<p>HLA alleles were first defined at the protein level by antibody recognition (serologically). A standard nomenclature for expressing serologically defined antigens was established by the World Health Organization (WHO) Nomenclature Committee for Factors of the HLA System. In this system, "HLA" refers to the entire gene region, and "A, B, D" refer to the particular locus; for example, HLA-A, HLA-B, or HLA-D. The HLA-D locus consists of subregions P, Q, M, O, and R, termed HLA-DP, HLA-DQ, HLA-DM, and so forth. Each of these subregions consists of genes that code for either an α or β chain polypeptide; for example, the first β polypeptide is encoded in the HLA-DRB1 gene (see Fig. 15-1). A small w is included in HLA-Cw, HLA-Bw4, and HLA-Bw6 allele nomenclature. The w denotation was originally a designation of alleles in "workshop" status or found in high prevalence in the population. The workshop designation is no longer required for the HLA-C locus; however, the w was retained for HLA-C alleles to distinguish them from the C designation used for complement genes. The w is retained with HLA-Bw4 and HLA-Bw6, which are considered "public" (high prevalence) antigens.</p>
<p>A list of the serologically defined alleles of the HLA genes accepted by the WHO is shown in Table 15.2. The WHO official nomenclature refers to serologically defined alleles: a number follows the gene region name; for example, HLA-B51 denotes HLA-B antigen 51 (defined by reaction to a known antibody). Number designations of new alleles of a previously-defined allele with broad specificity (parent allele) are followed by the number of the parent allele in parentheses. For example, HLA-A24(9) denotes the HLA-A antigen 24 from parent antigen 9. The derived antigens are called split specificities. Additional antigens have been defined by reactions between known antigens and serum antibodies (antiserum reactivity). For class I, there are 85, 188, and 42 HLA-A, B, and C alleles, respectively. For class II, there are 76, 32, and 221 HLA-DPB, DQB, and DRB alleles, respectively. These numbers will increase as new specificities are defined.</p>
<p>With the introduction of molecular biology techniques in the 1980s, HLA typing at the DNA level required no</p>
<p>Table 15.2 Serologically Defined HLA Specificities*</p>
<table><thead><tr><th>HLA-A</th><th>HLA-B</th><th>HLA-C</th><th>HLA-DR</th><th>HLA-DQ</th><th>HLA-DP</th></tr></thead><tbody><tr><td>A1</td><td>B5</td><td>Cw1</td><td>DR1, DR103</td><td>DQ1</td><td>DPw1</td></tr><tr><td>A2, A203, A210</td><td>B51(5), B5102, B5103</td><td>Cw2</td><td>DR2</td><td>DQ5(1)</td><td>DPw2</td></tr><tr><td>A3</td><td>B52(5)</td><td>Cw3</td><td>DR15(2)</td><td>DQ6(1)</td><td>DPw3</td></tr><tr><td>A9</td><td>B7, B703</td><td>Cw9(w3)</td><td>DR15(2)</td><td>DQ2</td><td>DPw4</td></tr><tr><td>A23(9)</td><td>B8</td><td>Cw10(w3)</td><td>DR3</td><td>DQ3</td><td>DPw5</td></tr><tr><td>A24 (9), A2403</td><td>B12</td><td>Cw4</td><td>DR17(3)</td><td>DQ7(3)</td><td>DPw6</td></tr><tr><td>A10</td><td>B44(12)</td><td>Cw5</td><td>DR18(3)</td><td>DQ8(3)</td><td></td></tr><tr><td>A25(10)</td><td>B45(12)</td><td>Cw6</td><td>DR4</td><td>DQ9(3)</td><td></td></tr><tr><td>A26(10)</td><td>B13</td><td>Cw7</td><td>DR5</td><td>DQ4</td><td></td></tr><tr><td>A34(10)</td><td>B14</td><td>Cw8</td><td>DR11(5)</td><td></td><td></td></tr><tr><td>A66(10)</td><td>B64(14)</td><td></td><td>DR12(5)</td><td></td><td></td></tr><tr><td>A11</td><td>B65(14)</td><td></td><td>DR6</td><td></td><td></td></tr><tr><td>A19</td><td>B15</td><td></td><td>DR13(6)</td><td></td><td></td></tr><tr><td>A74(19)</td><td>B62(15)</td><td></td><td>DR14(6), DR1403, DR1404</td><td></td><td></td></tr><tr><td>A68(28)</td><td>B63(15)</td><td></td><td>DR7</td><td></td><td></td></tr><tr><td>A69(28)</td><td>B75(15)</td><td></td><td>DR8</td><td></td><td></td></tr><tr><td>A29(19)</td><td>B76(15)</td><td></td><td>DR9</td><td></td><td></td></tr><tr><td>A30(19)</td><td>B77(15)</td><td></td><td>DR10</td><td></td><td></td></tr></tbody></table>
<p>Continued on following page</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<p>Table 15.2 Serologically Defined HLA Specificities* (continued)</p>
<table><thead><tr><th>HLA-A</th><th>HLA-B</th><th>HLA-C</th><th>HLA-DR</th><th>HLA-DQ</th><th>HLA-DP</th></tr></thead><tbody><tr><td>A31(19)</td><td>B16</td><td></td><td>DR51</td><td></td><td></td></tr><tr><td>A32(19)</td><td>B38(16)</td><td></td><td>DR52</td><td></td><td></td></tr><tr><td>A33(19)</td><td>B39(16), B3901, B3902</td><td></td><td>DR53</td><td></td><td></td></tr><tr><td>A36</td><td>B17</td><td></td><td></td><td></td><td></td></tr><tr><td>A43</td><td>B57(17)</td><td></td><td></td><td></td><td></td></tr><tr><td>A80</td><td>B58(17)</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>B18</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>B21</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>B49(12)</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>B50(12)</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>B22</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>B54(22)</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>B55(22)</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>B56(22)</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>B27, B2708</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>B35</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>B37</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>B40, B4005</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>B60(40)</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>B61(40)</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>B41</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>B42</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>B46</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>B47</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>B48</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>B53</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>B59</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>B67</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>B70</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>B71(70)</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>B72(70)</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>B73</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>B7801</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>B81</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Bw4</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Bw6</td><td></td><td></td><td></td><td></td></tr></tbody></table>
<p>*Alleles are listed in the order of the broad antigen groups, followed by split antigens for that group, with the broad antigen number in parentheses. Associated antigens, such as B40 and B4005, are listed together.</p>
<p>menclature for specific DNA sequences. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mrow><mn>14</mn><mo>−</mo><mn>16</mn></mrow></msup></mrow><annotation encoding="application/x-tex">^{14-16}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">14</span><span class="mbin mtight">−</span><span class="mord mtight">16</span></span></span></span></span></span></span></span></span></span></span></span></span>  Many new alleles have been and are currently being defined at the DNA level. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mrow><mn>17</mn><mo separator="true">,</mo><mn>18</mn></mrow></msup></mrow><annotation encoding="application/x-tex">^{17,18}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">17</span><span class="mpunct mtight">,</span><span class="mord mtight">18</span></span></span></span></span></span></span></span></span></span></span></span></span>  A revised nomenclature is used for denoting alleles defined by DNA sequence. The alleles are named in sequential order as they are discovered. The</p>
<p>gene name, such as HLA-DRB1, is followed by an asterisk,  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mo stretchy="false">(</mo><mo lspace="0em" rspace="0em">∗</mo></msup><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(^{*})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen"><span class="mopen">(</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6887em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∗</span></span></span></span></span></span></span></span></span><span class="mclose">)</span></span></span></span></span>  the allele sequence family number, and a number for the specific allele (DNA sequence). For example, A<em>2503 is the third specific allele, 03, of the HLA-A</em>25 family of alleles.</p>
<p>Copyright ©2007 by F. A. Davis.
DNA-Based Tissue Typing Chapter 15
383</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="advanced-concepts">Advanced Concepts<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#advanced-concepts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The WHO Nomenclature Committee has proposed addition of a third digit to the allele designation to accommodate more than 99 alleles; for example, A<em>2501 to A</em>2599 would expand to A*25999. Other ways to accommodate the growing number of reported alleles have been proposed.¹⁹</p>
<p>The letter N following the specific allele number indicates a null allele, or phenotypic absence of that antigen. For example, B<em>1307N denotes the 07 allele of the 13 allele family in the HLA-B locus at the DNA level. At the protein level, however, the encoded protein does not react with any antibody. The B</em>1307N null allele is due to a 15-bp deletion in the HLA-B gene. Null alleles can also result from nonsense, frameshift, splice site, or other premature stop mutations that prevent translation of the amino acids destined to bind to antibody.</p>
<p>Silent mutations (changes in the DNA sequence that do not change the amino acid sequence), also called synonymous changes, are designated by a number following the specific allele number. For example, A<em>030102 indicates a synonymous allele, 02, of the first specific allele, 01, from the HLA-A</em>03 family of alleles. A fourth number designation indicates that the synonymous change results from a polymorphism in intronic sequences beyond the coding regions (exons) of the genes. Thus, A<em>26070101 is the 01 subtype allele of the HLA-A</em>2607 allele, the second 01 indicating that the polymorphism is in an adjacent intron.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="advanced-concepts">Advanced Concepts<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#advanced-concepts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Other descriptive designations are less frequently used, including L, S, X and ?. The letters L and S indicate poor expression of the allele at the cell surface or a soluble allele, respectively. An X notation indicates that resolution of the allele was not done, for example B<em>08X. A ? indicates that the resolution was not clear: B</em>08?.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="advanced-concepts">Advanced Concepts<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#advanced-concepts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The National Marrow Donor Program assigns alphabetical allele codes, such as AD or RJH to allele combinations from submitted requests. Generic codes can be used with several loci and allele families. For example the combination of alleles, 1501/1501N/1511/1515/1533/1534/1557/1560, in any HLA gene is designated RDX so that B<em>1501/1501N/1511/1515/1533/1534/1557/1560 = B</em>15RDX. Allele-specific codes are used for allele combinations that include more than one serological family or that contain an N, L, or S expression character. The lists of these codes and submissions for new codes are available at <a href="http://www.nmdpresearch.org" target="_blank" rel="noopener noreferrer">www.nmdpresearch.org</a></p>
<p>Ambiguity is the recognition of two or more antigens by the same antibody, or cross-reaction, so that the exact allele cannot be called. Ambiguity is designated by “/” between the possible allele numbers or a “–” for a series of alleles in which the first and last allele are named. For example, if a typing test results in either B<em>0733 or B</em>0735, the notation is B<em>0733/B</em>0735. If a typing test indicates that the allele is either B<em>0733, B</em>0734, B<em>0735, or B</em>0736, the designation is B<em>0733-B</em>0736. Ambiguity also arises from the inability of some typing methods to assign heterozygous alleles to one or the other chromosome. A combination of methods may be used to resolve ambiguities. Family studies are also helpful in this regard.</p>
<p>Resolution is the level of detail to which the allele is determined. Low resolution identifies broad allele types or groups of alleles. A typing of A<em>26 is low resolution, which can be determined at the serological level. Typing methods that detect specific alleles in addition to identification of all serological types are at medium resolution. Typing result A</em>2601/A<em>2605/A</em>26010/A<em>2615 is medium resolution. High resolution typing procedures can discriminate between almost all specific alleles. A</em>2601 is high resolution determined by DNA analysis. A range of methods from serological typing to direct DNA sequence analysis affords the laboratory a choice of low, medium, or high resolution typing. Whereas low resolution is adequate for solid organ transplantation typ-</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<p>ing, bone marrow or stem cell transplants require high resolution methods.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="molecular-analysis-of-the-mhc">Molecular Analysis of the MHC<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#molecular-analysis-of-the-mhc" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>There are over 1900 HLA alleles identified so far in all loci (Table 15.3). Genetic (DNA-based) typing concentrated in the HLA-A, -B, -C, and DRB1 genes has identi</p>
<p>Table 15.3 Number of HLA Alleles Identified Serologically and by DNA Sequence*</p>
<table><thead><tr><th>Gene</th><th>Serology</th><th>Genetic</th></tr></thead><tbody><tr><td>Class I</td><td></td><td></td></tr><tr><td>HLA-A</td><td>28</td><td>207</td></tr><tr><td>HLA-B</td><td>29</td><td>412</td></tr><tr><td>HLA-C</td><td>10</td><td>100</td></tr><tr><td>Class II</td><td></td><td></td></tr><tr><td>HLA-DRA</td><td></td><td>2</td></tr><tr><td>HLA-DRB1</td><td>18</td><td>271</td></tr><tr><td>HLA-DRB2</td><td></td><td>1</td></tr><tr><td>HLA-DRB3</td><td>1</td><td>30</td></tr><tr><td>HLA-DRB4</td><td>1</td><td>10</td></tr><tr><td>HLA-DRB5</td><td>1</td><td>15</td></tr><tr><td>HLA-DRB6</td><td></td><td>3</td></tr><tr><td>HLA-DRB7</td><td></td><td>2</td></tr><tr><td>HLA-DRB8</td><td></td><td>1</td></tr><tr><td>HLA-DRB9</td><td></td><td>1</td></tr><tr><td>HLA-DQA1</td><td></td><td>20</td></tr><tr><td>HLA-DQB1</td><td>9</td><td>45</td></tr><tr><td>HLA-DMA</td><td></td><td>4</td></tr><tr><td>HLA-DMB</td><td></td><td>6</td></tr><tr><td>HLA-DPA1</td><td></td><td>19</td></tr><tr><td>HLA-DPB1</td><td></td><td>93</td></tr><tr><td>HLA-DOA</td><td></td><td>8</td></tr><tr><td>HLA-DOB</td><td></td><td>8</td></tr><tr><td>Extended MHC</td><td></td><td></td></tr><tr><td>HLA-E</td><td></td><td>6</td></tr><tr><td>HLA-F</td><td></td><td>1</td></tr><tr><td>HLA-G</td><td></td><td>14</td></tr><tr><td>MICA</td><td></td><td>57</td></tr><tr><td>MICB</td><td></td><td>18</td></tr><tr><td>TAP1</td><td>6</td><td>6</td></tr><tr><td>TAP2</td><td>4</td><td>4</td></tr></tbody></table>
<p>*The World Marrow Donor Association Quality Assurance and Working Group on HLA Serology to DNA Equivalents publishes a comprehensive dictionary of antigen and allele equivalents.</p>
<p>fied alleles that far outnumber the serological alleles defined for these genes. Over 400 new nucleotide sequences were defined in just 2 years, from 2002 to 2004. The WHO Nomenclature Committee devised rules for submission of new alleles for official numerical designation.¹⁹ Allele sequences are stored in the GenBank, the European Molecular Biology Laboratory, and the DNA Data Bank of Japan databases. A list of newly reported alleles is published monthly in the journals Tissue Antigens, Human Immunology, and the International Journal of Immunogenetics. A comprehensive dictionary of antigen-DNA sequence allele equivalents is published periodically.²⁰⁻²³</p>
<p>Identification of alleles in the laboratory serves several purposes. In addition to selection of organ donors, the extent of HLA-type matching between donor and recipient predicts the long-term survival of the donor organ in the recipient. Furthermore, because disease genes are located in and around the MHC locus, certain HLA gene alleles are linked to disease, affording another aid in diagnosis or prediction of disease phenotypes.</p>
<p>There are three approaches to analysis of HLA alleles in the HLA laboratory: typing, screening, and cross-matching. Typing is initial identification of the HLA alleles of a specimen through protein or DNA-based methods. Typing may be used both to define HLA haplotypes and to look for specific HLA types that are linked to disease states. Screening is detection of anti-human antibodies in serum that match known HLA alleles. Crossmatching is more specific screening of recipient sera for antibodies against antigens displayed by potential organ donors.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="serological-analysis">Serological Analysis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#serological-analysis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Traditionally, HLA typing for organ transplantation was performed serologically; that is, by antigen-antibody recognition. Although serological testing yields only low resolution typing results, there are some advantages to these methods. Serological typing is a relatively rapid method that reveals immunologically relevant epitopes. Also, serological studies can be used to resolve ambiguities or confirm null alleles detected by other methods. Serological tests include HLA phenotype determination, in which patient cells are tested with known antisera (HLA typing), and screening of patient sera for anti-HLA antibodies.</p>
<p>Copyright ©2007 by F. A. Davis.
DNA-Based Tissue Typing Chapter 15 385</p>
<p><img src="assets/images/image-20251222-6f49660d.jpeg" alt="img-390.jpeg">
Figure 15-5 Crossmatching to known antibodies is performed on lymphocytes (buffy coat, left) in a 96 well plate format where each well contains different known antibodies. If the antibody matches the cellular antigen (positive reaction, top), complement-dependent cytotoxicity will occur, and the dead cell will take up stain (green). If the antibody does not match the cellular antigen, there is no cytotoxicity.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="hla-typing">HLA Typing<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hla-typing" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Lymphocytes are HLA-typed using the complement-dependent cytotoxicity test (CDC; Fig. 15-5).²⁴ In this procedure, multiple alleles are determined using a panel of antibodies against known HLA types. These antibodies are prepared from cell lines or from donors or known HLA types. Plates preloaded with antibodies (typing trays) are commercially available. Alternatively, some laboratories construct their own antibody panels. The collection of antibodies can be modified to represent ethnic populations or antigens of high prevalence in particular geographical areas. As the antibody preparations are used repeatedly, the antigen binding characteristics of the various antibodies are recognized and recorded. Experienced technologists have detailed documentation of antibody panels, including which antibodies bind antigen well and which antibodies bind less strongly.</p>
<p>To begin the typing procedure, different antibodies are placed in each well of the typing tray. Donor or recipient lymphocytes to be typed are distributed to the wells. Cross reactivity is assessed by the uptake of trypan blue or eosin red dye in cells that have been permeabilized due to reaction with the antibody and with complement that is activated by the antigen-antibody complexes (Fig. 15-6). Cytotoxicity is scored by the estimated percentage of cells in a well that have taken up the dye. The American</p>
<p>Society for Histocompatibility and Immunogenetics (ASHI) has developed guidelines for numerical description of the observed cytotoxicity (Table 15.4). High cytotoxicity (reading &gt;6) in a well of the plate indicates that the cells being tested have cell surface antigens matching the known antibody in that well. As reading is somewhat</p>
<p><img src="assets/images/image-20251222-4df6c93f.jpeg" alt="img-391.jpeg">
Figure 15-6 Cells stained for cytotoxicity. Dead cells take up dye, and live cells remain transparent. (Photo courtesy of Dr. Andres Jaramillo, Rush University Medical Center.)</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<p>Table 15.4 Expression of CDC</p>
<table><thead><tr><th>% Dead or lysed (dyed)</th><th>Interpretation</th><th>Score</th></tr></thead><tbody><tr><td>0–10</td><td>Negative</td><td>1</td></tr><tr><td>11–20</td><td>Doubtful negative</td><td>2</td></tr><tr><td>21–50</td><td>Weak positive</td><td>4</td></tr><tr><td>51–80</td><td>Positive</td><td>6</td></tr><tr><td>81–100</td><td>Strong positive</td><td>8</td></tr><tr><td></td><td>Unreadable</td><td>0</td></tr></tbody></table>
<p>subjective, it is recommended that trays be read by at least two technologists independently. An example of partial results from a CDC test is shown in Table 15.5. The results indicate that the tested cells are HLA-type A28, B44.</p>
<p>Each HLA antigen has multiple epitopes, some unique to that HLA antigen and some cross-reactive epitope groups (CREG) shared by other HLA antigens. The CDC test can be performed with private antibodies, those that bind to one specific HLA type or antibodies to broad CREG (or "public" antigens). Analysis of antibodies with shared specificities aids in narrowing the specificity, as illustrated in Table 15.5. As shown, all antibodies with A28- or B44-specificity generated cytotoxicity, supporting the determination of an A28, B44 haplotype.</p>
<p>CREG matching or residue matching (determined from the amino acid sequences of the antigens) is considered for kidney transplant screening in order to define the spectrum of HLA-specific antibodies more precisely.</p>
<p>Table 15.5 Example of Results From a CDC Assay</p>
<table><thead><tr><th>Antibody</th><th>Score*</th></tr></thead><tbody><tr><td>A2, A28, B7</td><td>8</td></tr><tr><td>A2, A28</td><td>6</td></tr><tr><td>A10</td><td>1</td></tr><tr><td>A10, A11</td><td>1</td></tr><tr><td>B7, B42</td><td>8</td></tr><tr><td>B7, B27</td><td>8</td></tr><tr><td>B7, B55</td><td>8</td></tr><tr><td>B44, B45, B21</td><td>6</td></tr><tr><td>B44, B45</td><td>8</td></tr><tr><td>B44</td><td>8</td></tr><tr><td>B45</td><td>1</td></tr></tbody></table>
<p>*Scores are 1-8, depending on the percentage of dyed cells observed.</p>
<p>Some epitopes are more important than others with respect to organ rejection. Therefore, certain mismatches are allowable if the critical epitopes match.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="screening">Screening<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#screening" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Successful organ transplant depends on minimal reaction of the recipient immune system to the antigens of the donor organ. Normal sera do not have antibodies against human antigens, termed anti-human antibodies or alloantibodies. Persons who have had a previous organ transplant, blood transfusions, or pregnancies, however, will have anti-human antibodies (termed humoral sensitization) that may react against a new donor organ. The chance of a successful transplant is improved by defining the specificity of the alloantibodies and selecting a suitable organ that does not have HLA antigens corresponding to the antibodies in the patient's sera.[25] Humoral sensitization and the identity of alloantibodies present in the recipient serum are determined in a modified version of the CDC assay using the patient's serum as the source of antibodies and reference lymphocytes of known HLA types prevalent in the general population. The reference lymphocytes are defined by their recognition of panel reactive antibodies (PRA). This test against PRA reveals the percentage of the general population with whom the patient will cross-react.</p>
<p>The percentage of the panel of lymphocytes killed by the sera is referred to as  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">%</mi><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">R</mi><mi mathvariant="normal">A</mi></mrow></mrow><annotation encoding="application/x-tex">\% \mathrm{PRA}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">%</span><span class="mord"><span class="mord mathrm">PRA</span></span></span></span></span></span> . Patients with  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">%</mi><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">R</mi><mi mathvariant="normal">A</mi></mrow></mrow><annotation encoding="application/x-tex">\% \mathrm{PRA}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">%</span><span class="mord"><span class="mord mathrm">PRA</span></span></span></span></span></span>  activity of more than  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span>  are considered to be highly sensitized; finding cross-match-negative donors is more difficult in these cases.[26]</p>
<p>Screening of sera with microparticles (beads) is performed in laboratories with flow cytometry capability (Fig. 15-7). For this method, microparticles are attached to pools of antigens derived from cell lines of defined HLA types. The microparticles are exposed to test serum, and those beads carrying antigens that are recognized by antibodies present in the test serum will bind to those antibodies. After removal of unbound antibodies, a fluorescently labeled secondary reporter antibody is applied, and the antibody-bound beads are detected by flow cytometry. The advantages of this method over the CDC test are that the reaction is performed in a single tube and there is less subjectivity in the interpretation of results. Because this test uses pooled antigens, however, it can detect prevalence of anti-human antibodies in the test serum but not identify which specific antibodies are pres</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>DNA-Based Tissue Typing Chapter 15</p>
<p>ent. A negative result does preclude further alloantibody assessment. A variation of this method developed by Luminex Corp. and MiraiBio utilizes beads with their own internal fluorescence. By conjugating known antigens to beads of different internal fluorescence, the positively reacting antibodies can be identified while still performing the test in the same tube.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="crossmatching">Crossmatching<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#crossmatching" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The CDC test is also used for crossmatching potential organ donors and recipients. For crossmatching, recipient serum is the source of antibodies tested against donor lymphocytes (Fig. 15-8). If the recipient serum kills the donor lymphocytes, it is a positive crossmatch and contraindication for using the crossmatched donor.</p>
<p>Other methods used for crossmatching include variations on the lymphocytotoxicity assay and nonlymphocy</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="advanced-concepts">Advanced Concepts<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#advanced-concepts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>More detailed crossmatch information is achieved by separate analysis of B and T donor lymphocytes. Unactivated T cells display class I antigens, and B cells display both class I and class II antigens. Therefore, if B cells cross react with the serum antibodies and T cells do not, the serum antibodies are likely against class II antigens.</p>
<p><img src="assets/images/image-20251222-040d9439.jpeg" alt="img-392.jpeg"></p>
<p><img src="assets/images/image-20251222-d03b86ed.jpeg" alt="img-393.jpeg">
Figure 15-7 Detection of serum antibodies using bead arrays. In this illustration, separate preparations of beads are conjugated to two different known antigens. The patient serum tested contains an antibody to the antigen on the beads in (A) but not the antigen on the beads in (B). A secondary antibody targeting the bound serum antibody generates a fluorescent signal detected by flow cytometry. If a matching antibody is not present in the test serum as in (B), no antibody will be bound.</p>
<p>totoxic methods that utilize flow cytometry, such as the bead arrays just described. Alternative methods also include enzyme-linked immunosorbent assay (ELISA) using solubilized HLA antigens. ELISA can be used to monitor the change in antibody production over time or humoral sensitization developing after the transplant.</p>
<p><img src="assets/images/image-20251222-0660869d.jpeg" alt="img-394.jpeg">
Figure 15-8 Crossmatch by CDC. In this assay, the recipient serum is the source of antibodies to type lymphocytes from potential organ donors. The antibodies in the recipient serum can be identified if the HLA type of the lymphocytes is known.</p>
<p>Mixed Leukocyte Culture</p>
<p>T lymphocytes are primarily responsible for cell-mediated organ rejection. The mixed leukocyte culture (MLC) is an in vitro method used to determine T-cell cross reactivity between donor and recipient. The MLC assay measures growth of lymphocytes activated by cross reactivity as an indication of donor/recipient incompatibility. MLC can also test for cell-mediated cytotoxicity and cytokine production, by either the donor or recipient lymphocytes, so it can be used to predict GVHD as well as recipient-mediated transplant rejection. For this test, cells must be incubated together for several days. Cell activation and growth are assessed by uptake of^{3}H-thymine. Even though the MLC is more likely to detect HLA mismatches than serology techniques, the time and technical demands of the MLC precludes its routine use for pretransplant histocompatibility testing in the clinical laboratory.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="protein-gel-electrophoresis">Protein Gel Electrophoresis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#protein-gel-electrophoresis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>The protein products of the HLA genes can be distinguished by mobility differences in one-dimensional gel isoelectric focusing or two-dimensional gel electrophoresis methods.27,28 These typing methods have also been applied to forensic identification.29 Protein methods are limited by the demands of the methodology and the ability to distinguish only those proteins that have different net charges. With the advent of proteomics, the use of protein markers to evaluate tissue and organ transplantation may return.30</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="dna-based-typing">DNA-Based Typing<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#dna-based-typing" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Many people are waiting for transplant organs. Typing, screening, and crossmatch analysis are critical for selection of potential donors and successful engraftment. Methods differ in sensitivity. The choice and design of the method used, therefore, will affect the ability to predict rejection risk.</p>
<p>Limitations of serological and protein-based methods have led to the development of more refined molecular DNA typing with higher powers of resolution, especially for bone marrow transplantation typing. One of the first DNA methods for molecular typing was restriction fragment length polymorphism (RFLP) analysis by Southern blot. This method was used to identify HLA class II alleles.31,32 (See Chapter 6 for a description of the Southern blot technique.) Studies showed that kidneys matched by RFLP typing survived longer than those matched by serological typing.33,34 Just as with other applications of molecular testing, the development of amplification and direct sequencing methods greatly advanced the analysis of HLA polymorphisms at the DNA sequence level.</p>
<p>DNA typing focuses on the most polymorphic loci in the MHC, HLA-B, and HLA-DRB. HLA-A, HLA-B, HLA-C, and HLA-DRB are all considered important for successful transplantation outcomes.35 For this reason, the number of alleles in these particular loci has risen significantly compared with the number of serologically defined polymorphisms.</p>
<p>Whole blood patient specimens collected in ethylene diamine tetra-acetic acid anticoagulant are used for DNA-based typing. Cell lines of known HLA type are used for reference samples. Standards and quality assurance for DNA-based assays have been established by ASHI (<a href="http://www.ashi-hla.org" target="_blank" rel="noopener noreferrer">www.ashi-hla.org</a>). DNA isolation (see Chapter 4) can be performed from white blood cell preparations (buffy coat) or from isolated nuclei treated with proteinase K.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="sequence-specific-oligonucleotide-probe-hybridization">Sequence-Specific Oligonucleotide Probe Hybridization<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sequence-specific-oligonucleotide-probe-hybridization" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Hybridization of a labeled probe to immobilized amplicons of the HLA genes (dot blot) was one of the first methods that utilized polymerase chain reaction (PCR)--amplified DNA for HLA typing.36 For this procedure (Fig. 15-9), the HLA region under investigation is amplified by PCR using primers flanking the polymorphic sequences. Because the majority of polymorphic sequences are located in exon 2 of the class II genes and exons 2 and 3 of the class I genes, primers are designed to target these regions.</p>
<p>An assay using 30 probes requires approximately 70 μl of PCR product.37 The amplicons are denatured by addition of NaOH and spotted onto a membrane in 1--2--μl volumes. Spotting is done manually with a multichannel pipet or by a vacuum manifold with a 96 well plate format. The spotted DNA is dried, then permanently attached to the membrane by ultraviolet cross-linking (exposure to ultraviolet light) or baking. Separate membranes are produced for each probe to be used. Every membrane should include reference amplicons complementary (positive control) and noncomplementary (negative control) to all probes in the assay. Spotting consistency may be checked using a consensus probe that will hybridize to all specimens on a membrane.</p>
<p>The probes used in this assay are short (19--20 bases) single-stranded DNA chains (oligonucleotides) designed</p>
<p>Copyright ©2007 by F. A. Davis.
DNA-Based Tissue Typing Chapter 15 389</p>
<p><img src="assets/images/image-20251222-ad9dd5c1.jpeg" alt="img-395.jpeg">
Figure 15-9 The principle of the SSOP assay is shown. An HLA gene region is amplified from specimen DNA using generic primers (top). The amplicons are immobilized on a membrane and probed with labeled sequences complementary to specific alleles. Signal from the bound probe will indicate the allele of the immobilized DNA.</p>
<p>to hybridize to specific HLA alleles. The oligonucleotides are labeled; that is, covalently attached to biotin or digoxygenin. (See Chapter 6 for a description of nonradioactive signal detection.) Probe sequences are based on sequence alignments of HLA polymorphic regions. The probe sequences are aligned so that the polymorphic nucleotide is in the middle of the probe sequence. Hybridization conditions depend on the optimal binding of the probe matching a test sequence in comparison with another sequence, differing from (not complementary to) the probe by at least one base. Spots of immobilized specimens bound to specific probes give a positive colorimetric or chemiluminescent signal. Panels of probes define specific alleles according to which probe binds to the immobilized amplified DNA under investigation. The number of probes used depends on the design of the assay. For example, an intermediate resolution assay of the HLA-DRB locus might take 30–60 probes. Studies have achieved high resolution identification of the majority of HLA-A, B, and C alleles using 67 HLA-A, 99</p>
<p>HLA-B, and 57 HLA-C probes and intermediate resolution with 39 HLA-A and 59 HLA-B alleles.³⁸</p>
<p>Sequence-specific oligonucleotide probe (SSOP) may also be performed in a reverse dot blot configuration in which the allele-specific probes are immobilized on the membrane (Fig. 15-10). In this method, the specimen DNA is labeled by PCR amplification using primers covalently attached to biotin or digoxygenin at the 5′ end. In contrast to the SSOP described above where amplicons from each specimen are spotted on multiple membranes, each specimen is tested for multiple alleles on a single membrane. Therefore, instead of having a separate membrane of multiple specimens for each probe, a separate membrane of multiple probes is required for each specimen. Membranes with immobilized probes, such as Dynal RELI, SSO HLA-Cw, and DRB typing kits are commercially available.</p>
<p>A bead array system has been applied to the reverse dot blot strategy where fluorescently distinct beads carry the oligonucleotide probes (LABType SSO, One Lambda, Inc.). This system is commercially available for typing of HLA-A, B, C class I, and HLA-DRB1, DRB3, DRB4, DRB5, and DQB1 antigens.</p>
<p>SSOP is considered low to intermediate resolution, depending on the number and types of probes used in the assay. Probe panels are listed by the 13th International</p>
<p><img src="assets/images/image-20251222-f7370050.jpeg" alt="img-396.jpeg">
Figure 15-10 In reverse dot blot SSOP, the probe is immobilized on the membrane. Patient DNA is amplified using primers covalently bound to biotin or digoxygenin at the 5′ end. The amplicons are then hybridized to panels of probes immobilized on a membrane (top). If the sequence of the amplicon matches and hybridizes to that of the probe, a secondary reaction with enzyme-conjugated avidin or antidigoxygenin will produce a color or light signal when exposed to substrate. If the sequence of the amplicon differs from that of the probe, no signal is generated (bottom right).</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<p>Histocompatibility Workshop at <a href="http://www.ikwg.org" target="_blank" rel="noopener noreferrer">www.ikwg.org</a> and the National Marrow Donor Program (NMDP) at <a href="http://www.nmdp" target="_blank" rel="noopener noreferrer">www.nmdp</a> research.org. As some probes have multiple specificities, hybridization panels can be complex. Computer programs may be used for accurate interpretation of SSOP results.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="sequence-specific-pcr">Sequence-Specific PCR<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sequence-specific-pcr" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A faster method of sequence-based typing is the use of sequence-specific primers that will amplify only specific alleles (Fig. 15-11). As described in Chapter 7, the  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>3</mn><mo mathvariant="normal" lspace="0em" rspace="0em">′</mo></msup></mrow><annotation encoding="application/x-tex">3^{\prime}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7519em;"></span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7519em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">′</span></span></span></span></span></span></span></span></span></span></span></span></span>  end of a PCR primer must be complementary to the template for recognition by DNA polymerase. By designing primers that end on the polymorphic sequences, successful generation of a PCR product will occur only if the test sequence has the polymorphic allele complementary to the primer. Detection of the PCR product is used to indicate specific alleles. Sequence-specific PCR (SSP-PCR) is faster and easier than SSOP in that no probes or labeling steps are required and the results of SSP-PCR are determined directly by agarose gel electrophoresis.</p>
<p>For SSP-PCR, isolated DNA is amplified using sets of primers designed to specifically amplify a panel of alleles. Reactions are set up in a 96 well plate format, with different allele- or sequence-specific primer sets in each well. Each PCR reaction mix contains sequence-specific primers and amplification control primers in a multiplex format. The amplification control primers should yield a product for every specimen (except the negative control). The sequence-specific primers should only yield a product if the specimen has the allele complementary to (matching) the allele-specific primer sequence. The amplification primers are designed to yield a PCR product of</p>
<p>a size distinct from the product of the allele-specific primers. The two amplicons can then be resolved by agarose gel electrophoresis. An illustration of the results expected from SSP-PCR is shown in Figure 15-12. Specimens will yield two PCR products (amplification control and allele-specific product) only from those wells containing primers matching the specimen HLA allele. Wells containing primers that do not match the patient's HLA allele will have a band only from the amplification control.</p>
<p>PCR plates preloaded with reaction mixes (typing trays) containing primers specific for class I and class II DRB and DRQ genes are commercially available (MicroSSP, One Lambda, Inc., and Pel Freez SSP UniTray). To use these products, specimen DNA is introduced into the individual wells, and the plates are placed in the thermal cycler. Plate maps of allele-specific primers are provided for interpretation of the HLA-type. SSP-PCR has become a commonly-used method for testing potential donors before transplant.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="sequence-based-typing">Sequence-Based Typing<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sequence-based-typing" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The most definitive way to analyze DNA at the nucleotide sequence level is by direct DNA sequencing. This is true for any DNA test, no less for discovery and identification of HLA types. (See Chapter 10 for a description of DNA sequencing methodology.) Sequence-based typing (SBT) involves amplification of polymorphic regions; for example, exons 2 and 3 of the HLA-B gene (Fig. 15-13). The amplicons are then purified and added to a sequencing reaction mix (Fig. 15-14). Following gel or capillary gel electrophoresis, the fragment patterns or electropherograms are examined for specific polymorphisms. Because</p>
<p><img src="assets/images/image-20251222-716ab521.jpeg" alt="img-397.jpeg">
Figure 15-11 The sequence-specific primer ending in AGTACT will be extended only from a template carrying the polymorphism shown.</p>
<p>Copyright ©2007 by F. A. Davis.
DNA-Based Tissue Typing Chapter 15 391</p>
<p><img src="assets/images/image-20251222-f388e056.jpeg" alt="img-398.jpeg"></p>
<p>Figure 15-12 Results of an SSP-PCR of 95 primer sets detected by agarose gel electrophoresis. An amplification control is included with each reaction to avoid false-negative results due to amplification failure. Contamination is monitored by a reagent blank. (Photo courtesy of Christin Braun, Rush University Medical Center.)</p>
<p>HLA haplotypes are almost always heterozygous, the sequencing results often yield a heterozygous pattern at the site of the polymorphism (Fig. 15-15). Commercial systems including PCR and sequencing reaction mixes as well as software programs for interpretation of results are available.</p>
<p>Secondary structure and other artifacts may alter the mobility of some fragments and complicate interpretation. Furthermore, a number of events can occur that will compromise sequence quality (see Chapter 10). Manufacturers of sequencing reagents supply ways to correct most of these problems. As with any sequencing assay, it is useful to sequence both strands of the test DNA.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="other-dna-based-methods">Other DNA-Based Methods<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#other-dna-based-methods" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Almost any method that can determine DNA sequence or detect specific sequences or sequence differences can be applied to DNA-based HLA typing (see Chapter 9). There</p>
<p><img src="assets/images/image-20251222-2ae6d4da.jpeg" alt="img-399.jpeg"></p>
<p>Figure 15-13 Example of primer placement for amplification and sequence analysis. PCR primers (outer large arrows) are used to amplify the region of interest. The PCR product is then sequenced using four different primers (inner small arrows) in separate sequencing reactions.</p>
<p><img src="assets/images/image-20251222-b343fe7f.jpeg" alt="img-400.jpeg"></p>
<p>Figure 15-14 For sequenced-based typing, HLA regions from patient DNA are amplified by PCR. The PCR products are then purified from unused PCR reaction components by alcohol precipitation or column or gel purification methods. The amplicons are then sequenced to detect polymorphisms.</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<p><img src="assets/images/image-20251222-5b41ce8f.jpeg" alt="img-401.jpeg">
Figure 15-15 A sequence-based typing result for the HLA-A gene. Software is designed to analyze the sequence of patient DNA, compare it with the consensus sequence, and identify the specific alleles by sequence polymorphisms. (Sequence courtesy of Christin Braun, Rush University Medical Center.)</p>
<p>are several variations on SSOP, SSP, and SBT, such as nested PCR-SSP <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>39</mn></msup></mrow><annotation encoding="application/x-tex">^{39}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">39</span></span></span></span></span></span></span></span></span></span></span></span></span>  proposed for HLA typing. Another example is allele-specific nested PCR-SSP, which has been applied to subtyping of highly polymorphic alleles. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mrow><mn>40</mn><mo separator="true">,</mo><mn>41</mn></mrow></msup></mrow><annotation encoding="application/x-tex">^{40,41}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">40</span><span class="mpunct mtight">,</span><span class="mord mtight">41</span></span></span></span></span></span></span></span></span></span></span></span></span></p>
<p>Heteroduplex (HD) analysis has been used for assessment of compatible bone marrow donors at the HLA-DR and HLA-DP loci.42 Reference strand conformation polymorphism is a variation on the standard HD analysis; sample amplicons are mixed with fluorescently labeled reference DNA of known allele sequence before denaturation and renaturation to form heteroduplexes.43 The homo- and heteroduplexes formed between the specimen amplicons and the reference strand are then resolved by capillary gel electrophoresis.</p>
<p>Single strand conformation polymorphism (SSCP) has been applied to HLA-A, DR, DQ, and DP typing and subtyping.44,45 SSCP has been coupled with allele-specific PCR.46 High performance liquid chromatography (HPLC) has been proposed for HLA typing as well. Conformation analyses, such as HD, SSCP, and HPLC, however, are limited by the complexity of the raw data and the strict demands on reactions and electrophoresis conditions; they are not routinely used in the clinical laboratory.</p>
<p>Other DNA-based typing approaches include array technology <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>47</mn></msup></mrow><annotation encoding="application/x-tex">^{47}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">47</span></span></span></span></span></span></span></span></span></span></span></span></span>  and pyrosequencing. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>48</mn></msup></mrow><annotation encoding="application/x-tex">^{48}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">48</span></span></span></span></span></span></span></span></span></span></span></span></span>  No one method is without disadvantages with respect to technical demands, cost, or time consumption. To date, SSP, SSOP, and SBT</p>
<p>are the DNA-based methods used in most clinical laboratories. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mrow><mn>37</mn><mo separator="true">,</mo><mn>49</mn></mrow></msup></mrow><annotation encoding="application/x-tex">^{37,49}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">37</span><span class="mpunct mtight">,</span><span class="mord mtight">49</span></span></span></span></span></span></span></span></span></span></span></span></span></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="combining-typing-results">Combining Typing Results<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#combining-typing-results" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>At the DNA level, HLA polymorphisms differ from one another by as small as a single nucleotide base. Serological typing does not always distinguish subtle genetic differences between types. Serological typing also requires the proper specimen. A specimen consisting of mostly T cells, for example, from a patient treated with chemotherapy, will not provide B cells (which carry class II antigens) for testing of class II haplotypes. In contrast, DNA-based typing is not limited by specimen type as all cells have the same HLA haplotype at the DNA level, regardless of whether the cell type expresses the antigens. Furthermore, synonymous DNA changes and polymorphisms outside of the protein coding regions may not alter antigenicity at the protein level.</p>
<p>For DNA-based methods, the design of molecular methods (primer and probe selection) determines their level of resolution. SSOP and SSP methods require specific primers and/or probes for each particular HLA type. Only those HLA-types included in a given probe or primer set, therefore, will be identified. Sequence-based typing will only identify alleles included in the amplified regions that are sequenced.</p>
<p>Copyright ©2007 by F. A. Davis.
DNA-Based Tissue Typing Chapter 15
393</p>
<p>Results from serological and DNA-based methods can be combined to improve resolution and further define HLA types. Sequential use of SSP-PCR and PCR-RFLP or SSOP-PCR and SSP-PCR increases the typing resolution of DNA-based tests.³⁷,⁵⁰ Serological testing can be used to clarify or confirm the phenotype of alleles detectable by DNA-based methods. The resolution of results from various methods, therefore, reflects a range of resolution levels (Table 15.6). The choice of method will depend on the demand for high or low resolution typing.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="hla-test-discrepancies">HLA Test Discrepancies<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hla-test-discrepancies" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>HLA typing may produce discrepant results, especially if different methods are used to assess the same specimen. The most common discrepancies are those between serology and molecular testing results.⁵¹ DNA sequence changes do not always affect protein epitopes. A serology type may represent several alleles at the DNA level. Also, a serology type may look homozygous (match to only one antibody) where the DNA alleles are heterozygous, the second allele not recognized by serology. For example, a serology type of A2 is determined to be A<em>02, A</em>74 at the DNA level.</p>
<p>Discrepancies also arise when HLA types assigned to parent alleles based on DNA sequence homology differ from serology results that detect the same allele as a new antigen. For example, a DNA allele of B*4005 is detected as a new antigen by serology and named B50. Similarly, split alleles (subtypes of serologically defined antigens) can differ between DNA and serology typing due to the cross reactivity of antibodies used to define the HLA antigens.</p>
<p>The identification of new alleles can result in discrepant retyping results based on the recognition of new alleles that were not defined at the time of an initial typing. These discrepancies may be difficult to resolve, especially if the original typing data are not accessible.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="coordination-of-hla-test-methods">Coordination of HLA Test Methods<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#coordination-of-hla-test-methods" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Choice of the appropriate method and resolution of HLA testing are influenced by the type of transplant. For solid organ transplants, antibody screening and crossmatching of recipient serum against donor antigens are routinely performed, although not always before transplantation. Pretransplant HLA typing is often determined for kidney and pancreas transplants, as the extent of HLA matching is directly proportional to time of survival of the donor organ.⁵²,⁵³ Given the circumstances under which heart, lung, and liver transplants are performed, testing is frequently performed after the transplant. HLA typing for solid organs is usually at the low resolution serology level, although for heart and lung transplants, as with kidney transplants, studies have shown that matching HLA types are beneficial for organ survival.⁵⁴,⁵⁵ For stem cell and bone marrow transplants, typing to high resolution (specific alleles) is preferred in order to decrease the risk of rejection and to avoid GVHD.⁵⁶,⁵⁷</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="additional-recognition-factors">Additional Recognition Factors<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#additional-recognition-factors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="minor-histocompatibility-antigens">Minor Histocompatibility Antigens<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#minor-histocompatibility-antigens" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Any donor protein that can be recognized as nonself by the recipient immune system can potentially affect engraftment. Proteins outside the MHC that influence graft failure are called minor histocompatibility antigens (mHag). These antigens were the suspected cause of GVHD and graft rejection in MHC-identical transplants.⁵⁸,⁵⁹ The H-Y antigen was the first characterized mHag.⁶⁰ Investigations using molecular methods have led to the characterization of additional mHags, including HA-1, CD31, HPA-1, HPA-2, HPA-3, and HPA-5.⁶¹ Evaluation of mHags in stem cell transplants can be carried out by molecular methods such as SSP-PCR.⁶²</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="nonconventional-mhc-antigens">Nonconventional MHC Antigens<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#nonconventional-mhc-antigens" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Located within the MHC locus are the MHC class I related MICA and MICB genes. Three pseudogene fragments, MICC, MICD, and MICE are also found within</p>
<table><thead><tr><th>Table 15.6 Resolution of HLA Typing Methods</th><th></th><th></th></tr></thead><tbody><tr><td>Low Resolution</td><td>Intermediate Resolution</td><td>High Resolution</td></tr><tr><td>CDC (serology)</td><td>PCR-SSP</td><td>PCR-SSP</td></tr><tr><td>PCR-SSP</td><td>PCR-SSOP</td><td>PCR-SSOP</td></tr><tr><td>PCR-SSOP</td><td>PCR-RFLP</td><td>SSP-PCR + PCR-RFLP</td></tr><tr><td>SSOP-PCR + SSP-PCR</td><td></td><td></td></tr><tr><td>SBT</td><td></td><td></td></tr></tbody></table>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<p>the class I region. The products of the MICA and MICB genes along with those of the retinoic acid early transcript (RAET) gene cluster located on the long arm of chromosome 6 (6p21.3) bind to the receptor NKG2D on natural killer (NK) cells (killer cell lectin-like receptor, subfamily K, number 1 or KLRK1). These gene products participate in immune reactions against abnormal cells such as tumor cells through control of NK cells and cytotoxic T lymphocytes (CTL) expressing the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>γ</mi><mi>δ</mi></mrow><annotation encoding="application/x-tex">\gamma\delta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05556em;">γ</span><span class="mord mathnormal" style="margin-right: 0.03785em;">δ</span></span></span></span></span> T-cell receptor. Virus- or bacteria-infected cells may also be recognized and eliminated in part by this system.</p>
<p>The MICA and MICB genes are highly polymorphic. Approximately 60 MICA and 25 MICB alleles have been reported. In contrast to the MHC class I alleles, polymorphisms in the MIC genes are distributed throughout the coding regions, with no hypervariable regions. Anti-MIC antibodies have been detected after organ transplantation, similar to anti-HLA alloantibodies, supporting a role for these gene products in organ rejection.[63]</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="killer-cell-immunoglobulin-like-receptors">Killer Cell Immunoglobulin-like Receptors<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#killer-cell-immunoglobulin-like-receptors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>NK cells and some memory T cells express killer cell immunoglobulin-like proteins (KIR). The effect of these proteins was first observed as "hybrid resistance" in mice.[64] In these experiments, mice with compromised immune systems were still capable of rejecting grafts from unrelated mice. That is, graft rejection still occurred, even in the absence of a functional immune system. The KIR proteins have been proposed as one source of nonself recognition outside of the MHC. The KIR proteins interact with HLA antigens, specifically recognizing HLA-A, HLA-B, and HLA-C (class I) molecules. KIR proteins are also expressed on myelomonocytic lineage cells (leukocyte immunoglobulin-like receptor) and other leukocytes</p>
<p>(leukocyte-associated immunoglobulin-like receptor). A cluster of genes coding for these receptor proteins has been found on chromosome 19q13.4, the leukocyte receptor cluster (Fig. 15-16).</p>
<p>Recipient KIR may participate in graft rejection and donor KIR in GVHD.[65] Specific interactions between KIR and HLA genes are listed in Table 15.7. Just as with mHags, assessment of polymorphisms in KIR may be added to donor selection criteria in stem cell and bone marrow transplant, especially with unrelated donors.[66, 67] In contrast to HLA typing, testing for KIR is aimed at finding donors and recipients who do not match. A KIR SSO commercial system using bead array technology is available for typing of 16 KIR genes and variants (One Lambda, Inc.).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mhc-disease-association">MHC Disease Association<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mhc-disease-association" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Genetic diseases caused by single gene disorders obey mendelian laws. Their phenotypes are either dominant or recessive and are inherited in a predictable manner illustrated in pedigrees (see Chapter 13). Most diseases, however, are not caused by a single genetic lesion and therefore have complex segregation patterns. Multiple genes, epigenetics, and environmental factors combine to bring about these disease states. For diseases such as diabetes, high blood pressure, and certain cancers, genetic analysis yields results in terms of predisposition, probability, and risk of disease.</p>
<p>Autoimmune diseases, which affect <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">4\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">4%</span></span></span></span></span> of the population, fall in this category. At least one of the genetic factors involved in autoimmunity is linked to the MHC, as autoimmune diseases have MHC associations. Rheumatoid arthritis, multiple sclerosis, diabetes mellitus type 1, and systemic lupus erythematosus are associated with particular HLA haplotypes. Determination of a disease</p>
<p><img src="assets/images/image-20251222-0560f035.jpeg" alt="img-402.jpeg">
Figure 15-16 The KIR gene cluster includes a centromeric and a telomeric fragment. Gene content varies from one person to another. A KIR haplotype can contain from 8 to 14 genes in different combinations and gene orders. For example a haplotype may have a 2DL2 or 2DL3 gene between 2DS2 and 2DL5B genes, or the order of 2DS1 and 2DS4 can be 2DS1-2DS4 or 2DS4-2DS1.</p>
<p>Copyright ©2007 by F. A. Davis.
DNA-Based Tissue Typing Chapter 15
395</p>
<p>Table 15.7 KIR and HLA Gene Interactions</p>
<table><thead><tr><th>KIR</th><th>HLA Specificities</th></tr></thead><tbody><tr><td>2DL1, 2DS1, (2DS4)</td><td>Cw*02, *0307, *0310, *0315, *0304, *0305, *0306, *0707, *0709, *1204, *1205, *15 (except *1507), *1602, *17, *18</td></tr><tr><td>2DL2, 2DL3, (2DS2)</td><td>Cw*01, *03, (except *0307, *0310, *0315, *07 (except *0707, *0709), *0708, *12 (except *1204, *1205), *13, *14, *1507, *16 (except *1602)</td></tr><tr><td>2DL4</td><td>G</td></tr><tr><td>2DL5</td><td>Unknown</td></tr><tr><td>3DL1</td><td>Bw4</td></tr><tr><td>3DL2</td><td>A3, A11</td></tr><tr><td>3DL3</td><td>Unknown</td></tr><tr><td>2DS3</td><td>Unknown</td></tr><tr><td>2DS5</td><td>Unknown</td></tr><tr><td>3DS1</td><td>Unknown</td></tr></tbody></table>
<p>associated HLA haplotype aids in diagnosis or prediction of disease predisposition.</p>
<p>The presence of a haplotype associated with disease is not diagnostic on its own, however. An example is the HLA-B27 type found in all cases of ankylosing spondylitis. HLA-B27 is also the most frequently found HLA-B allele. Many people, therefore, with the B27 allele do not have this condition. The laboratory is usually asked to perform HLA typing in persons showing disease symptoms or family histories of such disease to aid or confirm the diagnostic decisions.</p>
<p>Normal states are also controlled by multiple genetic and environmental factors. The genes for olfactory sensation, histone genes, genes encoding transcription factors and the butyrophilin (a constituent of milk in mammals) gene cluster are found in the MHC. The MHC may play a role, not only in the predisposition to disease, but protection from disease as well, including some infectious diseases, notably HIV.[68,69] In this role, certain HLA types are considered "protective".</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="summary-of-laboratory-testing">Summary of Laboratory Testing<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#summary-of-laboratory-testing" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Standard HLA testing includes a range of methods and test designs (Table 15.8). Determining donor and recipient compatibility is the primary goal of pretransplant testing, especially for bone marrow transplant from unre</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="advanced-concepts">Advanced Concepts<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#advanced-concepts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>HLA types are also associated with absence of inherited disease. Protection from genetic diseases is naturally enhanced by "hybrid vigor" or avoidance of inbreeding. The MHC may bring about such natural protection by control of mating selection to ensure genetic mixing. For example, studies with mice have shown that olfactory sensation (sense of smell) may play a role in mate selection. In these studies, female mice were able to distinguish male mice with H-2 alleles different from their own.[77] This supports the idea of selective pressure to mate with HLA-dissimilar partners to increase genetic diversity. Another study in humans showed that women found the scent of T-shirts worn by some male subjects pleasant and others unpleasant. The odors detected as pleasant were from HLA-dissimilar males. The women were apparently able to distinguish HLA types different from their own through sweat odors of male test subjects.[78]</p>
<p>lated donors. The extent of HLA matching will increase the prospect of successful transplantation with minimal GVHD. For example, the NMDP requests HLA typing results for HLA-A, B, and C class I antigens and DRB1, DQB1, and DPB1 class II antigens for prospective bone marrow donors.</p>
<p>Combinations of molecular tests, serum screening, and crossmatching further define acceptable HLA mismatches, and the results are used to prevent hyperacute (almost immediate) rejection in organ transplants. Identification of HLA types associated with disease also provides important information, especially for disease caused by multiple genetic and environmental factors. Finally, MLC, although not generally part of routine clinical testing, can predict cellular factors involved in rejection.</p>
<p>Laboratory results are key for selection of compatible donors, post-transplant evaluation, selection of optimal treatment strategy, and genetic disease predisposition. Molecular analysis has significantly increased the ease and ability to detect subtle differences in the MHC and associated regions. Nucleic acid analysis will play an expanding role in this area of laboratory analysis.</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<p>Table 15.8 Summary of Testing for Pre- and Post-transplant Evaluation</p>
<table><thead><tr><th>Purpose</th><th>Test Design</th><th>Methods</th></tr></thead><tbody><tr><td>Determine HLA type</td><td>Determine HLA types with standard references or by DNA sequence</td><td>Serology DNA-based typing</td></tr><tr><td>Determine serum antibody status</td><td>Serum screening against known HLA antibodies</td><td>CDC ELISA Flow cytometry</td></tr><tr><td>Crossmatching</td><td>Compare serum of recipient with that of prospective donors</td><td>CDC ELISA Flow cytometry</td></tr><tr><td>Determine T-cell mediated cytotoxicity between donor and recipient</td><td>Alloreactive T-cell characterization and quantitation</td><td>MLC Cytokine production</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="38916c7d">Case Study 15·1<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#38916c7d" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A 50-year-old man complained of digestive disorders and what he presumed was allergy to several foods. He consulted his physician, who collected blood samples for laboratory testing. The man was in a high-risk group for certain diseases, notably celiac disease, which would produce symptoms similar to those experienced by this patient. A specimen was sent to the laboratory to test HLA-DQA and -DQB alleles. Almost all (95%) people with celiac disease have the DQA1<em>0501 and DQB1</em>0201 alleles, compared with 20% of the general population. A second predisposing heterodimer, DQ8, is encoded by the DQA1*0301</p>
<p>and the DQB1*0302 alleles. Most of the 5% of celiac patients who are negative for the DQ2 alleles display the DQ8 alleles. Serological results to detect the predisposing antigens, however, were equivocal. An SBT test was performed. The indicated alleles were detected by sequence analysis. The sequence results showed the following alleles at DQA1 and DQB1 loci:</p>
<p>DQA1<em>0501 DQB1</em>0201, DQB1*0401</p>
<p>Question: Is it possible that this man has celiac disease based on his HLA haplotype?</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="6934a532">Case Study 15·2<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#6934a532" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A 43-year-old man consulted his physician about a lump on his neck and frequent night sweats. A biopsy of the mass in his neck was sent to the pathology department for analysis. An abnormally large population of CD20-positive lymphocytes was observed by morphological examination. Flow cytometry tests detected a monoclonal B-cell population with coexpression of CD10/CD19 and CD5. This population was 88% kappa and 7% lambda. The results were confirmed by the observation of a monoclonal immunoglobulin heavy chain gene rearrangement that was also monoclonal for kappa</p>
<p>light chain gene rearrangement. The patient was initially treated with standard chemotherapy, but the tumor returned before the therapeutic program was completed. The tumor persisted through a second treatment with stronger chemotherapy plus local irradiation. Nonmyeloablative bone marrow transplant was prescribed. To find a compatible donor, the man's HLA type and the types of five potential donors were compared. HLA-A and -B types were assessed by serology, and HLA-DR type was determined by SSP-PCR and SSOP. The typing results are shown in the table.</p>
<p>Copyright ©2007 by F. A. Davis.
DNA-Based Tissue Typing Chapter 15 397</p>
<table><thead><tr><th>Recipient</th><th>Donor 1</th><th>Donor 2</th><th>Donor 3</th><th>Donor 4</th><th>Donor 5</th></tr></thead><tbody><tr><td>A*0302</td><td>A*6601/04</td><td>A*2601</td><td>A*0302</td><td>A*3103/04</td><td>A*2610</td></tr><tr><td>A*2610</td><td>A*0302</td><td>A*4301</td><td></td><td>A*0309</td><td>A*0309</td></tr><tr><td>B*3906</td><td>B*0711</td><td>B*1528</td><td>B*3801</td><td>B*2702</td><td>B*3508</td></tr><tr><td>B*5307</td><td>B*5701</td><td>B*3919</td><td>B*3901</td><td>B*3501</td><td></td></tr><tr><td>DRB1*0801</td><td>DRB1*0701</td><td>DRB1*1317</td><td>DRB1*0809</td><td>DRB1*0701</td><td>DRB1*1317</td></tr><tr><td></td><td>DRB1*1317</td><td>DRB1*0422</td><td></td><td>DRB1*1117</td><td>DRB1*0701</td></tr></tbody></table>
<p><strong>Questions:</strong> Which of the five donors is the best match for this patient? Which mismatches are acceptable? Using the donor bone marrow that matches most closely, is there more of a chance of graft rejection or GVHD?</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="d25cc07a">Case Study 15 • 3<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#d25cc07a" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A 19-year-old woman reported to a local clinic with painful swelling in her face. Routine tests revealed dangerously high blood pressure that warranted hospitalization. Further tests were performed, which led to a diagnosis of systemic lupus erythematosus. Due to complications of this disease, her kidney function was compromised, and she would eventually suffer kidney failure. With an alternative of life-long dialysis, a kidney transplant was recommended. Class I PRAs were assessed at 0% PRA for class I. An additional screen for class II PRA was performed by flow cytometry.</p>
<p>Class I and class II HLA typing was performed by SSP-PCR. An autocytotoxic crossmatch was also performed, revealing T-cell and B-cell positive antibodies, probably related to the lupus. The young woman's mother volunteered to donate a kidney to her daughter. Mother and daughter had matching blood group antigens and HLA-DR antigens, which are the most critical for successful organ transplant. The results from the typing tray are shown in the following figure:</p>
<p><img src="assets/images/image-20251222-ca08b64e.jpeg" alt="img-403.jpeg"></p>
<p><img src="assets/images/image-20251222-29b559aa.jpeg" alt="img-404.jpeg"></p>
<p><img src="assets/images/image-20251222-b3f32896.jpeg" alt="img-405.jpeg"></p>
<p>Flow cytometry analysis of HLA class II antigens in recipient serum. Top = negative control; middle = positive control; bottom = patient serum.</p>
<p>(continued on following page)</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="continued">(continued)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#continued" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><img src="assets/images/image-20251222-08e51a71.jpeg" alt="img-406.jpeg">
SSP-PCR results from an HLA-A typing tray for the daughter. Alleles were identified in lanes 7, 19, and 22.</p>
<p>SSP-PCR results for HLA-A, -B, and -DR and their serological equivalents are shown in the table.</p>
<p>Crossmatching of the daughter's serum and mother's cells was performed by cytotoxicity and flow cytometry. Both test results were negative.</p>
<p>Questions: Is the mother a good match for the daughter? Based on the antibody and crossmatching studies, what is the risk of rejection? Before performing the HLA studies, how many of the daughter's antigens would be expected to match those of her mother?</p>
<table><thead><tr><th>Daughter</th><th></th><th>Mother</th><th></th></tr></thead><tbody><tr><td>SSP-PCR</td><td>Serology</td><td>SSP-PCR</td><td>Serology</td></tr><tr><td>A<em>2419, A</em>3401</td><td>A24(9), 34(10)</td><td>A<em>1104, A</em>2419</td><td>A11, A24(9)</td></tr><tr><td>B<em>0802, B</em>5603</td><td>B8, B22</td><td>B<em>0804, B</em>5603</td><td>B8, B22</td></tr><tr><td>DRB1<em>0422, DRB1</em>1411</td><td>DR4, DR14(6)</td><td>DRB1<em>0422, DRB1</em>1317</td><td>DR4, DR13(6)</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="study-questions">STUDY QUESTIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#study-questions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Which of the following is a high resolution HLA typing result?</li>
</ol>
<p>a. B27
b. A<em>0202-0209
c. A</em>0212
d. A<em>2601/A</em>2605/A<em>26010/A</em>2615</p>
<ol start="2">
<li>Which of the following is a likely haplotype from parents with A25,Cw10,B27/A23,Cw5,B27 and A17, Cw4,B10/A9,Cw7,B12 haplotypes?</li>
</ol>
<p>a. A25,Cw10,B27
b. A25,Cw5,B27
c. A23,Cw4,B12
d. A17,Cw4,B27</p>
<ol start="3">
<li>
<p>Upon microscopic examination, over 90% of cells are translucent after a CDC assay. How are these results scored according to the ASHI rules?</p>
</li>
<li>
<p>An HLA-A allele is a CTC to CTT (leu → leu) change at the DNA level. How is this allele written?</p>
</li>
</ol>
<p>a. HLA-A<em>02
b. HLA-A</em>0201
c. HLA-A2
d. HLA-A*02N</p>
<ol start="5">
<li>
<p>A candidate for kidney transplant has a PRA of 75%. How will this affect eligibility for immediate transplant?</p>
</li>
<li>
<p>An SSOP probe recognizes HLA-DRB<em>0301-0304. Another probe recognizes HLA-DRB</em>0301/0304, and a third probe hybridizes to HLA-DRB*0301-0303. Test specimen DNA hybridizes to all except the third probe in a reverse dot blot format. What is the HLA-DRB type of the specimen?</p>
</li>
<li>
<p>What is the relationship between alleles HLA-A10 and HLA-A26(10)?</p>
</li>
</ol>
<p>Copyright ©2007 by F. A. Davis.
DNA-Based Tissue Typing Chapter 15
399</p>
<ol start="8">
<li>
<p>A CDC assay yields an 8 score for sera with the following specificities: A2, A28 and A2, A28, B7, and a 1 score for serum with an A2 specificity. What is the HLA-A type?</p>
</li>
<li>
<p>HLA-DRB1<em>1501 differs from DRB1</em>0101 by a G to C base change. If the sequence surrounding the base change is: ...GGGTGCGGTTGCTGGAAAGAT... (DRB1<em>0101) or ...GGGTGCGGTTCCTGGAAAGAT... (DRB1</em>1501), which of the following would be the 3′ end of a sequence-specific primer for detection of DRB1*1501?</p>
</li>
</ol>
<p>a. ...ATCTTTCCAGGAACCC
b. ...ATCTTTCCAGCAACCC
c. ...ATCTTTCCAGC
d. ...ATCTTTCCAGG</p>
<ol start="10">
<li>The results of an SSP-PCR reaction are the following: lane 1, one band; lane 2, two bands, lane 3 no bands. If the test includes an amplification control multiplexed with the allele-specific primers, what is the interpretation for each lane?</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="references">References<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#references" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>
<p>Dausset J, Nenna A. Présence d'une leuco-agglutinine dans le sérum d'un cas d'agranulocytose chronique. Comptes Rendues des Societe de Biologie 1952;146: 1539-41.</p>
</li>
<li>
<p>Payne R. Fetomaternal leukocyte incompatibility. Journal of Clinical Investigation 1958;37: 1756-63.</p>
</li>
<li>
<p>Bain B, Vaz MR, Lowenstein L. The development of large immature mononuclear cells in mixed lymphocyte cultures. Blood 1964;23:108-16.</p>
</li>
<li>
<p>Bach F, Hirschhorn K. Lymphocyte interaction: A potential histocompatibility test in vitro. Science 1964;142:813-14.</p>
</li>
<li>
<p>Jones E, Goodfellow PN, Bodmer JG, et al. Serological identification of HLA-linked human "Ia-type" antigens. Nature 1975;256:650-52.</p>
</li>
<li>
<p>Park M, Terasaki PI, Bernoco D, et al. Evidence for a second B-cell locus separate from the DR locus. Transplantation Proceedings 1978;10: 823-28.</p>
</li>
<li>
<p>Tosi R, Tanigaki N, Centis D, et al. Immunological dissection of human Ia molecules. Journal of Experimental Medicine 1978;148:1592-1611.</p>
</li>
<li>
<p>Inoko H, Trowsdale J. Linkage of TNF genes to the HLA-B locus. Nucleic Acids Research 1987;15: 8957-62.</p>
</li>
<li>
<p>Ruddy DA, Lee VK, Mintier GA, et al. A 1.1-Mb transcript map of the hereditary hemochromatosis locus. Genome Research 1997;7:441-56.</p>
</li>
<li>
<p>Feder J, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nature Genetics 1996;13: 399-408.</p>
</li>
<li>
<p>Powis S. Major histocompatibility complex class I molecules interact with both subunits of the transporter associated with antigen processing, TAP1 and TAP2l. European Journal of Immunology 1997;27:2744-47.</p>
</li>
<li>
<p>van Endert P. Genes regulating MHC class I processing of antigen. Current Opinion in Immunology 1999;11:82-88.</p>
</li>
<li>
<p>Dunn P, Day S, Williams S, et al. HLA-DQB1 sequencing-based typing using newly identified conserved nucleotide sequences in introns 1 and 2. Tissue Antigens 2005;66:99-106.</p>
</li>
<li>
<p>Wake CT, Long EO, Mach B. Allelic polymorphism and complexity of the genes for HLA-DR beta-chains: Direct analysis by DNA-DNA hybridization. Nature 1982;300:372-74.</p>
</li>
<li>
<p>Owerbach D, Lernmark A, Rask L, et al. Detection of HLA-D/DR-related DNA polymorphism in HLA-D homozygous typing cells. Proceedings of the National Academy of Sciences 1983;80: 3758-61.</p>
</li>
<li>
<p>Marsh S, Bodmer JG, Albert ED, et al. Nomenclature for factors of the HLA system, 2000. Tissue Antigens 2001;57:263-83.</p>
</li>
<li>
<p>Hwang S, Cha CH, Kwon OJ, et al. Novel HLA-Cw<em>06 allele, Cw</em>0612, identified by sequence-based typing. Tissue Antigens 2005;66:330-31.</p>
</li>
<li>
<p>Longhi E, Frison S, Colombini I, et al. HLA-A*2626, a new allele identified through external proficiency-testing exercise. Tissue Antigens 2005; 66:325-26.</p>
</li>
<li>
<p>Marsh S, Albert ED, Bodmer WF, et al. Nomenclature for factors of the HLA system, 2004. Human Immunology 2005;66:571-636.</p>
</li>
<li>
<p>Schreuder G, Hurley CK, Marsh SG, et al. The HLA dictionary 1999: A summary of HLA-A, -B, -C, -DRB1/3/4/5, -DQB1 alleles and their associa</p>
</li>
</ol>
<p>Copyright ©2007 by F. A. Davis.
400 Section 3 Techniques in the Clinical Lab</p>
<p>tion with serologically defined HLA-A, -B, -C, -DR, and -DQ antigens. Human Immunology 1999; 60:1157–81.</p>
<ol start="21">
<li>
<p>Schreuder G, Hurley CK, Marsh SG, et al. The HLA Dictionary 2001: A summary of HLA-A, -B, -C, -DRB1/3/4/5, -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR and -DQ antigens. Tissue Antigens 2001;58:109–40.</p>
</li>
<li>
<p>Schreuder G, Hurley CK, Marsh SG, et al. The HLA Dictionary 2004: A summary of HLA-A, -B, -C, -DRB1/3/4/5 and -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR and -DQ antigens. International Journal of Immunogenetics 2005;32:19–69.</p>
</li>
<li>
<p>Schreuder G, Hurley CK, Marsh SG, et al. HLA dictionary 2004: Summary of HLA-A, -B, -C, -DRB1/3/4/5, -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR, and -DQ antigens. Human Immunology 2005;66: 170–210.</p>
</li>
<li>
<p>Mittal KK, Mickey MR, Singal DP, et al. Serotyping for homotransplantation: Refinement of microdroplet lymphocyte cytotoxicity test. Transplantation 1968;6:913–27.</p>
</li>
<li>
<p>Laundry GJ, Bradley BA. The predictive value of epitope analysis in highly sensitized patients awaiting renal transplantation. Transplantation 1995;59: 1207–13.</p>
</li>
<li>
<p>Class F, Van Leeuwen A, Van Rood JJ. Hyperimmunized patients do not need to wait for an HLA-identical donor. Tissue Antigens 1999;34:23–29.</p>
</li>
<li>
<p>Westwood S, Sutton JG, Werrett DJ. Analysis of the common genetic variants of the human Gc system in plasma and bloodstains by isoelectric focusing in immobilized pH gradients. Journal - Forensic Science Society (London) 1984;24:519–28.</p>
</li>
<li>
<p>Baldwin G, Mickelson EM, Hansen JA, et al. Electrophoretic variation between class II molecules expressed on HLA-DRw8 homozygous typing cells reveals multiple distinct haplotypes. Immunogenetics 1985;21:49–60.</p>
</li>
<li>
<p>Kido A, Oya M, Komatsu N, et al. A stability study on Gc subtyping in bloodstains: Comparison by two different techniques. <em>Forensic Science International</em> 1984;26:39–43.</p>
</li>
<li>
<p>Borozdenkova S, Westbrook JA, Patel V, et al. Use of proteomics to discover novel markers of cardiac</p>
</li>
</ol>
<p>allograft rejection. Journal of Proteome Research 2004;3:282–88.</p>
<ol start="31">
<li>
<p>Bidwell J. DNA-RFLP analysis and genotyping of HLA-DR and DQ antigens. Immunology Today 1988;9:18–23.</p>
</li>
<li>
<p>Bidwell J, Bidwell EA, Savage DA, et al. A DNA-RFLP typing system that positively identifies serologically well-defined and ill-defined HLA-DR and DQ alleles, including DRw10. Transplantation 1988;45:640–46.</p>
</li>
<li>
<p>Mytilineos J, Scherer S, Opelz G. Comparison of RFLP-DR beta and serological HLA-DR typing in 1500 individuals. Transplantation 1990;50:870–73.</p>
</li>
<li>
<p>Opelz G, Mytilineos J, Scherer S, et al. Analysis of HLA-DR matching in DNA-typed cadaver kidney transplants. Transplantation 1993;55:782–85.</p>
</li>
<li>
<p>Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004;104:1923.</p>
</li>
<li>
<p>Olerup O, Zetterquist H, Ohlson L, et al. Genomic HLA-DR and -DQ typing by Taq I RFLP analysis: An alternative to serologic tissue typing. Transplantation Proceedings 1990;22:144.</p>
</li>
<li>
<p>Rose N, Hamilton RG, Barbara D. Manual of Clinical Laboratory Immunology, 6th ed. Washington, DC: ASM Press, 2002.</p>
</li>
<li>
<p>Cao K, Chopek M, Fernandez-Vina MA. High and intermediate resolution DNA typing systems for class I HLA-A, B, C genes by hybridization with sequence-specific oligonucleotide probes (SSOP). Reviews in Immunogenetics 1999;1:177–208.</p>
</li>
<li>
<p>Bein G, Glaser R, Kirchner H. Rapid HLA-DRB1 genotyping by nested PCR amplification. Tissue Antigens 1992;39:68–73.</p>
</li>
<li>
<p>Krausa P, Brywka M, Savage D, et al. Genetic polymorphism within HLA-A*02: Significant allelic variation revealed in different populations. Tissue Antigens 1995;45:223–31.</p>
</li>
<li>
<p>Bunce M, O'Neill CM, Barnardo MC, et al. Phototyping: Comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 &amp; DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 1995; 46:355–67.</p>
</li>
</ol>
<p>Copyright ©2007 by F. A. Davis.
DNA-Based Tissue Typing Chapter 15 401</p>
<ol start="42">
<li>
<p>Clay T, Bidwell JL, Howard MR, et al. PCR fingerprinting for selection of HLA-matched unrelated marrow donors: Collaborating centres in the IMUST study. Lancet 1991;337:1049–52.</p>
</li>
<li>
<p>Crowe D. HLA typing using reference strand conformation analysis (RSCA). ASHI Quarterly 2002;: 145–46.</p>
</li>
<li>
<p>Carrington M, Miller T, White M, et al. Typing of HLA-DQA1 and DQB1 using DNA single-strand conformation polymorphism. Human Immunology 1992;33:208–12.</p>
</li>
<li>
<p>Hayashi T, Seyama T, Ito T, et al. A simple and rapid method for HLA-DQA1 genotyping by polymerase chain reaction–single strand conformation polymorphism and restriction enzyme cleavage analysis. Electrophoresis 1992;13: 877–79.</p>
</li>
<li>
<p>Lo Y, Patel P, Mehal WZ, et al. Analysis of complex genetic systems by ARMS-SSCP: Application to HLA genotyping. <em>Nucleic Acids Research</em> 1992;20: 1005–1009.</p>
</li>
<li>
<p>Bang-Ce Y, Xiaohe C, Ye F, et al. Simultaneous genotyping of DRB1/3/4/5 loci by oligonucleotide microarray. Journal of Molecular Diagnostics 2005;7:592–99.</p>
</li>
<li>
<p>Entz P, Toliat MR, Hampe J, et al. New strategies for efficient typing of HLA class-II loci DQB1 and DRB1 by using Pyrosequencing. Tissue Antigens 2005;65:67–80.</p>
</li>
<li>
<p>Bunce M, Young NT, Welsh KI. Molecular HLA typing: The brave new world. Transplantation 1997;64:1505–13.</p>
</li>
<li>
<p>Arguello R, Avakian H, Goldman JM, et al. A novel method for simultaneous high resolution identification of HLA-A, HLA-B, and HLA-Cw alleles. Proceedings of the National Academy of Sciences 1996;93:10961–65.</p>
</li>
<li>
<p>Bozon MV, Delgado JC, Selvakumar A, et al. Error rate for HLA-B antigen assignment by serology: Implications for proficiency testing and utilization of DNA-based typing methods. Tissue Antigens 1997;50:387–94.</p>
</li>
<li>
<p>Opelz G, Mytilineos J, Scherer S, et al. Influence of HLA matching and DNA typing on kidney and heart transplant survival in black recipients. Transplantation Proceedings 1997; 29:3333–35.</p>
</li>
<li>
<p>Opelz G. Impact of HLA compatibility on survival of kidney transplants from unrelated live donors. Transplantation 1997;64:1473–75.</p>
</li>
<li>
<p>Hosenpud J, Edwards EB, Lin HM, et al. Influence of HLA matching on thoracic transplant outcomes: An analysis from the UNOS/ISHLT thoracic registry. Circulation 1996;94:170–74.</p>
</li>
<li>
<p>Opelz G, Wujciak T. The influence of HLA compatibility on graft survival after heart transplantation: The Collaborative Transplant Study. New England Journal of Medicine 1994;330:816–19.</p>
</li>
<li>
<p>Rocha V, Cornish J, Sievers EL, et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001;97:2962–71.</p>
</li>
<li>
<p>Erlich H, Opelz G, Hansen J. HLA DNA typing and transplantation. Immunity 2001;14:347–56.</p>
</li>
<li>
<p>Miklos D, Kim HT, Miller KH, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005;105:2973–78.</p>
</li>
<li>
<p>Voogt P, Fibbe WE, Marijt WA, et al. Rejection of bone-marrow graft by recipient-derived cytotoxic T lymphocytes against minor histocompatibility antigens. Lancet 1990;335:131–34.</p>
</li>
<li>
<p>Goulmy E, Termijtelen A, Bradley BA, et al. Alloimmunity to human H-Y. Lancet 1976;2:1206.</p>
</li>
<li>
<p>O'Kunewick J, Kociban DL, Machen LL, et al. Effect of donor and recipient gender disparities on fatal graft-vs.-host disease in a mouse model for major histocompatibility complex–matched unrelated donor bone marrow transplantation. Experimental Hematology 1993;21:1570–76.</p>
</li>
<li>
<p>Wilke M, Pool J, den Haan JM, et al. Genomic identification of the minor histocompatibility antigen HA-1 locus by allele-specific PCR. Tissue Antigens 1998;52:312–17.</p>
</li>
<li>
<p>Bahram S, Inoko H, Shiina T, et al. MIC and other NKG2D ligands: From none to too many. Current Opinion in Immunology 2005;17:505–509.</p>
</li>
<li>
<p>Cudkowicz G, Bennett M. Peculiar immunobiology of bone marrow allografts. I. Graft rejection by irradiated responder mice. Journal of Experimental Medicine 1971;134:83–102.</p>
</li>
<li>
<p>Tran T, Mytilineos J, Scherer S, et al. Analysis of KIR ligand incompatibility in human renal transplantation. Transplantation 2005;80:1121–23.</p>
</li>
</ol>
<p>Copyright ©2007 by F. A. Davis.
402 Section 3 Techniques in the Clinical Lab</p>
<ol start="66">
<li>
<p>Witt C, Dewing C, Sayer DC, et al. Population frequencies and putative haplotypes of the killer cell immunoglobulin-like receptor sequences and evidence for recombination. Transplantation 1999; 68:1784–89.</p>
</li>
<li>
<p>Dupont B, Hsu KC. Inhibitory killer Ig-like receptor genes and human leukocyte antigen class I ligands in haematopoietic stem cell transplantation. Current Opinion in Immunology 2004; 16:634–43.</p>
</li>
<li>
<p>Gao X, Bashirova A, Iversen AK, et al. AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis. Nature Medicine 2005;11: 1290–92.</p>
</li>
<li>
<p>Steck A, Bugawan TL, Valdes AM, et al. Association of non-HLA genes with type 1 diabetes autoimmunity. Diabetes 2005;54:2482–86.</p>
</li>
<li>
<p>Bover K. Homoisotransplantation van epidermis bei einigen Zwillingen. Beitrage zur klinischen Chirurgica 1927;141:442–47.</p>
</li>
<li>
<p>Gorer P. The genetic and antigenic basis for tumor transplantation. Journal of Pathology and Bacteriology 1937;44:691–97.</p>
</li>
<li>
<p>Snell G. Methods for the study of histocompatibility genes. Journal of Genetics 1948;49: 87–108.</p>
</li>
<li>
<p>Rosenthal A, Shevach E. Function of macrophages in antigen recognition by guinea pig T lymphocytes. I. Requirement for histocompatible macrophages and lymphocytes. Journal of Experimental Medicine 1973;138:1194–212.</p>
</li>
<li>
<p>Kindred B, Shreffler DC. H-2 dependence of cooperation between T and B cells in vivo. Journal of Immunology 1972;109:940–43.</p>
</li>
<li>
<p>Ndung’u T, Gaseitsiwe S, Sepako E, et al. Major histocompatibility complex class II (HLA-DRB and -DQB) allele frequencies in Botswana: Association with human immunodeficiency virus type 1 infection. Clinical and Diagnostic Laboratory Immunology 2005;12:1020–28.</p>
</li>
<li>
<p>Sahmoud T, Laurian Y, Gazengel C, et al. Progression to AIDS in French haemophiliacs: Association with HLA-B35. AIDS 1993;7:497–500.</p>
</li>
<li>
<p>Montag S, Frank M, Ulmer H, et al. “Electronic nose” detects major histocompatibility complex–dependent prerenal and postrenal odor components. Proceedings of the National Academy of Sciences 2001;98:9249–54.</p>
</li>
<li>
<p>Santos P, Schinemann JA, Gabardo J, et al. New evidence that the MHC influences odor perception in humans: A study with 58 Southern Brazilian students. Hormones and Behavior 2005;47:384–88.</p>
</li>
</ol>
<p>Copyright ©2007 by F. A. Davis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="chapter-16">Chapter 16<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-16" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Lela Buckingham</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="quality-assurance-and-quality-control-in-the-molecular-laboratory">Quality Assurance and Quality Control in the Molecular Laboratory<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#quality-assurance-and-quality-control-in-the-molecular-laboratory" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="outline">OUTLINE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#outline" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="specimen-handling">SPECIMEN HANDLING<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#specimen-handling" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ul>
<li>Collection Tubes for Molecular Testing</li>
<li>Precautions</li>
<li>Holding and Storage Requirements</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="test-performance">TEST PERFORMANCE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#test-performance" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ul>
<li>Controls</li>
<li>Quality Assurance</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="instrument-maintenance">INSTRUMENT MAINTENANCE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#instrument-maintenance" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ul>
<li>Calibrations</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="reagents">REAGENTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reagents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ul>
<li>Chemical Safety</li>
<li>Proficiency Testing</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="documentation-of-test-results">DOCUMENTATION OF TEST RESULTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#documentation-of-test-results" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ul>
<li>Gene Sequencing Results</li>
<li>Reporting Results</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="objectives">OBJECTIVES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#objectives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Describe proper specimen accession for molecular testing.</li>
<li>Describe the optimal conditions for holding and storage of specimens and nucleic acid.</li>
<li>Explain the basic components of molecular test performance, including quality assurance and controls.</li>
<li>Discuss instrument maintenance, repair, and calibration, particularly for instruments used in molecular analysis.</li>
<li>Describe recommendations for preparation and use of reagents in the molecular laboratory.</li>
<li>Explain documentation and reporting of results, including gene sequencing results.</li>
</ul>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<p>Congress passed the Clinical Laboratory Improvement Amendments (CLIA) in 1988 to establish quality testing standards to ensure consistent patient test results. CLIA specifies quality standards for proficiency testing, patient test management, quality control, personnel qualifications, and quality assurance for laboratories performing moderate- and/or high-complexity tests, including molecular testing. This chapter offers a brief overview of laboratory standards applied to molecular diagnostic tests.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="specimen-handling">Specimen Handling<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#specimen-handling" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Molecular tests, like any clinical laboratory tests, require optimal specimen handling and processing for accurate and consistent test results. The success of a test procedure is affected by the age, type, and condition of specimens. Therefore, specimen collection, transport, and handling in the laboratory require careful attention.</p>
<p>Preanalytical variables, both controllable and uncontrollable, must be taken into account for proper interpretation of test results. Preanalytical error is the consequence of erroneous or misleading results caused by events that occur prior to sample analysis. To minimize preanalytical error and maximize control of preanalytical variables, the Clinical and Laboratory Standards Institute (CLSI, formerly known as the National Committee for Clinical Laboratory Standards) provides recommendations for collection of specimens under standardized conditions.[1-3]</p>
<p>Each laboratory will have requirements for specimen handling, but general policies apply to all specimen collection. The condition of the specimen and, if necessary, the chain of custody is reviewed on receipt in the laboratory. If a specimen shows evidence of tampering or is otherwise compromised, the technologist must notify the supervisor. No specimen is accepted without proper labeling and identification on the specimen tube or container (placed by the person who collected the specimen), nor if the labeling on the specimen does not match that on the accompanying requisition. In addition to relevant patient identification, the test requisition includes the type of specimen material (e.g., blood or bone marrow), ordered test, date and time of collection, and a contact (pager or telephone number) of the ordering physician. When required (for molecular genetics or parentage testing), patient consent forms, ethnicity, photo identification of the individuals tested, and transfusion history or a</p>
<p>pedigree may also be supplied with the test specimen. Forensic specimens may require a documented chain of custody. Bar-coding of this information expedites specimen accession and decreases the chance for error.</p>
<p>The laboratory should have written procedures for documentation of specimen accession. Accession books or electronic records are used to record the date of receipt, laboratory identifier, and pertinent patient information associated with the accession. If a specimen is unacceptable, the disposal or retention of the specimen is recorded in the patient report or laboratory quality assurance records. If not processed immediately, specimens are maintained in secure areas with limited access under the appropriate conditions for the analyte being tested (Fig. 16-1).</p>
<p>Molecular amplification methods have enabled laboratory professionals to perform nucleic acid-based testing on specimens with minimal cellular content, such as buccal cell suspensions and cerebrospinal fluids. These samples are centrifuged to collect the cells before DNA or RNA is extracted. For routine specimens tested by amplification methods, the entire specimen is often not used. In this case, or if more than one test is to be performed on the same specimen, care must be taken to avoid cross-contamination of specimens. This can most likely occur</p>
<p><img src="assets/images/image-20251222-f6a8b721.jpeg" alt="img-407.jpeg">
Figure 16-1 Biohazard stickers are required for cabinets, refrigerators, or freezers that contain reagents or patient specimens.</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Quality Assurance and Quality Control in the Molecular Laboratory Chapter 16 405</p>
<p>from pipetting carryover. Moreover, an aliquot removed from a specimen is never returned to the original tube or vessel.</p>
<p>Hemoglobin inhibits enzyme activity. Specimens received in the laboratory should therefore be inspected for visual signs of hemolysis. Hemoglobin and coagulants are removed effectively in most DNA and RNA isolation procedures; however, if white blood cell lysis has also occurred, DNA or RNA yield will be reduced. This could result in false-negative results in qualitative testing or inaccurate measurements in quantitative analyses. Buffers such as BloodDirect (Novagen) and Extract-N-Amp (Sigma) or resins such as Chelex have been designed to sequester anticoagulants or hemoglobin for more rapid nucleic acid isolation without the inhibitory effects of these substances.</p>
<p>Solid tissues are best analyzed from fresh or frozen samples (Fig. 16-2), especially for Southern blot or long-range polymerase chain reaction (PCR) methods that require relatively high-quality (long, intact) DNA. Surgical specimens designated for molecular studies, if not processed immediately, should be snap-frozen in liquid nitrogen. This process both preserves nucleic acid and preserves gene expression patterns that may change upon tissue storage. Snap freezing is routinely performed in the surgical pathology laboratory as it is a common process for preserving tissue morphology for microscopic examination. Fixed, paraffin-embedded tissues generally yield lower quality DNA and RNA, depending on the type of fixative used, the amount of time of exposure of the tissue to the fixative, and how the specimen was handled prior to fixation. PCR and reverse transcription PCR (RT-PCR) amplification, however, are routinely performed on paraffin-embedded tissue samples. Methods such as Southern or Northern blot, requiring large fragments of DNA, are less likely to work consistently with fixed tissues.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="collection-tubes-for-molecular-testing">Collection Tubes for Molecular Testing<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#collection-tubes-for-molecular-testing" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Phlebotomy collection tubes are available with a number of different additives designed for various types of clinical tests. A selection of collection tubes commonly used for molecular biology studies is listed in Table 16.1. Some anticoagulants used in blood and bone marrow collection may adversely affect analytical results. Heparin has been shown to inhibit enzymes used in molecular analysis, such as reverse transcriptases and DNA polymerases in vitro.⁴ The influence of this inhibition on molecular analysis is commonly accepted; however, heparinized samples have been processed successfully in many laboratories. The various experiences with heparin may reflect levels of resistance of enzymes from different sources. The assay design also has an effect. For instance, the inhibition of DNA polymerases compromises amplification of larger PCR products more than short ones. Due to the possible effects of heparin, trisodium EDTA (lavender top) or acid citrate dextrose (yellow top) tubes are recommended for most nucleic acid assays involving enzymatic treatment of the sample nucleic acid (Fig. 16-3).⁵ High levels of disodium EDTA (royal blue capped tubes used for trace element studies) may also inhibit enzyme activity and should be avoided. One of the advantages of signal amplification methods such as bDNA technology is their decreased sus</p>
<p><img src="assets/images/image-20251222-941e1fb6.jpeg" alt="img-408.jpeg"></p>
<p>Figure 16-2 Tissue is received in the laboratory in fresh (left) or frozen (right) form. Fresh tissue may be supplied as a specimen on gauze or other substrate or in saline. The vial shown on the right contains tissue that was flash-frozen in isopentane. The vial is held immersed in liquid nitrogen, nitrogen vapors, or in a −70°C freezer.</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<p>Table 16.1 A Selection of Collection Tubes</p>
<table><thead><tr><th>Additive</th><th>Color</th><th>Nucleic Acid Testing</th></tr></thead><tbody><tr><td>None</td><td>Red</td><td>Chemistry, serum, viral antibody studies</td></tr><tr><td>Sodium heparin (freeze-dried)</td><td>Green</td><td>Immunology, virology studies</td></tr><tr><td>Sodium heparin</td><td>Brown</td><td>Cytogenetic studies, molecular studies</td></tr><tr><td>Tripotassium EDTA (7.5%-15% solution)</td><td>Lavender</td><td>Virology, molecular biology studies</td></tr><tr><td>Acid citrate dextrose solution</td><td>Yellow</td><td>Molecular biology studies</td></tr></tbody></table>
<p>ceptibility to chemical effects of anticoagulants. When a specimen is received in the laboratory, the anticoagulant is not usually noted in the accompanying documentation; the technologist should be aware of the type of collection tube used, especially if a specimen is received in heparin or other additive that may affect the test results.</p>
<p>In addition to the standard collection tubes, special collection tubes are designed particularly for stabilization of nucleic acids for molecular testing. These include the plasma preparation tubes (Vacutainer PPT, Becton Dickinson), which contain, in addition to the standard coagulants, a polymer gel that separates granulocytes and some lymphocytes from erythrocytes upon centrifugation. This type of tube is used for HIV and HCV analysis. The PPT tube is also used for separation of white cells for genetics and chimerism testing. The tube stoppers have a</p>
<p><img src="assets/images/image-20251222-e996196e.jpeg" alt="img-409.jpeg">
Figure 16-3 For molecular analysis, blood or bone marrow specimens collected in EDTA or ACD tubes are preferred. Some methods are performed on serum collected in tubes without coagulant.</p>
<p>black "tiger" pattern over the appropriate anticoagulant color designation. Tubes such as the Tempus RNA Blood tube (Applied Biosystems) or the PAXgene Blood RNA tube (PreAnalytix) are designed to stabilize RNA. These tubes contain proprietary RNA stabilization agents that maintain the integrity of the RNA from collection through isolation.[6-8] Separated white blood cells from standard collection tubes can also be lysed in Trizol or TriReagent (Sigma) and the lysate stored at  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo><msup><mn>70</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">-70^{\circ}\mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord">−</span><span class="mord">7</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span>  to stabilize RNA for several days. Stabilization of transcripts has become increasingly important, with more and more methods involving RNA transcript levels for measurement of gene expression. For example, quantitative RT-PCR analyses rely on transcript number to monitor the level of tumor cells or microorganisms. Serial analysis requires that the specimens received in the laboratory at different times be handled as consistently as possible. Immediate stabilization of the RNA is tantamount to having comparable results.[9] As an alternative to standard collection tubes, methods involving impregnated paper matrices have been proposed for nucleic acid analysis.[10,11]</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions">Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Standard precautions are recommended by the Centers for Disease Control and Prevention for handling potentially infectious specimens. All specimens are potentially infectious, so they should all be handled with standard precautions using proper personal protective equipment (PPE) to prevent disease transmission. Transmission-based precautions including respirators are used with airborne or contact-transmissible agents. Contact precautions are designed for direct patient care where there is the potential for direct exposure to infectious agents on or from the patient. In general, standard precautions including gloves and gowns as PPE are used by the molecular laboratory technologist who has no direct contact with patients. Eye protection or masks are required in cases where frozen tissue is being processed or where spraying or splashing of sample may occur.</p>
<p>Gloves are highly recommended not only as part of standard precautions but also to protect nucleic acids from nuclease degradation (Fig. 16-4). Gloves are absolutely required for handling of RNA (Fig. 16-5). DNA is less susceptible to degradation from contaminating DNases; however, repeated handling of samples with</p>
<p>Copyright ©2007 by F. A. Davis.
Quality Assurance and Quality Control in the Molecular Laboratory Chapter 16 407</p>
<p><img src="assets/images/image-20251222-2f405a05.jpeg" alt="img-410.jpeg">
Figure 16-4 Handling specimens with gloves is recommended to protect the technologist and to protect the sample nucleic acids from nucleases and other contaminants.</p>
<p>out gloves will adversely affect the integrity of the DNA over time. Standards and controls that are handled repeatedly are the most likely to be affected. Originally, having separate areas for DNA and RNA isolation was recommended. Some laboratories, however, isolate DNA and RNA on the same bench space. This requires maintenance of RNase-free conditions (see Chapter 4) for all nucleic acid isolation. In a common isolation arrangement such as this, care must be taken that if DNA samples</p>
<p><img src="assets/images/image-20251222-43dd7b40.jpeg" alt="img-411.jpeg">
Figure 16-5 Gloves are required for working with RNA.</p>
<p>are treated with RNase or RNA samples are treated with DNase that no inappropriate enzyme exposure occur.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="holding-and-storage-requirements">Holding and Storage Requirements<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#holding-and-storage-requirements" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Methods such as interphase and metaphase fluorescent in situ hybridization (FISH) and karyotyping require intact cellular structures or culture of cells so that only fresh specimens are acceptable. Many molecular methods, however, do not require integrity of tissue of cellular structure, only that the nucleic acid remains intact. In either case, circumstances may arise that require holding of specimens before analysis. DNA and RNA are stable when samples are collected and held under the proper conditions.[12,13] For example, multiple tests may be performed on snap-frozen specimens held at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo><msup><mn>70</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">-70^{\circ}\mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord">−</span><span class="mord">7</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span>. Although most amplification methods are capable of successful analysis of limiting and challenging specimens, Southern or Northern blot methods will not work consistently on improperly handled specimens or nucleic acids stored under less than optimal conditions. The College of American Pathologists (CAP), which provides accreditation standards that are followed by CAP-accredited laboratories to improve the quality of their testing, has published recommendations for sample and isolated nucleic acid storage (Table 16.2).</p>
<p>For long-term storage, isolated nucleic acid is preferred. Conditions for storage of isolated nucleic acid have been recommended (Table 16.3). Cryotubes and specially designed labels are available for long-term nucleic acid storage at ultralow temperatures (Fig. 16-6).</p>
<p>The general rules for holding specimens for processing differ depending on the analyte and its stability in the cell. Written procedures indicate the proper handling of specimens for optimal performance of that procedure. Blood and bone marrow specimens sent to outside laboratories for molecular analysis can be shipped overnight at room temperature or with ice packs. Tissue is best shipped frozen on dry ice.</p>
<p>Isolated DNA of sufficient purity can be stored at room temperature for several months or at least 1 year in the refrigerator. Purified DNA can be stored at freezer temperatures <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mo>−</mo><msup><mn>20</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">(-20^{\circ}\mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">−</span><span class="mord">2</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span> to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo><msup><mn>70</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">-70^{\circ}\mathrm{C})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">−</span><span class="mord">7</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span><span class="mclose">)</span></span></span></span></span> in tightly sealed tubes for up to 10 years or longer. Freezer temperatures are preferred for long-term storage; however, a clean DNA preparation in frequent use is better stored in the refrig</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<p>Table 16.2 Specimen Storage Requirements for Nucleic Acid Extraction33</p>
<table><thead><tr><th>Nucleic Acid</th><th>Sample</th><th>Temperature</th><th>Time</th></tr></thead><tbody><tr><td>DNA</td><td>Whole blood, buffy coat, bone marrow, fluids</td><td>22°–25°C</td><td>24 hours</td></tr><tr><td></td><td></td><td>2°–8°C</td><td>72 hours*</td></tr><tr><td></td><td></td><td>-20°C</td><td>At least 1 year*</td></tr><tr><td></td><td></td><td>-70°C</td><td>More than 1 year*</td></tr><tr><td></td><td>Tissue</td><td>22°–25°C</td><td>Not recommended</td></tr><tr><td></td><td></td><td>2°–8°C</td><td>Up to 24 hours†</td></tr><tr><td></td><td></td><td>-20°C</td><td>At least 2 weeks</td></tr><tr><td></td><td></td><td>-70°C</td><td>At least 2 years</td></tr><tr><td></td><td>Microorganisms in culture</td><td>22°–25°C</td><td>24 hours‡</td></tr><tr><td></td><td></td><td>2°–8°C</td><td>72 hours‡</td></tr><tr><td></td><td></td><td>-20°C</td><td>2–4 weeks‡</td></tr><tr><td></td><td></td><td>-70°C</td><td>More than 1 year</td></tr><tr><td></td><td>Cell lysates in GITC</td><td>22°–25°C</td><td>1–2 weeks§</td></tr><tr><td>RNA</td><td>Whole blood, buffy coat, bone marrow, fluids</td><td>22°–25°C</td><td>Not recommended§</td></tr><tr><td></td><td></td><td>2°–8°C</td><td>2–4 hours*</td></tr><tr><td></td><td></td><td>-20°C</td><td>2–4 weeks*</td></tr><tr><td></td><td></td><td>-70°C</td><td>More than 1 year*</td></tr><tr><td></td><td>Fluids collected in specialty RNA protection tubes</td><td>22°–25°C</td><td>5 days</td></tr><tr><td></td><td></td><td>2°–8°C</td><td>7 days</td></tr><tr><td></td><td></td><td>-20°C</td><td>2–4 weeks</td></tr><tr><td></td><td></td><td>-70°C</td><td>At least 7 months</td></tr><tr><td></td><td>Tissue</td><td>22°–25°C</td><td>Not recommended</td></tr><tr><td></td><td></td><td>2°–8°C</td><td>Not recommended</td></tr><tr><td></td><td></td><td>-20°C</td><td>Not recommended</td></tr><tr><td></td><td></td><td>-70°C</td><td>At least 2 years</td></tr><tr><td></td><td></td><td>-140°C (nitrogen vapor)</td><td>At least 2 years</td></tr><tr><td></td><td>Cell lysates in GITC¶</td><td>22°–25°C</td><td>1–2 weeks§</td></tr><tr><td></td><td>Cell lysates in RNA storage solution (Ambion)</td><td>22°–25°C</td><td>1 week</td></tr><tr><td></td><td></td><td>2°–8°C</td><td>1 month</td></tr><tr><td></td><td></td><td>-20°C</td><td>More than 1 year</td></tr><tr><td></td><td>Microorganisms in culture</td><td>22°–25°C</td><td>24 hours‡</td></tr><tr><td>2°–8°C</td><td></td><td>72 hours‡</td><td></td></tr><tr><td>-20°C</td><td></td><td>2–4 weeks‡</td><td></td></tr><tr><td>-70°C</td><td></td><td>More than 1 year</td><td></td></tr></tbody></table>
<p>*Separation of white blood cells is recommended to avoid hemoglobin released upon hemolysis of red blood cells.
Tissue types differ in stability and nuclease content.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>‡</mo></mrow><annotation encoding="application/x-tex">\ddagger</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">‡</span></span></span></span></span> Nucleic acid from cultured organisms is best isolated immediately on harvesting fresh cultures.
§ RNA status depends on the type of cell or tissue and the gene under study.34
Depending on gene expression, adequate RNA may be isolated within a few hours. Storage of cell lysates in a stabilizing buffer is best for maintaining RNA.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="double-struck">Q</mi><mrow><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi><mi mathvariant="normal">T</mi><mi mathvariant="normal">C</mi></mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">\mathbb{Q}\mathrm{GITC} =</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8556em; vertical-align: -0.1667em;"></span><span class="mord mathbb">Q</span><span class="mord"><span class="mord mathrm">GITC</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span>  guanidine isothiocyanate</p>
<p>Copyright ©2007 by F. A. Davis.
Quality Assurance and Quality Control in the Molecular Laboratory Chapter 16 409</p>
<p>Table 16.3 Nucleic Acid Storage Requirements³³</p>
<table><thead><tr><th>Nucleic Acid</th><th>Matrix</th><th>Temperature</th><th>Time</th></tr></thead><tbody><tr><td>DNA</td><td>TE* buffer or DNase-free water</td><td>22°–25°C</td><td>Up to 4 months</td></tr><tr><td></td><td>Freeze-dried or dried on collection paper³⁵</td><td>22°–25°C</td><td>More than 15 years</td></tr><tr><td></td><td>TE buffer or DNase-free water</td><td>2°–8°C</td><td>1–3 years†</td></tr><tr><td></td><td>TE buffer or DNase-free water</td><td>–20°C</td><td>At least 7 years</td></tr><tr><td></td><td>TE buffer or DNase-free water</td><td>–70°C</td><td>More than 7 years</td></tr><tr><td>RNA</td><td>TE buffer or RNase-free (DEPC‡-treated) water</td><td>22°–25°C</td><td>Not recommended</td></tr><tr><td></td><td>TE buffer or RNase-free (DEPC-treated) water</td><td>2°–8°C</td><td>Not recommended</td></tr><tr><td></td><td>TE buffer or RNase-free (DEPC-treated) water</td><td>–20°C</td><td>Up to 1 month</td></tr><tr><td></td><td>RNA storage solution (Ambion) §</td><td>–20°C</td><td>More than 1 month</td></tr><tr><td></td><td>Ethanol</td><td>–20°C</td><td>More than 6 months</td></tr><tr><td></td><td>TE buffer or RNase-free (DEPC-treated) water</td><td>–70°C</td><td>Up to 30 days</td></tr><tr><td></td><td>Ethanol</td><td>–70°C</td><td>More than 6 months</td></tr></tbody></table>
<p>*10 mM Tris, 1 mM EDTA, pH 8.0
†1 year for Southern blot
‡DEPC = diethyl pyrocarbonate
§1 mM sodium citrate, pH 6.4</p>
<p>erator so as to avoid DNA damage caused by multiple cycles of freezing/thawing. Shearing of DNA by freeze/thawing cycles can also occur in a frost-free freezer. As previously stated, PCR and methods that do not require large intact fragments of DNA are more forgiving with regard to the condition of the DNA.</p>
<p>Storage of isolated RNA at room temperature or refrigerator temperature is not recommended in the absence of stabilization. RNA suspended in ethanol can be stored at –20°C for several months. Long-term storage is best in ethanol at –70°C, although RNA suspended in diethylpy</p>
<p>rocarbonate-treated water is stable for at least 1 month. As with DNA, the long-term survival of the RNA depends on the quality of the initial isolation and handling of the specimen.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="test-performance">Test Performance<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#test-performance" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Many tests in the molecular laboratory are individually designed or are adaptations based on published methods. Development of new tests in the clinical laboratory requires validation of the performance of the method and</p>
<p><img src="assets/images/image-20251222-3da0e13e.jpeg" alt="img-412.jpeg"></p>
<p>Figure 16-6 Cryotubes with tight-fitting lids are recommended for long-term freezer storage of DNA and RNA.</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<p>Table 16.4 Measurements of Test Performance</p>
<table><thead><tr><th>Criteria</th><th>Definition</th><th>Example</th></tr></thead><tbody><tr><td>Analytic sensitivity</td><td>Lower limit of detection of the analyte</td><td>The t(14;18) translocation test can detect 1 translocated cell in 10,000 normal cells, an analytic sensitivity of 0.01%.</td></tr><tr><td>Clinical sensitivity</td><td>Ability of test result to predict a clinical condition</td><td>95 of 100 patients with a gene mutation have a disease state, a clinical sensitivity of 95%.</td></tr><tr><td>Analytic specificity</td><td>Ability to detect only the analyte and not nonspecific targets</td><td>The Invader assay for factor V Leiden successfully detected mutations in 18 positive specimens while yielding negative results for 30 normal specimens (no false positives).</td></tr><tr><td>Clinical specificity</td><td>Disease-associated results only in patients who actually have the disease conditions</td><td>1 of 100 normal specimens displayed a gene mutation (1 false positive), a clinical specificity of 99%.</td></tr><tr><td>Precision</td><td>Reproducibility of test results</td><td>A quantitative method yields 99 results in agreement out of 100 runs, a precision of 99%.</td></tr><tr><td>Analyte measurement range</td><td>The range within which a specimen may be measured directly (without dilution or concentration)</td><td>A qPCR HSV assay yields reproducible linear results from 10 to 107 copies of HSV per 20 μL of CSF. Specimens within this range are measured directly.</td></tr><tr><td>Analytic accuracy</td><td>Production of correct results</td><td>99 of 100 specimens with mutations in the HCM gene are detected by sequencing with no mutations detected in normal specimens.</td></tr></tbody></table>
<p>reagents in accurately detecting or measuring the analyte. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>14</mn></msup></mrow><annotation encoding="application/x-tex">^{14}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">14</span></span></span></span></span></span></span></span></span></span></span></span></span>  Test performance is assessed by several criteria (Table 16.4). These criteria are expressed as formulas.</p>
<p>The clinical sensitivity of an assay equals:</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mfrac><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">P</mi></mrow><mrow><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">P</mi></mrow><mo>+</mo><mrow><mi mathvariant="normal">F</mi><mi mathvariant="normal">N</mi></mrow></mrow></mfrac><mo>×</mo><mn>100</mn></mrow><annotation encoding="application/x-tex">\frac {\mathrm {T P}}{\mathrm {T P} + \mathrm {F N}} \times 1 0 0</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 2.1297em; vertical-align: -0.7693em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.3603em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">TP</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord"><span class="mord mathrm">FN</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">TP</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.7693em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">100</span></span></span></span></span></div>
<p>The clinical specificity of an assay equals:</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mfrac><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">N</mi></mrow><mrow><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">N</mi></mrow><mo>+</mo><mrow><mi mathvariant="normal">F</mi><mi mathvariant="normal">P</mi></mrow></mrow></mfrac><mo>×</mo><mn>100</mn></mrow><annotation encoding="application/x-tex">\frac {\mathrm {T N}}{\mathrm {T N} + \mathrm {F P}} \times 1 0 0</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 2.1297em; vertical-align: -0.7693em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.3603em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">TN</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord"><span class="mord mathrm">FP</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">TN</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.7693em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">100</span></span></span></span></span></div>
<p>The accuracy of an assay equals:</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mfrac><mrow><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">N</mi></mrow><mo>+</mo><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">P</mi></mrow></mrow><mrow><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">N</mi></mrow><mo>+</mo><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">P</mi></mrow><mo>+</mo><mrow><mi mathvariant="normal">F</mi><mi mathvariant="normal">N</mi></mrow><mo>+</mo><mrow><mi mathvariant="normal">F</mi><mi mathvariant="normal">P</mi></mrow></mrow></mfrac><mo>×</mo><mn>100</mn></mrow><annotation encoding="application/x-tex">\frac {\mathrm {T N} + \mathrm {T P}}{\mathrm {T N} + \mathrm {T P} + \mathrm {F N} + \mathrm {F P}} \times 1 0 0</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 2.1297em; vertical-align: -0.7693em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.3603em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">TN</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord"><span class="mord mathrm">TP</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord"><span class="mord mathrm">FN</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord"><span class="mord mathrm">FP</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">TN</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord"><span class="mord mathrm">TP</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.7693em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">100</span></span></span></span></span></div>
<p>TN=true negative, TP=true positive, FN=false negative, FP=false positive.</p>
<p>These criteria are documented as part of the test validation process.</p>
<p>Test validation is performed on specimens of the types that will be encountered in the routine use of the test, such as frozen tissue, paraffin-embedded tissue, body fluids, and cultured cells. The number of specimens tested varies with the procedure and the availability of test material. Archived specimens are often used for this purpose. The results from the new test are compared with those of</p>
<p>established procedures that may have been performed on these specimens or with the clinical diagnosis. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mrow><mn>15</mn><mo>−</mo><mn>17</mn></mrow></msup></mrow><annotation encoding="application/x-tex">^{15-17}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">15</span><span class="mbin mtight">−</span><span class="mord mtight">17</span></span></span></span></span></span></span></span></span></span></span></span></span>  A standard form may be designed for preparation of reaction mixes by the test parameters determined in the validation process (Fig. 16-7).</p>
<p>Predeveloped and FDA-approved molecular methods are increasingly available. When these methods are incorporated, the test performance is verified by using the purchased reagent sets to test validation specimens. This verification establishes that the results of the commercial test performed in the individual laboratory are as predicted by the developer. If the commercial test is modified, validation is required to show equal or superior performance of the modified procedure.[18]</p>
<p>Once a procedure has been established, the method is documented in the laboratory according to CLSI guidelines.[19] The procedure description should include detailed information; for instance, primer and probe sequences, their purification conditions, and labeling. A copy of the standard form used to set up reaction mixes is included in the procedure description. A clear description of formulas and reporting units are required for quantitative results. Interpretation of qualitative data, acceptable ranges such as band patterns, product sizes, melting temperatures, and reasons for rejecting results are required informa</p>
<p>Copyright ©2007 by F. A. Davis.
Quality Assurance and Quality Control in the Molecular Laboratory Chapter 16 411</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pcr-worksheet-ig-heavy-chain-gene-rearrangement">PCR WORKSHEET (Ig heavy chain gene rearrangement)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pcr-worksheet-ig-heavy-chain-gene-rearrangement" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Run # _______ Tech_____________ Date__________</p>
<table><thead><tr><th>Tube #</th><th>Patient name</th><th>Specimen/ treatment</th><th>μg/μl</th><th>μl DNA*</th><th>μl H₂O*</th></tr></thead><tbody><tr><td>1</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>2</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>3</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>4</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>5</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>6</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>7</td><td>Positive control</td><td></td><td></td><td></td><td></td></tr><tr><td>8</td><td>Sensitivity control</td><td></td><td></td><td></td><td></td></tr><tr><td>9</td><td>Negative control</td><td></td><td></td><td></td><td></td></tr><tr><td>10</td><td>Reagent blank</td><td></td><td></td><td></td><td></td></tr></tbody></table>
<ul>
<li>Dilute sample to 1μg/μl in a volume of 15μl.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pcr-reaction-mixture-for-test-primers">PCR reaction mixture for test primers<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pcr-reaction-mixture-for-test-primers" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(#rxns)</p>
<p>DNAse-free water 28.8μl x____ = ____μl</p>
<p>8 μM forward primer 2.5μl x____ = ____μl</p>
<p>8 μM reverse primer 2.5μl x____ = ____μl</p>
<p>1 mM dNTP 5.0μl x____ = ____μl</p>
<p>10x PCR buffer 5.0μl x____ = ____μl</p>
<p>750 μM (NH₄)₂SO₄ 1.0μl x____ = ____μl</p>
<p>Taq polymerase 0.2μl x____ = ____μl</p>
<p>Place 45μl of mixture into PCR tubes. Add 5μl (5 μg) template to each PCR tube.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="5b5292b8">PCR mixture for β-globin control primers<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#5b5292b8" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>DNAse water 30.8μl x____ = ____μl</p>
<p>2 μM β globin forward primer 1.25μl x____ = ____μl</p>
<p>2 μM β globin reverse primer 1.25μl x____ = ____μl</p>
<p>1 mM dNTP's 5.0μl x____ = ____μl</p>
<p>10x PCR buffer 5.0μl x____ = ____μl</p>
<p>50mM MgCl₂ 1.5μl x____ = ____μl</p>
<p>Taq polymerase 0.2μl x____ = ____μl</p>
<p>Place 45μl of mixture into the PCR tubes. Add 5μl template to each PCR tube.</p>
<p>■ Figure 16-7 Example of a worksheet used to prepare PCR reaction mixes. A single reaction mix is made for multiple samples by multiplying the number of reactions by the volume of each reaction component and adding that amount to the master mix. Information regarding reagent lot numbers, PCR programs, and specimen dilutions may be included on the worksheet or documented separately.</p>
<p>tion. Methods used to score FISH or array results relative to internal control loci are also part of the written procedure. It is useful to incorporate pictures of gel patterns or instrument output data showing positive, negative, heterozygous, or other reportable results.</p>
<p>In the course of validation, the accuracy of a test will determine its correlation with disease, as performed in the testing laboratory. The indications for ordering the test are determined, based on the clinical utility as determined by the validation process, and documented in the procedure manual. For forensic testing, all aspects of the test from validation to test reporting should adhere to guidelines established by the DNA Advisory Board Standards and the Scientific Working Group on DNA Analysis Methods.20</p>
<p>The procedure manual or standard operating procedure is maintained in the laboratory and reviewed at least annually. If a test is discontinued, the written procedure, noted with the dates of initial use and retirement, is kept for at least 2 years. Some laboratory professionals maintain retired procedures for longer periods.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="controls">Controls<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#controls" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Controls are samples of known type or amount that are treated like and run with patient specimens.21 Interpretation of test results always includes inspection of controls and standards to verify acceptable test performance. With qualitative tests, a positive, negative and, in some cases, a sensitivity control are required. The sensitivity control defines the lower limit of detection for more meaningful interpretation of negative results. These controls are sometimes called amplification controls when used with PCR techniques. Specifically, however, an amplification control is a target that should always amplify. The amplification control is used to distinguish true negative amplification results from false negatives resulting from amplification failure. In quantitative methods, high positive, low positive, and negative controls are included with each run. The high and low levels should be similar to critical points in the assay, such as the lowest detectable level of analyte.</p>
<p>Real-time PCR methods that automatically determine analyte levels require measurement of a standard curve or dilution series of analyte levels encompassing the levels expected from the patient specimens. On instruments, the standard curve must be run simultaneously with the specimens. In others, previously determined curves may be loaded into the software. Alternatively, results can be calculated manually by linear regression of the test results, using standard curve data in spreadsheet software.</p>
<p>In methods requiring detection of a target-specific product, or relative amounts of target, internal controls are run in the same reaction mix as the test specimen. For example, housekeeping genes are used as internal controls in methods quantifying infectious agents or detecting tumor cells by tumor-specific translocations. Centromere-specific probes serve as internal controls in FISH analyses as do housekeeping gene probes on microarrays. The presence of an internal control supplies a base for normalization of results. In PCR the internal control distinguishes false-negative results from failed amplifications (see Chapter 7). Internal controls that are amplified in the same tube with sample templates are designed to not interfere or inhibit target amplification, which could yield a false-negative result. Failed internal controls are documented and call for repeat of the assay.</p>
<p>The controls and standard curve should cover the critical detection levels or results of the method. Control results are continually monitored to spot trends or spikes outside of tolerance limits. Coefficients of variance or standard deviations of quantitative control levels should also be calculated at regular intervals. Laboratory professionals may establish criteria for control tolerance limits and document actions to be taken in the event of an unacceptable control result.</p>
<p>Controls are best prepared in larger quantities, aliquotted, and stored in conditions where they are most stable. Just as with new lots of other reagents, new aliquots are tested with old aliquots to verify consistent control results.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="quality-assurance">Quality Assurance<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#quality-assurance" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Periodic review and documentation of test results are required for all clinical testing, including molecular tests. Review might be, for example, in the form of rates of positive and negative results compared with expected rates from independent sources, such as published results, over time. This type of monitoring reveals trends or shifts in rates of positive or negative results. Critical values that require physician notification are established by validation and confirmed by monitoring.</p>
<p>As with other types of quantitative testing, molecular quantitative methods should have a defined dynamic range, sensitivity level, and accuracy.22, 23 For instance, a</p>
<p>Copyright ©2007 by F. A. Davis.
Quality Assurance and Quality Control in the Molecular Laboratory Chapter 16 413</p>
<p><img src="assets/images/image-20251222-9419e692.jpeg" alt="img-413.jpeg">
Figure 16-8 Tm ranges defined for two strains (A and B) of a theoretical microorganism are nonoverlapping. The melt curve shown would indicate that the test specimen contains strain A.</p>
<p>test that determines viral types by melt curves must include a defined narrow temperature range for the Tm of each viral type (Fig. 16-8). These values are established during the test validation and should be reviewed periodically. Test performance is monitored by inclusion of high, low, sensitivity, and negative standards in each run. Band patterns, melt curves, and peak characteristics should be defined with regard to how the results of the test are to be interpreted.</p>
<p>Assay levels that distinguish positive from negative results (cut-off values) must be well defined and verified at regular intervals. In assays such as single-strand conformation polymorphism (see Chapter 9), in which control patterns are not identical from run to run, normal controls for each scanned region are included in every run. Quantitative results should be within the linear range of the assay. The linear range is established by measuring dilutions or known concentrations of standard and establishing a direct correlation (standard curve) between test output and standard input. The technologist may observe that raw data are consistent with the final interpretation of the results. For example, if a viral load is interpreted as negative, the raw data should be below the cut-off value established for the test. Calculations and comparisons with standards used to verify test results should be described in the laboratory procedure manual.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="instrument-maintenance">Instrument Maintenance<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#instrument-maintenance" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Instruments used in the molecular laboratory must be monitored and maintained for consistent performance and accurate test results. Manufacturers supply recommendations for routine maintenance. Service contracts are used</p>
<p>to provide support from trained service technicians. Laboratory professionals maintain a schedule and instructions for all routine maintenance, such as checking temperature settings, timers, and background levels. Parts are replaced as required or specified by the instrument manufacturer. Maintenance schedules should reflect the amount of use of the instrument. Most routine maintenance and minor troubleshooting, such as replacing bulbs or batteries, may be performed by the technologist with the aid of clear instructions from the manufacturer or as prepared by laboratory management. These instructions must be readily available to the technologist in the event of instrument malfunction. Technologists should be aware of the limits of user-recommended repairs and when service calls are indicated (Fig. 16-9). Laboratory professionals must document all maintenance, service calls, calibrations, and parts replacements.</p>
<p>Refrigerators and freezers used to store patient material and reagents are monitored at least daily (Fig. 16-10). Maximum/minimum thermometers register the highest and lowest temperature reached between monitoring points. During a busy shift, refrigerators and freezers may be opened frequently, causing the temperature to increase temporarily. This must be taken into account while monitoring. Out-of-range temperatures (e.g., more than ±2°C of the set temperature) are recorded. Confirmatory temperature checks at different times during the shift are required before further action is taken. Heat blocks, incubators, ovens, and water baths are also monitored for temperature stability and accuracy. U.S. National Institute of</p>
<p><img src="assets/images/image-20251222-b65f140d.jpeg" alt="img-414.jpeg">
Figure 16-9 Routine maintenance, such as capillary replacement and instrument cleaning, is performed by the laboratory technologist. Dangerous or complex maintenance, such as repair or replacement of a laser source, is performed by the service representatives.</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<p><img src="assets/images/image-20251222-839e8483.jpeg" alt="img-415.jpeg">
Figure 16-10 Certified chamber thermometers are used for monitoring temperatures in incubators, refrigerators, ovens, and freezers. The thermometers are supplied in plastic resin bottles containing liquid glycol.</p>
<p>Standards and Technology (NIST)-certified standard thermometers are used for this type of monitoring. Thermometers verified by a NIST thermometer are also acceptable for this purpose. Specialized dry bath thermometers, which are encased in a 1.5-mL microfuge tube of mineral oil, are best for monitoring heat blocks. All storage and incubation equipment is kept clean and free of contaminated specimens and expired reagents. If out-of-date reagents are used for research or other purposes, they should be well marked and/or maintained in a separate area from the clinical test reagents.</p>
<p>Standard thermal cyclers, although they have no automated moving parts, decline in temperature control over time. This is especially true of block cyclers where hot and cold spots develop within the sample block. For this reason, thermal cyclers are checked periodically for proper temperature control. Thermometers with flexible probes (type K thermocouples) are convenient for checking representative wells in a block thermal cycler (Fig. 16-11). Approaches differ whether each well should be checked with each routine measurement or whether representative wells should be checked, with different wells</p>
<p><img src="assets/images/image-20251222-74eeabfe.jpeg" alt="img-416.jpeg">
Figure 16-11 Block thermal cyclers may be monitored using a thermometer with a flexible probe. More thorough monitoring is performed with temperature probes and software that follows the ramping temperatures as well as the holding temperatures.</p>
<p>checked each time. In some laboratories, test reactions are run in different wells to demonstrate successful amplification at each position on the block. More thorough and accurate temperature measurements are achieved with computer systems (e.g., Driftcon), with fixed or flexible probes designed to measure temperature in all wells throughout a PCR program, including ramping of the temperature up and down, overshooting set temperatures, and temperature drift during the hold phase of each step. Nonblock thermal cyclers, such as air-heated or modular instruments, are tested with probes modified to fit as the capillaries or tubes used in these instruments. Real-time thermal cyclers require additional maintenance of the detection system. Manufacturers supply materials for spectral calibrations. Background measurements are made using water or buffer samples. Each laboratory will establish the type and frequency of scheduled maintenance.</p>
<p>Centrifuges and microcentrifuges are monitored at least annually using a tachometer. In some institutions, technologists perform this calibration. Alternatively, an institutional engineering department may do it. The actual speed of rotation is determined and recorded along with the set speed or setting number on the centrifuge. This information is then posted on the instrument (Fig. 16-12).</p>
<p>Automatic pipettors used for dispensing specific quantities of reagents should be checked for accuracy before</p>
<p>Copyright ©2007 by F. A. Davis.
Quality Assurance and Quality Control in the Molecular Laboratory Chapter 16 415</p>
<p><img src="assets/images/image-20251222-4e831b1e.jpeg" alt="img-417.jpeg">
Figure 16-12 Centrifuge speeds are checked at least annually, and the results of actual and set speeds are posted on the instrument.</p>
<p>use and at 6-month intervals or as required according to use. Gravimetric methods, where measured samples of water are pipetted to a balance, have been used for many years.²⁴ The weights are converted to volumes. The mean of several measurements from the same pipet reveals its accuracy. The standard deviation or coefficient of variance is calculated to determine the degree of reproducibility (imprecision) of the pipet. Commercial pipet monitoring systems along with software are also available.²⁵ Alternatively, some laboratory professionals prefer to hire service providers who clean and check pipets on a per-pipet charge.</p>
<p>Electrophoresis power supplies are tested at least annually to ensure delivery of accurate voltage and current. Personnel should be trained in safe operation. Leads and connectors to gel baths should be free of precipitate (Fig. 16-13). This can be avoided by not leaving buffer in gel baths after electrophoresis runs. Capillary systems require cleaning of buffer and polymer delivery channels as well as replacing polymer at least twice per month. Capillaries should be replaced according to their suggested life span in number of uses. Temperature-controlled electrophoresis equipment, such as capillary systems and those used for constant temperature gel electrophoresis, is monitored for accurate temperature settings as recommended by the manufacturer.</p>
<p>Photographic equipment is frequently used in molecular laboratory procedures. Autoradiograms resulting from radioactive or chemiluminescent methods are developed in automated equipment or manually. The processing</p>
<p><img src="assets/images/image-20251222-3b48beed.jpeg" alt="img-418.jpeg">
Figure 16-13 Gel electrophoresis equipment must be maintained free of precipitate and properly handled to avoid shock exposure.</p>
<p>equipment is maintained with fresh fixing and developing solutions free of debris or sediment. Digital cameras are rapidly replacing Polaroid cameras for documenting gel data. Cameras should be firmly mounted and adjusted for optimal recording of gel data, free of shadows, dust, and other photographic artifacts (Fig. 16-14).</p>
<p>Periodically, background measurements are required on such instruments as fluorometric detectors (including real-time thermal cyclers), luminometers, and densitometers. Instrument manufacturers provide guidelines for acceptable background levels. Laboratory professionals may use these measurements or establish their own acceptable background levels. Corrective action, such as cleaning or filter adjustment, is documented in the laboratory maintenance records. Ultraviolet (UV) illuminators should be kept free of dust and properly shielded while in use. The technologists should keep track of the life span of the UV light source and replace it accordingly.</p>
<p>Spectrophotometers used to measure DNA, RNA, protein concentrations, and colorimetric assays and turbidity</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<p><img src="assets/images/image-20251222-fc8e4d9a.jpeg" alt="img-419.jpeg">
Figure 16-14 Cameras should be mounted securely for gel photography. A digital camera, shown here, is mounted on a photographic hood. A mask shields the ultraviolet light source except for the area where the gel is illuminated.</p>
<p>must be checked annually or as recommended by the manufacturer. Maintenance includes scanning through the range of wavelengths used (e.g., 200–800 nm) with supplied materials or filters. Operation manuals will include instructions for calibration and maintenance.</p>
<p>Fume hoods and laminar flow (biological safety) hoods (Fig. 16-15) are monitored annually for proper air flow. Fume hood testing requires special equipment and is likely to be performed by building engineers. Laminar flow hoods are tested for proper filter performance and air displacement. This testing is performed at least annually or upon installation or movement of the hood. Professional service technicians or the hood manufacturers usually provide this type of certification.</p>
<p>For all detection systems, regular monitoring of functional characteristics will reveal any drift or trends that might affect test results. Tolerance limits should be established to warrant intervention by maintenance or recalibration of the instrument. Scheduled and unscheduled maintenance is documented and kept in the laboratory records. These records should be readily available to the technologists using the equipment.</p>
<p><img src="assets/images/image-20251222-ed7d177d.jpeg" alt="img-420.jpeg">
Figure 16-15 Laminar flow hoods are used to protect against biological hazards and to help maintain a sterile environment.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="calibrations">Calibrations<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#calibrations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Calibration is fitting an instrument or test system output with the actual concentration of a reference analyte by testing and making appropriate adjustments. In calibration verification, materials of known concentration throughout the reportable range are tested as patient samples to ensure the test system is accurate. If calibration verification fails, recalibration is required. CLIA-88 Regulations, 42CFR493.1255(b)(3), recommend performance of calibration verification at least every 6 months or when major components, instrument software, or lots of reagents of the test system are altered. Recalibration is also required if proficiency or other quality control testing fails or in the event of major instrument malfunction and repair. Manufacturers of test systems may also provide calibration schedules and instructions on how to perform calibrations. Laboratory professionals must verify calibration of systems performed by the manufacturer.</p>
<p>A variety of materials may be used for calibration, including previously tested specimens, reference standards, and proficiency testing material. There must be</p>
<p>Copyright ©2007 by F. A. Davis.
Quality Assurance and Quality Control in the Molecular Laboratory Chapter 16 417</p>
<p>independent assessment of the actual measurement of the calibration material. Once established, calibrator results should always be specified ranges of values. Calibration materials should cover at least three levels of measurement: low, medium, and high points. Analytes used for calibration should be in the same matrix (e.g., plasma or urine) as the patient specimens.²⁶ Calibrators are prepared and used separately from quality control standards (e.g., positive, negative, sensitivity controls) for routine runs.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="reagents">Reagents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reagents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>When reagents are replaced in a test method, the new lot is ideally tested on a previously positive and negative specimen as well as the run controls. Instructions on the preparation of reagents and the quantities used in each assay are included in the written laboratory protocol for each procedure. Lot numbers and working stocks of probes and primers used in amplification methods are documented and matched to test performance in the runs in which they were used. The sequences of primers and probes are also documented, as any sequence errors made during ordering or synthesis of the primers will adversely affect amplification specificity or even result in amplification failure. Probes used for linkage analysis and array technology are periodically updated as new markers are discovered so that probe sequences used for a given test should be recorded.</p>
<p>Primers are a critical component of PCR procedures. Primers are most conveniently supplied in lyophilized (freeze-dried) form from the DNA synthesis facility (Fig. 16-16). The supplier will also provide information on the quality, method of purification, molecular weight, and number of micrograms of dried primers. This information is used to rehydrate the primers to a stock solution concentration required for the PCR protocol. The resuspended primers are then diluted into working stocks.</p>
<p>Probes used for real-time PCR are supplied in solution; for example, a 100-μM stock solution that is diluted to 4- or 5-μM working stock before use in the procedure. When new working stocks are prepared (diluted from the probe stocks or resuspended primers), they are treated as new reagent lots. Master mixes of primers, probe, buffer, nucleotides, and enzyme may be prepared or purchased and used as working stock.</p>
<p>As is required for all reagents, instructions on preparation of primers, probes, and working stocks, along with</p>
<p><img src="assets/images/image-20251222-8bb435fe.jpeg" alt="img-421.jpeg">
Figure 16-16 Primers are often purchased from DNA synthesis facilities. On receipt in freeze-dried form, the primers are easily resuspended in nuclease-free water or buffer to make a stock solution. The stock solution is then diluted into working stocks.</p>
<p>the sequences and binding sites of primers and the expected size of the amplicons, are documented as part of the written laboratory protocol. Polymorphisms or translocation breakpoints that affect primer binding should be noted in terms of the expected frequency in the population or in the number of successful amplifications.</p>
<p>For hybridization procedures, labeled probe solutions are treated as working stock and verified by parallel analysis with old lots. FISH probes are validated and verified according to recommended procedures.¹⁸ The quality of new microarray lots is verified by the manufacturer or by hybridizing labeled nucleotides that bind to all probes on a representative array from the lot. RNA probes are maintained under RNase-free conditions to protect their integrity.</p>
<p>It is important to document descriptive information on probes used in the laboratory. This information includes the type of probe (genomic, cDNA, oligonucleotide, plasmid, or riboprobe) and the species of origin of the probe sequence. The sequence of the probe, a GenBank number or other identification of the target sequence or gene region recognized by the probe, and a restriction enzyme map of that region are also important information. Any known polymorphisms, sites resistant to endonuclease digestion, and cross-hybridizing bands should be noted. Recombination frequencies and map</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<p>positions must be documented for linkage procedures. For inherited disease tests, chromosomal location of the target gene and known mutant alleles and their frequencies in various ethnic groups might be cited in published reports. Labeling methods and standards for adequacy of hybridization are included in the test procedure manual.</p>
<p>In multiplex reactions, primer and/or probe competition for substrates may affect results. Multiple fluorochrome signals in fluorescence assays may also cross into each other's detection ranges. For gel or capillary sizing, products of multiplex reactions should be reasonably different so that banding patterns do not complicate interpretation. For example, multiplex STR analysis by PCR includes 13 sets of primers that produce 13 amplicons labeled with three different fluorochromes (see Chapter 11). The range of sizes of each amplified STR locus is designed not to overlap others labeled with the same fluorochrome. The instrument that detects the fluorescence is also calibrated to subtract any overlap of detection of one fluorochrome with another.</p>
<p>Analyte-specific reagents (ASR) are probes, primers, antibodies, and other test components that detect a specific target, such as a cell surface protein or DNA mutation. ASRs comprise the active part of "home brew" tests. ASRs are usually purchased from an outside manufacturer. ASRs are classified as I, II, or III. Most ASRs used in the molecular laboratory are class I. Several molecular tests are available as ASRs in infectious disease, tissue typing, and other areas of molecular diagnostics. Approved molecular methods include tests that utilize FISH, Hybrid Capture, PCR, and microarray technologies. Class II and III ASRs include those used by blood banks to screen for infectious diseases and those used in diagnosis of certain contagious diseases such as tuberculosis. Class I ASRs are not subject to special controls by the U.S. Food and Drug Administration. The test performance of class I ASRs is established during test validation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="chemical-safety">Chemical Safety<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chemical-safety" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Volatile and flammable reagents are stored in properly vented and explosion-proof cabinets or refrigeration units (Fig. 16-17). The National Fire Protection Association (NFPA) has developed a series of warning labels for universal use on all chemical containers (Fig. 16-18).[27] Secondary or reinforced containers are required for trans</p>
<p><img src="assets/images/image-20251222-659a3dcd.jpeg" alt="img-422.jpeg">
Figure 16-17 Flammable and explosive materials are stored in designated protective cabinets or explosion-proof refrigerators.</p>
<p>port and handling of dangerous chemicals, such as concentrated acids and phenol.</p>
<p>Radioactive chemicals are used in some molecular methods (Table 16.5). Although methods involving radiation are increasingly being replaced by nonradioactive alternatives, some laboratory procedures still use these agents. The Nuclear Regulatory Commission requires that laboratory personnel working with radioactive</p>
<p><img src="assets/images/image-20251222-cb20adad.jpeg" alt="img-423.jpeg">
Figure 16-18 NFPA hazard labels have three parts, labeled with numbers 0 to 4, depending on the amount of hazard, from none (0) to severe (4). The fourth section has two categories. O indicates a strong oxidizer, which greatly increases the rate of combustion. The stricken W symbol indicates dangerous reactivity with water, which would prohibit the use of water to extinguish a fire in the presence of this chemical.</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Quality Assurance and Quality Control in the Molecular Laboratory Chapter 16 419</p>
<p>Table 16.5 Examples of Radionuclides Used in Laboratory Methods</p>
<table><thead><tr><th>Radioisotope</th><th>Half-Life*</th><th>Radiation (MeV)†</th><th>Travel in Air</th><th>Critical Organs</th></tr></thead><tbody><tr><td>³²P</td><td>14.29 days</td><td>β, 1.709</td><td>20 feet</td><td>Bone, whole body</td></tr><tr><td>³³P</td><td>25.3 days</td><td>β, 0.249</td><td>20 feet</td><td>Bone, whole body</td></tr><tr><td>³H</td><td>12.35 years</td><td>β, 0.019</td><td>0.65 inches</td><td>Body water</td></tr><tr><td>¹⁴C</td><td>5730 years</td><td>β, 0.156</td><td>10 inches</td><td>Whole body, fat</td></tr><tr><td>³⁵S</td><td>87.39 days</td><td>β, 0.167</td><td>11 inches</td><td>Whole body, testes</td></tr><tr><td>¹²⁵I</td><td>60.14 days</td><td>X,γ, 0.035</td><td>3 feet</td><td>Thyroid</td></tr></tbody></table>
<p>*Time for half of the radiation emission to dissipate
†Million electron volts</p>
<p>reagents maintain a radiation safety manual providing procedures for the safe handling of radioactive substances in both routine and emergency situations. The Occupational Safety and Health Administration (OSHA) has also developed regulations regarding ionizing and nonionizing radiation.</p>
<p>Radioactive reagents and methods are performed in designated areas. Working surfaces are protected with absorbent paper, drip trays, or other protective containers. Potentially volatile radioactive materials are handled under a fume hood. Radioactive waste is discarded in appropriate containers, separate from normal trash, according to regulations. Some isotopes with short half-lives may be stored over approximately seven half-lives, checked for residual emissions, and then discarded with regular waste. Containers and equipment used in these areas should be labeled with "Caution Radioactive Material" signs (Fig. 16-19). Signs should be posted on the rooms where radioactive materials are used. OSHA has specifications for accident prevention signs and tags for radiation and other occupational hazards.</p>
<p><img src="assets/images/image-20251222-45604dc2.jpeg" alt="img-424.jpeg">
Figure 16-19 Rooms, cabinets, and equipment containing radioactive chemicals are identified with radiation safety labels.</p>
<p>Laboratory personnel working with radioactive material should receive special training for safe handling, decontamination, and disposal of radiation. Laboratory instructions for working with radiation should include inspection and monitoring of shipments as required by the U.S. Department of Transportation. Work spaces are decontaminated daily and checked at least monthly by swipe testing or by Geiger counter. Technologists wear gloves, lab coat, and safety glasses when handling radioactive solutions. Radiation badges are worn when handling 1.0 mCi or more. Exposure increases with decreasing distance from the radioactive reagent (see Table 16.5), so exposure at close distance, such as working over open containers, should be avoided. For isotopes such as ³²P, acrylic shielding is required for work, storage, and waste areas (Fig. 16-20).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="proficiency-testing">Proficiency Testing<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#proficiency-testing" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Proficiency testing refers to the analysis of external specimens from a reference source supplied to independent laboratories.²⁸ Proficiency testing is performed to assess the skills (competency) of laboratory personnel performing molecular assays as well as the performance of the assay itself. Availability of comprehensive test specimens in the rapidly expanding area of molecular diagnostics is sometimes problematic. The CAP supplies specimens for molecular oncology, engraftment, and microsatellite instability testing among others (<a href="http://www.cap.org" target="_blank" rel="noopener noreferrer">www.cap.org</a>). A number of analytes, however, are not available, especially for tests that are offered in a small number of laboratories. If proficiency specimens are not commercially available, laboratories can exchange blinded split specimens; alternatively, blinded specimens measured or documented by independent means such as chart review can be tested</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<p><img src="assets/images/image-20251222-6bb57155.jpeg" alt="img-425.jpeg">
Figure 16-20 Acrylic shielding is required for working with gamma emitters, such as  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>32</mn></msup><mi mathvariant="normal">P</mi></mrow><annotation encoding="application/x-tex">^{32}\mathrm{P}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">32</span></span></span></span></span></span></span></span></span><span class="mord mathrm">P</span></span></span></span></span>  and  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>33</mn></msup><mi mathvariant="normal">P</mi></mrow><annotation encoding="application/x-tex">^{33}\mathrm{P}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">33</span></span></span></span></span></span></span></span></span><span class="mord mathrm">P</span></span></span></span></span> .</p>
<p>within the laboratory.[29,30] If at all possible, interlaboratory testing is preferable.</p>
<p>Proficiency testing is performed at least twice a year, with the proficiency samples tested within routine patient runs. The specific procedures should be defined and documented in the laboratory. Errors or incorrect responses for proficiency specimens are documented along with the corrective action taken, if necessary.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="documentation-of-test-results">Documentation of Test Results<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#documentation-of-test-results" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Test results in the form of electropherograms, gel images, and autoradiograms should be of sufficiently high quality that results are unequivocal. This includes clear bands or peaks without high background, cross hybridization, distortions, and other artifacts. Controls should also be clear and consistent and reflect the expected size or level. Molecular weight ladders on gels, autoradiograms, or electropherograms should cover the expected range of band or peak sizes produced from the specimen. For example, if primers used to detect a t(14;18) translocation test by PCR yield amplicons expected to range 150-500 bp, the molecular weight ladder used must range from less than 150 bp to more than 500 bp.</p>
<p>A record of the assay conditions and reagent lot numbers is kept with patient results. Identification of the technologist performing the assay may also be included. Documentation of quality and quantity of the isolated DNA or RNA is also required, especially if designated amounts of nucleic acids are used for an assay. Quantity and quality are documented in the form of spectrophotometry or fluorometry data or quantity or gel photographs of high molecular weight DNA or ribosomal RNA quality (see Chapter 4). The quality of RNA analyzed by Northern blot or RT-PCR may be assessed by monitoring a housekeeping gene, ribosomal RNA expression, or other calibrator.</p>
<p>If DNA is cut with restriction enzymes for Southern blot or PCR-restriction fragment length polymorphism, complete cutting by the restriction enzyme is verified on control targets and documented by photography of the cut DNA on the gel after electrophoresis. DNA digested with DNase for array analysis is also documented in this way to confirm proper fragment sizes. If specimen nucleic acid is labeled for hybridization arrays, labeling efficiency is assessed by measurement of the specific activity (signal per ng nucleic acid). For Southern blots, patient identification, gel lane (well) number, and probe target and type are also documented. It is also recommended that the test documentation should include prehybridization and hybridization conditions and probe and hybridization buffer lot numbers.</p>
<p>In situ results, such as FISH, are correlated with histological findings (stained sections) of tissue morphology. This is required when the molecular target detection is significant in specific cells; for example, with p53 detection in tumor cells. Documentation includes images of at least one normal cell with at least two abnormal cell results. These images are cross-referenced or retained together with photographs, films, and autoradiographs generated from additional testing of the same specimen. All these records are labeled with patient identification, sample numbers, run identifiers, and the date of assay.</p>
<p>All of the raw data are retained with the final report and clinical interpretation of the test results. Careful documentation is important because molecular diagnostic results may differ from results from other laboratories or from the clinical diagnosis. Such discrepancies occur most often with amplification methods because of their high sensitivity. If a molecular result is questioned, investigation of the discrepancy includes review of the raw</p>
<p>data. Results of this investigation along with any corrective action taken are noted in the laboratory records.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="gene-sequencing-results">Gene Sequencing Results<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#gene-sequencing-results" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Direct sequencing is increasingly used in clinical applications to detect gene mutations or to type microorganisms. Sequence data must be of adequate quality with acceptably low baseline, especially if heterozygous target states are to be detected. Each nucleotide peak or band should be unequivocal. Sequencing should be performed on both complementary strands of the template to confirm sequenced mutation or type. Repeated sequencing across the same area, or resequencing, for known sequence changes is sometimes performed only on one template strand; however, sequencing of both strands is best.</p>
<p>Criteria for acceptance of sequencing data include correct assignment of the nucleotide sequence in a defined region surrounding the critical area, not including the amplification primer binding sites. Furthermore, a specified level of band or peak quality (intensity or fluorescence levels, respectively) with reasonably low background is assigned. Defined limits of fluorescence ratios are set to identify true heterozygous base positions. Ideally, a heterozygous position will have equal fluorescence contribution from the two genotypes, and the peak height will be approximately half that of a homozygous genotype at that position. Results are expressed in the standard nomenclature for DNA or protein sequences (see Chapter 9).</p>
<p>The utility of sequence data requires published normal or type-specific sequences. In the case of gene mutations, electronic or published databases of known mutations and polymorphisms are available for frequently tested genes. These records, especially Internet databases, are updated regularly. Newly discovered mutations are classified according to the type of mutation; the laboratory director or consultant uses published guidelines to determine if the mutation is clinically significant.31 For example, a silent mutation will not affect protein function, whereas a frameshift mutation will.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="reporting-results">Reporting Results<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reporting-results" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Test results are reported in terms that are unambiguous to readers who may not be familiar with molecular methods or terminology. The test report must clearly convey the method or manufactured kit used, the locus, mutation or organism tested, the analytical interpretation of the raw data, and the clinical interpretation of the analytical result. This interpretation includes the penetrance of mutations; that is, the probability of having a mutation but not getting the associated disease.</p>
<p>The likelihood of false-positive or false-negative results are also included in a report. Mutation detection is not guaranteed, especially in large genes with hundreds of possible mutations that may or may not effectively compromise gene function. The mutation detection rate for this type of gene and the residual risk of undetected mutations are therefore included in the test report. Negative results from tests for specific point or chromosomal mutations are reported in terms of the sensitivity of the test, e.g. less than 0.01% chance of mutation, or, alternatively, negative accompanied with the sensitivity levels of the test. For parentage reports, the combined paternity index, the probability of paternity as a percentage, prior probability of paternity used in calculations, and the population used for comparison are reported.</p>
<p>The laboratory director, pathologist, or other clinical expert reviews the analytical interpretation, determines the clinical interpretation, and verifies the final results with an actual or electronic signature on the test report. An internal laboratory summary sheet is often useful for compiling pertinent information (Fig. 16-21). Test results should not be released before they are reviewed by the director. Molecular diagnostic tests, in particular, may have technical complexities that influence the meaning of the test result. These results are best communicated with the clinical significance of the laboratory findings.</p>
<p>When class I ASRs are used in an analytical method, the following disclaimer is included in the test report: “The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high complexity clinical laboratory testing.”32</p>
<p>The disclaimer is not required for tests using reagents that are sold together with other materials or an instrument as a kit nor for reagents sold with instructions for use.</p>
<p>Confidentiality of molecular test results is essential. All results, and particularly molecular genetic results, may affect insurability, employment, or other family members. Results are released only to the ordering physi</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Section 3 Techniques in the Clinical Lab</p>
<table><thead><tr><th>PATIENT SAMPLE STORAGE AND RESULT SUMMARY</th><th></th><th></th><th></th></tr></thead><tbody><tr><td></td><td></td><td>Date:</td><td></td></tr><tr><td>Patient ID Label</td><td>Sex:</td><td>Diagnosis:</td><td></td></tr><tr><td></td><td>DOB:</td><td>Specimen:</td><td></td></tr><tr><td></td><td>Age:</td><td>Surgical Path #:</td><td></td></tr><tr><td>I. Flow Cytometry Accession #</td><td>Date of Procedure:</td><td></td><td></td></tr><tr><td>Genetics Accession #</td><td>Date of Procedure:</td><td></td><td></td></tr><tr><td>Bone Marrow Aspirate #</td><td>Date of Procedure:</td><td></td><td></td></tr><tr><td>II. Tissue Storage: Freezer Box # RNA Storage Box # Volume</td><td></td><td></td><td></td></tr><tr><td>III. RNA Isolation</td><td></td><td></td><td></td></tr><tr><td>O.D. Value</td><td>260/280</td><td>Volume</td><td>Concentration</td></tr><tr><td>IV. DATA: RUN #</td><td></td><td></td><td></td></tr><tr><td>Previous Results:</td><td></td><td></td><td></td></tr><tr><td>Controls Acceptable: yes/no</td><td></td><td></td><td></td></tr><tr><td>Positive for BCR/ABL Translocation at M-bcr b2/a2 fusion</td><td></td><td></td><td></td></tr><tr><td>Positive for BCR/ABL Translocation at M-bcr b3/a2 fusion</td><td></td><td></td><td></td></tr><tr><td>Positive for BCR/ABL Translocation at m-bcr e1/a2 fusion</td><td></td><td></td><td></td></tr><tr><td>Negative for BCR/ABL Translocation</td><td></td><td></td><td></td></tr><tr><td>Pathology Result</td><td>Cytogenetics Result</td><td></td><td></td></tr><tr><td>V. Interpretation of lab results:</td><td></td><td></td><td></td></tr><tr><td>Remarkable case:</td><td></td><td></td><td></td></tr><tr><td>Verbal report to: Date By</td><td></td><td></td><td></td></tr><tr><td>VI. Physician's Interpretation:</td><td></td><td></td><td></td></tr><tr><td>Reviewed: Date</td><td></td><td></td><td></td></tr></tbody></table>
<p>Figure 16-21 Example of a patient result summary sheet used for documentation of test results of a BCR/ABL analysis by RT-PCR. Information included will differ depending on the disease and the type of test.</p>
<p>Copyright ©2007 by F. A. Davis.
Quality Assurance and Quality Control in the Molecular Laboratory Chapter 16 423</p>
<p>cian or other authorized personnel such as genetic counselors or nurse coordinators. Technologists should refer requests for patient data to supervisors. Data sent by facsimile must be accompanied by a disclaimer such as: "The documents accompanying this telecopy transmission contain confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party and is required to destroy the information after its stated need has been fulfilled. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distributing, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for return or destruction of these documents."</p>
<p>Test results are not released to employers, insurers, or other family members without the patient's expressed consent. Any data discussed in a public forum are presented such that no patient or pedigree is identifiable by the patient or the general audience. Written consent from the patient may be required under some circumstances. Each institution will have a department that oversees the lawful use of confidential information.</p>
<p>Technologists working in the area of molecular pathology will encounter tests in which the final details are determined empirically. As a result, a test procedure may differ from one laboratory to another. Even after the test procedure is established, troubleshooting is sometimes required as the procedure is put to use on a routine basis. Some reactions that work well for short-term research may prove to be less consistent and reproducible than is required in the clinical laboratory setting.</p>
<p>Biotechnology is fast developing standard reagent sets and instrumentation for the most popular tests, but these also differ from one supplier to another. Furthermore, due to market demands, test reagent kits may be modified or discontinued. If replacement reagents are available, they may not be identical to those previously used. Ongoing tests then have to be optimized. This can be a concern where turnaround times are critical.</p>
<p>It then becomes the responsibility of the technologist to perform and monitor tests on a regular basis to maintain consistency and accuracy of results. The technologist who understands the biochemistry and molecular biology</p>
<p>of these tests will be better able to respond to these problems. In addition, with the quickened evolution of the sciences, a knowledgeable technologist can better recognize significant discoveries that offer potential for test improvement.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="study-questions">STUDY QUESTIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#study-questions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>What actions should be taken in the following situations?</p>
<ol>
<li>An unlabeled collection tube with a requisition for a factor V Leiden test is received in the laboratory.</li>
<li>After PCR, the amplification control has failed to yield a product.</li>
<li>An isolated DNA sample is to be stored for at least 6 months.</li>
<li>A bone marrow specimen arrives at the end of a shift and will not be processed for the Bcl2 translocation until the next day.</li>
<li>The temperature of a refrigerator set at 8°C (±2°C) reads 14°C.</li>
<li>A PCR test for the BCR/ABL translocation was negative for the patient sample and for the sensitivity control.</li>
<li>A fragile X test result has been properly reviewed and reported.</li>
<li>A bottle of reagent alcohol with a 3 in the red diamond on its label is to be stored.</li>
<li>The expiration date on a reagent has passed.</li>
<li>Test results are to be faxed to the ordering physician.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="references">References<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#references" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Calam R, Bessman JD, Ernst DJ, et al. Procedures for the Handling and Processing of Blood Specimens: Approved Guideline, 3rd ed. St. John Hospital, 2004.</li>
<li>Rabinovitch A, Sarewitz SJ, Woodcock SM, et al. Routine Urinalysis and Collection, Transportation,</li>
</ol>
<p>Copyright ©2007 by F. A. Davis.
424 Section 3 Techniques in the Clinical Lab</p>
<p>and Preservation of Urine Specimens: Approved Guideline, 2nd ed. Specialty Laboratories, 2001.</p>
<ol start="3">
<li>
<p>Arkin C, Bessman JD, Calam RR, et al. Tubes and Additives for Venous Blood Specimen Collection: Approved Standard, 5th ed. Lahey Clinic/Maine Medical Center Research Institute, 2003.</p>
</li>
<li>
<p>Ghadessy F, Ong JL, Holliger P. Directed evolution of polymerase function by compartmentalized self-replication. Proceedings of the National Academy of Sciences 2001;98:4552–57.</p>
</li>
<li>
<p>Lam N, Rainer TH, Chiu RWK, et al. EDTA is a better anticoagulant than heparin or citrate for delayed blood processing for plasma DNA analysis. Clinical Chemistry 2004;50:256–57.</p>
</li>
<li>
<p>Tanner M, Berk LS, Felten DL, et al. Substantial changes in gene expression level due to the storage temperature and storage duration of human whole blood. Clinical and Laboratory Haematology 2002;24:337–41.</p>
</li>
<li>
<p>Chai V, Vassilakos A, Lee Y, et al. Optimization of the PAXgene blood RNA extraction system for gene expression analysis of clinical samples. Journal of Clinical Laboratory Analysis 2005;19:182–88.</p>
</li>
<li>
<p>Elbeik T, Nassos P, Kipnis P, et al. Evaluation of the VACUTAINER PPT Plasma Preparation Tube for use with the Bayer VERSANT assay for quantification of human immunodeficiency virus type 1 RNA. Journal of Clinical Microbiology 2005;43: 3769–71.</p>
</li>
<li>
<p>Rainen L, Oelmueller U, Jurgensen S, et al. Stabilization of mRNA expression in whole blood samples. Clinical Chemistry 2002;48:1883–90.</p>
</li>
<li>
<p>Rahman M, Goegebuer T, De Leener K, et al. Chromatography paper strip method for collection, transportation, and storage of rotavirus RNA in stool samples. Journal of Clinical Microbiology 2004;42:1605–1608.</p>
</li>
<li>
<p>Zhong K, Salas CJ, Shafer R, et al. Comparison of IsoCode STIX and FTA Gene Guard collection matrices as whole-blood storage and processing devices for diagnosis of malaria by PCR. Journal of Clinical Microbiology 2001;39:1195–96.</p>
</li>
<li>
<p>Farkas D, Drevon A, Kiechle FL, et al. Specimen stability for DNA-based diagnostic testing. Diagnostic Molecular Pathology 1996;5: 227–35.</p>
</li>
<li>
<p>Farkas D, Kaul KL, Wiedbrauk DL, et al. Specimen collection and storage for diagnostic molecular pathology investigation. Archives of Pathology and Laboratory Medicine 1996;120:591–96.</p>
</li>
<li>
<p>Statement AFMP. Recommendations for in-house development and operation of molecular diagnostic tests. American Journal of Clinical Pathology 1999;111:449–63.</p>
</li>
<li>
<p>Hirsh B, Brothman AR, Jacky PB, et al. Section E6 of the ACMG technical standards and guidelines: Chromosome studies for acquired abnormalities. Genetics in Medicine 2005;7:509–13.</p>
</li>
<li>
<p>Potter N, Spector EB, Prior TW. Technical standards and guidelines for Huntington disease testing. Genetics in Medicine 2004;6:61–65.</p>
</li>
<li>
<p>Ambros I, Benard J, Boavida M, et al. Quality assessment of genetic markers used for therapy stratification. Journal of Clinical Oncology 2003;21:2077–84.</p>
</li>
<li>
<p>Enns R. Fluorescence in situ hybridization (FISH) methods for medical genetics: Approved guideline. National Committee for Clinical Laboratory Standards, 2004.</p>
</li>
<li>
<p>Berte L. Clinical Laboratory Technical Procedure Manual, 4th ed. GP2-A4, 2002.</p>
</li>
<li>
<p>Board DA. Standards and guidelines. <em>Forensic Science Communications</em> 2001;3(4).</p>
</li>
<li>
<p>Ye J, Ingels SC, Parvin CA. Performance evaluation and planning for patient-/client-based quality control procedures. American Journal of Clinical Pathology 2000;113:240–48.</p>
</li>
<li>
<p>Madej R. Using standards and controls in molecular assays for infectious diseases. Molecular Diagnostics 2001;6:335–45.</p>
</li>
<li>
<p>Tse C, Brault D, Gligorov J, et al. Evaluation of the quantitative analytical methods real-time PCR for HER-2 gene quantification and ELISA of serum HER-2 protein and comparison with fluorescence in situ hybridization and immunohistochemistry for determining HER-2 status in breast cancer patients. Clinical Chemistry 2005;51:1093–1101.</p>
</li>
<li>
<p>Stevenson G, Smetters GW, Copper JA. A gravimetric method for the calibration of hemoglobin micropipets. American Journal of Clinical Pathology 1951;31:489–91.</p>
</li>
<li>
<p>Bray W. Software for the gravimetric calibration testing of pipets. American Clinical Laboratory 1995;14:14–15.</p>
</li>
</ol>
<p>Copyright ©2007 by F. A. Davis.
Quality Assurance and Quality Control in the Molecular Laboratory Chapter 16 425</p>
<ol start="26">
<li>
<p>Lasky F. Evaluation of Matrix Effects: Approved Guideline, 2nd ed. Clinical and Laboratory Standards Institute, 2005.</p>
</li>
<li>
<p>Association NFP. Fire Protection Guide to Hazardous Materials, 13th ed., 2001.</p>
</li>
<li>
<p>Clark G, Sarewitz SJ. Using proficiency testing (PT) to improve the clinical laboratory: Approved guideline. National Committee for Clinical Laboratory Standards, 1999.</p>
</li>
<li>
<p>Richards C, Grody WW. Alternative approaches to proficiency testing in molecular genetics. Clinical Chemistry 2003;49:717–18.</p>
</li>
<li>
<p>Sarewitz S. Assessment of laboratory tests when proficiency testing is not available: Approved guideline. National Committee for Clinical Laboratory Standards, 2002.</p>
</li>
<li>
<p>den Dunnen J, Antonarakis SE. Mutation nomenclature extensions and suggestions to describe complex mutations. Human Mutation 2000;15:7–12.</p>
</li>
<li>
<p>Molecular Pathology Checklist. College of American Pathologists, 2005.</p>
</li>
<li>
<p>Kiechle F, Chambers LM, Cox RS, et al. Patient preparation and specimen handling In: Reference guide for diagnostic molecular pathology and flow cytometry. Fascicle VII: College of American Pathologists, 1996.</p>
</li>
<li>
<p>Tuttle R, Waselenko JK, Yosseffi P, et al. Preservation of nucleic acids for polymerase chain reaction after prolonged storage at room temperature. Diagnostic Molecular Pathology 1998;7:302–309.</p>
</li>
<li>
<p>Dutton G. Thinking outside the icebox on DNA storage. The Scientist 2005;19:28.</p>
</li>
</ol>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>This page has been left intentionally blank.</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>STUDY QUESTION ANSWERS</p>
<p>Appendix</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="chapter-1">CHAPTER 1<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-1" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>
<p>What is the function of DNA in the cell?
Storage of genetic information</p>
</li>
<li>
<p>Compare the structure of the nitrogen bases. How do purines and pyrimidines differ?
Purines have a double ring; pyrimidines have a single ring.</p>
</li>
<li>
<p>Write the complementary sequence to the following:
5'AGGTCACGTCTAGCTAGCTAGA3'
3'TCCAGTGCAGATCGATCGATCT5'</p>
</li>
<li>
<p>Which of the ribose carbons participates in the phosphodiester bond?
5' carbon, 3' carbon</p>
</li>
<li>
<p>Which of the ribose carbons carries the nitrogen base?
1' carbon</p>
</li>
<li>
<p>Why does DNA polymerase require a primer?
A 3' hydroxyl group from an existing nucleotide must be present to form the phosphodiester bond.</p>
</li>
</ol>
<p>Restriction Enzyme Analysis</p>
<ol>
<li>A plasmid was digested with the enzyme HpaII. On agarose gel electrophoresis, three bands are observed: 100, 230, and 500 bp.
a. How many HpaII sites are present in this plasmid?
3
b. What are the distances between each site?
100 bp, 230 bp, 500 bp
c. What is the size of the plasmid?
830 bp
d. Draw a picture of the plasmid with the HpaII sites.</li>
</ol>
<p><img src="assets/images/image-20251222-84e41c6e.jpeg" alt="img-426.jpeg"></p>
<p>A second cut of the plasmid with BamH1 yields two pieces, 80 and x bp.
e. How many BamH1 sites are in the plasmid?
2
f. What is x in base pairs (bp)?
830 bp - 80 bp = 750 bp</p>
<ol start="2">
<li>
<p>How would you determine where the BamH1 sites are in relation to the HpaII sites?
Cut the plasmid with both enzymes at the same time.</p>
</li>
<li>
<p>The plasmid has one EcoR1 site into which you want to clone a blunt-ended fragment. What type of enzyme could turn an EcoR1 sticky end into a blunt end?
5' to 3' single-strand exonuclease
Recombination and DNA Transfer</p>
</li>
<li>
<p>Compare how DNA moves from cell to cell by a) conjugation, b) transduction, and c) transformation.
a) Cell-to-cell contact
b) Viral or bacteriophage vectors
c) Fragmented or plasmid DNA</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="chapter-2">CHAPTER 2<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-2" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>RNA Secondary Structure</p>
<ol>
<li>Draw the secondary structure of the following RNA. The complementary sequences (inverted repeat) are underlined.
5'CAUGUUCAGCUCAUGUGAACGCU3'</li>
</ol>
<p><img src="assets/images/image-20251222-21176f71.jpeg" alt="img-427.jpeg"></p>
<ol start="2">
<li>Underline the rest of the two inverted repeats in the following RNA, then draw the secondary structure.
5'CUGAACUUCAGUCAAGCAUGCACUGAUGCUU3'</li>
</ol>
<p><img src="assets/images/image-20251222-312130f4.jpeg" alt="img-428.jpeg"></p>
<p>Copyright ©2007 by F. A. Davis.
428 Appendix Study Question Answers
OK as set, same as Right Running head</p>
<p>The Lac Operon</p>
<ol>
<li>Using the depiction of the Lac operon in Figures 2-9 and 2-10 indicate whether gene expression (transcription) would be on or off under the following conditions:
(P = promoter; O = operator; R = repressor)
a. P+ O+ R+, no inducer present
OFF
b. P+ O+ R+, inducer present
ON
c. P- O+ R+, no inducer present
OFF
d. P- O+ R+, inducer present
OFF
e. P+ O- R+, no inducer present
ON
f. P+ O- R+, inducer present
ON
g. P+ O+ R-, no inducer present
ON
h. P+ O+ R-, inducer present
ON
i. P- O- R+, no inducer present
OFF
j. P- O- R+, inducer present
OFF
k. P- O+ R-, no inducer present
OFF
l. P- O+ R-, inducer present
OFF
m. P+ O- R-, no inducer present
ON
n. P+ O- R-, inducer present
ON
o. P- O- R-, no inducer present
OFF
p. P- O- R-, inducer present
OFF</li>
</ol>
<p>Epigenetics</p>
<ol>
<li>Indicate whether the following events would increase or decrease expression of a gene:
a. Methylation of cytosine bases 5' to the gene
Decrease
b. Histone acetylation close to the gene
Increase
c. siRNAs complementary to the gene transcript
Decrease</li>
</ol>
<p>CHAPTER 3</p>
<ol>
<li>
<p>Indicate whether the following peptides are hydrophilic or hydrophobic?
a. MLWILSS
Hydrophobic
b. VAIKVLIL
Hydrophobic
c. CSKEGCPN
Hydrophilic
d. SSIQKNET
Hydrophilic
e. YAQKFQGRT
Hydrophilic
f. AAPLIWWA
Hydrophobic
g. SLKSSTGGQ
Hydrophilic</p>
</li>
<li>
<p>Is the following peptide positively or negatively charged at neutral pH?
GWWMNKCHAGHLNGVYYQGGTY
Positive</p>
</li>
<li>
<p>Consider an RNA template made from a 2:1 mixture of C:A. What would be the three amino acids most frequently incorporated into protein?
Proline, histidine, threonine</p>
</li>
<li>
<p>What is the peptide sequence encoded in AUAUAUAUAUAUAUA...?
IYIYIYIYIY...</p>
</li>
<li>
<p>Write the anticodons, 5' to 3', of the following amino acids:
a. L
UAA, CAA, AAG, GAG, UAG, CAG
b. T
AGU, GGU, UGU, CGU
c. M
CAU</p>
</li>
</ol>
<p>Copyright ©2007 by F. A. Davis.
Study Question Answers Appendix 429</p>
<p>d. H
AUG, GUG</p>
<p>e. R
ACG, GCG, UCG, CCG, UCU, CCU</p>
<p>f. I
AAU, GAU, UAU</p>
<ol start="6">
<li>
<p>A protein contains the sequence LGEKKWCLRVNPKGLDESKDYLSLKSKYLLL. What is the likely function of this protein?
This protein has a leucine zipper and it is likely to be a transcription factor.</p>
</li>
<li>
<p>A histone-like protein contains the sequence: PKKGSKKAVTKVQKKDGKKRKRSRK. What characteristic of this sequence makes it likely to associate with DNA?
This protein has a lot of lysines. The resulting positive charges would bind favorably to the negatively charged DNA.</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="chapter-4">CHAPTER 4<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-4" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>DNA Quantity/Quality</p>
<ol>
<li>Calculate the DNA concentration in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>μ</mi><mi mathvariant="normal">g</mi><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow></mrow><annotation encoding="application/x-tex">\mu \mathrm{g} / \mathrm{mL}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord mathnormal">μ</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span><span class="mord">/</span><span class="mord"><span class="mord mathrm">mL</span></span></span></span></span></span> from the following information:</li>
</ol>
<p>a. Absorbance reading at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>260</mn><mrow><mi mathvariant="normal">n</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">260\mathrm{nm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">260</span><span class="mord"><span class="mord mathrm">nm</span></span></span></span></span></span> from a 1:100 dilution <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo><mn>0.307</mn></mrow><annotation encoding="application/x-tex">= 0.307</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">0.307</span></span></span></span></span>
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.307</mn><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">b</mi><mi mathvariant="normal">s</mi></mrow><mo>×</mo><mn>50</mn><mo stretchy="false">(</mo><mi>μ</mi><mrow><mi mathvariant="normal">g</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow><mo stretchy="false">)</mo><mo>×</mo><mn>100</mn><mo>=</mo><mn>1535</mn><mi>μ</mi><mrow><mi mathvariant="normal">g</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow></mrow><annotation encoding="application/x-tex">0.307\mathrm{Abs} \times 50(\mu \mathrm{g / mL}) \times 100 = 1535\mu \mathrm{g / mL}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7778em; vertical-align: -0.0833em;"></span><span class="mord">0.307</span><span class="mord"><span class="mord mathrm">Abs</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mopen">(</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mord mathrm">g/mL</span></span><span class="mclose">)</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1535</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mord mathrm">g/mL</span></span></span></span></span></span></p>
<p>b. Absorbance reading at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>260</mn><mrow><mi mathvariant="normal">n</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">260\mathrm{nm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">260</span><span class="mord"><span class="mord mathrm">nm</span></span></span></span></span></span> from a 1:50 dilution <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo><mn>0.307</mn></mrow><annotation encoding="application/x-tex">= 0.307</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">0.307</span></span></span></span></span>
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.307</mn><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">b</mi><mi mathvariant="normal">s</mi></mrow><mo>×</mo><mn>50</mn><mo stretchy="false">(</mo><mi>μ</mi><mrow><mi mathvariant="normal">g</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow><mo stretchy="false">)</mo><mo>×</mo><mn>50</mn><mo>=</mo><mn>767.5</mn><mi>μ</mi><mrow><mi mathvariant="normal">g</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow></mrow><annotation encoding="application/x-tex">0.307\mathrm{Abs} \times 50(\mu \mathrm{g / mL}) \times 50 = 767.5\mu \mathrm{g / mL}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7778em; vertical-align: -0.0833em;"></span><span class="mord">0.307</span><span class="mord"><span class="mord mathrm">Abs</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mopen">(</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mord mathrm">g/mL</span></span><span class="mclose">)</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">767.5</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mord mathrm">g/mL</span></span></span></span></span></span></p>
<p>c. Absorbance reading at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>260</mn><mrow><mi mathvariant="normal">n</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">260\mathrm{nm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">260</span><span class="mord"><span class="mord mathrm">nm</span></span></span></span></span></span> from a 1:100 dilution <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo><mn>0.172</mn></mrow><annotation encoding="application/x-tex">= 0.172</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">0.172</span></span></span></span></span>
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.172</mn><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">b</mi><mi mathvariant="normal">s</mi></mrow><mo>×</mo><mn>50</mn><mo stretchy="false">(</mo><mi>μ</mi><mrow><mi mathvariant="normal">g</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow><mo stretchy="false">)</mo><mo>×</mo><mn>100</mn><mo>=</mo><mn>860</mn><mi>μ</mi><mrow><mi mathvariant="normal">g</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow></mrow><annotation encoding="application/x-tex">0.172\mathrm{Abs} \times 50(\mu \mathrm{g / mL}) \times 100 = 860\mu \mathrm{g / mL}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7778em; vertical-align: -0.0833em;"></span><span class="mord">0.172</span><span class="mord"><span class="mord mathrm">Abs</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mopen">(</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mord mathrm">g/mL</span></span><span class="mclose">)</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">860</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mord mathrm">g/mL</span></span></span></span></span></span></p>
<p>d. Absorbance reading at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>260</mn><mrow><mi mathvariant="normal">n</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">260\mathrm{nm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">260</span><span class="mord"><span class="mord mathrm">nm</span></span></span></span></span></span> from a 1:100 dilution <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo><mn>0.088</mn></mrow><annotation encoding="application/x-tex">= 0.088</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">0.088</span></span></span></span></span>
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.088</mn><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">b</mi><mi mathvariant="normal">s</mi></mrow><mo>×</mo><mn>50</mn><mo stretchy="false">(</mo><mi>μ</mi><mrow><mi mathvariant="normal">g</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow><mo stretchy="false">)</mo><mo>×</mo><mn>100</mn><mo>=</mo><mn>440</mn><mi>μ</mi><mrow><mi mathvariant="normal">g</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow></mrow><annotation encoding="application/x-tex">0.088\mathrm{Abs} \times 50(\mu \mathrm{g / mL}) \times 100 = 440\mu \mathrm{g / mL}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7778em; vertical-align: -0.0833em;"></span><span class="mord">0.088</span><span class="mord"><span class="mord mathrm">Abs</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mopen">(</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mord mathrm">g/mL</span></span><span class="mclose">)</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">440</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mord mathrm">g/mL</span></span></span></span></span></span></p>
<ol start="2">
<li>If the volume of the above DNA solutions was 0.5 mL, calculate the yield for a. to d.</li>
</ol>
<p>1a. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1535</mn><mi>μ</mi><mrow><mi mathvariant="normal">g</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow><mo>×</mo><mn>0.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow><mo>=</mo><mn>767.5</mn><mi>μ</mi><mi mathvariant="normal">g</mi></mrow><annotation encoding="application/x-tex">1535\mu \mathrm{g / mL}\times 0.5\mathrm{mL} = 767.5\mu \mathrm{g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1535</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mord mathrm">g/mL</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">0.5</span><span class="mord"><span class="mord mathrm">mL</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">767.5</span><span class="mord mathnormal">μ</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span>
1b. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>767.5</mn><mi>μ</mi><mrow><mi mathvariant="normal">g</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow><mo>×</mo><mn>0.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow><mo>=</mo><mn>383.75</mn><mi>μ</mi><mi mathvariant="normal">g</mi></mrow><annotation encoding="application/x-tex">767.5\mu \mathrm{g / mL}\times 0.5\mathrm{mL} = 383.75\mu \mathrm{g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">767.5</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mord mathrm">g/mL</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">0.5</span><span class="mord"><span class="mord mathrm">mL</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">383.75</span><span class="mord mathnormal">μ</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></p>
<p>1c. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>860</mn><mi>μ</mi><mrow><mi mathvariant="normal">g</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow><mo>×</mo><mn>0.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow><mo>=</mo><mn>430</mn><mi>μ</mi><mi mathvariant="normal">g</mi></mrow><annotation encoding="application/x-tex">860\mu \mathrm{g / mL}\times 0.5\mathrm{mL} = 430\mu \mathrm{g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">860</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mord mathrm">g/mL</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">0.5</span><span class="mord"><span class="mord mathrm">mL</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">430</span><span class="mord mathnormal">μ</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span>
1d. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>440</mn><mi>μ</mi><mrow><mi mathvariant="normal">g</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow><mo>×</mo><mn>0.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow><mo>=</mo><mn>220</mn><mi>μ</mi><mi mathvariant="normal">g</mi></mrow><annotation encoding="application/x-tex">440\mu \mathrm{g / mL}\times 0.5\mathrm{mL} = 220\mu \mathrm{g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">440</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mord mathrm">g/mL</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">0.5</span><span class="mord"><span class="mord mathrm">mL</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">220</span><span class="mord mathnormal">μ</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></p>
<ol start="3">
<li>Three DNA preparations have the following <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">b</mi><mi mathvariant="normal">s</mi></mrow><mn>260</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{Abs}_{260}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8444em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Abs</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">260</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">b</mi><mi mathvariant="normal">s</mi></mrow><mn>280</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{Abs}_{280}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8444em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Abs</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">280</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> readings:</li>
</ol>
<table><thead><tr><th>Sample No.</th><th>Abs_{260}</th><th>Abs_{280}</th></tr></thead><tbody><tr><td>1</td><td>0.419</td><td>0.230</td></tr><tr><td>2</td><td>0.258</td><td>0.225</td></tr><tr><td>3</td><td>0.398</td><td>0.174</td></tr></tbody></table>
<p>For each sample 1-3, based on the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">b</mi><mi mathvariant="normal">s</mi></mrow><mn>260</mn></msub><mi mathvariant="normal">/</mi><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">b</mi><mi mathvariant="normal">s</mi></mrow><mn>280</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{Abs}_{260} / \mathrm{Abs}_{280}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Abs</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">260</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">/</span><span class="mord"><span class="mord"><span class="mord mathrm">Abs</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">280</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ratio, is each preparation suitable for further use? If not, what is contaminating the DNA?</p>
<ol>
<li><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">b</mi><mi mathvariant="normal">s</mi></mrow><mn>260</mn></msub><mi mathvariant="normal">/</mi><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">b</mi><mi mathvariant="normal">s</mi></mrow><mn>280</mn></msub><mo>=</mo><mn>0.419</mn><mi mathvariant="normal">/</mi><mn>0.230</mn><mo>=</mo><mn>1.82</mn></mrow><annotation encoding="application/x-tex">\mathrm{Abs}_{260} / \mathrm{Abs}_{280} = 0.419 / 0.230 = 1.82</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Abs</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">260</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">/</span><span class="mord"><span class="mord"><span class="mord mathrm">Abs</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">280</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.419/0.230</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1.82</span></span></span></span></span>, suitable</li>
<li><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">b</mi><mi mathvariant="normal">s</mi></mrow><mn>260</mn></msub><mi mathvariant="normal">/</mi><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">b</mi><mi mathvariant="normal">s</mi></mrow><mn>280</mn></msub><mo>=</mo><mn>0.258</mn><mi mathvariant="normal">/</mi><mn>0.225</mn><mo>=</mo><mn>1.14</mn></mrow><annotation encoding="application/x-tex">\mathrm{Abs}_{260} / \mathrm{Abs}_{280} = 0.258 / 0.225 = 1.14</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Abs</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">260</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">/</span><span class="mord"><span class="mord"><span class="mord mathrm">Abs</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">280</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.258/0.225</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1.14</span></span></span></span></span>, unsuitable, protein contamination</li>
<li><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">b</mi><mi mathvariant="normal">s</mi></mrow><mn>260</mn></msub><mi mathvariant="normal">/</mi><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">b</mi><mi mathvariant="normal">s</mi></mrow><mn>280</mn></msub><mo>=</mo><mn>0.398</mn><mi mathvariant="normal">/</mi><mn>0.174</mn><mo>=</mo><mn>2.28</mn></mrow><annotation encoding="application/x-tex">\mathrm{Abs}_{260} / \mathrm{Abs}_{280} = 0.398 / 0.174 = 2.28</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Abs</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">260</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">/</span><span class="mord"><span class="mord"><span class="mord mathrm">Abs</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">280</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.398/0.174</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2.28</span></span></span></span></span>, may be suitable, RNA contamination</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="rna-quantity-quality">RNA Quantity/Quality<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#rna-quantity-quality" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Calculate the RNA concentration in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>μ</mi><mi mathvariant="normal">g</mi><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow></mrow><annotation encoding="application/x-tex">\mu \mathrm{g} / \mathrm{mL}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord mathnormal">μ</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span><span class="mord">/</span><span class="mord"><span class="mord mathrm">mL</span></span></span></span></span></span> from the following information:</li>
</ol>
<p>a. Absorbance reading at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>260</mn><mrow><mi mathvariant="normal">n</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">260\mathrm{nm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">260</span><span class="mord"><span class="mord mathrm">nm</span></span></span></span></span></span> from a 1:100 dilution <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo><mn>0.307</mn></mrow><annotation encoding="application/x-tex">= 0.307</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">0.307</span></span></span></span></span>
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.307</mn><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">b</mi><mi mathvariant="normal">s</mi></mrow><mo>×</mo><mn>40</mn><mo stretchy="false">(</mo><mi>μ</mi><mrow><mi mathvariant="normal">g</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow><mo stretchy="false">)</mo><mo>×</mo><mn>100</mn><mo>=</mo><mn>1228</mn><mi>μ</mi><mrow><mi mathvariant="normal">g</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow></mrow><annotation encoding="application/x-tex">0.307\mathrm{Abs} \times 40(\mu \mathrm{g / mL}) \times 100 = 1228\mu \mathrm{g / mL}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7778em; vertical-align: -0.0833em;"></span><span class="mord">0.307</span><span class="mord"><span class="mord mathrm">Abs</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">40</span><span class="mopen">(</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mord mathrm">g/mL</span></span><span class="mclose">)</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1228</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mord mathrm">g/mL</span></span></span></span></span></span></p>
<p>b. Absorbance reading at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>260</mn><mrow><mi mathvariant="normal">n</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">260\mathrm{nm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">260</span><span class="mord"><span class="mord mathrm">nm</span></span></span></span></span></span> from a 1:50 dilution <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo><mn>0.307</mn></mrow><annotation encoding="application/x-tex">= 0.307</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">0.307</span></span></span></span></span>
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.307</mn><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">b</mi><mi mathvariant="normal">s</mi></mrow><mo>×</mo><mn>40</mn><mo stretchy="false">(</mo><mi>μ</mi><mrow><mi mathvariant="normal">g</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow><mo stretchy="false">)</mo><mo>×</mo><mn>50</mn><mo>=</mo><mn>614</mn><mi>μ</mi><mrow><mi mathvariant="normal">g</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow></mrow><annotation encoding="application/x-tex">0.307\mathrm{Abs} \times 40(\mu \mathrm{g / mL}) \times 50 = 614\mu \mathrm{g / mL}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7778em; vertical-align: -0.0833em;"></span><span class="mord">0.307</span><span class="mord"><span class="mord mathrm">Abs</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">40</span><span class="mopen">(</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mord mathrm">g/mL</span></span><span class="mclose">)</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">614</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mord mathrm">g/mL</span></span></span></span></span></span></p>
<p>c. Absorbance reading at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>260</mn><mrow><mi mathvariant="normal">n</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">260\mathrm{nm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">260</span><span class="mord"><span class="mord mathrm">nm</span></span></span></span></span></span> from a 1:100 dilution <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo><mn>0.172</mn></mrow><annotation encoding="application/x-tex">= 0.172</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">0.172</span></span></span></span></span>
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.172</mn><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">b</mi><mi mathvariant="normal">s</mi></mrow><mo>×</mo><mn>40</mn><mo stretchy="false">(</mo><mi>μ</mi><mrow><mi mathvariant="normal">g</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow><mo stretchy="false">)</mo><mo>×</mo><mn>100</mn><mo>=</mo><mn>688</mn><mi>μ</mi><mrow><mi mathvariant="normal">g</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow></mrow><annotation encoding="application/x-tex">0.172\mathrm{Abs} \times 40(\mu \mathrm{g / mL}) \times 100 = 688\mu \mathrm{g / mL}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7778em; vertical-align: -0.0833em;"></span><span class="mord">0.172</span><span class="mord"><span class="mord mathrm">Abs</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">40</span><span class="mopen">(</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mord mathrm">g/mL</span></span><span class="mclose">)</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">688</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mord mathrm">g/mL</span></span></span></span></span></span></p>
<p>d. Absorbance reading at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>260</mn><mrow><mi mathvariant="normal">n</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">260\mathrm{nm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">260</span><span class="mord"><span class="mord mathrm">nm</span></span></span></span></span></span> from a 1:100 dilution <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo><mn>0.088</mn></mrow><annotation encoding="application/x-tex">= 0.088</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">0.088</span></span></span></span></span>
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.088</mn><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">b</mi><mi mathvariant="normal">s</mi></mrow><mo>×</mo><mn>40</mn><mo stretchy="false">(</mo><mi>μ</mi><mrow><mi mathvariant="normal">g</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow><mo stretchy="false">)</mo><mo>×</mo><mn>100</mn><mo>=</mo><mn>352</mn><mi>μ</mi><mrow><mi mathvariant="normal">g</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow></mrow><annotation encoding="application/x-tex">0.088\mathrm{Abs} \times 40(\mu \mathrm{g / mL}) \times 100 = 352\mu \mathrm{g / mL}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7778em; vertical-align: -0.0833em;"></span><span class="mord">0.088</span><span class="mord"><span class="mord mathrm">Abs</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">40</span><span class="mopen">(</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mord mathrm">g/mL</span></span><span class="mclose">)</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">352</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mord mathrm">g/mL</span></span></span></span></span></span></p>
<ol start="2">
<li>If the volume of the above RNA solutions was <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow></mrow><annotation encoding="application/x-tex">0.5\mathrm{mL}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">0.5</span><span class="mord"><span class="mord mathrm">mL</span></span></span></span></span></span>, calculate the yield for a. to d.</li>
</ol>
<p>1a. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1228</mn><mi>μ</mi><mrow><mi mathvariant="normal">g</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow><mo>×</mo><mn>0.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow><mo>=</mo><mn>614</mn><mi>μ</mi><mi mathvariant="normal">g</mi></mrow><annotation encoding="application/x-tex">1228\mu \mathrm{g / mL}\times 0.5\mathrm{mL} = 614\mu \mathrm{g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1228</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mord mathrm">g/mL</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">0.5</span><span class="mord"><span class="mord mathrm">mL</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">614</span><span class="mord mathnormal">μ</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span>
1b. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>614</mn><mi>μ</mi><mrow><mi mathvariant="normal">g</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow><mo>×</mo><mn>0.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow><mo>=</mo><mn>307</mn><mi>μ</mi><mi mathvariant="normal">g</mi></mrow><annotation encoding="application/x-tex">614\mu \mathrm{g / mL}\times 0.5\mathrm{mL} = 307\mu \mathrm{g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">614</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mord mathrm">g/mL</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">0.5</span><span class="mord"><span class="mord mathrm">mL</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">307</span><span class="mord mathnormal">μ</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></p>
<p>Copyright ©2007 by F. A. Davis.
430 Appendix Study Question Answers</p>
<p>1c. 688 µg/mL × 0.5 mL = 344 µg
1d. 352 µg/mL × 0.5 mL = 176 µg</p>
<ol start="3">
<li>An RNA preparation has the following absorbance readings:
Abs₂₆₀ = 0.208
Abs₂₈₀ = 0.096
Is this RNA preparation satisfactory for use?
Abs₂₆₀/Abs₂₈₀ = 0.208/0.096 = 2.17, suitable</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="chapter-5">CHAPTER 5<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-5" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>
<p>You wish to perform a resolution of your restriction enzyme-digested DNA fragments. The size of the expected products ranges 500–100 bp. You discover two agarose gels polymerizing on the bench. One is 5% agarose. The other is 2% agarose. Which one might you use to resolve your fragments?
2%</p>
</li>
<li>
<p>After completion of the run of fragments along with the proper molecular weight standard on the agarose gel, suppose a. or b. was observed. What might be explanations for these? (Assume you have included a molecular weight marker in your run.)
a. The gel is blank (no bands, no molecular weight standard).
Samples were not loaded properly.
Electrodes were switched.
Gel was not stained properly.
b. Only the molecular weight standard is visible.
Samples were not loaded properly.
Samples were diluted, degraded, or otherwise compromised.
Gel was not stained evenly.</p>
</li>
<li>
<p>How does PFGE separate larger fragments more efficiently than standard electrophoresis?
Repeated reorientation forces larger fragments through the gel matrix more effectively.</p>
</li>
<li>
<p>A 6% solution of 19:1 acrylamide is mixed, deaerated, and poured between glass plates for gel formation. After an hour, the solution is still liquid. What might be one explanation for the gel not polymerizing?
No catalyst was added.</p>
</li>
<li>
<p>A gel separation of RNA yields aberrantly migrating bands and smears. Suggest two possible explanations for this observation.
Poor RNA sample quality.
Inadequate denaturation of the RNA before loading.</p>
</li>
<li>
<p>Why does DNA not resolve well in solution (without a gel matrix)?
The size and charge of DNA have opposing effects on migration.</p>
</li>
<li>
<p>Why is SyBr green less toxic than EtBr?
SyBr green binds in the minor groove of DNA, unlike EtBr, which intercalates between the bases.
Intercalation by EtBr is more likely to cause DNA mutations.</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="chapter-6">CHAPTER 6<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-6" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Calculate the melting temperature of the following DNA fragments using the sequences only:
a. AGTCTGGGACGGCGCGGCAATCGCA TCAGACCCTG CCGCG CCGTTAGCGT 84°C
b. TCAAAAATCGAATATTTGCTTATCTA AGTTTTTAGCTTATAAACGAATAGAT 64°C
c. AGCTAAGCATCGAATTGGCCATCGTGTG TCGATTCGTAGCTTAACCGGTAGCACAC 84°C
d. CATCGCGATCTGCAATTACGACGATAA GTAGCGCTAGACGTTAATGCTGCTATT 78°C</li>
</ol>
<p>Suppose you were to use single strands of these fragments as probes for a Southern blot.</p>
<ol start="2">
<li>
<p>If the fragments were dissolved in a solution of 50% formamide, is the stringency of hybridization higher or lower than if there were no formamide?
Higher</p>
</li>
<li>
<p>If a high concentration of NaCl were added to the hybridization solution, how would the stringency be affected?
The stringency would go lower.</p>
</li>
</ol>
<p>Copyright ©2007 by F. A. Davis.
Study Question Answers Appendix 431</p>
<ol start="4">
<li>
<p>Does heating of the solution from 65°C to 75°C during hybridization raise or lower stringency?
Raise</p>
</li>
<li>
<p>At the end of the procedure, what would the autoradiogram show if the stringency was too high?
No bands</p>
</li>
<li>
<p>In an array CGH experiment, three test samples were hybridized to three microarray chips. Each chip was spotted with 8 gene probes (genes A-H). Below are results of this assay expressed as the ratio of test DNA to reference DNA. Are any of the eight genes consistently deleted or amplified in the test samples? If so, which ones?</p>
</li>
</ol>
<table><thead><tr><th>Gene</th><th>Sample 1</th><th>Sample 2</th><th>Sample 3</th></tr></thead><tbody><tr><td>A</td><td>1.06</td><td>0.99</td><td>1.01</td></tr><tr><td>B</td><td>0.45</td><td>0.55</td><td>0.43</td></tr><tr><td>C</td><td>1.01</td><td>1.05</td><td>1.06</td></tr><tr><td>D</td><td>0.98</td><td>1.00</td><td>0.97</td></tr><tr><td>E</td><td>1.55</td><td>1.47</td><td>1.62</td></tr><tr><td>F</td><td>0.98</td><td>1.06</td><td>1.01</td></tr><tr><td>G</td><td>1.00</td><td>0.99</td><td>0.99</td></tr><tr><td>H</td><td>1.08</td><td>1.09</td><td>0.90</td></tr></tbody></table>
<p>Gene B is deleted in all three samples. Gene E is amplified in all three samples.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="chapter-7">CHAPTER 7<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-7" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>
<p>The final concentration of Taq polymerase is to be 0.01 unit/μL in a 50-μL PCR reaction. If the enzyme is supplied as 5 units/μl, how much enzyme would you add to the reaction?
b. 1 μl of a 1:10 dilution of Taq</p>
</li>
<li>
<p>Primer dimers result from:
d. 3' complementarity in the primer sequences</p>
</li>
<li>
<p>Which control is run to detect contamination?
d. Reagent blank</p>
</li>
<li>
<p>Nonspecific extra PCR products can result from:
a. Mispriming</p>
</li>
<li>
<p>Using which of the following is an appropriate way to avoid PCR contamination?
c. A separate area for PCR reaction setup</p>
</li>
<li>
<p>How many copies of a target are made after 30 cycles of PCR?
b. 2³⁰</p>
</li>
<li>
<p>What are the three steps of a standard PCR cycle?
Denaturation, annealing, extension</p>
</li>
<li>
<p>Which of the following is a method for purifying PCR product?
c. Put the reaction mix through a spin column.</p>
</li>
<li>
<p>In contrast to standard PCR, real-time PCR is:
a. Quantitative</p>
</li>
<li>
<p>In real-time PCR, fluorescence is not generated by
d. Tth polymerase</p>
</li>
<li>
<p>Complete the following table comparing various methods of nucleic amplification:</p>
</li>
</ol>
<table><thead><tr><th></th><th>PCR</th><th>LCR</th><th>bDNA</th><th>TMA</th><th>Qβ Replicase</th><th>Hybrid Capture</th></tr></thead><tbody><tr><td>Type of amplification</td><td>Target</td><td>Probe</td><td>Signal</td><td>Target</td><td>Probe</td><td>Signal</td></tr><tr><td>Target nucleic acid</td><td>DNA</td><td>DNA</td><td>DNA or RNA</td><td>RNA</td><td>DNA or RNA</td><td>DNA</td></tr><tr><td>Type of amplicon</td><td>DNA</td><td>DNA</td><td>Chemiluminescent signal</td><td>RNA</td><td>RNA</td><td>Chemiluminescent signal</td></tr><tr><td>Major enzyme(s)</td><td>DNA polymerase</td><td>Ligase</td><td>Alkaline phosphatase</td><td>RNA polymerase</td><td>Qβ replicase</td><td>Alkaline phosphatase</td></tr></tbody></table>
<p>Copyright ©2007 by F. A. Davis.
Appendix Study Question Answers</p>
<ol start="12">
<li>Examine the following sequence. You are devising a test to detect a mutation at the underlined position.</li>
</ol>
<p>5' TATTTAGTTA TGGCCTATAC ACTATTTGTG AGCAAAGGTG ATCGTTTTCT GTTTGAGATT TTTATCTCTT GATTCTTCAA AAGCATTCTG AGAAGGTGAG ATAAGCCCTG AGTCTCAGCT ACCTAAGAAA AACCTGGATG TCACTGGCCA CTGAGGAGCT TTGTTTCAAC CAAGTCATGT GCATTTCCAC GTCAACAGAA TTGTTTATTG TGACAGTTAT ATCTGTTGTC CCTTTGACCT TGTTTCTTGA AGGTTTCCTC GTCCCTGGGC AATTCCGCAT TTAATTCATG GTATTCAGGA TTACATGCAT GTTTGGTTAA ACCCATGAGA TTCATTCAGT TAAAAATCCA GATGGCGAAT 3'</p>
<p>Design one set of primers (forward and reverse) to generate an amplicon containing the underlined base.</p>
<p>The primers should be 20 bases long.</p>
<p>The amplicon must be 100-150 bp in size.</p>
<p>The primers must have similar melting temperatures (Tm), +/-2°C.</p>
<p>The primers should have no homology in the last three 3' bases.</p>
<p>Write the primer sequences 5' → 3' as you would if you were to order them from the DNA synthesis facility.</p>
<p>There are multiple answers to this question. Here is one example:</p>
<p>Forward: 5' GGAGCTTTGTTTCAACCAAG 3'
Reverse: 5' ATTAAATGCGGAATTGCCCA 3'</p>
<p>The product is 131 bp long. (The primer binding sites are italicized in the sequence.)</p>
<p>b. Write the Tm for each primer that you have designed.</p>
<p>Forward, 58°C Reverse, 56°C</p>
<p>Tm = (4°C × GC) + (2°C × AT)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="chapter-8">CHAPTER 8<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-8" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>During interphase FISH analysis of a normal specimen for the t(9;22) translocation, one nucleus was observed with two normal signals (one red for chromosome 22 and one green for chromosome 9) and one composite red/green signal. Five hundred other nuclei were normal. What is one explanation for this observation?</li>
</ol>
<p>Two normal chromosomes happened to fall on top of one another, resulting in an artificial "composite" signal. A low occurrence of this is accepted as background in interphase FISH.</p>
<ol start="2">
<li>Is 47; XYY a normal karyotype?</li>
</ol>
<p>No. 46, XY is normal. This is XYY Syndrome.</p>
<ol start="3">
<li>What are the genetic abnormalities of the following genotypes?</li>
</ol>
<p>47,XY, +18</p>
<p>Trisomy 18 (Edwards' syndrome)</p>
<p>46,XY, del(16)p(14)</p>
<p>Deletion in region 1, band 4 of the short arm of chromosome 16</p>
<p>iso(X)(q10)</p>
<p>Isochromosome comprised of the long arms of the X chromosome</p>
<p>46,XX, del(22)q(11.2)</p>
<p>Deletion in region 1, band 1, sub-band 2 of the long arm of chromosome 22 (diGeorge's syndrome)</p>
<p>45,X</p>
<p>Monosomy X (Turner's syndrome)</p>
<ol start="4">
<li>A chromosome with a centromere not located in the middle of the chromosome, but not completely at the end, where one arm of the chromosome is longer than the other arm, is called:</li>
</ol>
<p>b. Acrocentric</p>
<ol start="5">
<li>A small portion of chromosome 2 has been found on the end of chromosome 15, and a small portion of chromosome 15 has been found on the end of chromosome 2. This mutation is called a(n):</li>
</ol>
<p>a. Reciprocal translocation</p>
<ol start="6">
<li>Phytohemagglutinin is added to a cell culture when preparing cells for karyotyping. The function of the phytohemagglutinin is to:</li>
</ol>
<p>d. Stimulate mitosis in the cells</p>
<ol start="7">
<li>A CEP probe is used to visualize chromosome 21. Three fluorescent signals are observed in the patient's cells when they are stained with this probe. These results are interpreted as consistent with:</li>
</ol>
<p>b. Down's syndrome</p>
<ol start="8">
<li>Cells were harvested from a patient's blood, cultured to obtain chromosomes in metaphase, fixed onto a</li>
</ol>
<p>Copyright ©2007 by F. A. Davis.
Study Question Answers Appendix
433</p>
<p>slide, treated with trypsin, and stained with Giemsa. The resulting banding pattern is called:</p>
<p>a. G banding</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="chapter-9">CHAPTER 9<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-9" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Name three assays by which the Factor V Leiden R506Q mutation can be detected.</li>
</ol>
<p>Sequence specific PCR</p>
<p>PCR-RFLP</p>
<p>Invader™ Assay</p>
<ol start="2">
<li>Exon 4 of the HFE gene from a patient suspected to have hereditary hemachromatosis was amplified by PCR. The G to A mutation, frequently found in hemachromatosis, creates a single Rsa1 site in exon 4. When the PCR products are digested with Rsa1, what results (how many bands) would you expect to see if the patient has the mutation?</li>
</ol>
<p>two bands</p>
<ol start="3">
<li>Which of the following methods would be practical to use to screen a large gene for mutations?</li>
</ol>
<p>SSCP, DGGE</p>
<ol start="4">
<li>What is the phenotypic consequence of changing a codon sequence from TCT to TCC?</li>
</ol>
<p>None. This is a silent mutation.</p>
<ol start="5">
<li>A reference sequence, ATGCCCTCTGGC, is mutated in malignant cells. The following mutations in this sequence have been described. Express these mutations using the accepted nomenclature:</li>
</ol>
<p>ATGCGCTCTGGC</p>
<p>5C&gt;G</p>
<p>ATGCCCTCGC</p>
<p>9_10delTG or 9_10del</p>
<p>ATAGCCCTCTGGC</p>
<p>2_3insA</p>
<p>ATGTCTCCCGGC</p>
<p>4_9inv</p>
<p>ATGATATTCTGGC</p>
<p>4_6delinsATAT or 4_6delCCCinsATAT</p>
<ol start="6">
<li>A reference peptide, MPSGCWR, is subject to inherited alterations. The following peptide sequences have been reported. Express these mutations using the accepted nomenclature:</li>
</ol>
<p>MPSTGCWR</p>
<p>S3_G4insT</p>
<p>MPSGX</p>
<p>C5X</p>
<p>MPSGCWLVTGX</p>
<p>R7fs or R7LfsX5</p>
<p>MPSGR</p>
<p>C5_W6del</p>
<p>MPSGCWGCWR</p>
<p>4_6dupGCW</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="chapter-10">CHAPTER 10<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-10" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Read, 5′ to 3′, the first 20 bases of the sequence in the gel on the right pictured in Figure 10-8.</li>
</ol>
<p>5'GGAGAGGGTCCTGGGAGGGT3'</p>
<ol start="2">
<li>After an automated dye primer sequencing run, the electropherogram displays consecutive peaks of the following colors:</li>
</ol>
<p>red, red, black, green, green, blue, black, red, green, black, blue, blue, blue</p>
<p>If the computer software displays the fluors from ddATP as green, ddCTP as blue, ddGTP as black, and ddTTP as red, what is the sequence of the region given?</p>
<p>5'TTGAACGTAGCCC3'</p>
<ol start="3">
<li>After an automated dye terminator sequencing run, the electropherogram displays bright (high, wide) peaks of fluorescence, obliterating some of the sequencing peaks. What is the most likely cause of this observation? How might it be corrected?</li>
</ol>
<p>These are dye blobs. They can be removed by careful cleanup of the sequencing ladder after the sequencing reaction.</p>
<ol start="4">
<li>In a manual sequencing reaction, the DNA ladder on the polyacrylamide gel is very bright and readable at the bottom of the gel, but the larger (slower migrating) fragments higher up are very faint. What is the most likely cause of this observation? How might it be corrected?</li>
</ol>
<p>The ddNTP concentration is too high.</p>
<ol start="5">
<li>In an analysis of the p53 gene for mutations, the following sequences were produced. For each sequence, write the expected sequence of the opposite strand that would confirm the presence of the mutations detected. Normal:</li>
</ol>
<p>Copyright ©2007 by F. A. Davis.
434 Appendix Study Question Answers</p>
<p>5'TATCTGTTCACTTGTGCCCT3'
(Homozygous substitution)
5'TATCTGTTCATTTGTGCCCT3'
5' AGGGCACAAATGAACAGATA3'
(Heterozygous substitution)
5'TATCTGT(T/G)CACTTGTGCCCT3'
5' AGGGCACAAGTG(A/C)ACAGATA3'
(Heterozygous deletion)
5'TATCTGTT(C/A)(A/C)(C/T)T(T/G)(G/T)(T/G)
(G/C)CC(C/T)(T/...3'
5' AGGGCACAAGT(GA)A(A/C)(C/A)(A/G)(G/A)
(A/T)(T/A)(A/...3'</p>
<ol start="6">
<li>
<p>A sequence, TTGCTGCGCTAAA, may be methylated at one or more of the cytosine residues: After bisulfite sequencing, the following results are obtained:
Bisulfite treated: TTGCTGTGCTAAA
Untreated: TTGCTGCGCTAAA
Write the sequences showing the methylated cytosines as CMe.
TTGCMeTGCGCMeTAAA</p>
</li>
<li>
<p>In a pyrosequencing readout, the graph shows peaks of luminescence corresponding to the addition of the following nucleotides:
dT peak, dC peak (double height), dT peak, dA peak
What is the sequence?
TCCTA</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="chapter-11">CHAPTER 11<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-11" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="interpretation-for-case-study-11-1">Interpretation for Case Study 11-1:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#interpretation-for-case-study-11-1" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The recipient peak pattern had converted almost entirely to the donor peak pattern at 100 days. The percent residual recipient cells is calculated by analysis of the unshared alleles in this marker:</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mtable rowspacing="0.16em" columnalign="left" columnspacing="1em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="false"><mrow><mi mathvariant="normal">%</mi><mi mathvariant="normal">R</mi><mo>=</mo><mrow><mo fence="true">[</mo><msub><mi mathvariant="normal">R</mi><mtext>unshared</mtext></msub><mi mathvariant="normal">/</mi><mrow><mo fence="true">(</mo><msub><mi mathvariant="normal">R</mi><mtext>unshared</mtext></msub><mo>+</mo><msub><mi mathvariant="normal">D</mi><mtext>unshared</mtext></msub><mo fence="true">)</mo></mrow><mo fence="true">]</mo></mrow><mo>×</mo><mn>100</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="false"><mrow><mo>=</mo><mo stretchy="false">[</mo><mn>3171</mn><mi mathvariant="normal">/</mi><mo stretchy="false">(</mo><mn>40704</mn><mo>+</mo><mn>3171</mn><mo stretchy="false">)</mo><mo stretchy="false">]</mo><mo>×</mo><mn>100</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="false"><mrow><mo>=</mo><mn>7.2</mn><mi mathvariant="normal">%</mi></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{array}{l}
\% \mathrm{R} = \left[ \mathrm{R}_{\text{unshared}} / \left(\mathrm{R}_{\text{unshared}} + \mathrm{D}_{\text{unshared}}\right) \right] \times 100 \\
= [3171/(40704 + 3171)] \times 100 \\
= 7.2\%
\end{array}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3.6em; vertical-align: -1.55em;"></span><span class="mord"><span class="mtable"><span class="arraycolsep" style="width: 0.5em;"></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 2.05em;"><span style="top: -4.21em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">%</span><span class="mord mathrm">R</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">[</span><span class="mord"><span class="mord mathrm">R</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3361em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">unshared</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">/</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord mathrm">R</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3361em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">unshared</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord"><span class="mord mathrm">D</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3361em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">unshared</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span><span class="mclose delimcenter" style="top: 0em;">]</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">100</span></span></span><span style="top: -3.01em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mopen">[</span><span class="mord">3171/</span><span class="mopen">(</span><span class="mord">40704</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">3171</span><span class="mclose">)]</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">100</span></span></span><span style="top: -1.81em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mord">7.2%</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.55em;"><span></span></span></span></span></span><span class="arraycolsep" style="width: 0.5em;"></span></span></span></span></span></span></span></div>
<p>At 1 year, no recipient peaks are detectable at the level of detection (0.5%–1%) of the instrument. The patient is, therefore, reported to have more than 99% donor cells and less than 1% recipient cells in the test specimen.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="interpretation-for-case-study-11-2">Interpretation for Case Study 11-2:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#interpretation-for-case-study-11-2" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These results indicate that the two brothers are identical twins. This means that STR analysis cannot be used for monitoring engraftment after transplant. There is less chance of graft-versus-host-disease with this transplant; however, there is also no graft versus tumor effect that can improve the chance of removing all of the tumor cells.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="interpretation-for-case-study-11-3">Interpretation for Case Study 11-3:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#interpretation-for-case-study-11-3" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The results show that the tissue was not of the same genetic origin as the patient. Apparently this microscopic fragment of tissue was introduced into one of the patient's sections during the fixing and embedding process.</p>
<ol>
<li>Consider the following STR analysis:</li>
</ol>
<table><thead><tr><th>Locus</th><th>Child</th><th>Mother</th><th>AF1</th><th>AF2</th></tr></thead><tbody><tr><td>D3S1358</td><td>15/15</td><td>15</td><td>15</td><td>15/16</td></tr><tr><td>vWA</td><td>17/18</td><td>17</td><td>17/18</td><td>18</td></tr><tr><td>FGA</td><td>23/24</td><td>22/23</td><td>20</td><td>24</td></tr><tr><td>TH01</td><td>6/10</td><td>6/7</td><td>6/7</td><td>9/10</td></tr><tr><td>TPOX</td><td>11/11</td><td>9/11</td><td>9/11</td><td>10/11</td></tr><tr><td>CSF1PO</td><td>12/12</td><td>11/12</td><td>11/13</td><td>11/12</td></tr><tr><td>D5S818</td><td>10/12</td><td>10</td><td>11/12</td><td>12</td></tr><tr><td>D13S317</td><td>9/10</td><td>10/11</td><td>10/11</td><td>9/11</td></tr></tbody></table>
<p>a. Circle the child's alleles that are inherited from the father.
<strong>Bold numbers</strong></p>
<p>b. Which alleged father (AF) is the biological parent?
<strong>AF2</strong></p>
<ol start="2">
<li>The following evidence was collected for a criminal investigation.</li>
</ol>
<table><thead><tr><th>Locus</th><th>Victim</th><th>Evidence</th><th>Suspect</th></tr></thead><tbody><tr><td>TPOX</td><td>11/12</td><td>12, 11/12</td><td>11</td></tr><tr><td>CSF1PO</td><td>10</td><td>10, 9/10</td><td>9/10</td></tr><tr><td>D13S317</td><td>8/10</td><td>10, 8/10</td><td>9/12</td></tr><tr><td>D5S818</td><td>9/11</td><td>10/11, 9/11</td><td>11</td></tr><tr><td>TH01</td><td>6/10</td><td>6/10, 8/10</td><td>5/11</td></tr><tr><td>FGA</td><td>20</td><td>20, 20/22</td><td>20</td></tr><tr><td>vWA</td><td>15/17</td><td>18, 15/17</td><td>15/18</td></tr><tr><td>D3S1358</td><td>14</td><td>15/17, 14</td><td>11/12</td></tr></tbody></table>
<p>The suspect is heterozygous at the amelogenin locus.</p>
<p>Copyright ©2007 by F. A. Davis.
Study Question Answers Appendix 435</p>
<p>a. Is the suspect male or female?
Male</p>
<p>b. In the evidence column, circle the alleles belonging to the victim.
Bold numbers</p>
<p>c. Should the suspect be held or released?
Released</p>
<ol start="3">
<li>A child and an alleged father (AF) share alleles with the following paternity index:</li>
</ol>
<table><thead><tr><th>Locus</th><th>Child</th><th>AF</th><th>Paternity Index for shared allele</th></tr></thead><tbody><tr><td>D5S818</td><td>9,10</td><td>9</td><td>0.853</td></tr><tr><td>D8S1179</td><td>11</td><td>11,12</td><td>2.718</td></tr><tr><td>D16S539</td><td>13,14</td><td>10,14</td><td>1.782</td></tr></tbody></table>
<p>a. What is the combined paternity index from these three loci?
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.853</mn><mo>×</mo><mn>2.718</mn><mo>×</mo><mn>1.782</mn><mo>=</mo><mn>4.131</mn></mrow><annotation encoding="application/x-tex">0.853 \times 2.718 \times 1.782 = 4.131</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.853</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2.718</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1.782</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">4.131</span></span></span></span></span></p>
<p>b. With 50% prior odds, what is the probability of paternity from these three loci?
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>4.131</mn><mo>×</mo><mn>0.5</mn><mo stretchy="false">)</mo><mi mathvariant="normal">/</mi><mo stretchy="false">[</mo><mo stretchy="false">(</mo><mn>4.131</mn><mo>×</mo><mn>0.5</mn><mo stretchy="false">)</mo><mo>+</mo><mn>0.5</mn><mo stretchy="false">)</mo><mo stretchy="false">]</mo><mo>=</mo><mn>0.80</mn></mrow><annotation encoding="application/x-tex">(4.131 \times 0.5) / [(4.131 \times 0.5) + 0.5)] = 0.80</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">4.131</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.5</span><span class="mclose">)</span><span class="mord">/</span><span class="mopen">[(</span><span class="mord">4.131</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.5</span><span class="mclose">)</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.5</span><span class="mclose">)]</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">0.80</span></span></span></span></span> or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span></p>
<ol start="4">
<li>Consider the following theoretical allele frequencies for the loci indicated:</li>
</ol>
<table><thead><tr><th>Locus</th><th>Alleles</th><th>Allele Frequency</th></tr></thead><tbody><tr><td>CSF1PO</td><td>14, 14</td><td>0.332</td></tr><tr><td>D13S317</td><td>9, 10</td><td>0.210, 0.595</td></tr><tr><td>TPOX</td><td>8, 11</td><td>0.489, 0.237</td></tr></tbody></table>
<p>a. What is the overall allele frequency, using the product rule?
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.332</mn><mo>×</mo><mn>0.332</mn><mo>×</mo><mn>0.21</mn><mo>×</mo><mn>0.595</mn><mo>×</mo><mn>0.489</mn><mo>×</mo><mn>0.237</mn><mo>=</mo><mn>1.596</mn><mo>×</mo><msup><mn>10</mn><mrow><mo>−</mo><mn>3</mn></mrow></msup></mrow><annotation encoding="application/x-tex">0.332 \times 0.332 \times 0.21 \times 0.595 \times 0.489 \times 0.237 = 1.596 \times 10^{-3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.332</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.332</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.21</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.595</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.489</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">0.237</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1.596</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord">1</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span><span class="mord mtight">3</span></span></span></span></span></span></span></span></span></span></span></span></span></p>
<p>b. What is the probability that this DNA found at the two sources came from the same person?
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>1.596</mn><mo>×</mo><msup><mn>10</mn><mrow><mo>−</mo><mn>3</mn></mrow></msup><mo>=</mo><mn>626.5</mn></mrow><annotation encoding="application/x-tex">1 / 1.596 \times 10^{-3} = 626.5</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1/1.596</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord">1</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span><span class="mord mtight">3</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">626.5</span></span></span></span></span></p>
<ol start="5">
<li>STR at several loci were screened by capillary electrophoresis and fluorescent detection for informative peaks prior to a bone marrow transplant. The following results were observed:</li>
</ol>
<table><thead><tr><th>Locus</th><th>Donor Alleles</th><th>Recipient Alleles</th></tr></thead><tbody><tr><td>LPL</td><td>7, 10</td><td>7, 9</td></tr><tr><td>F13B</td><td>8, 14</td><td>8</td></tr><tr><td>FESFPS</td><td>10</td><td>7</td></tr><tr><td>F13A01</td><td>5, 11</td><td>5, 11</td></tr></tbody></table>
<p>Which loci are informative?
F13B is donor informative. FESFPS and LPL are informative.</p>
<ol start="6">
<li>
<p>An engraftment analysis was performed by capillary gel electrophoresis and fluorescence detection. The fluorescence as measured by the instrument under the FESFPS donor peak was 28,118 units and that under the FESFPS recipient peak was 72,691. What is the percent donor in this specimen?
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>28118</mn><mi mathvariant="normal">/</mi><mo stretchy="false">(</mo><mn>28118</mn><mo>+</mo><mn>72691</mn><mo stretchy="false">)</mo><mo>=</mo><mn>28</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">28118 / (28118 + 72691) = 28\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">28118/</span><span class="mopen">(</span><span class="mord">28118</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">72691</span><span class="mclose">)</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">28%</span></span></span></span></span> donor</p>
</li>
<li>
<p>The T-cell fraction from the blood sample in Question 6 was separated and measured for donor cells. Analysis of the FESFPS locus in the T-cell fraction yielded 15,362 fluorescence units under the donor peak and 97,885 under the recipient peak. What does this result predict with regard to T-cell mediated events such as graft-versus-host disease (GVHD) or graft-versus-tumor (GVT)?
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15362</mn><mi mathvariant="normal">/</mi><mo stretchy="false">(</mo><mn>15362</mn><mo>+</mo><mn>97885</mn><mo stretchy="false">)</mo><mo>=</mo><mn>13.6</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">15362 / (15362 + 97885) = 13.6\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">15362/</span><span class="mopen">(</span><span class="mord">15362</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">97885</span><span class="mclose">)</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">13.6%</span></span></span></span></span> donor cells; GVDH or GVT is unlikely</p>
</li>
<li>
<p>If a child had a Y haplotype including DYS393 allele 12, DYS439 allele 11, DYS445 allele 8, and DYS447 allele 22, what are the predicted Y alleles for these loci of the natural father?
DYS393 allele 12, DYS439 allele 11, DYS445 allele 8, and DYS447 allele 22</p>
</li>
<li>
<p>Which would be used for a surname test, Y-STR, mitochondrial typing or autosomal STR?
Y-STR</p>
</li>
<li>
<p>An ancient bone fragment was found and claimed to belong to an ancestor of a famous family. Living members of the family donated DNA for confirma</p>
</li>
</ol>
<p>Copyright ©2007 by F. A. Davis.
Appendix Study Question Answers</p>
<p>tion of the relationship. What type of analysis would likely be used for this test? Why?</p>
<p>Mitochondrial DNA typing might be indicated, because (1) the small circular, naturally amplified mitochondrial DNA is more likely to be attained from the old sample and (2) lineage across several generations can be determined using the maternal inheritance of mitochondrial type.</p>
<ol start="11">
<li>What are two biological exceptions to positive identification by autosomal STR?</li>
</ol>
<p>Identical twins and clones have identical nuclear DNA profiles.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-12">CHAPTER 12<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-12" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="interpretation-for-case-study-12-1">Interpretation for Case Study 12-1:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#interpretation-for-case-study-12-1" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Norovirus cannot be cultured. Laboratory tests include electron microscopy, serology, and RT-PCR. Electron microscopy and immune electron microscopy require specialized equipment and technical expertise. Detection of serum antibodies to the virus is not always straightforward, as most of the adult (but not child) population has serum antibodies to this virus. Furthermore, it can take several days after exposure to develop detectable IgM antibodies. RT-PCR, therefore, is the method of choice for detection of this RNA virus. The gene target is the viral RNA polymerase. Using this target, a broad spectrum of noroviral types can be detected. The results indicated that the virus was present in salad lettuce served at the hotel. Lettuce sampled directly from the distributor did not carry virus, indicating that the contamination occurred at the hotel. This assumption was supported by the discovery of viral RNA in hotel employees who had prepared the food. Direct sequencing of the RT-PCR products revealed identical sequences for all positive specimens, confirming that the guests, workers, and food source shared the same viral strain.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="interpretation-for-case-study-12-2">Interpretation for Case Study 12-2:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#interpretation-for-case-study-12-2" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Results from the culture of the isolates were consistent with MRSA. The results from the PFGE analysis indicated that all except one of the isolates from the students were the same strain. One isolate exhibited two differences from the others, indicating that it was closely related to these S. aureus isolates. Resistance to oxacillin/methicillin results from the expression of an altered penicillin-binding protein encoded by the mecA gene. All five isolates shared the type IV mecA gene, associated with MRSA. PVL, also found in these isolates, is thought to be responsible for tissue necrosis in MRSA infections.</p>
<p>Further investigation into the cases revealed that all the students had participated in a wrestling meet at one of the high schools. Passage of the organism during this event was the likely source of the infection. The meet location was thoroughly cleaned according to CDC recommendations, and students were encouraged to always wash their hands and maintain good hygiene.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="interpretation-for-case-study-12-3">Interpretation for Case Study 12-3:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#interpretation-for-case-study-12-3" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The fact that the patient's viral loads were gradually increasing was a sign that the virus was developing resistance to the antiviral drugs. Slight variations of viral quantity within 0.3 log₁₀ units are considered normal. This patient, however, was seeing significant increases in viral replication over the last 6 months.</p>
<p>This patient's virus has a mutation in the reverse transcriptase gene that has made the virus resistant to AZT. The patient's drug treatment needs to be changed immediately, with AZT being replaced by another reverse transcriptase inhibitor that would be unaffected by this mutation, such as didanosine or lamivudine. Viral load measurements should be taken regularly to make sure that the change in drug therapy causes a decrease in the viral load over the next few months. Genotyping should be performed again if the viral load starts to trend up.</p>
<ol>
<li>Which of the following genes would be analyzed to determine whether an isolate of Staphylococcus aureus is resistant to oxacillin?</li>
</ol>
<p>a. mecA</p>
<ol start="2">
<li>Which of the following is a genotypic method used to compare two isolates in an epidemiological investigation?</li>
</ol>
<p>c. Ribotyping</p>
<ol start="3">
<li>For which of the following organisms does caution need to be exercised when evaluating positive PCR results because the organism can be found as normal flora in some patient populations?</li>
</ol>
<p>b. Streptococcus pneumoniae</p>
<ol start="4">
<li>Which of the following controls are critical for ensuring that amplification is occurring in a patient sample</li>
</ol>
<p>Copyright ©2007 by F. A. Davis.
Study Question Answers Appendix 437</p>
<p>and that the lack of PCR product is not due to the presence of inhibitors?</p>
<p>d. Amplification control</p>
<ol start="5">
<li>A PCR assay performed to detect Bordetella pertussis on sputum obtained from a 14-year-old girl who has had a chronic cough had two bands, one consistent with the internal control and the other consistent with the size expected for amplification of the B. pertussis target. How should these results be interpreted?</li>
</ol>
<p>b. The girl has clinically-significant B. pertussis infection</p>
<ol start="6">
<li>Which of the following is a disadvantage of molecular-based testing?</li>
</ol>
<p>a. Results stay positive longer after treatment than do cultures</p>
<ol start="7">
<li>A molecular-based typing method that has high typing capacity, reproducibility, and discriminatory power, moderate ease of performance, and good to moderate ease of interpretation is:</li>
</ol>
<p>c. PCR-RFLP</p>
<ol start="8">
<li>A patient has antibodies against HCV and a viral load of 100,000 copies/mL. What is the next test that should be performed on this patient's isolate?</li>
</ol>
<p>d. Inno-LiPA HCV genotyping</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="chapter-13">CHAPTER 13<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-13" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Which of the following is not a triplet repeat expansion disorder?</li>
</ol>
<p>c. Factor V Leiden</p>
<ol start="2">
<li>A gene was mapped to region 3, band 1, sub-band 1 of the long arm of chromosome 2. How would you express this location from an idiogram?</li>
</ol>
<p>2q31.1</p>
<ol start="3">
<li>Which of the following can be detected by PCR?</li>
</ol>
<p>c. Mitochondrial point mutations</p>
<ol start="4">
<li>A patient was tested for Huntington's disease. PCR followed by PAGE revealed 25 CAG units.</li>
</ol>
<p>c. This patient is normal at the Huntingtin locus.</p>
<ol start="5">
<li>The factor V Leiden mutation can be detected by:</li>
</ol>
<p>d. All of the above methods</p>
<ol start="6">
<li>The most frequently occurring mutation in the HFE gene results in the replacement of cysteine (C) with tyrosine (Y) at position 282. How is this expressed according to the recommended nomenclature?</li>
</ol>
<p>C282Y</p>
<ol start="7">
<li>MELAS is a disease condition that results from an A to G mutation at position 3243 of the mitochondrial genome. This change creates a single ApaI restriction site in a PCR product, including the mutation site. What would you expect from a PCR-RFLP analysis for this mutation on a patient with MELAS?</li>
</ol>
<p>b. A single PCR product that cuts into two fragments upon digestion with ApaI</p>
<ol start="8">
<li>A father affected with a single gene disorder and an unaffected mother have four children (three boys and a girl), two of whom (one boy and the girl) are affected. Draw the pedigree diagram for this family.</li>
</ol>
<p><img src="assets/images/image-20251222-980e2ee7.jpeg" alt="img-429.jpeg"></p>
<p>D16S539, an STR, was analyzed in the family. The results showed that the father had the 6,8 alleles, and the mother had the 5,7 alleles. The affected children had the 5,6 and 6,7 alleles, and the unaffected children had the 5,8 and 7,8 alleles.</p>
<p>a. If D16S539 is located on chromosome 16, where is the gene for this disorder likely to be located?</p>
<p>Chromosome 16</p>
<p>b. To which allele of D16S539 is the gene linked?</p>
<p>The 6 allele</p>
<p>How might a DNA analysis be performed for the presence of the disorder?</p>
<p>a. Analyze D16S539 for the 6 allele by PCR.</p>
<ol start="9">
<li>Exon 4 of the HFE gene from a patient suspected to have hereditary hemachromatosis was amplified by</li>
</ol>
<p>Copyright ©2007 by F. A. Davis.
Appendix Study Question Answers</p>
<p>PCR. The G to A mutation, frequently found in hemachromatosis, creates an <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>R</mi><mi>s</mi><mi>a</mi><mn>1</mn></mrow><annotation encoding="application/x-tex">Rsa1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.00773em;">R</span><span class="mord mathnormal">s</span><span class="mord mathnormal">a</span><span class="mord">1</span></span></span></span></span> site in exon 4. When the PCR products are digested with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>R</mi><mi>s</mi><mi>a</mi><mn>1</mn></mrow><annotation encoding="application/x-tex">Rsa1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.00773em;">R</span><span class="mord mathnormal">s</span><span class="mord mathnormal">a</span><span class="mord">1</span></span></span></span></span>, which of the following results would you expect to see if the patient has the mutation?</p>
<p>c. The patient's PCR product will yield extra bands upon <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>R</mi><mi>s</mi><mi>a</mi><mn>1</mn></mrow><annotation encoding="application/x-tex">Rsa1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.00773em;">R</span><span class="mord mathnormal">s</span><span class="mord mathnormal">a</span><span class="mord">1</span></span></span></span></span> digestion.</p>
<ol start="10">
<li>Most people with the C282Y or H63D HFE gene mutations develop hemachromatosis symptoms. This is because of:</li>
</ol>
<p>c. High penetrance</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-14">CHAPTER 14<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-14" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>What are the two important checkpoints in the cell division cycle that are crossed when the regulation of the cell division cycle is affected?</li>
</ol>
<p>G1 to S and G2 to M</p>
<ol start="2">
<li>An EWS-FLI-1 mutation was detected in a solid tumor by RT-PCR. Which of the following does this result support?</li>
</ol>
<p>b. Ewing's sarcoma</p>
<ol start="3">
<li>Mutation detection, even by sequencing, is not definitive with a negative result. Why?</li>
</ol>
<p>Mutations may exist outside the sequenced area.</p>
<ol start="4">
<li>A PCR test for the bcl-2 translocation is performed on a patient with suspected follicular lymphoma. The results show a bright band at about 300 bp for this patient. How would you interpret these results?</li>
</ol>
<p>If 300 bp is within the expected size limits for translocation breakpoints, the patient is positive for the t(14;18) or bcl-2 translocation.</p>
<ol start="5">
<li>Which of the following misinterpretations would result from PCR contamination?</li>
</ol>
<p>a. False positive for the t(15;17) translocation</p>
<ol start="6">
<li>After amplification of the t(12;21) breakpoint by RT-PCR, the PCR products along with the proper molecular weight standard were loaded and resolved on an agarose gel. What might be the explanation for each</li>
</ol>
<p>of the following observations when the gel is exposed to UV light? (Assume that positive and amplification controls and a reagent blank control are included in the run.)</p>
<p>a. The gel is blank (no bands, no molecular weight standard).</p>
<p>Ethidium bromide or Sybr green staining was omitted.</p>
<p>b. Only the molecular weight standard is visible.</p>
<p>Reverse transcriptase or PCR reaction did not work.</p>
<p>c. The molecular weight standard is visible. There are bands in every lane at 200 bp, even in the reagent blank lane.</p>
<p>PCR contamination is present.</p>
<ol start="7">
<li>What is observed on a Southern blot for gene rearrangement in the case of a positive result?</li>
</ol>
<p>b. Germline bands plus rearranged bands</p>
<ol start="8">
<li>Cyclin D1 promotes passage of cells through the G1 to S checkpoint. What test detects translocation of this gene to chromosome 14?</li>
</ol>
<p>c. t(11;14) translocation analysis (BCL1/IGH)</p>
<ol start="9">
<li>Why is the Southern blot procedure superior to the PCR procedure for detecting clonality in some cases?</li>
</ol>
<p>b. The PCR procedure cannot detect certain gene rearrangements that are detectable by Southern blot.</p>
<ol start="10">
<li>Interpret the following results from a translocation assay.</li>
</ol>
<p>Are the samples positive, negative, or indeterminate?</p>
<p>Sample 1: Negative</p>
<p>Sample 2: Indeterminate, did not amplify</p>
<p>Sample 3: Positive</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-15">CHAPTER 15<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-15" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="interpretation-for-case-study-15-1">Interpretation for Case Study 15-1:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#interpretation-for-case-study-15-1" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>This patient most likely has celiac disease. Although the presence of these alleles cannot always be diagnostic of the disease, their absence excludes celiac disease as a likely diagnosis. The heterozygous DQB1 locus is associated with less severe symptoms than if the *0201 allele</p>
<p>Copyright ©2007 by F. A. Davis.
Study Question Answers Appendix
439</p>
<p>is homozygous. A more comprehensive test list would include detection of total IgA antibodies, autoantibodies, reticulin and transglutaminase, and gliadin IgG and IgA antibodies. The SBT test was useful in this case because the serological results were not clear.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="interpretation-for-case-study-15-2">Interpretation for Case Study 15-2:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#interpretation-for-case-study-15-2" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Donor 3 was selected as compatible, with two mismatches, one at HLA-A and one at HLA-B. These mismatches are in the graft-versus-host direction; that is, the graft would recognize the host as foreign more effectively than the host immune system will recognize the graft. After the transplant, the patient remained in a state of split chimerism for a year. At that time, 71% of monocytes, 62% of granulocytes, and 99% of lymphocytes were donor-derived. Throughout this time, the tumor gene rearrangement was not detectable by PCR, and the patient remained in remission more than a year post transplant.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="interpretation-for-case-study-15-3">Interpretation for Case Study 15-3:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#interpretation-for-case-study-15-3" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The alleles detected by SSP-PCR are identified using a worksheet that converts the lane numbers to allele specificity. Using this worksheet, primers in lanes 7 and 19 amplify the A<em>2419, and those in lane 22 amplify the A</em>3401 allele. The donor organ is a good match for this recipient. Mother and daughter are expected to match at least half of the HLA alleles. The presence of serum antigens was determined to predict the risk of rejection. Although antihuman antibodies were detected using flow cytometry and bead array technology, crossmatching results indicated that the antibodies were a consequence of the lupus and were not directed at the donor antigens. Even though the patient has lupus, the risk of rejection is low as established by the antigen and antibody studies. Following the transplant, the recipient will have to take immunosuppressive medication. Follow-up serum antibody tests may be performed to monitor the state of the transplant.</p>
<ol>
<li>
<p>Which of the following is a high-resolution HLA typing result?
c. A*0212</p>
</li>
<li>
<p>Which of the following is a likely haplotype from parents with A25,Cw10,B27/A23,Cw5,B27 and A17, Cw4,B10/A9,Cw7,B12 haplotypes?
a. A25,Cw10, B27</p>
</li>
<li>
<p>Upon microscopic examination, over 90% of cells are translucent after a CDC assay. How are these results scored according to the ASHI rules?
90%–100% viability (unstained cells) is scored as 1 or negative.</p>
</li>
<li>
<p>An HLA-A allele is a CTC to CTT (leu → leu) change at the DNA level. How is this allele written?
b. HLA-A*0201</p>
</li>
<li>
<p>A candidate for kidney transplant has a PRA of 75%. How will this affect eligibility for immediate transplant?
Because this patient has antibodies likely to react to 75% of the population, eligibility will be negatively affected.</p>
</li>
<li>
<p>An SSOP probe recognizes HLA-DRB<em>0301-0304. Another probe recognizes HLA-DRB</em>0301/0304, and a third probe hybridizes to HLA-DRB<em>0301-0303. Test specimen DNA hybridizes to all except the third probe in a reverse dot blot format. What is the HLA-DRB type of the specimen?
The HLA type is HLA-DRB</em>0304</p>
</li>
<li>
<p>What is the relationship between alleles HLA-A10 and HLA-A26(10)?
HLA-A10 is the parent allele of HLA-A26(10)</p>
</li>
<li>
<p>A CDC assay yields an 8 score for sera with the following specificities: A2, A28 and A2, A28, B7, and a 1 score for serum with an A2 specificity. What is the HLA-A type?
The HLA-A type is A28</p>
</li>
<li>
<p>HLA-DRB1<em>1501 differs from DRB1</em>0101 by a G to C base change. If the sequence surrounding the base change is: ...GGGTGCGGTTGCTGGAAA GAT... (DRB1<em>0101) or ...GGGTGCGGTTCCTG GAAAGAT... (DRB1</em>1501), which of the following would be the 3' end of a sequence-specific primer for detection of DRB1*1501?
d. ...ATCTTTCCAGG</p>
</li>
<li>
<p>The results of an SSP-PCR reaction are the following: lane 1, one band; lane 2, two bands, lane 3 no bands. If the test includes an amplification control</p>
</li>
</ol>
<p>Copyright ©2007 by F. A. Davis.
Appendix Study Question Answers</p>
<p>multiplexed with the allele-specific primers, what is the interpretation for each lane?</p>
<p>The test specimen does not contain the allele recognized by the primers in lane 1. Only the amplification control is visible.</p>
<p>The test specimen contains the allele recognized by the primers in lane 2. Both the amplification control and the allele-specific product are visible. The PCR reaction did not work for the reaction run in lane 3.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="chapter-16">CHAPTER 16<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-16" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>What actions should be taken in the following situations?</p>
<ol>
<li>
<p>An unlabeled collection tube with a requisition for a factor V Leiden test is received in the laboratory.
Notify the supervisor and reject the specimen.</p>
</li>
<li>
<p>After PCR, the amplification control has failed to yield a product.
Check the original DNA or RNA preparation.
If it is adequate, repeat the amplification. If not, reisolate the nucleic acid.</p>
</li>
<li>
<p>An isolated DNA sample is to be stored for at least 6 months.
Store at -70°C in a tightly sealed tube.</p>
</li>
<li>
<p>A bone marrow specimen arrives at the end of a shift and will not be processed for the Bcl2 translocation until the next day.
Place the specimen in the refrigerator.</p>
</li>
<li>
<p>The temperature of a refrigerator set at 8°C (±2°C) reads 14°C.
Recheck the temperature after a few hours. If it does not return to range, notify the supervisor.</p>
</li>
<li>
<p>A PCR test for the BCR/ABL translocation was negative for the patient sample and for the sensitivity control.
Repeat the PCR with the addition of a new sensitivity control.</p>
</li>
<li>
<p>A fragile X test result has been properly reviewed and reported.
File the test results, documents, and associated autoradiographs together in the laboratory archives.</p>
</li>
<li>
<p>A bottle of reagent alcohol with a 3 in the red diamond on its label is to be stored.
Place the alcohol bottle in a safety storage cabinet for flammable liquids.</p>
</li>
<li>
<p>The expiration date on a reagent has passed.
Discard the reagent. If it can be used for research or other nonclinical purposes, label and store it in a separate area away from patient testing reagents.</p>
</li>
<li>
<p>Test results are to be faxed to the ordering physician.
Fax the results with a cover sheet containing the proper disclaimer.</p>
</li>
</ol>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Index</p>
<p>Numbers followed by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>b</mi></mrow><annotation encoding="application/x-tex">b</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord mathnormal">b</span></span></span></span></span> represent boxes, numbers followed by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>f</mi></mrow><annotation encoding="application/x-tex">f</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.10764em;">f</span></span></span></span></span> represent figures, and numbers followed by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>t</mi></mrow><annotation encoding="application/x-tex">t</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6151em;"></span><span class="mord mathnormal">t</span></span></span></span></span> represent tables.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="a">A<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A site
ribosomal, 58–59, 60f</p>
<p>ABO blood group
in human identification, 229–230</p>
<p>Absorptivity constants
in spectrophotometry, 76</p>
<p>AccuProbe
in chlamydial detection, 277
in fungi detection, 299–300
in mycobacterial detection, 272
in <em>Neisseria gonorrhoeae</em> detection, 277</p>
<p>ACGT sequencing
in DNA structure, 2–4, 7, 7f</p>
<p>Acrocentric chromosomes
morphology of, 159, 159f</p>
<p>Acrylamide
in polyacrylamide structure, 84, 84b, 84f</p>
<p>Acute lymphoblastic leukemia
translocation in, 358f–361f, 358–361, 361b</p>
<p>Acyclovir
as modified nucleoside, 6, 6f</p>
<p>Adaptors
in restriction enzyme function, 14b</p>
<p>Additives
in electrophoresis buffer systems, 88, 88f</p>
<p>Adenine
as DNA nitrogen base, 2–3, 3f</p>
<p>Adenosine monophosphate
defined, 3</p>
<p>Adenosine triphosphate
defined, 3</p>
<p>Adler
on DNA polymerization, 9b</p>
<p>Affinity maturation, 350b</p>
<p>Affymetrix
in microarray technology, 115, 115f</p>
<p>Agarose gel
in electrophoresis, 75, 76f, 81–84
DNA resolution with, 82, 82f
gel concentrations in, 82, 82t
polyacrylamide gel versus, 85
pulsed field, 82–84, 83b, 83f
technique for, 88–89, 89b
physical properties of, 81, 81f
laboratory modifications of, 82b
in polymerase chain reaction, 131, 131f</p>
<p>Alanine
structure of, 50f
transfer RNA of, 35f</p>
<p>Alcohol
in DNA isolation, 68, 68b</p>
<p>Alkaline lysis
in solid-phase DNA isolation, 70b</p>
<p>Alkaline phosphatase
in hybridization technologies, 110, 110f–111f, 112t</p>
<p>Alleles
defined, 228</p>
<p>Allele-specific oligomer hybridization
in gene mutation detection, 179f, 179–180</p>
<p>Allelic discrimination with fluorogenic probes
in gene mutation detection, 185–186, 187f</p>
<p>Allelic exclusion
defined, 348</p>
<p>Allelic frequencies
in paternity testing, 238–240, 239b–240b, 239f, 239t–240t</p>
<p>Allelic ladders
defined, 232</p>
<p>Alloantibodies
in transplant screening, 386</p>
<p>Allogenic bone marrow transplantation
defined, 245</p>
<p>Alpha helices
in amino acid structure, 52–53, 54f</p>
<p>Alpha phosphate
in RNA synthesis, 29</p>
<p>Alpha satellite
in chromosomal function, 159, 159f</p>
<p>Altered processivity
in clinical polymerase applications, 12</p>
<p>Alternate splicing
Northern blot in analysis of, 101</p>
<p>Alternative RNA splicing
overview of, 33</p>
<p>Alu elements
in short interspersed nucleotide sequences, 226</p>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span>-Amanitin
in RNA polymerases, 37b</p>
<p>Ambiguity
in HLA nomenclature, 383</p>
<p>Amelogenin locus
in gender identification, 234–235, 235f</p>
<p>American Society for Histocompatibility and Immunogenetics
cytotoxicity guidelines of, 386t</p>
<p>Amino acids
classification of, 49, 49t, 51t
in gene mutation nomenclature, 194
structure of, 49, 50f–52f
quaternary, 54</p>
<p>secondary, 52–53, 53b, 54f
tertiary, 53–54</p>
<p>synthesis of, 49
transfer RNA in charging of, 57</p>
<p>Amino terminal
in amino acid structure, 51</p>
<p>Aminoacyl transfer RNA synthetases
in amino acid charging, 57, 58f</p>
<p>Amplicons
in polymerase chain reaction, 122, 126f
in dideoxy DNA sequencing, 208b</p>
<p>Amplicor MTD test
in mycobacterial detection, 272</p>
<p>Amplicor reverse transcriptase-polymerase chain reaction
in HIV viral load detection, 296, 296t</p>
<p>Amplification
nucleic acid, 121–149. See also specific techniques
probe, 144f–147f, 144–147
signal, 147f–149f, 147–149
target, 122–144. See also Polymerase chain reaction
transcription-based, 142–144, 143f
in polymerase chain reaction, 122–123
artifacts in, 237b</p>
<p>Amplification controls
in polymerase chain reaction, 132
in quality assurance procedures, 267, 412</p>
<p>Amplified fragment length polymorphism assay
in molecular epidemiology, 287, 288f–289f</p>
<p>Analyte-specific reagents
quality assurance in, 418</p>
<p>Ancestral haplotype
in single nucleotide polymorphisms, 253</p>
<p>Anderson sequence
of mitochondrial genome, 254</p>
<p>Aneuploidy
defined, 157, 334
detection in karyotyping of, 161–162, 162f–163f
incidence of, 311</p>
<p>Angelman’s syndrome, 325–326</p>
<p>Ankylosing spondylitis
HLA association in, 395</p>
<p>Annealing
in polymerase chain reaction, 123–124, 125f–126f</p>
<p>Antibiotics
peptide, 52b</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Index</p>
<p>Antibody diversity
gene rearrangement and, 350b</p>
<p>Anticodon
of transfer RNA, 35, 35f
in protein synthesis, 58b</p>
<p>Anti-human antibodies
in transplant screening, 386</p>
<p>Antimicrobial agents, 280–284
classification of, 280, 280t
overview of, 280b
resistance to, 280–282, 281t–282t, 282f
molecular detection of, 282–284, 283b
sites of action of, 280, 281f</p>
<p>Antiparallel orientation
of nucleotide sequences, 7, 7f</p>
<p>Antiretroviral agents
as modified nucleosides, 6, 6f
viral load and, 295–296</p>
<p>Antisense strand
in RNA polymerization, 28–29, 29f</p>
<p>Antiviral agents
as modified nucleosides, 6, 6f</p>
<p>Apoptosis
in chromosomal structure, 158, 159f
defined, 158, 333
oncogenes and, 333
tumor suppressor genes and, 334</p>
<p>Arbitrarily primed polymerase chain reaction
in molecular epidemiology, 286–287, 287f</p>
<p>Arg operon
function of, 40, 41f</p>
<p>Arginine
structure of, 50f</p>
<p>Array-based hybridization
dot/slot blot techniques in, 112–113, 113f
in gene mutation detection, 183–185, 184f
genomic array technology in, 113–117
macroarrays in, 113–114
microarrays in, 114b, 114f–116f, 114–117
limitations of, 116–117</p>
<p>Artifacts
in polymerase chain reaction, 237b</p>
<p>Asexual reproduction
recombination in, 18–22, 19f–22f, 20b, 22b</p>
<p>Aspergillus
DNA metabolizing enzyme from, 15</p>
<p>Asparagine
structure of, 50f</p>
<p>Aspartic acid
structure of, 50f</p>
<p>Ataxia telangiectasia mutated gene, 342</p>
<p>Attenuation
in transcription regulation, 40</p>
<p>Autoimmune diseases
MHC associations in, 394–395</p>
<p>Autologous bone marrow transplantation
defined, 245</p>
<p>Automated cell sorters
in T-cell separation, 249b</p>
<p>Automated fluorescent DNA sequencing approaches to, 210–212, 211f
dyes used in, 210, 210b, 210f
electrophoresis and interpretation of, 212b, 212–213, 213f–215
overview of, 210
sequencing ladder preparation in, 212
software applications in, 213, 215t–216t</p>
<p>Automatic pipettors
maintenance of, 414–415</p>
<p>Autophagy
defined, 315</p>
<p>Autosomal-dominant mutation transmission, 313, 313b, 314f</p>
<p>Autosomal-recessive mutation transmission, 313, 314f</p>
<p>Avery
on transformation, 21, 22f</p>
<p>Avian myelocytomatosis viral oncogene homolog, 343, 363</p>
<p>Azidothymidine
as modified nucleoside, 6, 6f</p>
<p>B</p>
<p>B cells
clonality detection in, 353
gene rearrangement in, 347–349, 348b</p>
<p>Bacteria. See also specific bacteria
drug-resistant. See Drug resistant bacteria recombination in, 18–22
conjugation and, 19f–20f, 19–20, 20b
transformation and, 21–22, 22b, 22f
restriction modification in, 5b
simultaneous transcription and translation in, 61</p>
<p>Bacterial targets, 268–280
molecular detection of, 269–270, 270f
respiratory tract pathogens as, 270–276, 271t
sequence selection in, 268–269, 269f
tests approved for, 269t
urogenital tract pathogens as, 276–280, 277t</p>
<p>Bacteriocins
colicinogenic factors and, 23</p>
<p>Bacteriophages
in transduction, 21, 21f</p>
<p>Balanced polymorphism
sickle cell anemia as, 156</p>
<p>Balanced translocations
detection in karyotyping of, 162–163, 164f</p>
<p>Baltimore
in Human Genome Project, 219</p>
<p>Band compression
in DNA sequencing, 212b</p>
<p>Banding patterns
clonality detected by, 355</p>
<p>Base excision sequence scanning
in gene mutation detection, 190–191, 191f</p>
<p>Base pairing
chromosome size and, 156t
in DNA alternatives, 4b
in DNA structure, 4, 4b</p>
<p>Basic Local Alignment Search Tool
in Human Genome Project, 220</p>
<p>Basic zipper
in amino acid structure, 53b</p>
<p>B-cell leukemia and lymphoma
translocation in, 356f–358f, 356–358</p>
<p>BCR gene
in leukemia, 358f–359f, 358–361, 361b</p>
<p>Bead arrays
in gene mutation detection, 184–185, 186f
in transplant screening, 386, 387f</p>
<p>Beer-Lambert law
in spectrophotometry, 76</p>
<p>Benign polymorphisms
clinical uses of, 311</p>
<p>Benzer
genetic mutations studied by, 54</p>
<p>Bessman
on DNA polymerization, 9b</p>
<p>Beta-pleated sheets
in amino acid structure, 52–53, 54f</p>
<p>Bidirectional dideoxy DNA fingerprinting
in gene mutation detection, 188</p>
<p>Bilateral symmetry
of restriction enzymes, 13</p>
<p>Binding sites
DNA defined, 7b</p>
<p>Bins and binning
in genotyping, 237, 237b</p>
<p>Bioinformatics
DNA sequencing terminology in, 218t
mixed base nomenclature in, 219, 219t
overview of, 218</p>
<p>Biotin labeling
in hybridization techniques, 106, 109–110, 110f</p>
<p>Bisulfite DNA sequencing, 216–218, 218f</p>
<p>BK virus
detection of, 295t</p>
<p>Bleach
in polymerase chain reaction, 132</p>
<p>Blot techniques
in hybridization. See also specific techniques
array-based, 112–113, 113f
Northern, 101–102, 102b</p>
<p>Copyright ©2007 by F. A. Davis.
Index 443</p>
<p>Southern, 96–101
Western, 102, 102b
Blunt ends
in restriction enzyme function, 13–14, 14b
Bone marrow transplantation
DNA polymorphisms in testing for, 245f–248f, 245–249, 246b–249b
DNA typing in monitoring of, 246–249
lack of pre-engraftment information in, 248b
types of, 245
Bordetella pertussis
detection of, 271t, 272–274
Botstein
in Human Genome Project, 219
Bover
on transplant rejection, 377
Bovine serum albumin
in polymerase chain reaction, 130
BOX elements
defined, 288
Branched DNA amplification, 147f, 147–148
in hepatitis C virus detection, 298
in HIV detection, 296, 296t
BRCA1 gene
detection of, 342
mapping of, 229b
mutations in, 175, 179, 342
BRCA2 gene
detection of, 342
mutations in, 175, 179, 342
Break-apart probes
in FISH chromosome analysis, 167, 167f
Breast cancer
gene mutations in, 175, 179, 229b, 335f, 335–336, 342
Brenner
paternity index formula of, 240b
Bromophenol blue
in electrophoresis, 90, 91t
5-Bromouridine
as modified nucleoside, 6
Brown
arrayer described by, 114b
Buffers
in electrophoresis, 86–88, 87b, 88f
in hybridization techniques, 108
in polymerase chain reaction, 129–130
Burkitt’s lymphoma
translocation in, 363, 363b, 363f
bZip
in amino acid structure, 53b</p>
<p>C banding
in chromosome visualization, 160, 160f
c-abl gene
in leukemia, 358f–359f, 358–361, 361b
Caenorhabditis elegans
RNA in, 34b, 35, 44
Calibrations
verification of, 416–417
Cambridge Reference Sequence
of mitochondrial genome, 254
Cameras
maintenance of, 415, 416f
Cancer. See also Molecular oncology; specific types of cancer
classification of, 333
molecular basis of, 333–334, 334f
Capillary electrophoresis, 85–86, 86f
Capillary transfer
in Southern blot, 100, 100b, 100f
Capping
in messenger RNA processing, 32, 32b
Carbon
as DNA component, 2
Carboxy terminal
in amino acid structure, 51
Carcinomas
as epithelial tumors, 333
CCND1 gene
in lymphoma and leukemia, 362
Celera
in Human Genome Project, 220f, 220–221
Cell division cycle
oncogenes and, 333
schematic of, 334f
tumor suppressor genes and, 333–334
Cell lysis
in nucleic acid extraction, 66
Cellulose
in hybridization techniques, 99, 99b
Centers for Disease and Prevention
standard precautions recommended by, 265b, 406
Centrifugation
in DNA isolation, 68
Centrifuges
maintenance of, 414, 415f
Centromeres
in chromosomal structure, 157, 159, 159f, 160t
staining of, 160, 160f
Centromeric probes
in FISH chromosome analysis, 167, 169f
Cephalosporins
history of, 280b
CFTR gene
mutations in, 175
Chain reaction
ligase, 144, 144f
polymerase, 122–144. See also Polymerase chain reaction
Chandroid, 279
Chaperones
molecular
in protein synthesis, 60, 61f
RNA, 38b
Chargaff
DNA observations of, 8b
Chase
on transformation, 22
Chelex
in DNA isolation, 71
Chemical cleavage of mismatches
in gene mutation detection, 192–193
Chemical safety, 418f–420f, 418–419, 419t
Chemical sequencing
DNA, 204f–205f, 204–205, 205b, 205t
Chemiluminescent detection systems
in hybridization technologies, 110, 111f, 112t
Chimera
defined, 246
Chimerism
full, 246
mixed, 246, 249
mosaicism versus, 246b, 311
split, 247b
Chip
in microarrays, 114–115, 115f
Chlamydia trachomatis
detection of, 276–278, 277t
high-volume, 264
strand displacement amplification in, 145
transcription-based amplification in, 144
Chlamydophila pneumoniae
detection of, 271t, 274
Chelating resin
in DNA isolation, 71
Chloroform
in nucleic acid isolation, 68, 73
Chromatin
in transcription regulation, 42
Chromogenic detection systems
in hybridization technologies, 110b, 110–111, 112t
Chromogenic in situ hybridization
in breast cancer, 336
Chromosomal mutations, 161–170
abbreviations used in, 165t
defined, 156
detection of
fluorescence in site hybridization in, 166f–170f, 166–169
karyotyping in, 161–163, 162f–165f, 165, 165t</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Index</p>
<p>Chromosomal mutations (Continued)
diseases associated with, 364t, 365
leukemia and lymphoma as, 364t
gene mutations versus, 156–157
overview and examples of, 312, 313t
in solid tumors, 339t, 339–341, 340f
structure-altering, 163, 165, 165f</p>
<p>Chromosomal painting
in fluorescence in situ hybridization, 168, 168f</p>
<p>Chromosomal translocations. See
Translocations</p>
<p>Chromosome spread
in karyotyping, 162</p>
<p>Chromosomes, 155–170
analysis of, 159–161, 160f–161f, 161b
classification by size and centromeres of, 160t
in Human Genome Project, 221, 221t
mutations of, 156, 161–170. See also
Chromosomal mutations
overview of, 156t, 156–157
size of human, 156t
structure of, 155–159, 157b–159b, 158f–159f, 160t
interspecies differences in, 22
morphologic types in, 159, 159b, 159f, 160t</p>
<p>Chronic myelogenous leukemia
translocation in, 358f–361f, 358–361, 361b</p>
<p>Cirrhosis
from hepatitis C, 298</p>
<p>Cis factors
in RNA synthesis, 39f, 39–40</p>
<p>Citrate dextrose
in specimen collection tubes, 405, 406t</p>
<p>Class-switch recombination, 348b</p>
<p>Cleavage
in gene mutation detection, 189–193, 190f–193f</p>
<p>Cleavage-based amplification, 148–149</p>
<p>Cleavase
in Invader assay, 191, 193f</p>
<p>Clinical Laboratory Improvement
Amendments
quality assurance and, 404</p>
<p>Clonality detection
in gene rearrangements, 356f–363f, 356–365, 361b–363b, 364t</p>
<p>c-myc gene
in Burkitt’s lymphoma, 363</p>
<p>coa typing
in molecular epidemiology, 289</p>
<p>Cobas Amplicor
in chlamydial detection, 277
in Neisseria gonorrhoeae detection, 278</p>
<p>Coccidioides
as laboratory hazard, 264</p>
<p>CODIS loci, 235b</p>
<p>Codons
in genetic code, 56, 56f</p>
<p>Colicinogenic factors
bacteriocin resistance of, 23</p>
<p>College of American Pathologists
specimen storage recommendations of, 407, 408t</p>
<p>Collins
in Human Genome Project, 220</p>
<p>Combinatorial control
in eukaryotic genes, 42b</p>
<p>Combined sibling index, 241</p>
<p>Combs
in electrophoresis, 89–90, 90f</p>
<p>Comparative genome hybridization, 116, 116f
in chromosome analysis, 169, 169f–170f</p>
<p>Complementarity determining regions
in immunoglobulin heavy chain gene rearrangement, 352</p>
<p>Complementary DNA
of messenger RNA
reverse transcription in, 31b
in reverse transcriptase polymerase chain reaction, 135</p>
<p>Complementary nucleotides
in DNA structure, 4, 7, 7f</p>
<p>Complement-dependent cytotoxicity
in HLA testing, 385f, 385–387, 386t, 387f</p>
<p>Complete penetrance
defined, 314</p>
<p>Computational biology
bioinformatics as, 218</p>
<p>Concatamers
defined, 16</p>
<p>Condensin complex
in chromosomal function, 158b</p>
<p>Conditioning
in bone marrow transplantation, 245</p>
<p>Confidentiality
of molecular test results, 421, 423</p>
<p>Conformation-sensitive gel electrophoresis
in gene mutation detection, 183</p>
<p>Conformer
in single-strand conformation polymorphism, 175–176, 177f</p>
<p>Congenital central hypoventilation syndrome
Hirschsprung’s disease, 324, 343</p>
<p>Congenital diseases
inherited diseases versus, 311</p>
<p>Conjugated proteins
defined, 54</p>
<p>Conjugation
in DNA recombination, 19f–20f, 19–20, 20b</p>
<p>Consensus primer
in immunoglobulin heavy chain gene rearrangement, 353</p>
<p>Conservative gene mutations, 174, 174t</p>
<p>Constant gradient gel electrophoresis, 178–179</p>
<p>Constitutive transcription
of messenger RNA, 31</p>
<p>Contact precautions
for specimen handling, 265b, 406</p>
<p>Contamination control
in polymerase chain reaction, 131–133, 133b
in quality assurance, 267</p>
<p>Continuous allele system
restriction fragment length polymorphism as, 230</p>
<p>Contour-clamped homogeneous electric field electrophoresis, 83, 83f</p>
<p>Controls
in quality assurance procedures, 266–268, 412</p>
<p>Corepressor
in transcription regulation, 40</p>
<p>Corey and Pauling
protein structure described by, 52, 54f</p>
<p>Coronavirus
detection of, 294t</p>
<p>CpG islands
DNA, 43, 43f</p>
<p>Crick
on DNA double helix, 2–3, 4b, 8b
as genetic code breaker, 55–56</p>
<p>Cross-hybridization
in hybridization technologies, 109b</p>
<p>Crossing over
recombination and, 18, 18f</p>
<p>Crossmatching
HLA typing, 385, 385f, 387, 387b, 387f</p>
<p>Cross-reactive epitope groups
in HLA typing, 386</p>
<p>Cruciform structure
of transfer RNA, 35, 35f</p>
<p>Crude lysis
in DNA isolation, 71, 71f</p>
<p>Culture
in chlamydial detection, 276–277
of Neisseria gonorrhoeae, 276–277</p>
<p>Cut-off values
in quality assurance procedures, 413</p>
<p>Cyanine dye
in comparative genome hybridization, 169</p>
<p>Copyright ©2007 by F. A. Davis.
Index 445</p>
<p>Cycle sequencing
in dideoxy DNA sequencing, 210</p>
<p>Cycles
in polymerase chain reaction, 123, 125t</p>
<p>Cycling probe amplification, 149, 149f</p>
<p>Cysteine
structure of, 50f</p>
<p>Cystic fibrosis
gene mutations in, 175, 318–319</p>
<p>Cytochrome P-450
variants of, 319</p>
<p>Cytomegalovirus
detection of, 293t</p>
<p>Cytosine
as DNA nitrogen base, 2–3, 3f</p>
<p>Cytosine arabinoside
as modified nucleoside, 6</p>
<p>Cytosine methyltransferases
in DNA metabolism, 16b</p>
<p>Cytotoxicity
complement-dependent
in HLA testing, 385f, 385–387, 386t, 387f</p>
<p>D</p>
<p>D loop
in transfer RNA structure, 35, 35f</p>
<p>DAPI staining
in chromosome visualization, 161</p>
<p>DEAD-box helicases
RNA, 38b</p>
<p>Deaeration
in polyacrylamide gel electrophoresis, 85</p>
<p>Deaza guanosine triphosphate
in dideoxy DNA sequencing, 208b
in polymerase chain reaction, 128b, 129</p>
<p>Deletion
chromosomal
FISH in detection of, 166, 166f
karyotyping in detection of, 163, 165f</p>
<p>DeLici
in Human Genome Project, 219</p>
<p>Denaturation
in FISH chromosome analysis, 168
in Northern blot, 101, 101b
in polymerase chain reaction, 123, 125f–126f
in Southern blot, 98</p>
<p>Denaturing agents
action on DNA of, 7b
in electrophoresis buffer systems, 88</p>
<p>Denaturing gradient gel electrophoresis
constant gradient gel electrophoresis versus, 178–179
in gene mutation detection, 177–179, 178b, 178f</p>
<p>genomic, 178
single-strand conformation polymorphism versus, 178b
temporal temperature gradient versus, 178–179</p>
<p>Denaturing high-performance liquid chromatography
in gene mutation detection, 183</p>
<p>Dengue virus
RNA polymerases in, 37</p>
<p>Deoxyadenosine monophosphate
structure of, 5f</p>
<p>Deoxycytidine monophosphate
structure of, 5f</p>
<p>Deoxyguanosine monophosphate
structure of, 4f–5f</p>
<p>Deoxyinosine triphosphate
in dideoxy DNA sequencing, 208b</p>
<p>Deoxynucleoside
structure of, 6f</p>
<p>Deoxynucleotide
in dideoxy DNA sequencing, 206–210, 207f–208f</p>
<p>Deoxyribonuclease I
in DNA metabolism, 15</p>
<p>Deoxyribonucleic acid. See DNA</p>
<p>Deoxyribonucleotide bases
in polymerase chain reaction, 128b, 128–129</p>
<p>Deoxyribose
in DNA structure, 2–3, 4f</p>
<p>Deoxythymidine monophosphate
structure of, 5f</p>
<p>Deoxyuridine triphosphate-uracil-N-glycosylate
in polymerase chain reaction, 132–133</p>
<p>Depurination
in Southern blot, 97–98, 98f</p>
<p>Derivative chromosomes
karyotyping in detection of, 165, 165f</p>
<p>DExDH-box helicases
RNA, 38b</p>
<p>Dideoxy DNA fingerprinting. See also
Dideoxy DNA sequencing
in gene mutation detection, 186–188, 187f</p>
<p>Dideoxy DNA sequencing, 205–210
cycle sequencing in, 210
dideoxynucleotide and deoxynucleotide in, 206–210, 207f–208f
internal labeling in, 206
M13 bacteriophage in, 205–206, 206b, 206f
manganese in, 208b
PCR products in, 208b
sequencing ladder in, 209, 209f</p>
<p>Dideoxynucleoside
structure of, 6f</p>
<p>Dideoxynucleotide
in dideoxy DNA sequencing, 206–210, 207f–208f</p>
<p>Dideoxynucleotides
in polymerase chain reaction, 123b</p>
<p>Digital cameras
maintenance of, 415, 416f</p>
<p>Digoxygenin labeling
in hybridization techniques, 106, 109–110, 110f</p>
<p>Dihydrouridine
in transfer RNA, 35</p>
<p>Dimer
defined, 54</p>
<p>Dipeptides
defined, 49</p>
<p>Diploid organisms
humans as, 156–157</p>
<p>Discriminatory capacity
in Y-short tandem repeat matching, 242–243</p>
<p>Discriminatory power
in genotype test evaluation, 290</p>
<p>Dispersive DNA replication
historical highlights of, 8b</p>
<p>Dissociation constant
in acid-base buffer equilibrium, 86–87</p>
<p>Dithiothreitol
in polymerase chain reaction, 130</p>
<p>Dmnt1
in DNA methylation, 16b</p>
<p>DNA, 1–24
ACGT sequences in, 2–4, 7, 7f</p>
<p>A-form, 4b
analysis of
electrophoresis in, 75–76, 76f, 81–92. See also Electrophoresis
fluorometry in, 77–78
probes in, 103, 105–107, 106f
restriction enzyme mapping in, 95f–96f, 95–96
Southern blot in, 96–101, 97t, 98f, 99b–100b, 100f–101f
spectrophotometry in, 77</p>
<p>B-form, 4b
in chromosomal structure, 157b–158b, 157–158, 158f–159f
defined, 2</p>
<p>discovery of
history of, 2b, 2–3, 8b</p>
<p>hydrated versus dehydrated forms, 4b</p>
<p>isolation of, 66–72
alcohol use in, 68b
choice of procedure in, 66b
crude lysis in, 71, 71f</p>
<p>Copyright ©2007 by F. A. Davis.
446 Index</p>
<p>DNA (Continued)
inorganic methods in, 68–69, 69f
mitochondrial, 71–72, 72b
organic methods in, 67–68, 68f
precipitation in, 69b
sample preparation in, 66–67, 67t
solid-phase, 69–70, 70b, 70f
storage materials in, 69b
metabolism of
enzymes in, 12b–16b, 12–16, 13f
methylation of, 16b, 43f, 43–44
mitochondrial
isolation of, 71–72, 72b
plasmids of, 22–24, 23b–24b, 23f
recombination in
in asexual reproduction, 18–22, 19f–22f, 20b, 22b
in sexual reproduction, 17b, 17–18, 18f–19f
replication of, 6f, 6–12, 8b–12b, 9f–12f, 10t. See also DNA replication
in RNA polymerization, 28–29, 29f
sequencing in, 2–4, 7, 7b. See also DNA sequencing
specimen storage requirements for, 407, 408t–409t, 409, 409f
storage function of, 2, 28
structure of, 1–3, 3f, 4b, 6–7, 7b
synthesis of
antiparallel orientation in, 7, 7f
Z-form, 4b
DNA IQ system
in solid-phase DNA isolation, 70
DNA ligase
in DNA metabolism, 14
DNA polymerase
in polymerase chain reaction, 129
DNA polymorphisms. See also Mutations; Polymorphisms
in engraftment testing, 245f–248f, 245–249, 246b–249b
human identification and, 225–256. See also specific techniques
mitochondrial, 253–256, 254f, 255b
DNA replication, 6–12
in dideoxy DNA sequencing, 207, 207f
dispersive, 8b
historical highlights in, 8b
polymerases in, 8–12, 9b–12b, 10f–12f, 10t
replication fork in, 8, 9f
semiconservative, 7
DNA resequencing, 222
DNA sequences
association with gene mutations of, 174–175
chromosomal arrangement and, 156
DNA structure and, 2–4, 7, 7b</p>
<p>DNA sequencing, 203–222
automated fluorescent, 210b, 210f–211f, 210–213, 212b, 213f–215f, 215t
bioinformatics and, 218t–219t, 218–219
bisulfite, 216–218, 218f
defined, 204
direct, 204–214
chemical, 204f–205f, 204–205, 205b, 205t
dideoxy, 205–210, 206b, 206f–209f, 208b
indirect versus, 204
Maxam-Gilbert, 204f–205f, 204–205, 205b, 205t
Sanger, 205–210, 206b, 206f–209f, 208b
Human Genome Project and, 219–222, 220f, 220t–221t
overview of, 204
in p53 detection, 341, 341t
pyrosequencing in, 214, 216, 216b, 217f
DNA template. See also DNA sequencing
creation of radioactive, 204b
defined, 204
in polymerase chain reaction, 122, 128
DNA viruses
genomes of, 292t
DNA-based tissue typing, 376–396. See also specific techniques
DNA/RNA hybrid capture assays, 148, 148f
DNase
in RNA isolation, 73
Documentation of test results
quality assurance in, 420–421, 422f, 423
Donor loci
in bone marrow transplantation, 246, 246f
Dot blot techniques
allele-specific oligomer hybridization as, 179, 179f
Dot/slot blot techniques
in array-based hybridization, 112–113, 113f
Double helix
as DNA structure, 2–3, 3f, 4b, 6–8, 7b–8b
Double-strand DNA break
helicase function and, 16
Down’s syndrome
aneuploidy in, 157
Drug resistance
antiretroviral, 297–298, 298b
gene mutations in
antibiotics and, 281–282, 282f, 282t
antiretroviral agents and, 297–298, 298b
plasmids in, 22–23
in tuberculosis, 283
Drug-resistant bacteria, 280–282, 281t–282t, 282f
detection of, 282–284, 283b
cycling probe method in, 149</p>
<p>Dulbecco
in Human Genome Project, 219
Duplications
gene mutation nomenclature for, 194
Dye blobs
in automated fluorescent DNA sequencing, 213
Dye primer method
in automated fluorescent DNA sequencing, 210–211, 211f
Dye terminator method
in automated fluorescent DNA sequencing, 210, 211f, 212
in gene mutation detection, 188, 188f</p>
<p>E
E site
ribosomal, 59
EDTA
in DNA isolation, 67–68, 69b
in electrophoresis, 87
in specimen collection tubes, 405, 406f, 406t
Electroendosmosis
in electrophoresis, 82b
Electropherograms
in automated fluorescent DNA sequencing, 212–213, 213f–215f
in Y-short tandem repeat testing, 242f
Electrophoresis, 80–92
agarose gels in, 81f–83f, 81–84, 82b–83b, 82t
alternating field, 83f, 83–84
in automated fluorescent DNA sequencing, 212–213, 213f–215f
buffer systems in, 86–88, 87b, 88f
bufferless systems in, 90b–91b
capillary, 85–86, 86f
conformation-sensitive gel, 183
constant gradient gel, 178–179
contour-clamped homogeneous electric field, 83, 83f
denaturing gradient gel, 177–179, 178b, 178f
detection systems in, 91–92
equipment in, 88–90, 89b–90b, 89f–90f
maintenance of, 415, 415f
field inversion gel, 83, 83b, 83f
gel loading in, 90–91, 91b, 91t
in HLA testing, 388
in molecular epidemiology, 285f, 285–286, 286t
in nucleic acid analysis, 75f–76f, 75–76
nucleic acid-specific dyes and additives in, 88, 91–92
overview of, 81, 81b, 81f</p>
<p>Copyright ©2007 by F. A. Davis.
Index 447</p>
<p>polyacrylamide gels in, 83t, 84b, 84f, 84–85
in polymerase chain reaction, 131, 134, 134f
pulsed field, 82–84, 83b, 83f
in short tandem repeat genotyping, 232, 233f, 237
silver stain in, 92
in single-strand conformation polymorphism, 175, 177f
in Southern blot, 100, 101f
temporal temperature gradient gel, 178–179
tracking dyes in, 90, 91t
in Western blot, 102
Encephalopathy
prion-induced, 54
End-labeling
of DNA probes, 106
Endonucleases
in DNA metabolism, 12b, 12–13
in restriction enzyme mapping, 84
Endpoint analysis
in quantitative polymerase chain reaction, 137
Engraftment testing
DNA polymorphisms in, 245f–248f, 245–249, 246b–249b
Enhanceosome
in transcription regulation, 42
Enhancers
in gene expression, 42
Enterobacterial repetitive intergenic consensus sequences, 287–288, 289f–290f
Enteroviruses
detection of, 295t
Enzyme adaptation
defined, 39b
Enzyme immunoassay
for human immunodeficiency virus, 295
in Treponema pallidum detection, 278
Enzyme mapping
restriction, 95f–96f, 95–96
Enzymes. See also Polymerases; specific enzymes
in DNA metabolism, 12b–16b, 12–16, 13f
Epidemic
defined, 284
Epidemiology, 284–291
overview of, 284
typing methods in, 284t, 284–291, 285f, 286t, 287f–290f, 290t–291t
Epidermal growth factor receptor
in solid tumors, 336f–337f, 336–337
Epigenetic alterations
types of, 311
Epigenetic regulation
of transcription, 42f–43f, 42–44, 43b</p>
<p>Epitopes
defined, 102
Epstein-Barr virus
association with Burkitt’s lymphoma of, 363b
detection of, 293t
first complete genome sequencing in, 219, 220t
ErbB growth factor receptor family structure of, 336f
Escherichia coli
DNA metabolizing enzymes from, 14–15
in DNA polymerization, 9b, 10, 10t
M13 bacteriophage and, 205, 206f
in polymerase chain reaction discovery, 122, 129
protein synthesis in, 61
recombination in, 20b
ribosomes in, 57
Ethanol
in DNA isolation, 68, 68b
Ethidium bromide
in electrophoresis, 75, 76f, 91
in quantitative polymerase chain reaction, 138, 139b, 139f
Ethnicity
genotype matching and, 235, 235t, 238
Ethylenediaminetetraacetic acid. See EDTA
Euchromatin
in transcription regulation, 43b
Eukaryotes
ribosomes in, 58
transcription regulation in, 40–42, 41f, 42b
Euploidy
defined, 157
European Molecular Laboratory databases of mitochondrial DNA, 254
Ewing’s sarcoma
translocations in, 339t, 339–340, 340f
Exons
in messenger RNA splicing, 32–33, 33f
Exonucleases
in DNA metabolism, 14–15
DNA polymerases as, 10–11, 11f
Expression arrays
in microarray technology, 116, 116f
Extended haplotype
components of, 243b
Extraction methods
nucleic acid, 66–78. See also specific methods
Eye protection
for specimen handling, 406</p>
<p>F
F factor
in conjugation, 20f, 20–21</p>
<p>Factor V Leiden mutation
detection of, 316–317, 317f
cleavage-based methods in, 148, 189–190, 190f
False-positive and false-negative test results prevention of, 267
FAM dye
in allelic discrimination, 186, 187f
Family studies
linkage analysis in, 250f–251f, 250–251
Y-short tandem repeats in, 241–245, 242f, 243b, 243t–244t
Federal Bureau of Investigation
CODIS of, 235b, 236b
Fertility factor
in bacterial conjugation, 19–20, 20f
Feulgen staining
in chromosome visualization, 160
Ficoll
in DNA isolation, 66
Fidelity
in polymerase biotechnology, 12, 129
Field inversion gel electrophoresis, 83, 83b, 83f
Fields
on proteome, 114b
FISH. See Fluorescence in situ hybridization
Fixed bins
in genotyping, 237b
Flammable agents
storage of, 418, 418f
Flemming
Walther
writings on nucleus of, 2
Floating bins
in genotyping, 237b
FlowMetrix bead array system
in gene mutation detection, 184–185
Fluorescence
in quantitative polymerase chain reaction, 137–141, 138b–139b, 138f–142f
Fluorescence in situ hybridization
in breast cancer, 336
in chromosomal mutation detection, 166f–170f, 166–169
Fluorescent labeling
in electrophoresis, 75–76
in microarray technology, 115
Fluorescent polarization-template-directed dye terminator incorporation, 188, 188f
dideoxynucleotides in, 123b
Fluorescent resonance energy transfer
in cleavage-based amplification, 148
in high resolution melt curve analysis, 180–181, 181f
in quantitative polymerase chain reaction, 140–141, 142f</p>
<p>Copyright ©2007 by F. A. Davis.
448 Index</p>
<p>Fluorescent spectroscopy
in nucleic acid isolation, 77–78</p>
<p>Fluorometry
in nucleic acid analysis, 77–78</p>
<p>FMR protein, 324b</p>
<p>Forensic testing
capillary electrophoresis in, 86
CODIS loci in, 235b, 236b
mitochondrial DNA polymorphisms in, 254
restriction fragment length polymorphism in, 230, 230b, 231f
validation in, 412
Y-short tandem repeats in, 241</p>
<p>Formaldehyde
in Northern blot, 101, 102b</p>
<p>Formamide
in hybridization techniques, 108</p>
<p>Fragile X syndrome, 322b, 322f–323f, 322–323
Huntington’s disease versus, 324</p>
<p>Fragment analysis
in bone marrow transplantation, 247–248</p>
<p>Frameshift gene mutations, 174, 174b, 174t
nomenclature for, 194</p>
<p>Framework regions
in immunoglobulin heavy chain gene rearrangement, 352–353</p>
<p>Franklin
DNA studies by, 3</p>
<p>Freezers
maintenance of, 413–414, 414f</p>
<p>Full sibling test, 241</p>
<p>Fume hoods
maintenance of, 416</p>
<p>Fungi
detection and identification of, 299–300</p>
<p>Fusion gene
in translocation, 358</p>
<p>G</p>
<p>G1 and G2 checkpoints
in cell division cycle, 334, 334f</p>
<p>G banding
in chromosome visualization, 160f–161f, 160–161, 161b</p>
<p>Gain of function mutations, 313
oncogene, 334</p>
<p>Gamow
as RNA Tie Club founder, 55b</p>
<p>GC clamps
in denaturing gradient gel electrophoresis, 177</p>
<p>Gel electrophoresis, 81–85
agarose, 75, 76f, 81f–83f, 81–84, 82b–83b, 82t
conformation-sensitive, 183</p>
<p>constant gradient, 178–179
denaturing gradient, 177–179, 178b, 178f
in HLA testing, 388
loading in, 90–91, 91b, 91t
in microsatellite instability, 345, 346f
polyacrylamide, 83t, 84b, 84f, 84–85
pulsed field, 83, 83b, 83f
temporal temperature gradient, 178–179</p>
<p>Gel mobility shift assay
in solution hybridization, 117–118, 118f</p>
<p>GenBank
mitochondrial DNA data in, 254</p>
<p>Gender identification
short tandem repeats in, 234–235, 235f</p>
<p>Gene expression
defined, 28
importance of, 29
microarray analysis of, 116, 116f
RNA transcription regulation and, 38–44, 39b, 39f–43f, 42b–43b</p>
<p>Gene mutations, 173–195
in cancer, 334–335
chromosomal mutations versus, 156–157
detection of, 174–194. See also specific techniques
cleavage methods in, 189–193, 190f–193f
combined methods in, 193
hybridization-based methods in, 175–185, 177f–184f, 178b, 180b
overview of, 174–175, 176t, 193
sequencing-based methods in, 185f–189f, 185–189
in drug resistance
antibiotic, 281–282, 282f, 282t
antiretroviral, 297–298, 298b
early studies of, 54
nomenclature of, 194–195
overview of, 174
in solid tumors, 335f–339f, 335–346, 338t–339f, 339b, 341t, 343b, 344f–346f, 344t
types of, 174, 174t</p>
<p>Gene rearrangements
detection of clonality in, 350–355, 351b–352b, 351f–355f, 351t
overview of, 347, 347f
translocations in malignancy as, 356f–363f, 356–365, 361b–363b, 364t
V(D)J recombination as, 347–350, 348b, 348f–351f, 350b</p>
<p>Gene Recognition and Assembly Internet Link
in Human Genome Project, 220</p>
<p>Gene sequencing
test result documentation in, 421</p>
<p>Genes
defined, 54
expression of. See Gene expression
mutations of, 173–195. See also Gene mutations
number of human, 221
overview of, 54–57
recombinant DNA technology and, 18
structural and regulatory sequences of, 54–55, 55f
tumor suppressor, 333–334</p>
<p>Genetic code
biotechnological implications of, 56–57
breaking of, 55–56
defined, 55
historical highlights of, 55b
natural versus computer-generated, 57b
schematic of, 56f</p>
<p>Genetic concordance
defined, 236</p>
<p>Genetic counseling
in Huntington’s disease, 324
limitations of, 326</p>
<p>Genetic mapping
with restriction fragment length polymorphisms, 228–229, 229b</p>
<p>Genetic profiling
with restriction fragment length polymorphisms, 230, 230b</p>
<p>Genomes
characteristics of human, 156
mitochondrial, 253–254, 254f
mutations of
clinical examples of, 312t
defined, 157
nomenclature for, 194
proteome production by, 51
viral, 292t</p>
<p>Genomic array technology
macroarrays in, 113–114
microarrays in, 114b, 114f–116f, 114–117</p>
<p>Genomic denaturing gradient gel electrophoresis, 178</p>
<p>Genomic imprinting, 325–326
examples of, 320b</p>
<p>Genomics
defined, 114b</p>
<p>Genotype
defined, 156</p>
<p>Genotyping, 225–256. See also specific techniques
of hepatitis C virus, 298–299
of human immunodeficiency virus, 297–298, 298b
rationale for, 156</p>
<p>GenProbe</p>
<p>Copyright ©2007 by F. A. Davis.
Index 449</p>
<p>in chlamydial detection, 278
in mycobacterial detection, 272
in Neisseria gonorrhoeae detection, 278</p>
<p>Germline
immunoglobulin heavy chain, 347</p>
<p>Giemsa stain
in chromosome visualization, 160</p>
<p>Gilbert
in Human Genome Project, 219</p>
<p>Gloves
for specimen handling, 406–407, 407f</p>
<p>Glutamic acid
structure of, 50f</p>
<p>Glutamine
structure of, 50f</p>
<p>Glycine
structure of, 50f</p>
<p>Glycoproteins
as conjugated proteins, 54</p>
<p>Gonadal mosaicism, 319, 320f</p>
<p>Gonorrhea, 276</p>
<p>Gorer
genetic studies of, 377</p>
<p>G-proteins
ras genes related to, 338</p>
<p>Graft failure
DNA evidence of, 246, 247f</p>
<p>Graft-versus-host disease
in bone marrow transplantation, 245
HLA antigens in, 377</p>
<p>Graft-versus-tumor effect
in bone marrow transplantation, 245</p>
<p>Gram staining
of Neisseria gonorrhoeae, 276</p>
<p>Griffith
on transformation, 21–22, 22f</p>
<p>Grooves
in DNA structure, 7b</p>
<p>Guanine
as DNA nitrogen base, 2–3, 3f</p>
<p>Guanosine monophosphate
structure of, 4f–5f</p>
<p>Guanosine triphosphatase
ras activity of, 338b</p>
<p>Guanosine triphosphatase activating proteins, 338</p>
<p>Guanosine triphosphate
in messenger RNA splicing, 32b</p>
<p>Guanylyl transferase
in messenger RNA capping, 32b</p>
<p>Gyrases
in DNA metabolism, 16, 16b</p>
<p>H</p>
<p>Haemophilus ducreyi
detection of, 277t, 279</p>
<p>Hairpin structures
in micro RNA, 35</p>
<p>Half sibling test, 241</p>
<p>Haploid complement
defined, 157</p>
<p>Haploid gene set
in human inheritance, 156</p>
<p>Haplotype
defined, 241, 380, 380f
extended, 243b
minimal, 243b</p>
<p>Haplotype diversity
in Y-short tandem repeat matching, 242</p>
<p>HapMap Project, 222, 252–253, 253f</p>
<p>Hapten
defined, 104</p>
<p>Hardy Weinberg equilibrium
overview of, 238b</p>
<p>Harvey rat sarcoma viral oncogene homolog, 337</p>
<p>Hayes
on recombination, 19</p>
<p>Heavy strand
of mitochondrial genome, 253–254, 254f</p>
<p>Helicases
in DNA metabolism, 15–16, 16b
in DNA replication, 9b
RNA, 38, 38b</p>
<p>Hemachromatosis, 317–318, 318f</p>
<p>Hematological malignancies. See also
Leukemia; Lymphoma
classification of, 333
gene rearrangements in, 346–365</p>
<p>Hematopoietic stem cells
in bone marrow transplantation, 245</p>
<p>Hemoglobin
as conjugated protein, 54</p>
<p>Henderson-Hasselbach equation
acid-base status predicted by, 87
ionization status predicted by, 87b</p>
<p>Heparin
in specimen collection tubes, 405, 406t</p>
<p>Hepatitis B virus
detection of, 293t
NA amplification in, 148</p>
<p>Hepatitis C virus
detection of, 264, 294t, 298–299
NA amplification in, 148
transcription-based amplification in, 143
Western blot in, 102b
genotyping of, 298–299
RNA polymerases in, 37</p>
<p>Hepatocellular carcinoma
from hepatitis C, 298</p>
<p>HercepTest
in breast cancer, 335–336</p>
<p>Herceptin
in breast cancer, 335</p>
<p>Hereditary nonpolyposis colorectal cancer
gene mutations in, 343, 345–346</p>
<p>HER2/neu
in breast cancer, 335f, 335–336</p>
<p>Herpes simplex virus
detection of, 293t</p>
<p>Hershey
on transformation, 22</p>
<p>Heteresis
recombination and, 18</p>
<p>Heterochromatin
in chromosomal structure, 158
chromosome visualization and, 161b
in transcription regulation, 43b</p>
<p>Heteroduplex analysis
in gene mutation detection, 183, 183f
in HLA testing, 392</p>
<p>Heteroduplex analysis with single-strand specific nucleases
in gene mutation detection, 190, 190f</p>
<p>Heterologous controls
in quality assurance, 267</p>
<p>Heteronuclear RNA
splicing of, 32</p>
<p>Heterophage
defined, 315</p>
<p>Heteroplasmy
in mitochondrial DNA polymorphisms, 255</p>
<p>Heterozygosity
defined, 228</p>
<p>Hierarchical shotgun sequencing
in Human Genome Project, 220f, 220–221</p>
<p>High density oligonucleotide arrays
in gene mutation detection, 183–184
in microarray technology, 115</p>
<p>High performance liquid chromatography
capillary electrophoresis versus, 85
denaturing, 183</p>
<p>High resolution banding
staining of, 160</p>
<p>High resolution melt curve analysis
in gene mutation detection, 180</p>
<p>Highly active antiretroviral therapy
in HIV infection, 295</p>
<p>Hirschsprung’s disease, 324, 343</p>
<p>Histidine
structure of, 50f
synthetic pathway of, 49</p>
<p>Histones
in chromosomal structure, 157, 157b, 158f
historical highlights on, 157b
in transcription
DNA release and, 28b
modification and, 42, 43b</p>
<p>Copyright ©2007 by F. A. Davis.
450 Index</p>
<p>Histoplasma
as laboratory hazard, 264</p>
<p>HIV. See Human immunodeficiency virus</p>
<p>HLA. See Human leukocyte antigens</p>
<p>Hodgkin's disease
non-Hodgkin's lymphoma versus, 333</p>
<p>Hoechst dye
in fluorometry, 77–78</p>
<p>Hogness and White
R loop mapping of, 31b</p>
<p>Holley
yeast transfer RNA discovered by, 36b</p>
<p>Holocentric chromosomes, 159b</p>
<p>Holoenzyme
in DNA replication, 9
in RNA polymerase, 36f, 37</p>
<p>Homogeneous MassExtend
defined, 123b
in gene mutation detection, 188, 188f</p>
<p>Homologous extrinsic controls
in quality assurance, 267</p>
<p>Homozygosity
defined, 228</p>
<p>Hood
in Human Genome Project, 219</p>
<p>Hormones
peptide, 52b</p>
<p>Horseradish peroxidase
in hybridization technologies, 110, 112t</p>
<p>Hot-start polymerase chain reaction, 133–134</p>
<p>Housekeeping genes
as internal controls, 412</p>
<p>Human epidermal growth factor receptor 2
in breast cancer, 335–336</p>
<p>Human Genome Organization
history and goals of, 235</p>
<p>Human Genome Project, 219–222
diagnostic significance of, 221–222
history of, 219–221, 220f, 220t–221t
laboratory effects of, 222</p>
<p>Human Haplotype Mapping Project
goal of, 222, 253
overview of, 252–253, 253f</p>
<p>Human identification
DNA polymorphisms and, 225–256. See also specific techniques
RLFP in, 229–230, 230b–231b, 230f–231f</p>
<p>Human immunodeficiency virus
antiretroviral therapy and, 295–296
detection of, 264, 293t
NA amplification in, 148
transcription-based amplification in, 143–144
of viral load, 295–297, 296t
Western blot in, 102b
genotyping of, 297–298, 298b</p>
<p>Human leukocyte antigens
clinical applications of, 226
combined test results in, 392–393, 393t
DNA-based typing of, 388–392, 389f–392f
in human identification, 230
hybrid vigor and
olfactory sensation in, 395
polymorphisms of, 379–384
nomenclature in, 380–384, 381t–382t, 383b
overview of, 379f–380f, 379–380
serologic testing of, 384–388, 385f, 386t, 387b, 387f
test discrepancies in, 393
in transplantation, 377</p>
<p>Human papillomavirus
detection of, 293t
hybrid capture assays in, 148</p>
<p>Huntingtin gene
in Huntington’s disease, 323–324, 324b, 324f</p>
<p>Huntington’s disease, 323–324, 324f</p>
<p>Hybrid capture assays, 148, 148f</p>
<p>Hybridization technologies
allele-specific oligomer, 179f, 179–180
comparative genome, 116, 116f, 169, 169f–170f
detection systems in, 109b–110b, 109f–111f, 109–111, 112t
fluorescence in situ, 166f–170f, 166–169
interpretation of results in, 111–112, 112f</p>
<p>Northern blot in, 97t, 101–102, 102b
probes in, 104–109. See also Probes
quality assurance procedures in, 417–418
solution hybridization as, 117f–118f, 117–118</p>
<p>Southern blot in, 96–101, 97t, 98f, 99b–100b, 100f–101f
Western blot in, 97t, 102, 102b, 107b</p>
<p>Hybridomas
defined, 105</p>
<p>Hydrochloric acid
in Southern blot, 98f, 99b</p>
<p>Hydrogen bonding
in DNA structure, 3f, 4
as molecular diagnostics basis, 4</p>
<p>Hydrolysis
in nucleotide-nucleoside conversion, 3</p>
<p>Hypervariable regions
of mitochondrial genome, 254, 254f</p>
<p>Iatrogenic infections
defined, 284</p>
<p>Idiopathic congenital central hypoventilation
syndrome, 324, 325f</p>
<p>Illumina bead array technology
in gene mutation detection, 185</p>
<p>Immunoglobulin heavy chain
gene rearrangements in, 347–348, 348f, 351f–353f, 351–353</p>
<p>Immunoglobulin light chain
gene rearrangements in, 348–349, 349f, 353–354, 354f</p>
<p>Immunohistochemistry
in breast cancer, 335–336
in p53 detection, 341, 341t</p>
<p>Imprinting
DNA
methylation as source of, 16b
genomic, 320b, 325–326</p>
<p>In vitro synthesized protein
in gene mutation detection, 188–189, 189f</p>
<p>In vitro transcription/translation
in gene mutation detection, 188–189, 189f</p>
<p>Inducible transcription
RNA, 31</p>
<p>Induction
in gene expression, 39b, 40f</p>
<p>Influenza viruses
detection of, 294t</p>
<p>Informative loci
in bone marrow transplantation, 246, 246f, 248, 248f, 250f</p>
<p>Inheritance
gene as unit of, 54
probability in, 156</p>
<p>Inherited diseases
congenital diseases versus, 311
molecular basis of, 311
molecular detection of, 310–326. See also specific diseases
limitations of, 326</p>
<p>Initiation
transcription, 39</p>
<p>Initiation complex
ribosomal, 58</p>
<p>Inorganic isolation methods
DNA, 68–69, 69f</p>
<p>Insertions
gene mutation nomenclature for, 194</p>
<p>Instrument maintenance
calibration verification in, 416–417
laboratory personnel in, 413, 413f
quality assurance in, 413f–416f, 413–417
of specific instruments, 413–416, 414f–416f</p>
<p>Insulin
amino acid sequence of, 52b</p>
<p>Intercalating agents
defined, 7b</p>
<p>Interference
RNA, 34, 34b, 44</p>
<p>Copyright ©2007 by F. A. Davis.
Index 451</p>
<p>Internal controls
in quality assurance procedures, 267, 412</p>
<p>Internal labeling
in dideoxy DNA sequencing, 206</p>
<p>Internal size standards
defined, 232</p>
<p>Internal transcribed spacer elements
in molecular epidemiology, 288</p>
<p>International Genome Database
purpose of, 235b</p>
<p>International Society for Forensic Genetics
short tandem repeat nomenclature of, 232–234, 234t</p>
<p>International Union of Biochemistry and
Molecular Biology
mixed base nomenclature of, 219, 219t</p>
<p>Interphase chromosomes
structure of, 158</p>
<p>Interphase fluorescence in situ hybridization
in chromosomal mutations, 166f–167f, 166–168</p>
<p>Interspersed repetitive elements
in molecular epidemiology, 287–288, 289f–290f</p>
<p>Introns
defined, 32
in messenger RNA splicing, 32b–33b, 32–33, 33f</p>
<p>Invader assay
in gene mutation detection, 191, 193f</p>
<p>Inversion
karyotyping in detection of chromosomal, 163, 165, 165f
nomenclature for nucleotide, 94</p>
<p>Inversion probe assay
in gene mutation detection, 181–183, 182f</p>
<p>Ionization
of amino acids, 49, 51f
in electrophoresis buffer systems, 87, 87b</p>
<p>Isochromosomes
karyotyping in detection of, 165, 165f</p>
<p>Isoelectric focusing gel
in Western blot, 102</p>
<p>Isoleucine
structure of, 50f</p>
<p>Isopropanol
in DNA isolation, 68, 68b</p>
<p>Isothermal amplification
strand displacement as, 144–145, 145f</p>
<p>J</p>
<p>Jacob
Monod and
on operon expression, 39, 39b
on transduction, 20–21</p>
<p>Jeffreys
DNA fingerprinting developed by, 230, 230b, 236b</p>
<p>K</p>
<p>Kappa deleting element
in immunoglobulin light chain, 348–349, 349f</p>
<p>Karyotype
defined, 161
normal, 162, 162f</p>
<p>Karyotyping
in chromosomal mutation detection, 161–163, 162f–165f, 165, 165t
defined, 161</p>
<p>Khorana
as genetic code breaker, 55–56
on terminal transferase, 15b</p>
<p>Killer cell immunoglobulin-like receptors,
394, 394f, 395t</p>
<p>Kinetochore
in chromosomal function, 159, 159f</p>
<p>King
BRCA1 gene mapped by, 229b</p>
<p>Kinship index, 241</p>
<p>Kinship testing
Y-short tandem repeats in, 241–245, 242f, 243b, 243t–244t</p>
<p>Kirsten rat sarcoma viral oncogene homolog,
337–339, 338b, 338f–339f, 338t</p>
<p>Klenow fragment
in DNA polymerization, 10</p>
<p>Kohler and Milstein
hybridomas described by, 105</p>
<p>Kornberg and Kornberg
on DNA polymerization, 9b</p>
<p>K-ras
cellular membrane interactions of, 339b
mutations in cancer of, 337–339, 338b, 338f–339f, 338t</p>
<p>L</p>
<p>Labeling
of hybridization probes, 105–106, 106f</p>
<p>Laboratory procedures manual
annual review of, 412</p>
<p>Lac operon
structure and function of, 39–40, 40f–41f</p>
<p>β-Lactamase
in antibiotic resistance, 281, 283</p>
<p>Lagging strand
in DNA replication, 8, 9f</p>
<p>Lambda repressor
structure of, 53b</p>
<p>Lariat structure
in RNA splicing, 32, 33f</p>
<p>Leading strand
in DNA replication, 8, 9f</p>
<p>Leder
as genetic code breaker, 55–56</p>
<p>Lederberg
on recombination, 19, 20b</p>
<p>Legionella pneumophila
detection of, 271t, 274</p>
<p>Legionnaire’s disease, 274</p>
<p>Lehman
on DNA polymerization, 9b</p>
<p>Length heteroplasmy
in mitochondrial DNA polymorphisms, 255</p>
<p>Leucine
structure of, 50f</p>
<p>Leucine zipper
in amino acid structure, 53b</p>
<p>Leukemia
acute lymphoblastic
translocation in, 358f–361f, 358–361, 361b</p>
<p>B-cell
translocation in, 356f–358f, 356–358
chromosomal mutations in, 264t
chronic myelogenous
translocation in, 358f–361f, 358–361, 361b
defined, 333
myelocytic
translocation in, 361–362, 362b, 362f</p>
<p>Li-Fraumeni syndrome
molecular diagnosis of, 341–342</p>
<p>Ligase
DNA, 11, 14
RNA, 14b</p>
<p>Ligase chain reaction, 144, 144f</p>
<p>Light strand
of mitochondrial genome, 253–254, 254f</p>
<p>Likelihood ratio
in genotyping, 238</p>
<p>Limiting mobility
in electrophoresis, 82</p>
<p>Lineage studies
mitochondrial DNA polymorphisms in, 256</p>
<p>Linear range
in quality assurance procedures, 413</p>
<p>Linkage analysis
short tandem repeats in, 249–251, 250f–251f</p>
<p>Linkage disequilibrium
defined, 253</p>
<p>Linkage equilibrium
product rule and, 238</p>
<p>Linker region
in chromosomal structure, 158</p>
<p>Lipoproteins
as conjugated proteins, 54</p>
<p>Copyright ©2007 by F. A. Davis.
452 Index</p>
<p>Locked nucleic acids
probes for, 103–104, 105f</p>
<p>Locus
defined, 228</p>
<p>Locus genotype
short tandem repeat, 232, 232f, 236</p>
<p>Long interspersed nucleotide sequences
defined, 226</p>
<p>Loss of function mutations, 313
tumor suppressor gene, 334</p>
<p>Loss of heterozygosity
in cancer, 346</p>
<p>Luminescence
in pyrosequencing, 214, 217f</p>
<p>Lymphoma
B-cell
translocation in, 356f–358f, 356–358</p>
<p>Burkitt’s
translocation in, 363, 363b, 363f
chromosomal mutations in, 264t
defined, 333
mantle cell
translocation in, 362f, 362–363
non-Hodgkin’s, 333</p>
<p>Lynch syndrome
gene mutations in, 343</p>
<p>Lyon hypothesis, 311b</p>
<p>Lysine
structure of, 50f</p>
<p>Lysis
crude, 71, 71f
in DNA isolation, 71, 71f
in nucleic acid extraction, 66
proteolytic, 71
in RNA isolation, 73, 73f</p>
<p>Lysosomal storage diseases, 315–316, 316t</p>
<p>Lysosome
structure of, 315f</p>
<p>M</p>
<p>M13 bacteriophage
in dideoxy DNA sequencing, 205–206, 206b, 206f</p>
<p>MacLeod
on transformation, 21, 22f</p>
<p>Macroarrays
defined, 113
in genomic array technology, 113–114</p>
<p>Magnesium
in polymerase chain reaction, 129–130</p>
<p>Major breakpoint region
translocation in, 356</p>
<p>Major groove
in DNA structure, 7b</p>
<p>Major histocompatibility antigens
nonconventional, 393–394</p>
<p>Major histocompatibility complex
analysis of, 384–393
combined results in, 392–393, 393t
DNA-based, 388–392, 389f–392f
HLA test discrepancies in, 393
serologic, 384–388, 385f, 386t, 387b, 387f
test method coordination in, 393
antigen fragments in, 379b
disease association with, 394–395, 395b
genes of, 377b, 377–378, 378t
history of, 377
locus of, 377–379, 378f
overview of, 377
structure of, 379f
summary of laboratory testing in, 395, 396t</p>
<p>Mal operon
function of, 40, 41f</p>
<p>Manganese
in dideoxy DNA sequencing, 208b</p>
<p>Mantle cell lymphoma
translocation in, 362f, 362–363</p>
<p>Markers
polymorphisms as, 228</p>
<p>Master mix
in polymerase chain reaction preparations, 130</p>
<p>Maternal inheritance
mitochondrial genome and, 254</p>
<p>Maxam-Gilbert chemical sequencing
DNA, 204f–205f, 204–205, 205b, 205t</p>
<p>McCarty
on transformation, 21, 22f</p>
<p>Measles virus
detection of, 294t</p>
<p>Mendelian genetics
overview of, 17b, 17–18</p>
<p>Melt curve analysis
in bacteria detection, 269, 270f
in gene mutation detection, 180b, 180f–181f, 180–181</p>
<p>Melting temperature
in hybridization techniques, 107f, 107–108</p>
<p>Membranes
in Southern blot, 99, 99b</p>
<p>Meselson and Stahl
on DNA replication, 8b, 66</p>
<p>Messenger RNA
in gene expression, 28
isolation of, 74–75, 75f
overview of, 30–31
processing of, 31f, 31–33, 32b–33b, 33f</p>
<p>Metacentric chromosomes
morphology of, 159, 159f</p>
<p>Metalloproteins
as conjugated proteins, 54</p>
<p>Metaphase chromosomes
structure of, 157, 157b, 158f</p>
<p>Metaphase fluorescence in situ hybridization
in chromosomal mutations, 168f–170f, 168–169</p>
<p>Metapneumovirus
detection of, 294t</p>
<p>Metastasis
defined, 333</p>
<p>Methicillin resistance
cycling probe method in detection of, 149</p>
<p>Methicillin-resistant Staphylococcus aureus, 28b, 283</p>
<p>Methionine
structure of, 50f</p>
<p>Methylation
DNA
in gene expression regulation, 43f, 43–44
imprinting from, 16b, 43</p>
<p>Methylmercuric hydroxide
in electrophoresis buffer systems, 88</p>
<p>Methyltransferases
in DNA metabolism, 16, 16b</p>
<p>MHC. See Major histocompatibility complex</p>
<p>Micro RNA
solution hybridization in analysis of, 117
structure and function of, 35–36</p>
<p>Microarrays
defined, 114
in genomic array technology, 114b, 114f–116f, 114–117
limitations of, 116–117</p>
<p>Microbiology
molecular detection of microorganisms in, 264. See also Microorganisms; specific organisms</p>
<p>Micrococcal nuclease
in DNA metabolism, 15</p>
<p>Microdeletion
karyotyping in detecting chromosomal, 163</p>
<p>Microelectronic arrays
in gene mutation detection, 184
in microarray technology, 115, 115f</p>
<p>β-2Microglobulin
human leukocyte antigens and, 378, 379f</p>
<p>Microorganisms
detection and identification of, 263–300.
See also specific microorganisms
antimicrobial agents in, 280b, 280t–281t, 280–284
bacterial targets in, 268f, 268–280, 269t
fungi in, 299–300
molecular epidemiology in, 284t, 284–291, 285f
overview of, 264
parasites in, 300</p>
<p>Copyright ©2007 by F. A. Davis.
Index</p>
<p>quality control in, 266–268
sample preparation in, 266
specimen collection in, 264–266, 265b, 265t
viruses in, 291–299, 292t–296t, 298b
in DNA isolation, 66–67</p>
<p>Microsatellites
instability of
in cancer, 343–346, 344f–346f, 344t
short tandem repeats as, 231</p>
<p>Microvariant alleles
short tandem repeats and, 231, 236, 236f</p>
<p>Miescher
DNA discovered by, 2, 2b, 66</p>
<p>Milstein and Kohler
hybridomas described by, 105</p>
<p>Minimal haplotype
components of, 243b</p>
<p>Minisatellites
defined, 230</p>
<p>Minitransplant procedures
bone marrow, 245</p>
<p>Minor cluster region
translocation in, 356</p>
<p>Minor groove
in DNA structure, 7b</p>
<p>Minor histocompatibility antigens, 393</p>
<p>Mismatch repair
defined, 343</p>
<p>Mismatch repair system
genes of, 343–344, 344f, 344t</p>
<p>Mismatches
in DNA structure, 4</p>
<p>Mispriming
in polymerase chain reaction, 127, 127f
prevention in, 133–134</p>
<p>Mitochondria
transfer RNA in, 35b</p>
<p>Mitochondrial DNA
isolation of, 71–72, 72b
polymorphisms of, 253–256, 254f, 255b
in forensics, 254
in human identification, 255
in lineage studies, 256
nomenclature of, 255b
in public databases, 254</p>
<p>Mitochondrial genes
mutations in, 319–321, 320f–321f, 321t</p>
<p>Mitochondrial genome
structure of, 253–254, 254f</p>
<p>Mitogen
in karyotyping, 162</p>
<p>Mitogen stimulation
in carcinogenesis, 337, 337f</p>
<p>Mixed chimerism
in bone marrow transplantation, 246, 249</p>
<p>Mixed leukocyte culture
in HLA testing, 388</p>
<p>Molecular beacons
in quantitative polymerase chain reaction, 140, 140f–141f</p>
<p>Molecular biology
definitions and applications of, 2</p>
<p>Molecular chaperones
in protein synthesis, 60, 61f</p>
<p>Molecular epidemiology, 284–291
defined, 284
typing in, 284t, 284–289, 285f, 286t, 287f–290f, 290t
comparison of methods in, 289–291, 291t</p>
<p>Molecular inversion probe
in gene mutation detection, 181–183, 182f</p>
<p>Molecular laboratory
quality assurance and quality control in, 403–423. See also Quality assurance</p>
<p>Molecular oncology, 332–365. See also specific mutations and types of cancer
analysis targets in, 334–346
loss of heterozygosity as, 346
microsatellite instability as, 343–346, 344f–346f, 344t
mutations in solid tumors as, 335f–340f, 335–343, 341t
overview of, 334–335
in leukemia and lymphoma, 346–365. See also Leukemia; Lymphoma</p>
<p>Monoclonal antibodies
epidermal growth factor receptor inhibited by, 337
polyclonal antibodies versus, 105</p>
<p>Monoclonality
characteristics of, 350</p>
<p>Monod and Jacob
on operon expression, 39</p>
<p>Monomer
defined, 54</p>
<p>Monosomy
defined, 311</p>
<p>MOPS buffer
in RNA electrophoresis, 88</p>
<p>Mosaicism
chimerism versus, 246b, 311
gonadal, 319, 320f
overview and examples of, 311–312, 312t</p>
<p>MRSA
history and updated meaning of, 283, 283b</p>
<p>Mullis
polymerase chain reaction conceived by, 122, 123b–124b</p>
<p>Multilocus sequence typing
in molecular epidemiology, 289</p>
<p>Multiple endocrine neoplasia syndromes, 343</p>
<p>Multiple locus probe-restriction fragment
length polymorphism system, 230</p>
<p>Multiplex assays
for bacterial pneumonia, 275</p>
<p>Multiplex inversion probe
in gene mutation detection, 182–183</p>
<p>Multiplex polymerase chain reaction, 134–135
allele-specific
in gene mutation detection, 185, 186f
for urogenital pathogens, 280</p>
<p>Mumps virus
detection of, 294t</p>
<p>Mung bean nuclease
in DNA metabolism, 15</p>
<p>Mutations. See also Polymorphisms; specific mutations
chromosomal, 156, 161–170. See also Chromosomal mutations
defined, 156
DNA polymerase function and, 10–11
gain of function, 313
gene, 173–195. See also Gene mutations
genome, 157
clinical examples of, 312t
loss of function, 313
mitochondrial, 319–321, 320f–321f, 321t
nuclear gene, 321, 322t
oncogene, 334
range of, 311
silent, 174, 174t, 383
in solid tumors, 335f–340f, 335–343, 341t</p>
<p>Mycobacterium tuberculosis
detection of, 264, 271t, 271–272, 286
strand displacement amplification in, 145
transcription-based amplification in, 143–144
multidrug-resistant, 283</p>
<p>Mycoplasma genitalium
detection of, 277t, 279–280</p>
<p>Mycoplasma hominis
detection of, 277t, 279–280</p>
<p>Mycoplasma pneumoniae
detection of, 271t, 274–275</p>
<p>Myeloablative bone marrow transplantation, 245</p>
<p>Myelocytic leukemia
translocation in, 361–362, 362b, 362f</p>
<p>N</p>
<p>National DNA Database
overview of, 236b</p>
<p>National Fire Protection Association
hazard labels designed by, 418, 418f</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>454 Index</p>
<p>National Institutes of Health
in Human Genome Project, 220f, 220–221</p>
<p>National Marrow Donor Program
on HLA nomenclature, 383b</p>
<p>Negative template control
in polymerase chain reaction, 132
in quality assurance, 267</p>
<p>Neisseria gonorrhoeae
detection of, 264, 276–278, 277t</p>
<p>Neoplasms
classification of, 333
defined, 333</p>
<p>Nested polymerase chain reaction, 136f, 136–137</p>
<p>Neuroblastoma ras, 337</p>
<p>Nick
defined, 11</p>
<p>Nick translation
in DNA polymerization, 11, 12b
in DNA probe labeling, 106</p>
<p>Nirenberg
as genetic code breaker, 55–56</p>
<p>Nitrocellulose
in Southern blot, 99, 99b</p>
<p>Nitrogen
as DNA component, 2, 2b</p>
<p>Nitrogen bases
in DNA structure, 2–5, 3f–5f, 4b
modified, 4b–5b, 4–6, 6f
purine, 3
pyrimidine, 3</p>
<p>n-myc gene, 343, 343b</p>
<p>Nonconservative gene mutations, 174, 174t</p>
<p>Non-Hodgkin’s lymphoma
classification of, 333b
Hodgkin’s disease versus, 333</p>
<p>Noninformative loci
in bone marrow transplantation, 246, 246f</p>
<p>Nonisotopic RNase cleavage assay
in gene mutation detection, 191, 192f</p>
<p>Nonmyeloablative bone marrow transplantation, 245</p>
<p>Nonprotein prosthetic group
in conjugated proteins, 54</p>
<p>Nonsense codons
in genetic code, 56
in protein synthesis, 61</p>
<p>Nonsense gene mutations, 174, 174t</p>
<p>Nonsense-mediated decay
in translation, 61</p>
<p>NOR staining
in chromosome visualization, 161</p>
<p>Northern blot
interpretation of results in, 112, 112f
in RNA analysis, 97t, 101–102, 102b</p>
<p>Norwalk virus
detection of, 294t</p>
<p>Nosocomial infections
defined, 284</p>
<p>Nuclear gene mutations
disorders caused by, 321, 322t</p>
<p>Nuclear Regulatory Commission
laboratory regulations of, 418–419</p>
<p>Nuclease Bal31
in DNA metabolism, 14</p>
<p>Nucleic acid sequence-based amplification, 142–144
in HIV viral load detection, 296, 296t</p>
<p>Nucleic acids. See also DNA; RNA
amplification of, 121–149. See also specific techniques
analysis and characterization of, 94–118. See also specific techniques
defined, 6
electrophoresis of, 80–92
extraction methods of, 78. See also specific techniques
measurement of, 75–78
electrophoresis in, 75f–76f, 75–76
fluorometry in, 77–78
spectrophotometry in, 76–77, 77b
potential clinical applications of, 2
replication of, 6, 6f
resolution and detection of, 80–92. See also specific techniques
specimen storage requirements for, 407, 408t–409t, 409, 409f</p>
<p>Nuclein
as Miescher’s term for DNA, 2, 2b</p>
<p>Nucleosides
conversion from nucleotides to, 3
defined, 3
in DNA structure, 3, 4f, 6, 6f
modified
clinical applications of, 6, 6f</p>
<p>Nucleosomes
in chromosomal structure, 157–158, 158f
in transcription regulation, 42, 42f</p>
<p>Nucleolus
RNA synthesis in, 28</p>
<p>Nucleotides
complementary, 4
conversion to nucleosides of, 3
defined, 2
in DNA structure, 2–6, 4b–5b, 4f–5f
monophosphate
carbon position numbering in, 4, 5f</p>
<p>Null allele
in HLA nomenclature, 383</p>
<p>O</p>
<p>Occupational Safety and Health
Administration
radiation exposure regulated by, 419</p>
<p>Office of Human Genome Research
in Human Genome Project, 220</p>
<p>Okazaki fragments
in DNA replication, 8, 9f</p>
<p>Oligoclone
monoclonal tumor cell population versus, 351b</p>
<p>Oligodeoxynucleotides
in polymerase chain reaction, 124, 124f</p>
<p>OliGreen
in fluorometry, 78</p>
<p>Olimer
defined, 54</p>
<p>Oncogenes
in cell cycle, 333
mutations in, 334</p>
<p>Oncology
defined, 333
molecular, 332–365. See also Molecular oncology; specific mutations and types of cancer</p>
<p>Open reading frame
defined, 32</p>
<p>Operator
in gene expression, 39, 40f</p>
<p>Operon
defined, 39</p>
<p>Organic isolation methods
DNA, 67–68, 68b, 68f
RNA, 73, 73f</p>
<p>Orthophosphate
in DNA replication, 8</p>
<p>Overhangs
in restriction enzyme function, 13, 13f</p>
<p>Oxford sequence
of mitochondrial genome, 254</p>
<p>Oxygen
as DNA component, 2</p>
<p>P</p>
<p>P site
ribosomal, 58–59, 60f</p>
<p>Paired box-Forkhead
in rhabdomyosarcoma, 340–341</p>
<p>Palindromic
defined, 13</p>
<p>Panel reactive antibodies
in transplant screening, 386</p>
<p>Parainfluenza viruses
detection of, 294t</p>
<p>Parasites
detection and identification of, 300</p>
<p>Parentage testing
capillary electrophoresis in, 86</p>
<p>Copyright ©2007 by F. A. Davis.
Index 455</p>
<p>restriction fragment length polymorphisms
in, 22, 229f
short tandem repeats in, 238–240, 239b–240b, 239f, 239t
Parvovirus B19
detection of, 293t
Paternal lineage testing
Y-short tandem repeats in, 241, 244–245
Paternity
probability equation for, 240
Paternity index
formulas for, 240, 240b
Paternity testing
genetic concordance and, 236
restriction fragment length polymorphisms
in, 229, 229f
short tandem repeats in, 238–240, 239b–240b, 239f, 239t, 244
Pauling and Corey
protein structure described by, 52, 54f
PCR. See Polymerase chain reaction
Pedigree
defined, 312, 313f
Penetrance
defined, 314
Penicillin
resistance to, 281, 283
Peptide bonds
of amino acids, 49, 52f
Peptide nucleic acids
probes for, 103–104, 104f
Peptides
biological activity of, 52b
Peptidyl transferase
in protein synthesis, 58–59
Personal protective equipment
for specimen handling, 406–407, 407f
pH
amino acid ionization and, 49, 51f
pH drift
in electrophoresis buffer systems, 88
Phenol
in nucleic acid isolation, 68, 73
as spectrophotometry contaminant, 76
Phenotype
defined, 156
Phenylalanine
structure of, 50f
Philadelphia chromosome
in leukemia, 358
Phosphodiester bond
in DNA replication, 8
in DNA structure, 2
Phosphorus
as DNA component, 2, 2b
radioactive labeling with
in hybridization, 105</p>
<p>Photographic equipment
maintenance of, 415, 416f
Photolithography
in microarray technology, 115, 115f
PHOX2b gene
in idiopathic congenital central hypoventilation syndrome, 324, 325f
pI value
defined, 49
PicoGreen
in fluorometry, 78
Piperidine
in DNA sequencing, 204–205
pK value
defined, 49
Plasma cell neoplasms
in cancer classification, 333
Plasma preparation tubes
in specimen collection, 406
Plasmid fingerprinting, 285
Plasmids
analysis of
in molecular epidemiology, 285
classification of, 23
defined, 22
in electrophoresis, 75, 75f
restriction enzyme mapping of, 96, 96f
structure and function of, 22–24, 23b–24b, 23f
PML/RARA fusion gene
in leukemia, 361, 362b
Pneumonia
chlamydial, 274
mycoplasmal, 274
streptococcal, 275
Point heteroplasmy
in mitochondrial DNA polymorphisms, 255
Point mutations
consequences of, 174
defined, 174
PolyA RNA
isolation of, 74–75, 75f
Polyacrylamide gel
in DNA sequencing, 204–205, 205b, 205f, 209, 209f
in electrophoresis
DNA resolution with, 84, 84f
technique for, 84–85, 89f–90f, 89–90
in single-strand conformation polymorphism, 175
structure of, 84, 84f
in Western blot, 102
Polyadenylate polymerase
in messenger RNA processing, 31
Polyadenylation
in messenger RNA processing, 31, 32b</p>
<p>Polycistronic
defined, 30
Polyclonal antibodies
defined, 105
in Western blot, 104–105
Polyclonality
characteristics of, 350
Polymerase chain reaction, 122–142
in allele-specific oligomer hybridization, 179–180
amplification refractory mutation system, 185
in antibiotic resistance detection, 283
artifacts in, 237b
in bone marrow graft transplantation, 245–249, 247f
in Bordetella detection, 273–274
clonality detected by, 352b, 352–355, 353f–355f
components of, 124t, 125–132
buffers as, 129–130
controls as 131–132
deoxyribonucleotide bases as, 128b, 128–129
DNA template as, 128
primers as, 126–128, 127b, 127f–128f
thermal cyclers as, 130–131, 131f
contamination control in, 132–133, 133b
cycles in, 123, 125t
in dideoxy DNA sequencing, 208b
in DNA pyrosequencing, 216b
in Haemophilus ducreyi detection, 279
history of, 122, 123b–124b
hot-start, 133–134
in Legionella detection, 274
in melt curve analysis, 180, 180b, 180f
mispriming prevention in, 133–134
in mitochondrial DNA polymorphisms, 255
modifications of, 134–142
arbitrarily primed PCR as, 141–142, 142f
multiplex PCR as, 134–135
nested PCR as, 136f, 136–137
quantitative PCR as, 137b–139b, 137–141, 138f–142f
real-time PCR as, 137b–139b, 137–141, 138f–142f
reverse transcriptase PCR as, 135–136
in molecular epidemiology, 286–287, 287f
in Mycoplasma detection, 274–275
in mycoplasmal detection, 279
in parasite detection, 300
procedure for, 122–125, 124f–126
product cleanup in, 134–135ff
quality assurance procedures in, 417, 417f
sequence-specific, 185, 185f</p>
<p>Copyright ©2007 by F. A. Davis.
456 Index</p>
<p>Polymerase chain reaction (Continued)
in short tandem repeats, 231–241, 232b, 232f–233f, 234t–235t, 235b–236b
in <em>Streptococcus pneumoniae</em> detection, 275–276
tetra primer, 185
in translocations, 356–365, 357f–358f, 360f–361f
in <em>Treponema pallidum</em> detection, 279
two-step, 125
in ureaplasmal detection, 279
worksheet for, 411f</p>
<p>Polymerase chain reaction-restriction fragment length polymorphism, 189–190, 190f</p>
<p>Polymerases
DNA
in biotechnology, 12
in DNA replication, 8–12, 9b–12b, 10f–12f
classification by sequence homology of, 10t
in polymerase chain reaction, 129
nomenclature of, 129b
RNA, 28–29, 29f, 36f, 36–37, 37b, 37t</p>
<p>Polymerization
in DNA replication, 6f, 8–12
RNA, 28–29, 29f</p>
<p>Polymorphisms. See also Mutations
balanced, 156, 311
benign, 311
defined, 156
in engraftment testing, 245f–248f, 245–249, 246b–249b
HLA, 379f–380f, 379–384, 381t–382t, 383b
mitochondrial DNA, 253–256, 254f, 255b
single nucleotide, 226. See also Single nucleotide polymorphisms
types of, 226
laboratory methods for, 226, 226t</p>
<p>Polypeptides
proteins as, 51</p>
<p>Polyploidy
defined, 311</p>
<p>Population databases
of mitochondrial DNA polymorphisms, 255–256</p>
<p>Population genotype matching
short tandem repeats in, 235t, 235–236</p>
<p>Population migration tracking
mitochondrial DNA polymorphisms in, 256</p>
<p>Position effects
chromosomal, 157
defined, 43b</p>
<p>Positive controls
in quality assurance, 266</p>
<p>Post-transcriptional processing
of messenger RNA, 30, 31f</p>
<p>PowerPlex system
in bone marrow transplantation, 247</p>
<p>Prader-Willi syndrome, 325</p>
<p>Precautions
for specimen handling, 265b, 406–407, 407f</p>
<p>Precipitation
in DNA isolation, 68, 69b</p>
<p>Prehybridization
in Southern blot, 100–101</p>
<p>Preribosomal RNA, 30</p>
<p>Primary resistance mutations
in antiretroviral drug resistance, 297</p>
<p>Primary structure
amino acid, 51–52</p>
<p>Primase
in DNA replication, 8, 9b, 10f</p>
<p>Primer dimers
in polymerase chain reaction, 127, 128f</p>
<p>Primers
for bacterial target sequences, 268, 268f
in denaturing gradient gel electrophoresis, 178b
M13 universal, 206b
in polymerase chain reaction, 126–128, 127f–128f
for clonality detection, 352b, 352–353, 353f
commercially available, 127b
extension of, 125, 125f–126f
reverse transcriptase, 135
quality assurance in, 417f, 417–418</p>
<p>Prions
proteins denatured by, 54</p>
<p>Probability of paternity
equation for, 240</p>
<p>Probe amplification
nucleic acid, 144f–147f, 144–147
cycling, 149, 149t</p>
<p>Probes
in allelic discrimination, 185–186, 186f
for bacterial target sequences, 268, 268f
in fluorescent resonance energy transfer, 181
in high resolution melt curve analysis, 180–181, 181f
in hybridization
allele-specific oligomer, 179, 179f
design of, 106–107
DNA, 103, 106
fluorescence in situ, 166f, 166–169, 169f
labeling of, 105–106, 106f</p>
<p>length in, 108–109
other nucleic acid types, 104, 104b, 104f–105f
protein, 104–105, 107b
RNA, 103–104, 104b
in Southern blot, 97
quality assurance in, 417–418
in restriction fragment length polymorphism, 230, 231b</p>
<p>Procedure manual
annual review of, 412</p>
<p>Product rule
in genotyping, 238</p>
<p>Proficiency testing
in quality assurance, 419–420
in HIV genotyping, 298
in HIV viral load determinations, 297</p>
<p>Profiles
genetic, 236
matching of, 237–238, 238b</p>
<p>Prokaryotes
ribosomes in, 57–58
transcription regulation in, 40, 41f</p>
<p>Proline
structure of, 49, 50f</p>
<p>Promoter
defined, 28
in gene sequences, 55f</p>
<p>Proofreading
exonuclease function and, 11</p>
<p>Protein gel electrophoresis
in HLA testing, 388</p>
<p>Protein truncation test
in gene mutation detection, 188–189, 189f</p>
<p>Proteins, 48–61
amino acids as, 49–54. See also Amino acids
analysis of, 94–118
microarrays in, 113
probes in, 104f–105f, 104–105, 107b
Western blot in, 97t, 102, 102b, 107b
in chromosomal structure
histone, 157, 157b, 158f
nonhistone, 158
conjugated, 54
fibrous, 54
globular, 54
overview of, 49
sequence of
DNA sequence and, 52b
primary, 52b
Sm, 34
solubility of, 54
structure of, 49, 50f, 51–54, 52f, 53b, 54f
translation of, 57–61</p>
<p>Copyright ©2007 by F. A. Davis.
Index</p>
<p>amino acid charging in, 57
transfer RNA in, 57–60, 58b, 58f–61f</p>
<p>Proteolytic lysis
in DNA isolation, 71</p>
<p>Proteome
defined, 51
early description of, 114b</p>
<p>Proteomics
defined, 114b</p>
<p>Prothrombin mutations
PCR-RFLP in detection of, 190, 190f</p>
<p>Pseudogenes
defined, 226</p>
<p>Pseudouridine
in transfer RNA, 35</p>
<p>Psoralens
clinical applications of, 133b
in polymerase chain reaction, 132</p>
<p>Pulsed field electrophoresis, 82–84, 83b, 83f
in molecular epidemiology, 285f, 285–286, 286t</p>
<p>Purine
defined, 3</p>
<p>Pyrimidine
defined, 3</p>
<p>Pyrimidine dimer, 11b</p>
<p>PyroMark KRAS kit, 339</p>
<p>Pyrophosphate
in DNA pyrosequencing, 214, 217f</p>
<p>Pyrophosphate exchange
in DNA polymerization, 9–10</p>
<p>Pyrophosphorolysis
in DNA polymerization, 9–10</p>
<p>Pyrosequencing
DNA, 214, 216, 216b, 217f</p>
<p>Q</p>
<p>Q banding
in chromosome visualization, 160, 160f, 161b</p>
<p>Qβ replicase
in probe amplification, 145–147, 146f</p>
<p>Qiagen BioRobot system
in solid-phase DNA isolation, 70</p>
<p>Quality assurance, 403–423
Clinical Laboratory Improvement Amendments and, 404
in instrument maintenance, 413f–416f, 413–417
calibrations and, 416–417
overview of, 266–268
in reagents, 417f–420f, 417–420, 419t
chemical safety and, 418f–420f, 418–419, 419t
proficiency testing in, 419–420
in specimen handling, 404–409</p>
<p>collection tubes and, 405–406, 406f, 406t
cross-contamination and, 404–405
hemolysis and, 405
holding and storage in, 407, 408t–409t, 409, 409f
labeling in, 404, 404f
preanalytical variables and, 404
precautions in, 406–407, 407f
short tandem repeats in, 251–252, 252f
snap freezing in, 405, 405f
of solid tissues, 405, 405f</p>
<p>in test performance, 409–413
assessment criteria for, 410, 410t
controls in, 412
documentation in, 410, 412
overview of, 409–410
periodic review of, 365, 412–413, 413f
validation and, 410, 411f, 412
in test result documentation, 420–421, 422f, 423</p>
<p>Quantitative polymerase chain reaction, 137b–139b, 137–141, 138f–142f
in bacteria detection, 269–270</p>
<p>Quaternary structure
amino acid, 54</p>
<p>Quencher
in quantitative polymerase chain reaction, 139, 139b, 139f</p>
<p>Quinacrine
in chromosome visualization, 160</p>
<p>R</p>
<p>R banding
in chromosome visualization, 160, 160f</p>
<p>R factors
plasmids as, 23, 23b</p>
<p>R loop mapping
history of, 31b</p>
<p>Radionuclides
safety and, 418–419, 419t, 420f</p>
<p>Ramp
defined, 130</p>
<p>Random amplified polymorphic DNA assay
in molecular epidemiology, 286–287, 287f</p>
<p>Random coils
in amino acid structure, 52</p>
<p>Random priming
in DNA probe labeling, 106</p>
<p>Randomly amplified polymorphic DNA
in quantitative polymerase chain reaction, 141–142, 142f</p>
<p>Rapid plasma reagin
in Treponema pallidum detection, 278</p>
<p>Rapid polymerase chain reaction
thermal cycling in, 130</p>
<p>Reagent blank
in polymerase chain reaction, 131–132
in quality assurance, 267</p>
<p>Reagents. See also specific reagents
quality assurance in, 417f–420f, 417–420, 419t</p>
<p>REAL classification
of non-Hodgkin’s lymphoma, 333b</p>
<p>Real-time polymerase chain reaction, 137b–139b, 137–141, 138f–142f
thermal cycling in, 130</p>
<p>Rearranged During Transfection (RET) proto-oncogene, 343</p>
<p>recBC nuclease
in DNA metabolism, 15</p>
<p>Receptor tyrosine kinases
in molecular oncology, 335f, 363–365</p>
<p>Recessive diseases
gene mutation nomenclature in, 194</p>
<p>Recipient loci
in bone marrow transplantation, 246, 246f</p>
<p>Reciprocal translocations
detection of
karyotyping in, 162–163, 164f</p>
<p>Recognition sites
DNA defined, 7b
restriction enzyme binding to, 13b, 95</p>
<p>Recombinant DNA technology
defined, 18
plasmids in, 23–24, 24b</p>
<p>Recombination
in asexual reproduction, 18–22, 19f–22f, 20b, 22b
defined, 17
historical highlights of, 17b, 20b
in sexually reproducing organisms, 17b, 17–18, 19f–18f</p>
<p>Recombination activating genes, 348b</p>
<p>Red blood cells
in DNA isolation, 66</p>
<p>Redundant tilting
in high-density oligonucleotide arrays, 184</p>
<p>Refrigerators
maintenance of, 413–414, 414f</p>
<p>Regulatory transcription
RNA, 31</p>
<p>Release factors
in protein synthesis, 61</p>
<p>Repair endonucleases
in DNA metabolism, 12b</p>
<p>Repair polymerases
in DNA replication, 11b</p>
<p>Repetitive extragenic palindromic sequence, 288, 289f–290f</p>
<p>Replication errors
in microsatellite instability, 344–345, 345f</p>
<p>Copyright ©2007 by F. A. Davis.
458 Index</p>
<p>Replication fork
DNA, 8, 9f</p>
<p>Replisome
in DNA replication, 9b</p>
<p>Reporting of test results
quality assurance in, 421, 422f, 423</p>
<p>Repressor
in transcription regulation, 39, 40f</p>
<p>Reproducibility
in genotype test evaluation, 290</p>
<p>Reptation
in electrophoresis, 82</p>
<p>Resequencing
DNA, 222
in gene sequencing test results, 421</p>
<p>Resistance factor
episomal nature of, 23</p>
<p>Resistance transfer factors
plasmids as, 23, 23b</p>
<p>Resolution
in HLA nomenclature, 383</p>
<p>Respiratory syncytial virus
detection of, 294t</p>
<p>Respiratory tract pathogens. See also specific
pathogens
detection and identification of, 270–276,
271t
overview of, 270</p>
<p>Restriction enzymes
in DNA metabolism, 12b–14b, 12–14, 13f
endonucleases as, 84
mapping of, 95f–96f, 95–96, 226–228
DNA, 95f–96f, 95–96, 226–228
plasmid, 96, 96f
nomenclature and classification of, 13
in Southern blot, 97, 98f</p>
<p>Restriction fragment length polymorphisms
in bone marrow graft transplantation,
246
defined, 96
in enzyme mapping, 96, 226–227
in gene mutation detection, 189–190, 190f,
226
genetic mapping with, 228–229, 229b
human identification with, 229–230,
230b–231b, 230f–231f
inheritance patterns of, 227–229, 228f–229f
in molecular epidemiology, 286
overview of typing with, 226–228,
227f–228f
parentage testing with, 229, 229f
polymerase chain reaction, 189–190,
190f
probes in, 230, 231b
Standard Reference Material DNA Profiling
Standard, 228</p>
<p>Restriction map
enzyme, 95–96, 96f, 226–227
of germline immunoglobulin heavy chain
gene, 351f</p>
<p>Restriction modification
defined, 5b
RET proto-oncogene, 343</p>
<p>Retroviruses
reverse transcription in, 28b</p>
<p>Reverse dot blot
in genomic array technology, 113</p>
<p>Reverse dot blot techniques
allele-specific oligomer hybridization as,
179–180</p>
<p>Reverse transcriptase-polymerase chain reaction, 135–136
in Ewing’s sarcoma, 340, 340f
in HIV viral load detection, 296,
296t</p>
<p>Reverse transcription
complementary DNA version of messenger
RNA by, 31b
in retroviruses, 28b, 292</p>
<p>RFLP. See Restriction fragment length
polymorphisms</p>
<p>Rhabdomyosarcoma
translocations in, 340–341</p>
<p>Ribonucleases
in RNA metabolism, 37
used in laboratory procedures, 38t</p>
<p>Ribonucleic acid. See RNA</p>
<p>Ribose
in RNA structure, 28</p>
<p>Ribosomal binding site
in protein translation, 58, 60f</p>
<p>Ribosomal RNA
isolation of, 72
structure and function of, 30, 30b, 30f</p>
<p>Ribosomes
defined, 57
in protein translation, 57–60, 59f–60f</p>
<p>Ring chromosomes
karyotyping in detection of, 165, 165f</p>
<p>RNA, 27–44
analysis of
electrophoresis in, 75–76, 76f, 81–92.
See also Electrophoresis
fluorometry in, 78
probes in, 103–104, 104b, 106
solution hybridization in, 117, 117f
spectrophotometry in, 77
transcription-based amplification in,
143–144
classification of, 28, 30
crystallographic study of synthesis of,
38b</p>
<p>defined, 28
degradation of
reverse transcriptase polymerase chain
reaction and, 136
as DNA precursor, 28b
heteronuclear, 32
isolation of, 72–75
extraction of total RNA in, 72–74,
73f–74f, 74t
of messenger RNA, 74–75, 75f
RNases and, 72, 72b
of total RNA, 72
laboratory precautions in handling,
406–407, 407f
messenger, 30–31. See also Messenger
RNA
micro, 35–36
overview of, 28
polymerases of
eukaryotic, 37, 37b, 37t
prokaryotic, 36f, 36–37
RNA-dependent, 37
in transcription, 28–29, 29f
preribosomal, 30
ribosomal, 30, 30b, 30f
isolation of, 72
small interfering, 34, 34b
small intermediate, 34
small modulatory, 36
small nuclear, 32b, 34, 34t
small nucleolar, 36
small temporal, 36
specimen storage requirements for, 407,
408t–409t, 409
stabilization of
specimen collection tubes and, 406
structure of, 28
tiny noncoding, 36
transcription in, 28–29, 29f
transfer, 34–35, 35b–36b, 35f
uracil in, 28, 28f</p>
<p>RNA chaperones, 38b
RNA induced silencing complex
in RNA interference, 44
RNA integrity control
in translocation detection, 360
RNA interference, 34, 34b, 44
laboratory uses of, 44b
potential clinical uses of, 44
RNA ligase
functions of, 14b
RNA Tie Club, 55b
RNA viruses
genomes of, 292t
transcription-based amplification in detection of, 143</p>
<p>Copyright ©2007 by F. A. Davis.
Index 459</p>
<p>RNase
in RNA isolation, 72, 72b</p>
<p>RNase H
in DNA replication, 9b</p>
<p>RNase protection
in solution hybridization, 117</p>
<p>Robertsonian translocations
karyotyping in detection of, 163, 164f</p>
<p>Roche MagnaPure system
in solid-phase DNA isolation, 70</p>
<p>Rotating gel electrophoresis, 83, 83f</p>
<p>Rotavirus
detection of, 294t</p>
<p>Rubella virus
detection of, 294t</p>
<p>S</p>
<p>S1 nuclease
in DNA metabolism, 15</p>
<p>Saccharomyces cerevisiae
RNA polymerase in, 37b</p>
<p>Salting out
in DNA isolation, 69, 69f</p>
<p>Sample preparation
in DNA isolation, 66–67, 67t
overview of, 266</p>
<p>Sanger
insulin amino acid sequence described by, 52b</p>
<p>Sanger DNA sequencing, 205–210, 206b,
206f–209f, 208b. See also Dideoxy DNA sequencing</p>
<p>Sarcomas
tissue of origin of, 333</p>
<p>Scientific Working Group for DNA Methods
mitochondrial DNA database of, 255</p>
<p>Scorpion primers
in quantitative polymerase chain reaction, 140, 141f</p>
<p>Secondary resistance mutations
in antiretroviral drug resistance, 297</p>
<p>Secondary structure
amino acid, 53, 53b, 54f</p>
<p>Sedimentation coefficient
of ribosomal RNA, 30</p>
<p>Selenocysteine, 51b, 57b</p>
<p>Selenoproteins, 51b, 57b</p>
<p>Self-splicing
RNA, 33</p>
<p>Self-sustaining sequence replication, 142–143</p>
<p>Semiconservative DNA replication, 7</p>
<p>Seminested polymerase chain reaction, 136, 136f</p>
<p>Sense strand
in RNA polymerization, 28–29, 29f</p>
<p>Sensitivity control
in quality assurance, 266–267</p>
<p>Sequence complexity
in hybridization techniques, 108, 108b, 108f</p>
<p>Sequence-based typing
HLA, 390–391, 391f–392f</p>
<p>Sequence-specific oligonucleotide probe hybridization
in HLA testing, 388–390, 389f</p>
<p>Sequence-specific polymerase chain reaction
in gene mutation detection, 185, 185f–186f
in HLA testing, 390, 390f–391f</p>
<p>Sequencing
in DNA structure, 2–4, 7, 7b</p>
<p>Sequencing ladder
in automated fluorescent DNA sequencing, 212
in dideoxy DNA sequencing, 209, 209f</p>
<p>SEQUENOM MassExtend
in gene mutation detection, 188, 188f</p>
<p>Serine
structure of, 50f</p>
<p>Serologic testing
HLA typing as, 384–388, 385f, 386t, 387b, 387f
for Treponema pallidum, 278</p>
<p>Sex-linked disorders, 313–314, 314f</p>
<p>Sexual reproduction
recombination in, 17b, 17–18, 18f–19f</p>
<p>Shark’s tooth combs
in electrophoresis, 90, 90f</p>
<p>Short interspersed nucleotide sequences
defined, 226</p>
<p>Short tandem repeats
in bone marrow graft transplantation, 246
defined, 226
in linkage analysis, 249–251, 250f–251f
polymerase chain reaction in, 231–241
analysis of test results in, 235t, 235–237, 236b
in gender identification, 234–235, 235b, 235f
nomenclature in, 232, 234, 234t
overview of, 231–232, 232b, 232f–233f
in paternity test, 238–240, 239b–240b, 239f, 239t
profile matching in, 237–238, 238b
in sibling test, 240–241
subpopulation matching probability of, 235t, 235–236
in surgical specimen quality assurance, 251–252, 252f
in Y-STR testing, 241–245, 242f, 243b, 243t–244t</p>
<p>Shrimp alkaline phosphatase (SAP)
in polymerase chain reaction, 134</p>
<p>Sibling index, 241</p>
<p>Sibling testing
short tandem repeats in, 240–241</p>
<p>Sickle cell anemia
amino acid substitution in, 51–52
as balanced polymorphism, 156</p>
<p>Side chains
amino acid, 49, 49t</p>
<p>Sigma factor
in RNA polymerase, 37</p>
<p>Signal amplification
nucleic acid, 147f–149f, 147–149</p>
<p>Signal-to-noise ratio
in hybridization technologies, 111</p>
<p>Silencers
in gene expression, 42</p>
<p>Silent mutations
gene, 174, 174t
in HLA nomenclature, 383</p>
<p>Silica
in capillary electrophoresis, 85</p>
<p>Silver stain
in electrophoresis, 92</p>
<p>Single locus probe-restriction fragment
length polymorphism system, 230, 231f</p>
<p>Single nucleotide polymorphisms
classification of, 252, 252t
defined, 226
in Human Haplotype Mapping Project, 252–253, 253f
overview of, 252</p>
<p>Single strand conformation polymorphism
in HLA testing, 392</p>
<p>Single-gene disorders, 312–326
cystic fibrosis as, 175, 318–319
cytochrome P-450 variants as, 319
factor V Leiden as, 148, 189–190, 190f, 316–317, 317f, 317t
genomic imprinting in, 325–326
hemachromatosis as, 317–318, 318f
inheritance patterns in, 312–314, 313b, 313f–314f
nonclassical, 319–321, 320b, 320f–321f, 321t–322t
lysosomal storage diseases as, 315f, 315–316, 316t
mitochondrial mutations in, 319–321, 320f–321f, 321t
molecular basis of, 314, 315t
multifactorial inheritance in, 326
nuclear gene mutations in, 321, 322t
trinucleotide repeat expansion, 322b, 322–325, 323f–325f, 324b, 325t</p>
<p>Copyright ©2007 by F. A. Davis.</p>
<p>Index</p>
<p>Single-strand conformation polymorphism
in gene mutation detection, 175–177, 177f</p>
<p>Single-strand DNA break
helicase function and, 16</p>
<p>Sinsheimer
in Human Genome Project, 219</p>
<p>Slot blot techniques
in array-based hybridization, 112–113, 113f</p>
<p>Sm proteins
in small nuclear RNA, 34</p>
<p>Small interfering RNA
solution hybridization in analysis of, 117
structure and function of, 34, 34b</p>
<p>Small intermediate RNA
structure and function of, 34</p>
<p>Small modulatory RNA, 36</p>
<p>Small nuclear RNA
isolation from cancer cells of, 34t
in RNA splicing, 32b
structure and function of, 34</p>
<p>Small nucleolar RNA, 36</p>
<p>Small temporal RNA, 36</p>
<p>SMC proteins
in chromosomal function, 158b</p>
<p>Smith
in Human Genome Project, 219</p>
<p>Snell
on histocompatibility, 377</p>
<p>SNP. See Single nucleotide polymorphisms</p>
<p>SNP Consortium
as data resource, 252</p>
<p>Sodium hypochlorite
in polymerase chain reaction, 132</p>
<p>Software applications
in automated fluorescent DNA sequencing, 213, 215t–216t
for genotyping, 232</p>
<p>Solid tumors. See also specific tumor types
classification of, 333
mutations in, 335f–340f, 335–343, 341t</p>
<p>Solid-phase isolation
DNA, 69–70, 70b, 70f
RNA, 73, 74f</p>
<p>Solution hybridization, 117f–118f, 117–118</p>
<p>Somatic hypermutation, 350b</p>
<p>Southern blot, 96–101
blotting technique in, 99b–100b, 99–101, 100f–101f
clonality detected by, 351–352, 352f, 354, 355f
DNA preparation in, 97–98, 98f, 99b
dot/slot variations on, 112–113, 113f
interpretation of results in, 111–112, 112f
in molecular epidemiology, 286
restriction enzyme cutting and resolution in, 97, 98f</p>
<p>restriction fragment length polymorphisms
detected by, 226t, 226–228, 228f
in translocations, 356, 357f, 359, 359f</p>
<p>spa typing
in molecular epidemiology, 289</p>
<p>Specimen collection
for molecular testing, 264–266, 265t, 405f, 405–406, 406t</p>
<p>Spectral karyotyping
in FISH chromosome analysis, 168</p>
<p>Spectrophotometers
maintenance of, 415–416</p>
<p>Spectrophotometry
in nucleic acid analysis, 76–77
advances in, 77b</p>
<p>Spin columns
in polymerase chain reaction, 134, 135f
in solid-phase DNA isolation, 69</p>
<p>Spliceosome
RNA, 34</p>
<p>Splicing
alternative RNA, 33
in messenger RNA processing, 32b–33b, 32–33, 33f
of transfer RNA, 33b</p>
<p>Split chimerism, 247b</p>
<p>Stacking
in denaturing gradient gel electrophoresis, 177</p>
<p>Stahl and Meselson
on DNA replication, 8b, 66</p>
<p>Staining
in chromosome visualization, 159–161, 160f–161f, 161b</p>
<p>Standard curve
in quality assurance procedures, 412</p>
<p>Standard precautions
for specimen handling, 265b, 406</p>
<p>Standard Reference Material DNA Profiling Standard
in restriction fragment length polymorphism, 228</p>
<p>Standard tilting
in high-density oligonucleotide arrays, 184, 184f</p>
<p>Staphylococcus aureus
vancomycin-resistant, 282, 282f</p>
<p>Stem cells
in bone marrow transplantation, 245</p>
<p>Sticky ends
in restriction enzyme function, 13f, 13–14, 14b</p>
<p>Stoffel fragment
in polymerase chain reaction, 129</p>
<p>Storage
of molecular laboratory specimens, 407, 408t–409t, 409, 409f</p>
<p>STR. See Short tandem repeats</p>
<p>Strand displacement amplification, 144–145, 145f–146f</p>
<p>Streptococcus pneumoniae
detection of, 271t, 275–276</p>
<p>Streptococcus pyogenes
detection of, 264</p>
<p>Stringency
in hybridization techniques, 107f, 107–108</p>
<p>Stutter
in polymerase chain reaction, 237b</p>
<p>Submarine gels
in electrophoresis, 88, 89f</p>
<p>Substituted nucleotides
clinical applications of, 6, 6f
discovery in nature of, 4b–5b
in DNA structure, 4–5</p>
<p>Substitutions
in gene mutations, 174
nomenclature for, 194</p>
<p>Substrate specificity
in clinical polymerase applications, 12</p>
<p>Sugar-phosphate backbone
in DNA structure, 3f, 6</p>
<p>Supercoil
plasmid structure as, 22, 23f</p>
<p>Suppressor transfer RNA
defined, 58b</p>
<p>Surname
in Y-short tandem repeats, 244</p>
<p>Susceptibility testing
in drug resistance, 282</p>
<p>SyBr green
in electrophoresis, 75, 91–92
in fluorometry, 78
in quantitative polymerase chain reaction, 138, 139b, 139f, 269</p>
<p>Synovial sarcoma translocation, 340</p>
<p>Syphilis, 278</p>
<p>T</p>
<p>T cells
separation of, 249b</p>
<p>Tag single nucleotide polymorphisms, 253</p>
<p>Tailed primers
in polymerase chain reaction, 128f</p>
<p>Tandem repeats
defined, 226
in human identification, 230, 230f</p>
<p>TaqMan
in polymerase chain reaction, 139b, 139f, 139–140, 361</p>
<p>Target amplification</p>
<p>Copyright ©2007 by F. A. Davis.
Index 461</p>
<p>nucleic acid, 122–144. See also Polymerase chain reaction defined, 122
transcription-based, 142–144, 143f
Tatum
on recombination, 20b
T-cell lineages
in bone marrow transplantation, 249b
T-cell receptor
gene rearrangement in, 349–350, 350b, 350f–351f, 351t, 354–355, 355f
Telocentric chromosomes
morphology of, 159, 159f
Telomeres
defined, 22, 167
Telomeric probes
in FISH chromosome analysis, 167, 167f, 169f
Template
in DNA replication, 7
in polymerase chain reaction, 122, 128
Temporal temperature gradient gel electrophoresis, 178–179
Teratocarcinomas
defined, 333
Terminal transferase
discovery of, 15b
in DNA polymerization, 11
Tertiary structure
amino acid, 53–54
Test results
quality assurance in documenting, 420–421, 422f, 423
Tetramer
defined, 54
The Institute for Genomic Research (TIGR)
in Human Genome Project, 220
Thermal cycler
in dideoxy DNA sequencing, 210
Thermal cyclers
in allelic discrimination with fluorogenic probes, 185–186
in dideoxy DNA sequencing, 210
maintenance of, 414, 414f
in melt curve analysis, 181
in polymerase chain reaction, 130–131, 131f
Therminator
in dideoxy DNA sequencing, 209–210
Thermometers
in quality assurance protocols, 414, 414f
Thermosequenase
in dideoxy DNA sequencing, 209–210
Threonine
structure of, 50f</p>
<p>Threshold cycle
in quantitative polymerase chain reaction, 137, 138b, 138f
Thymine
as DNA nitrogen base, 2–3, 3f
Thymine dimer
defined, 11b
Tiny noncoding RNA, 36
Tissue samples
in DNA isolation, 66
Tissue typing
DNA-based, 376–396. See also specific techniques
Tissue-specific genes
in molecular oncology, 334
Topoisomerases
in DNA metabolism, 16, 16b
t(8;14)(q24;q11)
in Burkitt’s lymphoma, 363, 363f
t(9;22)(q34;q11)
in leukemia, 358f–361f, 358–361, 361b
t(11;14)(q13;q32)
in lymphoma and leukemia, 362–363
t(14;18)(q32;q21)
leukemia and lymphoma associated with, 356f–358f, 356–358
t(15;17)(q22;q11.2-q12)
in leukemia, 361–362, 362b
Trans factors
in RNA synthesis, 39f, 39–40
Transcription
constitutive, 31
inducible, 31
regulatory, 31
RNA, 28–31, 29f
regulation of, 38–44, 39b, 39f–43f, 42b–43b
Transcription factors
therapeutic strategies using, 29
Transcription-based target amplification systems, 142–144, 143f
Transcription-mediated amplification, 142–144
Transduction
in DNA recombination, 20–21, 21f
Transfer
in Northern blot, 101b, 101–102
in Southern blot, 99b–100b, 99–101, 100f–101f
in Western blot, 102
Transfer RNA
in amino acid charging, 57
splicing of, 33b
structure and function of, 34–35, 35b–36b, 35f</p>
<p>Transformation
in DNA recombination, 21–22, 22b, 22f
experimental versus natural DNA, 22b
Transforming factor
discovery of DNA, 22, 22f
Translocations
in cancer
hematological, 356f–363f, 356–365, 361b–363b, 364t
overview of, 334–335
defined, 356
FISH in detection of, 166f–167f, 166–167
karyotyping in detection of, 162–163, 164, 165f
balanced, 162–163, 164f
reciprocal, 162–163, 164f
robertsonian, 163, 164f
Transmembrane proteins
structure of, 49, 51f
Transmission
sex-linked, 313–314, 314f
Transmission patterns
autosomal-dominant, 313, 313b, 314f
autosomal-recessive, 313, 314f
defined, 312
Transplantation
bone marrow, 245f–248f, 245–249, 246b–249b
crossmatching in, 387, 387b, 387f
DNA-based typing in, 388–392, 389f–392f
HLA antigens in, 377
laboratory testing for, 395, 396t
serological HLA analysis, 385f, 385–388, 386t, 387b, 387f
Transport systems
specimen, 265, 265t
Transverse alternating field electrophoresis, 83f, 83–84
Trastuzumab
in breast cancer, 335
Treponema pallidum
detection of, 277t, 278–279
Trimer
defined, 54
Trimming
as synonym for deletion, 350
Trinucleotide repeat expansion disorders, 322b, 322–325, 323f–325f, 324b, 325t
Triploidy
in Down’s syndrome, 157
FISH in detection of, 166, 166f
Tris buffers
in electrophoresis, 87, 87b
in polymerase chain reaction, 130</p>
<p>Copyright ©2007 by F. A. Davis.
462 Index</p>
<p>Trisomy
defined, 311
examples of, 312t</p>
<p>Tropheryma whipplei
detection of, 264</p>
<p>Tryptophan
structure of, 50f</p>
<p>Tth polymerase
in polymerase chain reaction, 129, 136</p>
<p>Tuberculosis, 271
multidrug-resistant, 283</p>
<p>Tumor
defined, 333</p>
<p>Tumor cells
single-strand conformation polymorphism
in, 176–177</p>
<p>Tumor protein 53
in cancer, 341t, 341–342</p>
<p>Tumor suppressor genes
in cell cycle, 333–334
mutations in, 334</p>
<p>Tumors. See also specific tumor types
classification and nomenclature of, 333</p>
<p>Tumor-specific genes
in molecular oncology, 334</p>
<p>Typing capacity
in genotype test evaluation, 290</p>
<p>Tyrosine
structure of, 50f</p>
<p>Tyrosine kinase inhibitors
in cancer therapy, 337</p>
<p>U</p>
<p>Ultraviolet light
clinical applications of, 133b
in polymerase chain reaction, 132
pyrimidine dimer formation and, 133b
in spectrophotometry, 76–77, 77b</p>
<p>Ultraviolet light illuminators
maintenance of, 415</p>
<p>Unwindases
RNA, 38b</p>
<p>Uracil
in RNA structure, 28, 28f</p>
<p>Ureaplasma urealyticum
detection of, 277t, 279–280</p>
<p>Urethritis
chlamydial, 276
mycoplasmal, 279
ureaplasmal, 279</p>
<p>Urogenital tract pathogens. See also specific
pathogens
detection and identification of, 276–280,
277t
overview of, 276</p>
<p>V</p>
<p>Vacuum transfer
in Southern blot, 100, 101f</p>
<p>Validation
of laboratory tests, 268, 410, 411f, 412</p>
<p>Valine
structure of, 50f</p>
<p>Vancomycin resistance, 281–283, 282f, 282t
cycling probe method in detection of,
149</p>
<p>Variable expressivity
defined, 314</p>
<p>Variable loop
in transfer RNA structure, 35, 35f</p>
<p>Variable number tandem repeats
defined, 226, 230
in human identification, 230
short tandem repeats versus, 231</p>
<p>V(D)J recombination
gene rearrangements in, 347–350, 348b,
348f–351f, 350b</p>
<p>Venereal Disease Research Laboratory
in Treponema pallidum detection, 278</p>
<p>Venter
in Human Genome Project, 220</p>
<p>VIC dye
in allelic discrimination, 186, 187f</p>
<p>Viral load
in HIV infection, 295–297, 296t</p>
<p>Viruses. See also specific viruses
detection of, 291–299
amplification tests for, 293t–295t
hepatitis C, 264, 294t, 298–299
human immunodeficiency, 264, 292,
293t, 295–297, 296t
overview of, 291–292, 299</p>
<p>DNA, 292t
genomes of, 292t
genotyping of, 297–298, 298b
restriction modification in, 5b</p>
<p>RNA
genomes of, 292t
reverse transcription in, 28b
transduction in, 20–21, 21f</p>
<p>V-myc avian myelocytomatosis viral-related
oncogene, 343</p>
<p>VNTR. See Variable number tandem
repeats</p>
<p>Von Hippel-Lindau gene, 342–343</p>
<p>Von Hippel-Lindau syndrome, 342</p>
<p>W</p>
<p>Wada
in Human Genome Project, 219</p>
<p>Watson
on DNA double helix, 2–3, 4b, 8b
in Human Genome Project, 220
molecular biology defined by, 2</p>
<p>Wells
in electrophoresis, 89–90, 90f</p>
<p>West Nile virus
detection of, 294t</p>
<p>Western blot
for human immunodeficiency virus, 295
interpretation of results in, 112, 112f
in protein analysis, 97t, 102, 102b, 107b</p>
<p>White and Hogness
R loop mapping of, 31b</p>
<p>White blood cells
in DNA isolation, 66</p>
<p>WHO Nomenclature Committee
on HLA nomenclature, 383b</p>
<p>Whole chromosome paints
in fluorescence in situ hybridization, 168,
168f</p>
<p>Whole genome shotgun sequencing
in Human Genome Project, 220f, 221</p>
<p>Whooping cough, 272–273</p>
<p>Wobble
in genetic code, 56</p>
<p>Wollman
on transduction, 20–21</p>
<p>X</p>
<p>X-linked disorders, 313–314, 314f</p>
<p>Xylene
in DNA isolation, 66</p>
<p>Xylene cyanol green
in electrophoresis, 90, 91t</p>
<p>Y</p>
<p>Y chromosome
Y-short tandem repeats and, 241–242</p>
<p>Yeast
transfer RNA of, 36b</p>
<p>Y-short tandem repeats
in kinship testing, 241–245, 242f, 243b,
243t–244t
loci of, 243t–244t</p>
<p>Z</p>
<p>Zamecnik
ribosome studies of, 57</p>
<p>Zimmerman
on DNA polymerization, 9b</p>
<p>Zinc finger motif
in amino acid structure, 53b</p>
<p>Zwitterions
amino acids as, 49</p></div></div></div></div></div></div></div><div data-testid="stAppIframeResizerAnchor" data-iframe-height="true" class="st-emotion-cache-1dumvfu eht7o1d9"></div></section></div></div></div><div data-testid="portal" id="portal" class="st-emotion-cache-1q6lfs0 e19n7mk11"></div></div><div class=""></div></div>
  

</body></html>
